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RÉSUMÉ 
Le développement de vecteurs de livraison non viraux à des fins thérapeutiques a pris de l’ampleur 
dans les dernières années. Le chitosane est un polymère cationique naturel ayant la capacité de 
former des nanoparticules lorsqu’il est mélangé à des molécules polyanioniques comme les petits 
ARN interférents (pARNi). Les efforts pour identifier les paramètres moléculaires favorisant une 
bioactivité optimale n’ont pas été concluants en raison de différences expérimentales, d’un manque 
d’uniformité des protocoles de transfection, de la faible caractérisation du polymère et des 
différences au niveau des sources de chitosane utilisé. Cette thèse a été entreprise afin de répondre 
aux objectifs suivants: 1) Tester et valider l’efficacité de transfection de formulations, 
précédemment identifiées comme optimales pour la livraison d’ADN plasmidique, 2) Examiner 
l’influence des paramètres intrinsèques (dégrée de deacetylation (DDA), la masse moléculaire 
(Mn) et le ratio N:P) et extrinsèques (sérum, pH, force ionique et conditions de mélange) sur les 
caractéristiques physicochimiques des particules, leur internalisation dans les cellules, l’efficacité 
de silençage, la toxicité métabolique, la génotoxicité et l’hémocomptabilité, en utilisant une 
chimiothèque de chitosanes hautement caractérisés, et 3) Sélectionner des formulations ayant des 
caractéristiques optimales relatives à la taille, le potentiel zêta, l’intégrité des nanoparticules et la 
capacité de ces dernières à induire un silençage spécifique du gène en question tout en étant 
sécuritaire, et 4) Caractériser la biodistribution des nanoparticules, leurs toxicités et leurs potentiel 
de silençage génique suite à des injections intraveineuses chez la souris. 
 
Une étude initiale a démontré que le chitosane interfère avec l’extraction d’acide nucléique de 
cellules transfectées in vitro. Une méthode enzymatique simple et peu coûteuse a permis de 
récupérer l’ARN totale pour des applications moléculaires tel que la PCR en temps réel. De plus, 
cette étude a permis de réduire le biais (~ 10-15 %) associé aux nanoparticules adsorbées à la 
surface des cellules lors de mesures du niveau d’internalisation par cytométrie en flux.  
En outre, la digestion enzymatique du chitosane pourrait être effectuée en présence de guanidium, 
un agent chaotropique présent dans le tampon de lyse, démontrant ainsi l’efficacité et la simplicité 
de cette méthode. Avec la résolution de cet obstacle technique, nous avons sélectionné des 
formulations ayant démontré, auparavant, une efficacité de transfection élevée pour la livraison 
d’ADN plasmidique. Ces formulations ont été caractérisés pour leur taille, leur forme, leur potentiel 
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surfacique (potentiel zêta), leur capacité de protéger les pARNi contre les nucléases et leur 
efficacité à transfecter, de façon non toxique, différentes lignées cellulaires. 
Les nanoparticules ainsi formées étaient sphériques et leur taille variait entre 40 et 100 nm. De 
plus, les résultats ont démontré que la protection contre les nucléases dépendait de la masse 
moléculaire et du ratio N:P. Par ailleurs, une haute efficacité (~80%) de silençage génique, en 
présence de sérum (10%), a pu être atteinte dans plusieurs lignées cellulaires. Pour la première fois, 
des nanoparticules avaient pu être obtenues à un faible ratio N:P marquant ainsi une différence 
frappante avec la littérature. Nos résultats ont pu démontrer la cause de ce bais favorisant la 
sélection de nanoparticules à haut ratio N :P testée dans la littérature. 
 
Dans la perspective de comprendre l’influence du degré de désacétylation (DDA) et de la masse 
moléculaire (Mn) du chitosane ainsi que du ratio N :P sur l’efficacité de transfection in vitro, la 
toxicité, la génotoxicité, l’hémocompatibilité et la biodistribution in vivo, une chimiothèque de 
chitosans hautement caractérisés a été produite à de différents DDA (98%, 92%, 80% et 72%) et 
Mn (5, 10, 40, 80 et 120 kDa) et mélangée avec des pARNi à des ratios N :P de 5 :1 et 30 :1. Les 
nanoparticules, ainsi formées, ont été caractérisées pour leurs tailles et potentiel surfacique en 
présence de 10 et 150 mM de sel. L’efficacité d’encapsulation (EE) et de transfection a été mesurée 
à pH 6.5 et 8 (EE) et à pH 6.5 et 7.4 respectivement. Les formulations les plus performantes ont 
été sélectionnées pour une caractérisation plus poussée de l’influence de la Mn et du ratio N:P sur 
l’internalisation des nanoparticules, l’activité métabolique cellulaire, la génotoxicité et l’efficacité 
de transfection in vitro en présence de sérum. L’hémocompatibilité et la biodistribution in vivo ont 
également été examinées pour différents Mn, ratios N :P et doses. Nos résultats ont démontré que 
l’internalisation des nanoparticules et l’efficacité de silençage étaient positivement corrélées à 
l’augmentation du potentiel surfacique, obtenu en augmentant le DDA et la Mn. Une longueur 
minimale de ~60-70 monomères (Mn ~10 kDa) était requise pour garantir une stabilité et un 
silençage en présence ou absence de sérum. L’efficacité de silençage a atteint des niveaux 
équivalents (~ 80-90%) à ceux du contrôle positif (DharmaFECT®) sans toxicité métabolique ou 
génotoxicité démontrant ainsi la supériorité de notre système comparativement aux lipides 
cationiques qui ont diminué l’activité métabolique des cellules. La présence de concentration 
croissante de sérum a négativement influencé la transfection in vitro. Nos résultats indiquent que 
l’influence négative du sérum est inversement proportionnelle à une augmentation du DDA, de la 
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Mn et du ratio N :P. L’hémocompatibilité s’est révélée être dépendante de la dose, du DDA et de 
la masse moléculaire suggérant ainsi l’utilisation d’acide hyaluronique (HA), un polymère 
anionique et biocompatible, pour diminuer l’interaction avec les composantes du sang et améliorer 
la stabilité colloïdale. 
Les études de toxicité in vivo ont démontré que les nanoparticules de chitosane formulées à N:P 5 
pourraient être tolérées jusqu’à une dose de 2.5mg/kg siRNA, tandis que celles revêtues de HA 
améliorent la tolérabilité par un facteur d’au moins 4. 
Contrairement aux nanoparticules lipidiques, les nanoparticules avec ou sans revêtement n’ont ni 
entraîné l’expression de cytokines pro-inflammatoires (ex. IL-1β, IL-6, TNF-α, IFN-γ et KC) ni 
l’augmentation de biomarqueurs sérologiques tels que l’ALT, AST, ALP, l’urée sanguine, et la 
créatinine. Une diminution des thrombocytes a été uniquement observée avec les formulations 
lipidiques soulignant ainsi des différences majeures avec le chitosane. 
L’analyse histopathologique des tissus et le suivit des masses corporelles ont confirmés le profil 
d’innocuité observé avec le chitosane. L’étude de biodistribution chez la souris démontre une 
accumulation spécifique de nanoparticules dans les tubules épithéliaux proximaux du rein où 40-
50% de silençage a été observé, suggérant ainsi des applications potentielles du système au niveau 
des maladies rénales. 
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ABSTRACT 
Research to develop safe and efficient non-viral gene delivery vectors for clinical applications has 
gained momentum in recent years. Chitosan is a natural cationic polymer with a characteristic 
property of self-assembly with small interfering RNA (siRNA) to form nanoparticles with high in 
vitro and in vivo transfection efficiencies. Previous efforts to identify molecular parameters 
favoring optimal bioactivity failed to produce conclusive results because of experimental 
discrepancies, lack of uniformity in transfection protocols, differences in chitosan sources, and 
poor characterization. In the light of these lacunae, The project presented in this thesis was carried 
out with the following objectives 1) Test and validate the transfection efficiency of formulations, 
previously identified as optimal for plasmid DNA, 2) Investigate the effect of intrinsic (DDA, Mn 
and N:P ratio) and extrinsic parameters (serum, pH, ionic strength and mixing conditions) on 
nanoparticle physicochemical characteristics, in vitro cell uptake, knockdown efficiency, 
metabolic toxicity, genotoxicity and hemocompatibility using a library of precisely characterized 
chitosans, and 3) Identify formulations with optimal characteristics with respect to size, surface 
charge, integrity, knockdown, toxicity followed by the characterization of their in vivo 
biodistribution; toxicity and gene knockdown potential following intravenous administration.  
An initial study demonstrated that chitosan interferes with column based extractions of total RNA 
from low cell numbers. The digestion of chitosan using a relatively simple and inexpensive 
enzymatic method permitted total recovery of high-quality RNA. In addition, surface bound 
chitosan was shown to bias flow cytometry data, evaluating nanoparticle uptake through 
fluorescently labeled siRNA. Treatment of cells using the chitosanase method reduced false 
positive events by around 10-15%. Surprisingly, enzymatic digestion could be performed in 
guanidium, a chaotropic agent, containing lysis buffer demonstrating the convenience of the 
method and allowing for the extracted RNA to be used in quantitative PCR experiment. With the 
technical hurdle solved, specific formulations based on designs parameters for plasmid DNA were 
characterized for their size, shape, surface charge, nuclease protection and ability to transfect 
different cell lines and produce non-toxic target specific knockdown. In contrast to plasmid DNA, 
nanoparticles formed with siRNA were all spherical, and their size ranged from 40-100 nm. For 
the first time, nanoparticles could be obtained at low N:P ratio in striking difference with the 
literature. Nuclease protection was found to be molecular weight dependent, and gene silencing in 
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the presence of 10 % serum reached around 80%. This study demonstrated that nanoparticles 
formulated at low N:P ratio were able to form stable nanoparticles and induce target knockdown.  
In an attempt to understand the influence of chitosan molecular weight and degree of deacetylation 
on in vitro transfection efficiency, toxicity, genotoxicity, hemocompatibility and in vivo 
biodistribution, a library of precisely characterized chitosans was produced at different DDAs 
(98%, 92%, 80% and 72%) and Mn (5, 10, 40, 80 and 120 kDa). They were then mixed with siRNA 
at N:P ratios of 5:1 and 30:1, and nanoparticles were characterized for their size and surface charge 
in the presence of 10 and 150 mM salt. Encapsulation (EE) and transfection efficiencies were 
characterized at pH 6.5 and 8 for EE and pH 6.5 and 7.4 for in vitro transfection. Formulations 
were selected for further characterization of the influence of Mn and N:P ratio on nanoparticle 
uptake, metabolic activity, genotoxicity, and in vitro transfection in the presence of increasing 
concentrations of serum. Hemocompatibility and in vivo biodistribution were also investigated for 
several Mn, N:P ratio, and dose. Nanoparticle uptake and gene silencing correlated positively with 
increased surface charge, which in turn was obtained at high DDA and high Mn. A minimum 
polymer length of ~60-70 monomers, or Mn of ~10kDa, was required for stability and in vitro 
knockdown in the presence or absence of serum. In vitro knockdown reached levels equivalent to 
the DharmaFECT® (~ 80-90%) with no metabolic toxicity or genotoxicity, the former in contrast 
to the lipid-based control which severely impaired metabolic activity. Serum had negative dose-
dependent effects on biological performance, which correlated inversely with increased DDA, Mn 
and N:P. The poor in vitro performance above 50% serum concentration is believed to be 
multifactorial in cause and could not be elucidated. Despite the negative effect of serum on in vitro 
transfection efficiency, several reports have demonstrated in vivo efficacy. Hemocompatibility was 
found to be dose-dependent and increased with both Mn and DDA prompting the use of hyaluronic 
acid (HA), a biocompatible and negatively charged polymer, to coat nanoparticles for limited blood 
interaction and improved colloidal stability. Single ascending dose toxicity studies showed that 
uncoated chitosan-formulated at N:P 5 could be tolerated up to 2.5mg/kg siRNA dose, with 
nanoparticle coating improving tolerability by at least 4-folds. In contrast to commercially 
available, and liver-restricted lipid nanoparticles (LNPs), both uncoated and HA-coated did not 
induce pro-inflammatory cytokines such as. IL-1β, IL-6, TNF-α, IFN-γ, and KC, nor had obvious 
effects on the liver (ALT, AST, ALP) and kidney (BUN, Creatinine) biomarkers. 
Thrombocytopenia was only observed with the LNPs formulated with a native siRNA sequence 
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confirming previous reports and highlighting differences with chitosan. Repeated administration 
and histopathological analysis confirmed the safety profile of chitosan versus LNPs. In vivo 
biodistribution in mice showed accumulation of nanoparticles in the proximal epithelial tubules of 
the kidney, where 40-50% functional knockdown was observed and confirmed using multiple 
techniques, suggesting potential applications in kidney diseases. 
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 INTRODUCTION 
1.1 Introduction 
The traditional drug-based toolbox employs small molecules, and biologics, as target agonists or 
antagonists to promote the intended therapeutic effects. This approach has been historically 
effective in controlling, and sometimes alleviating, symptoms without completely remediating the 
fundamental causes of the disease. Advancement in the understanding of molecular mechanisms 
underlying pathologies, protein-protein interactions and the mechanism of action of small 
molecules enabled the discovery of new targets, and improvement of treatment modalities without 
curing the disease. Gene therapy is an experimental technique that uses genes to treat or prevent 
diseases. In contrast to the traditional drug-based toolbox, i.e. small molecules and biologics, gene 
therapy offers the potential and promise to correct the underlying cause of the disease. 
Traditionally, the concept relied on the idea of replacing a defective gene with the correct sequence 
for proper expression. However, the discovery of RNA interference (RNAi), a process by which 
short single or double stranded oligonucleotides induce gene knockdown, has revolutionized the 
concept. 
In the RNAi process, short double-stranded RNAs (siRNA) are recognized by a protein complex 
and guide, through base complementarity, the cleavage of target genes [1]. This powerful and 
specific technique was later found to be difficult to implement as a therapeutic modality due to 
nuclease sensitivity and rapid elimination through the kidneys [2-4]. In addition, off-target effects 
have been associated with the introduction of siRNAs in the body. These off-target effects were 
divided into two categories viz. sequence-dependent and sequence-independent effects [5]. 
Sequence-dependent mechanisms are related to either the partial complementarity of the siRNA 
sequence to other transcripts in the cell cytoplasm or through recognition of the siRNA sequence 
by endogenous pattern recognition receptors (PRR) and subsequent immune stimulation [5, 6]. 
Sequence-independent effects occur when exogenous siRNA sequences compete with endogenous 
regulators of gene expression for the RNAi machinery resulting in dysregulated gene expression 
patterns (i.e. inhibition and/or expression of genes and pathways). Altogether, these barriers limit 
the translation of siRNA into a clinical reality. Early human trials failed to produce the intended 
effect and were associated with toxicities [4, 7, 8].  
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Strategies to improve nuclease resistance and reduce off-target effects were developed and include 
chemical modifications and the use of delivery systems. The latter provide means to protect the 
payload by physically encapsulating and isolating it from nucleases. In addition, delivery systems 
augment cell entry and facilitate payload release into the cell cytoplasm [9, 10]. Endosomal release 
can be achieved by different means and depends on the material used for delivery. The most 
advanced systems in clinical trials are composed of lipid- and polymer-based nanoparticles or 
molecular conjugates [11-13]. Lipid nanoparticles (LNPs) demonstrate high efficiency in vivo but 
are associated with severe toxicity [14-17] and limit payload delivery to the liver prompting the 
development of safer delivery systems with hepatic and extrahepatic capabilities [4, 18]. 
Chitosan is a natural cationic polymer characterized by its tunable properties, biodegradability, 
ease of production, low cost and is generally recognized as safe [19]. In acidic conditions, chitosan 
spontaneously forms nanoparticles in the presence of nucleic acid, and molecular properties (i.e. 
degree of deacetylation and molecular weight) can be adjusted to favor nanoparticle stability and 
efficient transfection [19-21]. Most reports evaluating physicochemical parameters for efficient in 
vitro siRNA delivery were performed using partly deacetylated (DDA ~ 80-85%) chitosan-
formulated at very high amine to phosphate ratio (N:P ratio >25) [20, 22-27]. Such formulations 
could pose significant practical problems for in vivo delivery such as premature dissociation, 
limited dosing, blood incompatibility and non-specific effects due to large quantities of free excess 
chitosan. Although potent in vitro gene knockdown (KD) has been achieved, experimental 
discrepancies, differences in chitosan sources, and lack of characterization rendered results 
inconclusive in identifying optimal parameters for siRNA delivery [28]. Reports correlating in vitro 
transfection efficiency (TE) as a function of chitosan degree of deacetylation (DDA), molecular 
weight (Mn) and N:P ratio have been contradictory [20, 21, 23, 25, 29]. In addition, due to its 
cationic nature, chitosan can interact with blood components, activate platelets, induce erythrocyte 
lysis [30] and, depending on its DDA, cause cytokine expression through macrophage/monocyte 
stimulation following in vitro stimulation or local administration [31, 32]. These aspects of toxicity, 
at least in the nanoparticle field, have been neglected [20-25, 27, 29, 33-40] with in vivo reports 
often using extremely high N:P ratios, based on in vitro findings, without reporting any signs of 
toxicity and/or parameters such as clinical signs, hematological and/or serological biomarkers [22, 
24, 41-44]. In addition, and in contrast to LNPs, in vivo induction of cytokines was never 
characterized. Therefore, a systemic study with accurately characterized chitosans that investigates 
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the effect of intrinsic (DDA, Mn and N:P ratio) and extrinsic parameters (serum, pH, ionic strength 
and mixing conditions) on cell uptake, in vitro transfection efficiency, toxicity, genotoxicity, 
hemocompatibility and in vivo biodistribution, acute toxicity and demonstrates knockdown 
following I.V. administration of nanoparticles is needed to ensure successful translation of this 
promising polymer into an effective delivery system with potential applications in the clinic. 
The research presented in this thesis attempts to address the aforementioned issues and elucidate 
the effect of chitosan molecular parameters on nanoparticle physicochemical characteristics and 
bioactivity. In addition, the research aims to characterize the toxicity and biodistribution profiles 
of chitosan nanoparticles following intravenous administration and compare it to commercially 
available lipid nanoparticles. 
1.2 Problematic 
Several papers have been published demonstrating the efficacy of chitosan and chitosan-based 
nanoparticles to induce in vitro and in vivo target specific knockdown. Attempts to identify 
molecular properties favoring efficient knockdown failed to generate conclusive results as to the 
role of chitosan degree of deacetylation (charge), molecular weight (chain length), and amine to 
phosphate ratio (mixing ratio) on nanoparticle physicochemical characteristics and bioactivity. In 
addition, the role of extrinsic factors such as pH, serum proteins, and ionic strength was not 
elucidated for chitosan-based nanoparticles encapsulating siRNA and was simply assumed based 
on previous experiences with plasmid. Earlier studies have reported application of nanoparticles 
formed at high molecular weight and mixing ratio (N:P ratio > 25), therefore limiting dosing and 
potentially causing dramatic in vivo side effects. Buschmann et al as well as several other groups 
clearly stated, while reviewing past data, that lack of uniformity in transfection protocols, and 
differences in chitosan sources, cell lines, methods and poor characterization render general 
conclusions difficult. 
Moreover, none of the published work characterized the acute or chronic in vivo toxicity following 
single or repeated administration. Therefore, data on immune stimulation, hematological and 
serological (systemic) toxicities is much needed to understand the limitations of the system and 
mechanisms thereof. Therefore, three objectives were elaborated to decorticate the aforementioned 
problematic, and are stated in section 1.3 of this chapter. 
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1.3 Research Hypotheses and Objectives 
 General objective 
The research presented here was carried out with an objective to explore and identify molecular 
properties, or parameters (factors), favoring efficient and non-toxic delivery of small interfering RNA, 
both in vitro and in vivo. Furthermore, acute toxicity, biodistribution and potency of selected 
formulations were investigated in animal studies designed as per regulatory guidelines and compared 
to lipid nanoparticles.   
 Study 1  
The purpose of this study was to test selected formulations proven to be optimal for in vitro plasmid 
DNA delivery and demonstrate the efficiency of said formulations to transfect multiple cells lines 
and induce potent gene knockdown at low N:P ratio.   
1.3.2.1 Hypothesis 1 
We hypothesized that, contrary to previous literature [20, 22, 23, 25, 26], low molecular weight 
chitosans complexed at low N:P ratios represent suitable formulations for siRNA delivery and gene 
knockdown; similar to observations with plasmid DNA. Specific hypotheses tested through this 
study included the following: 
 low molecular weight chitosans formulated at low N:P ratio are able to transfect multiple 
cell lines and induce potent gene knockdown; 
 formulations at low N:P ratios assure sufficient protection and efficient delivery of the 
siRNA cargo; 
 the requirement for high N:P ratio observed in the previous literature is due to erroneous 
assessment of nanoparticle stability at high pH and subsequent selection of stable 
nanoparticles for in vitro assessment.  
1.3.2.2 Objective 1 
Select formulations based on design parameters in Lavertu et al, prepare nanoparticles at a low N:P 
ratio and characterize their physicochemical properties (i.e. size, surface charge, stability at 
different pH), and ability to transfect multiple cell lines.  
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 Study 2 
The purposes of this study were to 1) understand the correlation between nanoparticle 
physicochemical properties and knockdown efficiency, 2) identify molecular parameters favoring 
efficient delivery and potent target gene knockdown and 3) characterize the effects of these 
parameters on cell viability and genotoxicity.  
1.3.3.1 Hypothesis 2 
We hypothesized that molecular parameters favoring efficient siRNA delivery are different than 
those found for plasmid DNA. Specific hypotheses tested through this study included the 
following: 
 nanoparticle surface charge is the most important parameter dictating transfection 
efficiency; 
 in contrast to plasmid DNA delivery, transfection and knockdown efficiencies are not 
influenced by media pH, and nanoparticles integrity is conserved at high pH with an 
increase in the degree of deacetylation, molecular weight and N:P ratio; 
 in contrast to plasmid DNA delivery, nanoparticles prepared at high degrees of 
deacetylation and molecular weights are able to transfect cells and induce potent gene 
knockdown; 
 serum has a negative impact on low molecular weight formulations through nanoparticle 
destabilization; 
 increasing both molecular weight and N:P ratio does not influence toxicity and 
genotoxicity; 
 nanoparticle hemocompatibility shows a dose, degree of deacetylation and molecular 
weight dependence; 
 nanoparticle hemocompatibility can be abrogated with hyaluronic acid coating permitting 
improved in vivo dosing. 
1.3.3.2 Objective 2 
Produce and screen a library of fully characterized chitosans to investigate the influence of 
physicochemical parameters (i.e. degree of deacetylation, molecular weight and N:P ratio) on 
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nanoparticle size, surface charge (ζ-potential), integrity (± serum and at different pH), metabolic 
toxicity, genotoxicity,  hemocompatibility, cell uptake and target knockdown efficiency.  
 Study 3 
The aims of this study were to 1) investigate in vivo biodistribution, 2) investigate immunological 
(i.e. cytokine production), hematological, serological and histopathological toxicity of single 
ascending dose, and 3) investigate the efficacy of chitosan-siRNA nanoparticles following 
intravenous administration in mice. 
1.3.4.1 Hypothesis 3 
We hypothesized that administration of sub-hemolytic doses of chitosan is non-toxic compared to 
lipid nanoparticles and induces potent gene knockdown at the site of accumulation. Specific 
hypotheses tested through this study included the following: 
 both uncoated and hyaluronic acid coated nanoparticles do not induce cytokine expression 
following intravenous administration;  
 both uncoated and hyaluronic acid coated nanoparticles do not induce hematological and 
serological toxicities such as thrombocytopenia, and increased kidney and liver biomarkers;  
 both uncoated and hyaluronic acid coated nanoparticles do not induce histopathological 
changes in main tissues and losses in body weights;  
 similar to polyethyleneimine (PEI), uncoated chitosan nanoparticles are eliminated by the 
reticuloendothelial system and accumulate in lungs, liver, spleen and kidney where they 
induce potent gene knockdown; 
 hyaluronic acid coated nanoparticles have a different biodistribution pattern compared to 
uncoated formulations; 
 hyaluronic acid nanoparticles demonstrate higher knockdown efficiency in accumulated 
sites due to improved hemocompatibility and increased doses.  
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1.3.4.2 Objective 3 
Inject nanoparticles to mice and investigate biodistribution using whole animal in vivo imaging to 
define the site of accumulation, and confirm findings using ex-vivo imaging followed by confocal 
microscopy. Formulate nanoparticles with a native (inflammatory) and chemically modified (non-
inflammatory) siRNA sequences, and inject (at increasing doses) into mice via the tail vein. Assess 
pro-inflammatory cytokine induction 4 hours post-administration using a multiplex system, collect 
blood and main organs 24 hours post-administration of nanoparticles and assess hematological, 
serological and histopathological toxicity. Formulate nanoparticles with a chemically modified 
siRNA targeting the glyceraldehyde-3 phosphate gene (GAPDH) as a model to demonstrate 
functional gene knockdown in target tissues. 
 
1.4 Brief structure of the thesis 
The thesis is composed of nine chapters, starting with a general introduction of the subject, and a 
brief description of the problematic, objectives and thesis structure. Chapter 2 presents a concise 
literature review of the following subject matters 1) RNAi mechanism of action, 2) the 
pharmacokinetic and pharmacodynamics considerations for the proper translation of small 
interfering RNA (siRNA) based RNAi, 3) the main delivery systems including chitosan and 4) a 
brief description of the mechanism of cell entry and endosomal escape in order to familiarize the 
reader with the subject of this thesis. Chapter 3 introduces the core of the thesis, and describes 
subsequent chapters. Chapters 4, 5, 6 and 7, present the main findings as published and submitted 
manuscripts. These manuscripts are incorporated in the thesis with modifications only in the 
formatting and represent an exact copy of the published or submitted material. The thesis concludes 
with the last two chapters composed of a short discussion in Chapter 8, and conclusions/future 
perspectives in Chapter 9. The bibliography of Chapters 4, 5, 6 and 7, can be found at the end of 
each chapter, while the bibliography of chapters 1, 2, and 8 can be found at the end of the thesis.   
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 LITERATURE REVIEW 
Small interfering RNA (siRNA) and antisense oligonucleotides (ASO) are potent molecules with 
therapeutic potential [2, 4, 12, 13, 45, 46]. The pharmacokinetic (PK) and pharmacodynamics (PD) 
properties of these molecules depend on several factors such as structure, modifications, 
formulation, and route of administration [2, 4]. This chapter presents a brief summary of the RNAi 
process, pharmacodynamics, and kinetic properties, chemical modification, different delivery 
systems, including chitosan and the mechanism of endosomal entry and escape. In this chapter, the 
reader is referred to reviews of more limited scope and of greater depth on particular topics. 
2.1 RNAi mechanism of action  
RNA interference (RNAi) was discovered in 1998 and quickly recognized as a promising approach 
to block disease-promoting genes via gene-specific silencing. RNAi revolutionized the concept of 
gene regulation and shed light on the function of non-coding sequences in the genome. RNAi was 
found to be responsible for the regulation of vital processes such as cell growth, tissue 
differentiation, and cell proliferation. Dysregulation in the endogenous RNAi process was linked 
to cardiovascular and neurological diseases as well as a plethora of cancers [1]  
In the RNAi process, gene-specific silencing is guided by three types of small noncoding double 
stranded oligonucleotides namely microRNAs (miRNA), PIWI-interacting RNAs (piRNA) and 
small interfering RNAs (siRNA). PIWI-interacting RNAs are restricted to germline cells and will 
not be further explored in this chapter. microRNAs are naturally transcribed from intragenic 
regions of the genome or within introns as long double-stranded primary microRNA (pri-
miRNAs); such transcripts are at least 1000 nt long and contain single or clustered double-stranded 
hairpins (Figure 2-1). The pre-miRNA is processed in the nucleus into an approximately 70 
nucleotides (~ 70nt) stem-loop structure called the precursor microRNA (pre-miRNA) [47, 48] by 
the microprocessor complex (MPC). The MCP is composed of Drosha [47, 48], a type 2 
ribonuclease III with an important role in ribosomal RNA possessing [49], and the dsRNA-binding 
protein Pasha [50]. The pre-miRNA is exported to the cytoplasm [51] via an Exportin-5 mediated 
process [52] where it is further shortened by a type III RNase enzyme called Dicer into an 
approximately 22-nucleotide mature double-stranded miRNA (Figure 2-1). One of the duplex 
strands, the guide strand, also known as the antisense strand (AS), is recognized and incorporated 
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into a nucleic acid-protein complex called RISC (RNA-Induced Silencing Complex), where 
AGO2, a member of the conserved Argonaute family of proteins, is the catalytic core in plants and 
animals [53]. The miRNA guide strand directs RISC to the 3’ untranslated (3’UTR) region of the 
target messenger RNA (mRNA) (Figure 2-1). 
In contrast to miRNA, small interfering RNAs are exogenous 21 nucleotide duplexes (Figure 2-4) 
and bypass the processing steps of miRNA and directly enter the RNAi pathways through direct 
RISC loading. As for miRNA, the siRNA guide, or AS strand is incorporated into RISC which then 
guides the silencing complex to the target mRNA (Figure 2-1). Both miRNA and siRNA duplexes 
demonstrate strand asymmetry summarized by preferential loading of one of the strands into RISC. 
It was proposed that the duplex strand displaying weaker thermodynamic energy (binding energy) 
at its 5’ end is always incorporated into the RISC and mediates gene silencing [54, 55] through 
direct sequence specific mRNA cleavage (PTGS) or translational repression (TR). The choice 
between PTGS and TR is dictated by the extent of sequence complementarity between the seed 
region and target mRNA; with full sequence complementarity promoting PTGS while partial 
complementarity, as in the case of most miRNAs, favors translational repression and accumulation 
of mRNA in P bodies (Figure 2-1).  
 
Figure 2-1: Mechanism of RNA interference induced the siRNA (left side) and the miRNA (right 
side) pathways. Adapted from [8]. Copyright 2017, with Nature Publishing Group permission. 
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2.2 Pharmacokinetic and pharmacodynamic considerations for 
effective RNAi 
Several factors limit the efficacy of siRNA to induce the intended effects in the cell cytoplasm 
(pharmacological site of action). These barriers affect both the pharmacokinetics and 
pharmacodynamics of siRNA and are presented in section 2.2.1, 2.2.2, and 2.2.3 of this chapter. 
 Physiological barriers to siRNA delivery  
In order to mediate their intended effects, the relatively large (~ 14 kDa), hydrophilic and 
polyanionic siRNA molecules need to 1) circulate in the bloodstream, 2) extravasate to the intended 
target tissue, 3) diffuse locally, 4) pass through the cytoplasmic membrane, 5) escape from the 
acidic environment of the endosome and finally 6) load into the RNAi machinery; the first two 
steps are eliminated in the case of local delivery. In each and every step of this process, a defense 
mechanism has been warranted through evolution in order to protect the integrity of cells and their 
higher structures. In blood, naked and unmodified siRNA face rapid recognition and degradation 
by serum endo- and exo-nucleases. In addition, siRNAs and their degradation products are readily 
eliminated through glomerular filtration and hepatobiliary excretion [56]. Rapid renal elimination 
occurs due to the relatively small size of the siRNA molecules (size below the ~ 8-10 nm pores 
[57] of the filtration slits in the glomeruli). Numerous studies have shown that naked, and non-
chemically modified siRNAs were rapidly eliminated from the bloodstream with half-lives of less 
than 5 minutes [41, 58]. In contrast to naked siRNA, metabolically stabilized siRNAs have been 
shown to circulate up to 50 minutes [41, 58]. For instance, phosphorothioate (PS) modification of 
the backbone favors interactions with serum proteins and limits renal secretion. Although such 
modification improves nuclease resistance, permitting extravasation to tissue, additional hurdles 
such as specific targeting and cellular translocation remain. Moreover, electrostatic repulsion 
forces between the negatively charged siRNA phosphate and the negatively charged membrane 
limit passive diffusion [2]. Encapsulation, or conjugation, of siRNA (see section 2.3) breaks down 
several of these barriers permitting potent gene knockdown (reviewed in [2, 4, 11, 59]). However, 
delivery materials face similar challenges with endosomal escape being the most rate-limiting step 
[2, 9, 13, 60, 61]. 
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Table 2-1 Biological barriers for siRNA delivery, the impact of each barrier on performance and 
strategies to overcome the barriers. 
Barriers Impact  Solutions 
Serum proteins 
and nucleases 
 Aggregation  Surface modifications e.g. PEGylation  
 Rapid clearance  Physical encapsulation of payload 
 Nonspecific uptake 
 Payload metabolic stabilization (e.g. chemical 
modifications) 
 Toxicity   
Tissue specificity  Nonspecific uptake  Size 
Cell uptake or 
internalization 
 Poor intended effect  
 Nanoparticle decoration or payload conjugation 
with tissue or cell specific ligands (e.g. antibodies, 
transferrin, galactose, GalNAc, etc) 
Endosomal escape  
 Poor target knockdown 
efficiency 
 Endosomal escape agents i.e. cell penetrating 
peptides, membrane destabilizing agents (e.g. 
Mellitin, PBAVE).  
 Optimization of lipid formulations, composition, 
and inclusion of fusogenic lipids and cholesterol 
 Acid labile bonds 
 Optimization of lipid pKa (e.g. ionizable lipids)  
RISC loading  
 Optimization of payload sequence (e.g. 
thermodynamics), 5’stabilization 
Off-target effects  
 Toxicity (e.g. immune 
stimulation, knockdown 
of unspecific genes, 
genotoxicity 
 Payload designs 
 In vitro high throughput screening 
 Metabolic stabilization and pattern designs 
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 Structural factors affecting siRNA-induced RNAi 
Several factors can affect the potency of the RNAi effect. For instance, incorrect strand selection 
can trigger the silencing of off-target genes complementary to the intended passenger, or sense, 
strand and decrease the potency of the antisense strand. Increasing the asymmetry of the duplex 
through A-U enrichment in the 5’ end of the AS strand helps to ensure that the desired strand (i.e. 
antisense) is selected by RISC. In addition, strategies such as the incorporation of unlocked nucleic 
acids (UNA) into the 5’ end of the AS strand enhance asymmetry and strand selection [62]. 
Asymmetry can also be enhanced by blocking intracellular phosphorylation of the 5’-OH using 
selective modification (i.e. methylation) of the hydroxyl group at the 5’ end of the sense strand 
during solid phase synthesis [63]. As activated RISC are devoid of helicase activity [1, 64], mRNA 
secondary structures can block access to the target site and reduce potency. Several algorithms (i.e. 
OligoWalk) were developed in order to optimize the design of siRNA duplexes, and select potent 
sequences for further in vitro screening. These algorithms not only take into account mRNA 
structures [65] but also incorporate design rules to consider the internal stability of the duplex [66]. 
The general rules for effective siRNA can be summarized as follows 1) Low G/C content (36 to 
50%), 2) A or U base preferred in position 1 of the AS strand, 3) a bias toward low internal stability 
at the S strand 3’- terminus (5’ AS terminus); 4) absence of internal repeats, 5) at least 3 A/U bases 
at position 15–19, 6) A/U bases at position 10 (substrate for Ago2 cleavage) and 19, and 7) AU-
richness in positions 1-7 [66]. Irrespective of how accurate these predictive algorithms are, it is 
always encouraged to carry out in vitro screening for potency and validate on- and off-target effects 
using proper controls [7]. 
  Potential toxicities 
Three types of toxicities or off-target effects have been reported in the literature and are described 
in sections 2.2.3.1, 2.2.3.2 and 2.2.3.3 below. It is important to mention that these off-target effects 
or toxicities are dependent not only upon the siRNA sequence but also upon the composition of the 
delivery vehicle.  
2.2.3.1 MicroRNA like off-target effects 
In general, miRNA-like off-target effects occur through non-specific partial complementarity 
between the antisense sequence and the 3’untranslated regions (3’UTR) of the mRNA pool [5] 
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(Figure 2-2). miRNA like off-target effects were discovered when different siRNA sequences 
targeting the same gene led to different transcriptomic signatures [67]. In a follow-up study, 
Jackson et al showed that nucleotide mismatch in the AS strand (5’ position) decreased off-target 
knockdown, but introduced new genomic signatures with a new set of genes being silenced [68]. 
The analysis of the off-target transcript sequences revealed partial complementarities with the seed 
region of the siRNA; the seed region is a sequence of 8-nucleotides that plays a key role in target 
recognition through base complementarity. miRNA off-target effects are not restricted to 3’UTRs 
but could also be induced if siRNA share partial complementarity with coding regions (ORFs) [67]. 
Design algorithms, incorporating basic local alignment search tools (BLAST), have been 
developed to select for minimal seed region complementarity with 3’UTR [69-71]. However, these 
strategies are not error proof and/or are limited since partial homology with available 3’UTR is 
unavoidable [71]. In addition to careful designs, chemical modifications such as methylation 
(2’OMe) have demonstrated impressive use in mitigating miRNA like-off target effects [68]. 
Incorporation of other chemical modifications such as UNA (seed region) and locked nucleic acid 
(LNA) abrogated the number of off-target transcripts by more than 90% [72]. Both these 
modifications seem to affect the interaction between the AS and Ago2 (RISC) and decrease 
complementarity with the 3’UTRs without affecting potency [62, 68, 73]. 
 
  
Figure 2-2: The different categories of off-target effects observed with small interfering RNAs. 
The cartoon depicts the on-target, or the intended effect (left), the off-target, or miRNA-like off-
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target silencing, occurring after siRNA recognition of imperfectly matched 3’UTRs sequences in 
the transcriptome (middle) and the immune stimulation off-target effect of siRNA and/or delivery 
material used i.e. lipid nanoparticle (right). Note: other off-target effects such as RISC saturation 
are not depicted in this cartoon. Image adapted from [5]. Copyright 2017, with Nature publishing 
group permission 
2.2.3.2 Immune stimulation properties 
siRNA, and the delivery materials (section 2.3), have the potential to activate the innate immune 
response and stimulate the production of cytokines. Immune activation is generally associated with 
the activation of pattern recognition receptors (PRR) such as Toll-Like Receptors (TLR) (Figure 
2-2). siRNA-dependent immune stimulation has been associated with the endosome bound TLR-
3, TLR-7, and TLR-8; TLR-3 is also expressed on plasma membranes. The interaction between a 
TLR and a siRNA sequence activates downstream signaling pathways leading to the transcription 
and subsequent expression of proinflammatory genes (i.e. cytokines) such as Tumor Necrosis 
Factor-alpha (TNF-α) and Interleukin-6 (IL-6). In contrast to TLR-3, the activation of TLR-7 and 
8 have been demonstrated to be sequence dependent [74-78]. Beside TLRs, cytoplasmic sensors 
such as the retinoic acid inducible gene (RIG-1) and protein kinase R (PKR) are able to recognize 
double-stranded RNA and mediate interferon (IFN) responses [6, 79]. These intracytoplasmic 
sensors represent a second layer of protection that evolved to counteract direct cytoplasmic loading 
of dsRNA (viruses) or poor TLR recognition. In an attempt to relate sequence motifs and TLRs, 
several groups revealed the importance of features such as RNA length, sequence and structure of 
siRNA on immune activation. However, no consensus on either the nature of the immune-
stimulatory motifs or on the design rules has been reported to date. It seems that uridine (U) and 
guanosine (G) rich sequences including UG dinucleotides and 5’-UGU-3’ are potent activators of 
TLR [5, 80]. Nevertheless, GU-rich sequences do not account for all immune responses to siRNA 
since sequences lacking U and G nucleotides can still elicit potent TLR activation [76, 78]. These 
findings demonstrate the difficulty in defining immune-stimulatory motifs and suggest that proper 
selection of inert sequences is best achieved through experimental screening. However, the most 
promising strategy to reduce immune stimulation seems to involve chemical modifications (Section 
2.2.4). For instance, it has been established that 2’ modification of the ribose ring can reduce or 
even eliminate the innate immune response. Judge et al demonstrated that a minimum of two 
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modifications is required in selected positions to abrogate immune stimulation in PBMCs [81]. 
Several other types of modifications (i.e. LNA, UNA, 2’-F, etc.) described in section 2.2.4 have 
also been demonstrated to inhibit immune activity to some extent.  
2.2.3.3  Sequence-independent off-target effects. 
As siRNA and endogenous microRNA share the same machinery, competition between these two 
types of molecules can potentially disturb endogenous gene regulation. Several studies 
demonstrated the saturability of the RNAi pathway and showed toxic effects both in vitro and in 
vivo [82-85]. For instance, mice lethality was demonstrated following the delivery of plasmid DNA 
encoding short hairpin RNA (shRNA); shRNA are transcribed in the nucleus, mimic pre-
microRNA, processed by Drosha and exported to the cytoplasm via Exportin-5 where they are 
further processed by Dicer, load RISC and mediate RNAi [84]. The observed lethality was related 
to Exportin-5 saturation and impairment of nuclear transport due to the improper cleavage by 
Drosha [85, 86]. Sequence-independent off-target effects were also demonstrated to occur 
downstream of Exportin-5, in the cytoplasm, via direct competition for RISC loading [83, 87]. 
Although chemical modification can abrogate sequence-dependent off-target effects, improve 
nuclease resistance, reduce immune stimulation (section 2.2.4) and improve potency, they are 
unable to reduce such sequence independent off-target effects. In fact, chemical modifications, 
especially with novel chemistries being incorporated could increase this type of negative effects. 
In light of a recent report demonstrating long-lasting knockdown (6 month) following single 
administration in human [13], and the subsequent announcement by Alnylam Pharmaceuticals, that 
immunoprecipitation experiments in mouse hepatocytes showed that siRNA AS strands remain 
loaded into RISC months after dosing [88], sequence independent off-target effects should, 
therefore, be seriously investigated for long-term toxicity. 
 Improvement of siRNA PK/PD properties through chemical 
modifications 
RNAi clinical application has met with some significant obstacles such as low cellular uptake due 
to the polyanionic nature of siRNA, serum instability, and low pharmacokinetics, off-target effects, 
toxicity and potent immune stimulation. A variety of chemical modification has been proposed to 
address these issues. Such modifications can be classified into four major categories: 1) sugar 
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modifications, 2) backbone modifications, 3) base modifications and 4) terminal modifications. A 
number of successful siRNA modifications have focused on the 2’ position in the sugar moiety 
since the 2’-OH is not required for siRNA activity [89]. Such modifications include 2’-O-
methylation (2’-O-ME), 2’-O-methoxylethyl (2’-O-MOE), 2’-O-allyl, 2’-O-ethylamine, 2’-O-
alkylamine, fluorine modification (2’-F), 2’-deoxy-2’-fluoroarabinonucleic acid (2’F ANA) and 
Locked Nucleic Acid (LNA) among others (Figure 2-3). In general, all these modifications improve 
serum stability, binding affinity and reduce immune stimulation while preserving potency. 2’-O-
methylation of sugar moieties can be well tolerated throughout the duplex siRNA making it one of 
the most popular and versatile siRNA modifications. However, contradicting results have been 
observed with some groups reporting that large numbers of 2’-O-Me modification on either strand 
decrease siRNA activity [89-92] while others reported that fully modified siRNA are functional 
[93]. 2’-O-MOE modified siRNA has been used to target the pain related cation-channel P2X3 and 
resulted in successful gene targeting in vivo [94]. This modification was found to be most effective 
when used on the 3’-overhang in the siRNA sequence most probably due to the fact that bulkier 
nucleotides are not well tolerated in the siRNA duplexes. 
The fluorine modification is probably one of the best-known siRNA modifications that confer 
improved serum stability [95] and increased binding affinity (Figure 2-3). Reports demonstrated 
that 2’-F modification is well tolerated when a partial modification is performed on both strands 
[89, 96, 97] or when the siRNA sequence is fully modified [98]. Change in the stereochemistry of 
2’-F RNA leads to 2’-F ANA, a well-tolerated modification that increases serum stability and 
binding affinity [99, 100] that was initially developed as a DNA analog [101, 102]. Another kind 
of accepted modifications involves the use of DNA bases. Such modifications are well tolerated as 
3’-overhangs and/or in limited numbers within the base-paired region of a siRNA duplex [103]. 
Substitution with the dsDNA in the 8-nt region at the 5’-end of the guide strand gives active 
duplexes with reduced off-target effects [104, 105]. 
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Figure 2-3: Different chemical modification used in siRNA design. RNA, ribonucleic acid; PS, 
phosphothioate, PS2, phosphodithioate; EA, 2 0 -aminoethyl; DNA, deoxyribonucleic acid; 20 -
F, 20 -fluoro; 20 -OMe 20 -O-methyl; 2 0 -MOE, 20 -O-methoxyethyl; F-ANA, 20 -deoxy-20 -
fluoro-β-d-arabinonucleic acid; HM, 40 -C-hydroxymethyl-DNA; LNA, locked nucleic acid; 
carboxylic LNA 2 0 ,40 -carbocyclic-LNA-locked nucleic acid; OXE, oxetane-LNA; UNA, 
unlocked nucleic acid; 40 -S, 40 -thioribonucleis acid; F-SRNA, 2 0 -deoxy-20 -fluoro-40 -
thioribonucleic acid; ME-SRNA, 2 0 -O-Me-40 -thioribonucleic acid; 40 -S-F-ANA, 20 -fluoro-
40 -thioarabinonucleic acid; ANA, altritol nucleic acid; HNA, hexitol nucleic acid; B, base. 
Adapted from [106]. Copyright 2017, with permission from Frontiers. 
 
Backbone modifications include the phosphorothioate (PS), the boranophosphate, the amide linked 
and the 2’,5’ linked nucleotide. PS offers comparable [97, 107] or lower potencies [89] compared 
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to native siRNA. Excessive or fully modified duplexes were associated with increased toxicity 
[107] and decreased potency when modifications occur at the center of the duplex [108]. 
Boranophosphate modified siRNA demonstrated increased performance – potency and serum 
stability – compared to native and PS modified siRNAs [109]. The 2’,5’-linkage was shown to be 
a viable option for the sense strand and demonstrated a reduction in potency [110]. Base 
modification such as 2-thiouracil and the c-linked Ψ-uracil (ΨU) [111-113] was shown to increase 
potency and specificity when appropriately placed within the duplex. On the contrary, A-U 
stabilizing bases such as 5-I-Ura instead of uracil and diamino purine instead of adenine 
demonstrated a reduction in siRNA activity [89]. Pyrimidine methylation is a common 
modification in conjunction with sugar modification such as DNA, 2’F ANA and LNA. Terminal 
modifications such as the addition of lipids and steroid moieties or DNA bases at the 3’ overhangs 
were successfully used to improve potency and stability [58, 114]; refer to section 2.3.3.1 for 
details regarding lipophilic conjugation. 
The duplex architecture was also demonstrated to be an important aspect influencing siRNA 
stability, immune activation, off-target effects, and potency [115]. For example, small internally 
segmented interfering RNA (sisiRNA), a three strand siRNA, demonstrated increased potency and 
reduced off-target effects [116] (Figure 2-4). Another example of a successful non-canonical 
architecture is the single stranded antisense RNA. The latter enters the RNAi pathway with similar 
potency as siRNAs [107, 117]. An alternative strategy to increase potency consists of increasing 
duplex length [118]. However, it is necessary to keep in mind that siRNA duplexes above 30 nt are 
potent activators of the interferon response [119]. 
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Figure 2-4: Different architectures of siRNA used in the literature. The canonical 21-nt siRNA is 
the most popular siRNA design and continue to be used in most of the studies. Dicer-substrate 
siRNAs such as 27-nt siRNA, shRNA, pre-miRNA mimics, or fork siRNA have been associated 
with enhanced potency. Asymmetrical siRNAs (aiRNA), asymmetric shorter-duplex siRNA 
(asiRNA), bulge-siRNAs and sisiRNA were shown to improve silencing specificity and when 
associated with lipophilic conjugates become self-delivering. Blunt-end siRNA are reported to be 
more nuclease resistant but can be recognized by PRK and RIG-1. Single-stranded siRNAs (ss-
siRNAs) and 16 nt are functional but may require higher siRNA concentrations. Dumbbell-
shaped circular siRNAs may have longer silencing duration. Passenger strands are shown in 
black and guide strands in red. Adapted from [106]. Copyright 2017, with permission from 
Frontiers. 
 
In spite of the fact that these modifications enhance nuclease resistance, increase potency, reduce 
off-target effects and reduce immune stimulation; they do not resolve cell or tissue specific 
targeting, the delivery into the pharmacological site of action, biodistribution and endosomal 
escape. Therefore, safe and efficient siRNA delivery systems are still required to achieve the full 
potential of RNAi. Several strategies to improve tissue/cell targeting, and delivery siRNA into the 
cytoplasm are presented in section 2.3 below.  
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2.3 Strategies for siRNA delivery  
Improvement in siRNA design, selection, and chemical modifications confer drug-like properties 
and demonstrate potency to mediate specific target knockdown with no off-target effects. However, 
a key challenge with respect to the translation of the broad potential of siRNA-based therapeutics 
is the delivery problem. As a consequence, strategies including chemical conjugation with targeting 
moieties or encapsulation in delivery systems were developed and, some, have reached clinical 
trials. These strategies include the use of lipids, polymers, proteins (including antibodies) and 
aptamers to address the challenges of in vivo delivery. 
In this section, a concise review of systems that are considered most promising and/or those that 
reached clinical trials is presented. 
 Nanoparticles based systems 
Nucleic acid encapsulation into nanoparticles provides multiple attractive properties such as 
nuclease protection, improved circulation time, targeting, cellular internalization and endosomal 
release. In the subsequent section, lipid and polymeric based nanoparticles will be presented. 
2.3.1.1  Lipid nanoparticles (LNPs) 
Lipid nanoparticles (LNPs), or liposomes, represent the most advanced nucleic acid carrier, or 
platform enabling in vivo delivery of siRNA. LNPs have reached clinical trials for the treatment of 
hypercholesterolemia, transthyretin-mediated amyloidosis, hepatitis B and liver cancers [11, 12, 
18]. LNPs are endowed with natural hepatocyte targeting through LDLr-ApoE mediated 
endocytosis [120] and exhibit potent gene knockdown activity in rodents and non-human primates 
[120-123]. Electrostatic interaction between the cationic head group and the negatively charged 
siRNA generates multilamellar structures with positively charged lipid bilayers separated from one 
another by sheets of negatively charged siRNA (Figure 2-5) [10]. Different types of structures, 
such as unilamellar or electron dense nanoparticles, can also be fabricated using different processes 
(Figure 2-6). N-[1-(2,3-dioleyloxy) propyl]-N, N,N-trimethylammonium chloride (DOTMA), a 
quaternary amine-containing lipid, that was used for nucleic acid delivery [124] in the presence or 
absence of co-lipids, and form small sized unilamellar liposomes (< 100 nm). The addition of co-
21 
 
lipids such as dioleoyl phosphatidylethanolamine (DOPE) improved transfection efficiency of 
cationic lipids. 
The use of DOTMA, or other cationic lipids, in the presence or absence of co-lipids, confers a net 
positive charge to the liposome facilitating interaction with negatively charged membranes and 
subsequent nanoparticle endocytosis [9, 125]. However, cationic lipids, or liposomes, with 
constitutive or net positive charge, due to quaternary amine group, have been associated with 
spontaneous dissociation [126-128], rapid clearance, severe in vivo toxicity, and unfavorable 
biodistribution via interaction with blood components, aggregation, and activation of immune 
responses (i.e. cytokine and/or complement) [14-16, 128, 129]. Rapid clearance of positively 
charged liposomes, or lipid nanoparticles, by the reticuloendothelial system (RES) in liver and 
spleen, has been correlated to protein deposition and surface interactions with higher PB parameter 
(protein binding ability expressed as g of protein/mol lipids) associated with accelerated clearance 
profiles [130, 131]. Elimination, via accumulation in the capillary beds in the lungs, has been 
observed and is believed to be the result of aggregation [131]. Strategies to improve stability and 
reduce blood interaction – and RES clearance – mainly consist in nanoparticle decoration with 
hydrophilic polyethylene glycol (PEG), or the use of neutral or negatively charged LNPs. 
PEGylation has the benefit of reducing toxicity at the cost of compromising potency owing to 
decreased nanoparticle-cell interactions. Increased potency was achieved with PEG coatings 
designed to dissociate at constant rates thereby dynamically shifting the equilibrium from a stable 
to a transfection competent nanoparticle over time [132]. The diffusion rate, or shedding, of the 
PEG depends on the length of the lipid anchor with shorter chains (C14) dissociating faster [133]. 
In addition, the lipid anchor and its length were demonstrated to play a crucial role in the 
immunogenicity of PEGylated LNPs with long acyl anchors promoting antibody-mediated 
clearance upon multiple administration [134, 135]. 
22 
 
 
Figure 2-5 Molecular structure and local arrangement of nucleic acid in lipid nanoparticles. A) 
Schematic of the local arrangement of the nucleic acid between the lipid bilayers of multilamellar 
(MLV) lipid nanoparticles. B) Cryo-TEM images of fusion of DOTAP/Cholesterol (1:1) 
liposomes induced by the addition of oligonucleotides. Black arrows indicate membrane 
junctions and white arrows indicate a paired membrane. Scale bar: 50 nm. C) Schematic model of 
MLV liposome or lipoplex formation. Adapted from [136]. Copyright, 2017, Elsevier with 
permission.  
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Figure 2-6: Structure of the major siRNA delivery systems. A) First generation lipid nanoparticle 
(LNP) used in pre-clinical and clinical settings [12, 121]. This type of LNPs is composed of a 
mixture of helper lipids i.e. DSPC (yellow), cholesterol (orange), the ionizable lipid DLinDMA 
and PEG-C-DMA. b) Cyclodextrin-based polymer nanoparticle (CDP). CDPs are synthesized 
through polymerization of diaminated cyclodextrin (dark green) yielding an oligomer with 
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diamine groups (blue). The polymer is end-capped with imidazole to improve endosomal escape. 
Adamantan (AD), a hydrophobic molecule is used to conjugate both PEG and targeting ligands. 
AD incorporate into the cyclic core of the cyclodextrin. c) First generation dynamic 
polyconjugate composed of PBAVE, GalNAc, PEG and the siRNA. d) Trivalent GalNAs siRNA 
conjugate. The metabolically stabilized siRNA is conjugated at the 3ʹ terminus of the passenger 
strand to three GalNAc molecules through a triantennary spacer molecule. GalNAc mediates 
hepatocyte entry through receptor-based recognition and subsequent endocytosis. Adapted from 
[59]. Copyright 2017, Nature Publishing Group with permission. 
 
To avoid in vivo toxicity, increase stability, and augment potency of cationic lipids, ionizable head 
groups with primary, secondary and tertiary amines have been developed. Ionizable lipids are 
positively charged at low pH (pH < pKa), and neutral in circulation. This property is beneficial 
since it allows siRNA encapsulation at low pH, reduced protein and blood interaction at 
physiological pH and promotes endosomal escape following re-ionization in acidic conditions. 
Significant improvement occurred since the introduction of the first ionizable lipid (1,2- dioleoyl-
3-dimethylammonium propane or DODAP) [137] with the number of double bonds in acyl chains 
controlling encapsulation and gene knockdown. Maximization of in vitro knockdown occurred 
with acyl chains containing 2 and 3 double bonds while payload encapsulation seemed optimal 
with 2 double bonds containing lipids [138]. As a consequence, the linoleyl lipid (Lin) became the 
acyl chain of choice and demonstrated potent in vivo knockdown in NHPs [121]. The plasma half-
life was extended to 38 minutes when siRNA was formulated with linoleyl containing LNPs. 
However, this formulation showed limited efficacy and caused cytokine induction and complement 
activation in initial clinical trials [12]. Immune stimulation is a major problem with lipid-based 
nanoparticles and is responsible for the discontinuation of several programs that were halted by the 
US Food and Drug Administration after severe flu-like symptoms occurring during or post-infusion 
[12]. Innate stimulation can be significantly reduced with metabolic stabilization of the payload 
(i.e. 2’OMe modification) and/or co-administration anti-inflammatory steroids [81, 135, 139]. 
Immune stimulation would benefit from increased potency since toxicity is a concept related to 
both dose and exposure. Therefore, significant improvement in potency, and consequently safety 
has been achieved through 1) rational design and/or 2) generation of libraries and screening for 
novel formulations. The first approach identified two ionizable lipids i.e. DLin-KC2-DMA and 
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DLin-MC3-DMA with superior potency (100 and 1000-fold respectively) in comparison with the 
1st generation DLin-DMA lipid [122, 140]. Maximization of potency, or the decrease in median 
effective dose (ED50), was strongly correlated with the pKa of ionizable lipids (optimal at 6.44) 
and their ability to adopt cone structures in acidic environments [140]. In fact, data suggest that the 
final liposome pKa is more important than the pKa of individual lipid constituents [122]. DLin-
MC3-DMA based lipid nanoparticles demonstrated potent TTR knockdown in NHP and moved to 
clinical trials [12]. Although increased potency at lower doses was obtained, clinical administration 
of the second generation LNPs (DLin-MC3-DMA) still requires steroid pre-treatment to alleviate 
infusion reactions [46, 141]. The results of Patisiran phase III study, a DLin-MC3-DMA LNPs 
targeting the transthyretin protein (TTR) are expected in the third quarter of 2017 and a potential 
FDA approval in 2018. 
In spite of the high potency and advanced clinical development, optimization and screening for 
new formulations are still ongoing. In an attempt to improve biodegradability, or intracellular β-
oxidation, of DLin-MC3-DMA, ester groups were introduced in the alkyl chain [123]. These ester-
modified lipids were well tolerated in mice and readily eliminated from tissues while retaining 
exceptional potency.  
A recent approach using chemical libraries of lipid-like molecules termed lipidoids (L), combined 
with cholesterol and PEG-ceramide, identified L98N12-5 as a novel formulation with high 
tolerability, and in vivo potency in both mice and NHPs [142, 143]. L98N12-5 was administered 
at doses comparable to the first generation LNPs described by Zimmermann et al [121]. In contrast, 
an epoxide-derived lipidoid library identified a formulation, C12-200, with outstanding 
knockdown efficacy in mice and NHP. Target gene knockdown exceeded 80% at a dose of 0.1 
mg/kg [144]. The clinical translation of these two lipids, as well as the aforementioned ester 
modified DLin-MC3-DMA, and their performance in human is still pending strategic decisions in 
a space where GalNAc is rapidly replacing LNPs for liver delivery. As seen in this section, LNPs 
appears to be restricted to the liver through natural targeting properties to accumulate in liver 
hepatocytes. The mechanism of liver accumulation and endosomal escape will be presented in 
section 2.4.1 of this chapter.  
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 Polymer-based systems or polymer based nanoparticles 
2.3.2.1 Polyethyleneimine (PEI) 
Polyethyleneimine (PEI) is one of the most broadly used cationic polymers for the delivery of 
nucleic acids [9, 145]. PEI can be synthesized in a linear (lPEI) or branched (bPEI) forms and its 
molecular weight controlled [9]. Linear PEIs have demonstrated decreased in vitro toxicity and 
improved in vivo tolerability profiles compared to their branched counterparts [146-148] 
motivating their frequent use in the literature. Bonnet et al, showed that intravenous administration 
of lPEI induces potent gene knockdown with no significant increase in pro-inflammatory cytokines 
or liver transaminases [147]. However, PEIs are generally associated with toxicity [8, 149] and 
colloidal instability [150] limiting their use in clinical trials. PEI cytotoxicity was characterized as 
a two-phase process where polycation-cell interaction induces loss of cell membrane integrity and 
initiation of programmed cell death [151]. Insights into the molecular mechanisms of toxicity 
revealed the importance of physical interactions between the polycation and the mitochondria 
leading to the release of proapoptotic proteins and subsequent initiation of apoptosis. In vivo, lPEI 
demonstrates rapid blood clearance (1-5 minutes) and predominately accumulate in the lungs 
followed by liver, spleen, and kidneys [41]. The two to ten-fold increased accumulation in lungs is 
hypothesized to be due to salt and protein induced colloidal instability in serum and subsequent 
physical capture within pulmonary capillary beds. 
Improved pharmacokinetic and altered biodistribution profiles can be achieved with PEI surface 
modification [152, 153]. PEG decorated PEIs (PEG-PEI) showed decreased liver accumulation 
indicative of improved stability and longer circulation time with no activation of the complement 
system [154]. Despite the encouraging results, PEG-PEI dissociated upon liver passage 
underscoring the shortcomings of this system for systemic application [154]. 
PEI-siRNA systems have been used for local administration with high target knockdown 
demonstrated in lungs and other organs. Despite numerous reports of cytotoxicity and limited 
performance following systemic administration [148, 155], PEI-based systems are being tested in 
clinical trials in Europe, Canada, and Israel. PEI-based nanoparticles (lPEI, 25kDa) were locally 
injected into pancreatic tumors using ultrasound endoscopy [156]. Buscail et al reported a favorable 
in human safety profile with mild treatment-related toxicities in 4/22 patients (↑ transaminases). A 
dose-dependent increase in CYL-02 transgene expression was demonstrated with no objective 
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clinical responses. However, nine patients (9/22) showed stable disease and two of these patients 
(2/9) experienced long-term survival demonstrating that PEI could potentially be used for local 
clinical applications [156]. 
Newer generations of PEI-based systems, based on polycaprolactone-block-PEG copolymers, poly 
D, L-lactic acid-coglycolic acid (PLGA), or lipid conjugation, are being developed for improved 
colloidal stability and increased potency [150]. Nevertheless, PEI systems have been associated 
with off-target and transcriptomic effects [148] that need to be fully investigated, in different cell 
lines (and potentially in vivo) in order to establish proper safety profiles and allow clinical 
translation. 
2.3.2.1 Poly (β-amino ester) (PBAE) systems 
Poly (β-amino ester), or PBAE, represents an interesting class of polymers that was first developed 
in the Langer laboratory at MIT by Lynn et al [157]. These polymers offer facile synthesis through 
classical or combinatorial approaches to construct screening libraries for structure-activity 
relationship (SAR) and selection of efficient formulations. PBAE are synthesized by the 
conjugation of amine (side chains) to diacrylates monomers (backbone) using a one-step chemical 
reaction; Michael addition reaction [158, 159]. The diacrylate-terminated polymer can be end 
capped with a variety of molecules increasing its versatility/modularity. Surface modifications can 
be performed via conjugation or electrostatic coating with negatively charged peptides/ molecules 
(i.e. poly E) [160] to reduce deleterious effects associated with cationic surfaces and 
improved/controlled targeting to tissues.  
Due to their positive charge and amine content (primary, secondary and tertiary), PBAE polymers 
are able to spontaneously condense nucleic acid into nanoparticles and escape the endosome. Initial 
studies of these polymers showed that optimal formulations had Mn ≥10 kDa and effective 
diameters below 250 nm with quasi-neutral ζ-potentials (~10 mV) [83, 161]. In comparison with 
PEI, Poly (β-amino esters) showed at least 4 to 8-fold improvement in transfection efficiency (TE) 
coupled with decreased cytotoxicity. The latter is attributed to the biodegradable ester bond in 
PBAEs; with a half-life between 2-7h depending on the polymer [159]. Although, PEI and PBAE 
have a quasi-similar proton buffering capabilities [162], or ability to escape from the endosomes, 
the enhanced TE observed with PBAE versus PEI can be attributed to improved endosomal escape 
probably via hydrophobic interactions in the endosomal compartment, differences in SAR, nucleic 
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acid binding/unpacking, and most probably their degradability/low toxicity. As PBAE degrade 
inside cells and cause less toxicity compared to nondegradable polymers (i.e. PEI), higher 
polymer/nucleic acid mass ratio can be used to achieve a higher extrinsic buffering capacity per 
mass of nucleic acid [163]. Principal component analysis (PCA) revealed that hydrophobicity and 
molecular weights represent major parameters which increase transfection efficiency between 
related PBAE structures [164]. Studies from the same group (i.e. Green J.J. at John Hopkins), 
showed that different PBAE polymers are needed for the delivery of siRNA versus plasmid DNA, 
and that chemical composition of the PBAE end group (capping monomer), rather than the core 
polymer, play a major role in promoting cellular uptake [159, 165, 166]. This is probably due to 
the role of the end-group in mediating/facilitating an interaction between the surface of the 
nanoparticles and cells and/or the influence of the end group on the bio-nano interface. 
   PBAE have been administered in vivo using different routes of administration (i.e. intravenous, 
intraperitoneal, intraocular, etc.) [158-160, 167] and are currently the focus for intratumoral 
injection in the brain [159]. Intravenous administration of PBAE nanoparticles lead to 
accumulation in major organs causing toxicity. Electrostatic coating with negatively charged 
peptides (i.e. Poly-E) alleviate in vivo toxicity and directs nanoparticles to either the liver or the 
bone marrow depending on the coating density [160]. Intracranial CED delivery of PBAE 
nanoparticles encoding the herpes simplex virus induced thymidine kinase (HSVtk) demonstrated 
good tumor penetrability reaching the tumor margins and achieved significant survival benefits in 
rat gliosarcoma models [168]. These polymers continue to be developed in the Green and Langer 
laboratories for different applications (i.e. mRNA delivery [169]) and show promising results. 
However, further development needs to be conducted to improve their PK/PD profiles and to 
understand why PBAE polymers require bio reducible disulfide bonds for siRNA delivery and not 
another type of nucleic acids. 
2.3.2.2 Cyclodextrin-based systems 
Cyclodextrin polymers (CDP) are polycationic oligomers synthesized by step-growth 
polymerization between diamine containing cyclodextrin monomers and dimethyl subermidate to 
generate oligomers with amidine functional groups. CDPs mediate efficient condensation of 
nucleic acids, including siRNA, at very low amidine to phosphate ratio (N:P ratio less than 3) due 
to the strong basicity – or positive charge – of the functional groups. Endosomal release is usually 
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dependent on imidazole functional groups grafted by end-capping. In vivo application of these 
systems required PEGylation to prevent protein induced aggregation in serum. Non-covalent PEG 
shielding was performed following conjugation with a hydrophobic molecule, adamantane (AD), 
that incorporates through hydrophobic interactions into the cyclic, and hydrophobic, core of the 
cyclodextrin structure (Figure 2-6). PEG shielding, improves colloidal stability, and reduce in vitro 
and in vivo transfection efficacy through reduced nanoparticle-cell interaction. Modification of the 
AD-PEG with targeting ligands such a transferrin (Tf) or mannose (M), rescues the efficacy of the 
CDP NPs lost with PEG shielding through receptor-mediated interaction and subsequent 
endocytosis. 
The CDP targeted system, developed in the Mark Davis Lab at the California Institute of 
Technology, was the first targeted nanoparticle system to be tested in clinical trials and to 
demonstrate the application of RNAi in humans [11, 45]. The system was injected as a two vial 
component that is mixed at the bedside prior to an intravenous infusion protocol of 30 minutes. 
In vivo delivery of siRNA using the CDP system was demonstrated in multiple animal models 
across species. Potent knockdown and antiproliferative effects were displayed in a syngeneic 
subcutaneous mouse tumor model and in a xenograft model for Ewing Sarcoma, respectively [170, 
171]. Positive data from these initial experiments prompted the initiation of a pre-clinical program 
where clinical translatability was evaluated in non-human primates. The targeted-CDP system was 
found to be tolerated following intravenous administration at doses up to 27 mg/kg and 
demonstrated a large therapeutic index (potency ~0.6-1.2mg/kg, toxicity ~ above 27 mg/kg) with 
mild activation of pro-inflammatory cytokines [172]. Evidence of RNAi was shown for the first 
time in a human phase I clinical trial using 5’Rapid Amplification of cDNA Ends (RACE) [45]. 
Although the system demonstrated fast translatability into clinical trials, mainly due to properties 
such as low toxicity in preclinical studies, high encapsulation efficiency, the inclusion of targeted 
moieties and PEG stabilization, phase I clinical trial failed to progress into subsequent phases (i.e. 
Phase II and III). Arrowhead Research, parent company owning Calando Pharmaceuticals, 
terminated the Phase Ib trial with the CDP based investigational product CALAA-01; Phase Ib 
trials are usually extension studies. In-depth analysis of the clinical data and correlation with 
preclinical animal models showed dose-dependent toxicities in several patients, infusion reactions 
that were correlated with increased pro-inflammatory cytokine release, and acute dose-dependent 
hematological toxicities (i.e. thrombocytopenia and lymphopenia) [173]. Importantly, all patients 
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had no objective tumor responses (79%) as per RECIST 1.0 criteria and 7/19 patients had increased 
tumor size highlighting the absence of therapeutic effect. Pharmacokinetic data correlated between 
animal and human accompanied with rapid elimination of CALAA-01 occurring through kidney 
and bladder without liver toxicity. Kidney toxicity was rate limiting in animal studies but not in 
human despite accumulation and elimination of the CALAA-01 system through the glomeruli 
[173]. These findings indicate that the system seems to lack stability in blood and needs further 
investigation. In addition, poor pharmacodynamics and immune stimulation were potentially 
related to the use of poorly selected siRNA (IC50 in nM versus pM range for current designs) and 
its immune stimulating potential in the absence of chemical modifications. However, the system 
continues to be evaluated in preclinical models where CDP has been used for the delivery of siRNA 
to mesangial cells of the kidney [174]. Both Tf and M targeting revealed mesangial accumulation 
of siRNA and knockdown with potential application in kidney diseases. 
In summary, the lessons learned from the CDP system provide guidelines for the design of future 
polymeric and polycationic systems. These include 1) dosing in humans which could be achieved 
at least twice a week with repeated administration, 2) infusion could be tolerated with 
premedication, 3) long term stability (CMC) is an important issue that hinders PD and plays an 
important role in toxicity, and 4) NPs can accumulate in tumor following systemic administration 
and the enhanced permeation retention effect (EPR) which constitute a positive news in respect to 
the growing skepticism about EPR effect in humans.  
 
  Conjugation-based systems 
2.3.3.1 Lipid-siRNA conjugates 
Lipophilic conjugation was first introduced by Soutschek et al in 2004. Cholesterol-conjugated 
siRNA (Chol-siRNA) displayed improved pharmacokinetic (PK) properties with increased 
circulation time (t1/2 95 min) compared to its unconjugated form (t1/2 6 min). Improved PK was 
attributed to increased binding to serum proteins such as albumin [58], which limits renal clearance 
and promotes endothelial transcytosis. Tissue distribution improved following conjugation with 
siRNA detected in liver, heart, kidney and adipose tissues 24 hours post administration versus none 
with the unconjugated siRNA. This enhanced PK and biodistribution profile led to potent apoB-1 
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knockdown in liver and jejunum (~ 57 % mRNA and 68% protein) and a subsequent phenotypic 
decrease in low density lipoprotein (40%), high density lipoprotein (25%), chylomicron (50%) and 
plasma cholesterol (37%) levels [58].  
Wolfrum et al demonstrated that cholesterol (C27), stearoyl (C18), and docosanyl (C22)-siRNA 
conjugates exhibit potent apoB-1 knockdown following multiple injections (3 injections at 50 
mg/kg) confirming previous results and showing that long chain sterols – or bile acids – could be 
used as lipophilic conjugates [175]. In addition, the authors showed that altered biodistribution 
profile and improved circulation time (↑ t1/2) were not dependent on albumin binding, as 
hypothesized by Soutschek et al [58], but on the incorporation of lipophilic conjugates into serum 
lipoproteins. In normal physiology, both high (HDL) and low-density lipoprotein (LDL) play a 
critical role in cholesterol transport and exchange [176, 177]. FPLC analysis revealed that 
cholesterol, and long chain lipid-siRNA conjugates, selectively associate with HDL, LDL, and 
albumin with a small fraction remaining unbound following incubation in plasma. It became clear 
that association with lipoproteins improves nuclease protection and promote tissue-specific 
distribution responsible of potent knockdown observed in liver and jejunum. The mechanism of 
cell uptake was determined to be independent of HDL and LDL endocytosis but required 
association between these lipoproteins and their receptors (scavenger receptor B 1 (SR-B1) and 
LDL receptor) and the subsequent transfer of conjugates through a mechanism involving, in part, 
the mammalian homologue of SID-1; a transmembrane receptor involved in systemic dsRNA 
uptake [178]. It is believed that HDL and LDL loaded particles, after association between the 
lipophilic conjugate and lipoproteins, bind to their receptor and transfer the lipophilic conjugate 
through SID1T mediated dsRNA recognition and subsequent internalization. 
Lipophilic conjugates with lipoprotein pre-treatments (i.e. HDL) demonstrate improved 
knockdown (~ 8 to 15 fold) versus conjugates with albumin, or without, pre-treatment indicating 
that: 1) lipophilic conjugates (i.e. cholesterol-siRNA) do not readily associate with lipoproteins 
following systemic administration, 2) albumin-bound fraction is not functional and/or cannot be 
internalized in hepatocytes, and 3) lipoprotein particles are efficient delivery systems for lipophilic-
siRNA conjugates. 
α-tocopherol (vitamin E) conjugation of a Dicer substrate siRNA (DsiRNA) (Figure 2-4) inhibited 
apoB-1 gene expression in the liver following single administration of a 2 mg/kg dose [179]. The 
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α-tocopherol conjugate demonstrated liver-specific accumulation, dose-dependent knockdown and 
resulted in phenotypic changes in serum triglyceride and cholesterol without induction of IFN-α/β. 
The improved potency (~ 25 fold) relative to cholesterol-siRNA conjugates, used as a control, or 
in [58, 175], might be attributed to differences in payload potency, mechanism of conjugate 
internalization into hepatocytes and endosomal release. Although the mechanism of cell uptake 
was not investigated, it was hypothesized that binding of α-tocopherol to serum lipoproteins – other 
than LDH and HDL – mediated receptor specific endocytosis in hepatocytes. The improved 
potency versus cholesterol-siRNA conjugates requires further investigation, including a systemic 
study on the effect of conjugate position vis-à-vis the siRNA strands, to identify α-tocopherol-
siRNA mechanism of uptake, and endosomal release. In order to improve cholesterol based 
conjugates, the length of the linker between the cholesterol and the siRNA has been investigated. 
Petrova et al found that increased length improved in vitro knockdown efficiency [180]. In 
comparison with first-generation lipid nanoparticles (LNPs) administered in mice and non-human 
primate [121], lipophilic conjugates demonstrated very low in vivo potency (~100 fold). Factors 
such as 1) poor endosomal escape and 2) metabolic stabilization of the siRNA might have 
contributed in the low in vivo potency. The concomitant delivery of a reversibly masked 
endosomolytic polymer and a cholesterol-siRNA conjugate ameliorated (500 fold) in vivo potency 
[181] indicating that endosomal escape is a major bottleneck for these lipophilic-conjugate 
systems. The rate of receptor recycling and the extent of metabolic stabilization of siRNA are 
considered to be extremely important for the potency of GalNAc conjugates [2, 4, 182]. 
Despite the low potency, when administered without endosmolytic agents, lipophilic conjugation 
seems to survive in the RNAi delivery system space with novel hydrophobic conjugates being 
developed for local delivery [2, 4]. Lipophilic conjugation with asymmetric siRNA induce potent 
gene silencing in vitro and support robust in vivo efficacy following local injections [183, 184] and 
are in phase I/IIa clinical trials (NCT02030275, NCT02079168, NCT02599064, NCT02246465). 
Efforts led by the Khvorova group, at the University of Massachusetts, led to the identification of 
molecules that could be co-delivered with lipophilic-siRNA conjugates to enhance in vitro potency 
[185], and could, in the future, be used in formulations for, at least, local delivery. In addition, 
strategies to conjugate fatty acids – i.e. docosahexaenoic acid (DHA) – with intrinsic anti-
inflammatory properties and improved tissue diffusion [184] indicate that extrahepatic, and mainly 
local, delivery using these systems could be achievable [4]. 
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2.3.3.2 Dynamic Polyconjugates (DPC) 
Dynamic Polyconjugates (DPC) were modeled based on the physical characteristics of viruses and 
designed to break down intracellular barriers limiting the delivery process. The delivery system 
was designed to incorporate several components intended to play particular roles under specific 
physiological conditions. A fundamental characteristic of this prototypical delivery system (Figure 
2.5) is the reversible modification of the poly-butyl amino vinyl ether (PBAVE) polymer with 
polyethylene glycol (PEG) and tissue-specific ligands (L) for increased stability, reduced toxicity 
and tissue-specific targeting. PBAVE has amphipathic side chains that include alkyl groups 
interspersed with primary amine (NH2) functional groups. The polymer was chosen for its 
membrane lytic potential, that is dependent on both the positively charged amines and the 
hydrophobic alkyls side chains; with longer chains (i.e. propyl or butyl) demonstrated to improve 
membrane disrupting properties of the polymer [186]. In order to prevent non-specific interactions 
with serum proteins and hemolytic activity vis-à-vis erythrocytes, amine groups were modified, or 
masked, using carboxy dimethylmaleic anhydride (CDM) containing PEG and targeting ligands to 
form acid-labile maleamate groups. These CMD linkers are relatively stable at pH 7.2-7.4 but fully 
reversible in acidic environments such as those present in the endosomes and lysosomes. 
Unmasking of the amines reactivate the membrane lytic activity and promote endosomal 
disruption. In order to induce gene knockdown, siRNA is conjugated to the polymer side chains by 
a disulfide linker allowing for payload release under bio-reducing conditions (i.e. cytoplasm). The 
prototypical DPC was designed to target liver hepatocytes by attaching the asialoglycoprotein 
receptor (ASGPR) ligand GalNAc. 
This first generation GalNAc targeted DPCs (DPC™ 1.0) demonstrated potent apolipoprotein B-1 
(apob-1) and peroxisome proliferator-activated receptor alpha (ppara) gene knockdown in mice. 
apob-1 showed dose-dependent knockdown reaching ~80% when administered at 2 mg/kg (50 µg) 
and translated in phenotypic responses such as reduction (~ 40%) in serum cholesterol [187]. The 
decreases in apob-1 mRNA and cholesterol remained significant for 10 and 4 days respectively and 
returned to nadir around 15 days. Liver transaminase levels and pro-inflammatory cytokine 
expression (TNF-α and IL-6) transiently increased and returned to baseline less than 48 hours post-
administration. The importance of the targeting moieties and the reversible linkage (maleate 
linkage) was demonstrated to be critical for tissue-specific accumulation and knockdown 
efficiency. Mannose targeting directed DPC uptake to nonparenchymal liver cells expressing the 
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receptor. Shielding with non-hydrolysable linkers abrogated knockdown highlighting the 
importance of unmasking, or polymer reversal from inert-to-membrane lytic states, for optimal 
endosomal release [187]. 
The uncontrolled nature of the polymerization process used in the production of PBAVE led to 
heterogeneity in respect to size and composition; therefore, limiting manufacturing reproducibility 
and entailing the development of sophisticated purification and analytical methods [188]. The 
clinical translation of this potent technology, at least from a control and manufacturing (CMC) and 
regulatory standpoint, required an improved synthesis process. Homogeneous polymers amenable 
to large scale manufacturing were therefore developed using novel chemistries such as atom 
transfer radical polymerization (ATRP) and reversible addition-fragmentation chain transfer 
(RAFT) [11, 188]. In addition, the incorporation of hydrolyzable bonds in both the polymer 
backbone and side chains was used to reduce toxicity upon multiple administration; preventing 
cytoplasmic accumulation of membrane lytic polymers. However, the aforementioned 
improvements did not alleviate the manufacturing complexity associated with the conjugation 
chemistry or product stability [188]. 
Exploiting the natural liver-targeting properties of lipophilic-siRNA conjugates, possibly through 
LDL and HDL incorporation and subsequent shuttling to the liver [175], Wong et al showed that 
PBAVE co-administration improves apob-1 knockdown (~ 500 fold) in mice and non-human 
primates [181]. Consistent with PBAVE blood clearance and liver accumulation kinetics [189], 
separately injected components – i.e. polymer and lipophilic-siRNA – were able to colocalize in 
endosomes and trigger potent knockdown within two hours. This co-administration strategy 
simplifies the manufacturing process – i.e. decreased conjugation steps, increased yield, etc. – and 
permit exploration and use of alternative membrane disrupting agents. Indeed, the original PBAVE 
polymer has been replaced with a reversibly masked mellitin-like peptide (MLP) [190]. The exact 
reasons for the replacement of PBAVE with MLP (EX®1) are not publicly available but could be 
due to manufacturing and/or toxicity problems. The novel MLP based DPC system demonstrated 
potent and safe gene knockdown in mice and NHP [190] and tested in phase II clinical trials for 
the treatment of hepatitis B (HBV) [191] and reductions of liver α-1 antitrypsin [192]. Two clinical 
drug candidates (ARC-520 and 521) contain two cholesterols–siRNAs targeting conserved regions 
of HBV transcripts show potent knockdown in human with mild adverse events reported [193]. 
The tolerability of ARC-520, ARC-521, and ARC-AAT in human clinical trials appears to be 
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favorable; with more than 300 patients generally tolerating the infusions (e.g. 6% infusion reaction 
and 3 serious adverse events (SAE) were reported for ARC-520 [191, 193]. Despite human 
tolerability, Arrowhead Pharmaceuticals decided to discontinue the EX®1-containing programs, 
following the death of an NHP injected at the highest dose, and deploy its resources to develop 
subcutaneously (SubQ) administered GalNAc targeted systems [194]. 
2.3.3.3 GalNAc conjugates 
N-acetylgalactosamine (GalNAc) conjugates are emerging as important components of the 
oligonucleotide liver-targeted delivery toolbox. GalNAc conjugates are rapidly replacing LNPs in 
clinical trials with major companies  (i.e. Alnylam, Arrowhead, Dicerna, Ionis, and Silence) 
shifting toward the GalNAc technology and dropping their LNP or proprietary based pipelines 
products [2, 194]. Increased interest stems from 1) simplistic design (i.e. direct conjugation) versus 
LNP (i.e. multi-component) or DPCs (i.e. complex chemistry), 2) high efficiency to deliver 
oligonucleotides, including siRNAs, to hepatocytes, 3) induce potent target specific knockdown in 
said cells and 4) their facile and straightforward manufacturing process. GalNAc conjugated 
siRNA can be synthesized using solid-state synthesizers and characterized using mass spectrometry 
[195, 196]. 
The trivalent GalNAc system is designed to bind with high avidity to the hepatocyte lectin 
asialoglycoprotein receptor (ASGPr) (Box. 2-1). In this system, GalNAc is attached to the 3’ end 
of the siRNA sense – or passenger – strand using a linker (Figure 2-6). The system for siRNA 
delivery was developed at Alnylam Pharmaceuticals under the leadership of Manoharan [195-197]. 
The potency of the system increased with increased GalNAc valence [195]; with trivalent siRNAs 
demonstrating highest uptake and knockdown in mouse primary hepatocytes. The specificity of the 
GalNAc system to target hepatocytes was demonstrated in the presence of the EGTA Ca2+ chelator 
since Ca2+ is required for GalNAc binding on the carbohydrate recognition domain (CRD) of the 
receptor [198] as well as in ASGPr-/- knockout cells. Metabolic stabilization of the siRNA payload 
was shown to be necessary with the trivalent GalNAc system. Increased phosphorothioate (PS) 
modifications of the antisense (guide strand) backbone, increased in vivo potency (5-fold) 
compared to the lightly PS modified anti-TTR siRNA [195]. 5-vinyl phosphonate (5’-VP) 
modification of a fully PS modified antisense strand increased the siRNA concentration in liver 
and improved potency (5-fold) [182]. This synergistic effect – 5’-VP and PS modification of the 
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GalNAc-siRNA conjugate – is believed to be due to increased phosphatase stability in serum and 
intracellular XRN nucleases [4]. Interestingly, trivalent GalNAc conjugated siRNAs demonstrated 
improved in vivo performance following subcutaneous (SubQ) versus intravenous administration 
[195]. Knockdown efficiency correlated with siRNA concentration in the liver for each route of 
administration. Given that the ASGPr has a recycling half-life around 15-30 minutes, potent 
knockdown could be explained by the interplay between receptor kinetics and the GalNAc 
conjugate circulation (elimination) time. The SubQ route offers a sustained release model since, 
injected conjugates have to diffuse, enter lymphatic and capillary circulation before accessing 
systemic circulation and the ASGP receptor. Preclinical studies in NHPs demonstrated potent 
antithrombin (AT) knockdown following single and repeated SubQ administration. The 
comparison between standard template (STC) and the enhanced (ESC) chemistries showed a 10-
fold improvement in functional gene knockdown in mouse, normalization of thrombin generation 
and the time to nadir return in NHP with no adverse events or immune activation [199]. These data 
demonstrate that the GalNAc system, in combination with stabilized-siRNAs, is an extremely 
potent system, with long lasting effects, that could be used to treat a variety of liver diseases. 
Alnylam Pharmaceuticals advanced several GalNAc programs into clinical trials (Table 2-2). As 
of October 2016, the revusiran program, in Phase III clinical trials, has been terminated due to an 
imbalanced mortality rate in the treatment versus placebo arm [88]. However, the association 
between observed mortality and components of the payload (i.e. siRNA, or the delivery system) or 
other factors still need to be mechanistically understood. The revusiran program used an STC 
modified siRNA and was administered at high doses corresponding to a yearly exposure of 20-25 
g [4]. In contrast, the inclisiran program, an ESC modified siRNA, has moved to a phase II clinical 
trial (NCT 02597127) following positive data [13]. Inclisiran is administered at lower doses than 
revusiran and is not expected to show adverse events in advanced trials. Alnylam continues to 
believe in the GalNAc pipeline with other companies following the path. 
 
Table 2-2 GalNAc based clinical candidates in development. 
Drug Sponsor Chemistry Target Disease Status 
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Revusiran Alnylam STC Transthyretin  
Hereditary ATTR 
amyloidosis 
Retracted  
Fitusiran Alnylam ESC Antithrombin Hemophilia Phase 2 
Inclisiran Alnylam 
ESC 
PCSK9 Hypercholesterolemia Phase 2 
ALN-CC5 Alnylam 
ESC 
Complement protein C5 
Complement-mediated 
diseases 
Phase 1/2 
ALN-AS1 Alnylam 
ESC Aminolevulinic acid 
synthase 
Liver porphyrias. Phase 1 
  
38 
 
Box. 2-1 The hepatic ASGP receptor 
In humans, ASGPr is a trimeric receptor assembled of two distinct subunits (i.e. H1 and H2); 
with the most abundant form consisting of two H1 and one H2 subunit [200]. The receptor is 
highly expressed on hepatocytes (i.e. 0.5-1 million copies per cell) and is responsible for 
asialoglycoprotein clearance through clathrin-mediated endocytosis and subsequent trafficking 
to the lysosomes for elimination [201]. ASGPr has been detected at lower abundance on 
peritoneal macrophages, in testis (including sperm), human intestinal cells and peripheral blood 
monocytes. The extracellular domain of each subunit is composed of a calcium-dependent 
carbohydrate domain (CRD) with three Ca2+ binding sites [202]. High-affinity GalNAc binding 
occurs through cooperative hydrogen and hydrophobic forces between the ligand and amino 
acids in the CDR; the reader is referred to Huang et al for a detailed review on ligand-receptor 
interaction and the importance of geometry for high-affinity binding [200]. Important 
information to retain for the delivery of GalNac conjugated nucleic acids include: 1- Highest 
avidity achieved with higher valence, 2- linker (antenna) and spacer length are important for 
binding, 3- ligand spacing play a major role for improved binding with 20 Å being optimal 
[203], and 4- ASGPr promote clathrin-mediated endocytosis and fast recycling time (~ 15-30 
minutes). The importance of the last point (point 4) will be mentioned in section 2.4.3 of this 
chapter. 
 
 Chitosan for gene delivery 
Chitosan is a linear copolymer composed of glucosamine (D-unit) and N-acetylglucosamine (A-
unit) linked by β(14) glycosidic bonds (Figure 2-7), and derived by partial deacetylation of 
chitin. The latter and its derivative chitosan, are the second most abundant polysaccharides on earth 
after cellulose [204]. 
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Figure 2-7: Chemical structure of chitosan (A and D units represent N-acetyl-D-glucosamine and 
D-glucosamine, respectively). Adapted from [28] Copyright 2017, with Elsevier’s permission. 
 
Chitosan is characterized by its degree of deacetylation (DDA), molecular weight (MW), and 
polydispersity index (PdI) [28]. The DDA correspond to the molar fraction of D units and plays a 
major role in controlling the solubility and biodegradability of the polymer as degradation requires 
a specific pattern of A and D-units. The degree of deacetylation can be accurately measured using 
1H-NMR [205] and is calculated using the following equation: 
𝐷𝐷𝐴 = 𝐷/((𝐷 + 𝐴) )   ×  100 Eq. 2-1 
The MW, expressed as number (M̅n) and/or weight average (M̅w), corresponds to the length of the 
polymer, wherefrom the degree of polymerization (Dp), or the number of monomers, can be 
derived using the following equation: 
𝐷𝑝 =  
𝑀𝑛̅̅ ̅̅  𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛
𝑀𝑤̅̅ ̅̅ ̅ 𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑎𝑡 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐷𝐷𝐴
 Eq. 2-2 
The molecular weight is generally measured using size exclusion chromatography (SEC) coupled 
with single, double or triple detectors [19]. The PdI relates to the actual distribution of chain lengths 
following depolymerization (e.g. chemical or enzymatic) to target molecular weight and is 
calculated using the following equation: 
𝑃𝑑𝐼 =  
𝑀𝑤̅̅ ̅̅ ̅
𝑀𝑛̅̅ ̅̅
 Eq. 2-3 
 
Chitosan is a weak polybase with an intrinsic pKa of approximately 6.5-6.7, therefore, at lower pH 
values, the majority of amine containing D-units become protonated enabling interactions with 
polyanions (Figure 2-8). Electrostatic interaction between chitosan and nucleic acids leads to 
spontaneous formation of nanoparticles of different sizes and shapes [19, 206]. Additional 
properties such as mucoadhesive nature, biocompatibility, biodegradability, low toxicity, and 
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affordable cost of production [19, 207, 208] favored the extensive research and use of chitosan as 
a nucleic acid delivery system for in vitro and in vivo applications.  
  
 
Figure 2-8: Spontaneous assembly of a chitosan-nucleic acid polyelectrolyte complex, or 
nanoparticle through electrostatic interactions. The nucleic acid depicted in this figure is a 
circular supercoiled plasmid DNA with a negatively charged phosphate backbone (blue) and the 
polymer is positively charged (red). The ball of wool or scrambled egg like structure has pKa 
above the pKa of free polymer (pKa ~6.5). Adapted from [209]. Copyright 2017, with American 
Chemical Society permission. 
In the following sections of this chapter, the influence of chitosan molecular parameters (i.e. DDA, 
Mn, mixing ratio) on in vitro and in vivo transfection efficiency will be briefly presented. The effect 
of chitosan parameters on nanoparticle physicochemical properties i.e. size, surface charge, and 
shape will not be discussed unless otherwise stated. The reader is referred to Buschmann et al [19] 
for an excellent review on the subject. 
2.3.4.1 Chitosan for the delivery of plasmid DNA  
The influence of physicochemical parameters on in vitro transfection efficiency of chitosan-pDNA 
nanoparticles was investigated and maximum transgene expression was found to occur for 
particular combinations of DDA and molecular weights [37]. These results suggested that a fine 
equilibrium between payload condensation (avidity) and intracellular de-condensation is essential 
for high transfection efficiency. Isothermal titration calorimetry revealed that an increase in both 
DDA and Mn was accompanied with augmented binding affinities between the polyelectrolytes 
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[210]. Intracellular trafficking and nanoparticle de-complexation kinetics were measured using 
Fӧrster-resonance energy transfer to confirm that nanoparticles with high binding affinity were 
unable to escape the endosome and release their cargo [39]. In Thibault et al, high DDA/low Mn 
chitosan disassembled at the same time as they escaped the endo-lysosomal vesicles around 12-
hours post-transfection [39]. Increasing the Mn, and consequently, the binding affinity resulted in 
nanoparticles inability to disassemble following endosomal escape. In contrast, a decrease in both 
the Mn and/or DDA, thus in binding affinity, was shown to limit cell uptake [39] probably due to 
premature disassembly and reduced cargo protection in the nuclease-rich acidic endosome. In 
agreement with the above said, Kiang et al showed a positive correlation between decreased 
degrees of deacetylation, at a fixed Mn, and transfection efficiency [211]. Given that chitosan 
intrinsic pKa is around 6.5-6.7, a decrease in charge density (deprotonation) occurs at higher pH 
and is expected to decrease the binding affinity between the polyelectrolytes. Several studies have 
shown that optimal gene delivery is obtained between pH 6.5 and 7.0, efficiency quickly declining 
at higher pH due to the payload release [37, 38, 212, 213]. Lavertu et al showed that the increase 
in pH displaces the optimal Mn required for efficient transfection toward higher values (longer 
chains) in order to maintain nanoparticle integrity [37]. The N:P ratio, or chitosan amine-to-nucleic 
acid phosphate molar ratio, represent important parameter influencing nanoparticle 
physicochemical and biological properties [28, 206]. The N:P ratio was found to be important to 
balance nanoparticle stability and affect, along the degree of deacetylation, the net surface charge 
(ζ-potential) [213]. Ceteris paribus, an increase in N:P ratio is required to compensate for a decrease 
in Mn and/or DDA [211, 214]. Asymmetric field-flow fractionation (AF4) revealed that a 
significant fraction of polycations, in chitosan-based systems prepared at N:P above 2, are not 
associated with the nanoparticles [215]. The importance of this fraction in the promotion of 
efficient transfection was demonstrated in rescue experiments [216]. Human embryonic kidney 
cells (HEK-293), were transfected with nanoparticles prepared at N:P 2 and 5, and transgene 
expression occurred only for the N:P 5 formulation or those that were transfected with N:P 2 and 
rescued with free polycations. The role of free chitosan was hypothesized to facilitate endosomal 
swelling and subsequent escape through the proton sponge effect [216]. Low serum concentrations 
(~5-20%) have been shown, despite their negative effect on colloidal stability, to have a beneficial 
effect on in vitro transfection possibly due to increased cell activity or improved free chitosan 
uptake [38, 212]. 
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In vivo, chitosan based nanoparticles were administered, mostly using local routes of 
administration probably due to 1) poor colloidal stability in blood and, 2) adjuvant effect. Intranasal 
administration showed the successful generation of a systemic Th1/Th2 immune response, with 
nanoparticles (~350 nm) able to elicit anti-HBsAg IgG levels above the clinical protective levels 
of 10 mU/mL [217]. Klausner et al showed that intra-corneal injection of ultra pure oligomeric 
chitosan-pDNA nanoparticles led to a 5-fold increase in gene expression compared to PEI [218]. 
Jean et al selected a number of formulations shown to maximize in vitro transfection in Lavertu et 
al, and found that maximum in vivo gene expression can be obtained with low Mn/High DDA 
formulations following intramuscular and subcutaneous administration [219, 220]. In contrast, the 
lower DDA/higher MW formulation (CS 80-80-5) produced high levels of neutralizing antibody 
resulting in very low detection of the recombinant protein [220] suggesting a differential use of 
specific formulations for gene delivery or genetic vaccination. In light of these encouraging results, 
chitosan-plasmid nanoparticles have been increasingly studied for therapeutic gene expression, as 
well as vaccination and the immunogenicity effect of high Mn/Low DDA elucidated [32]. 
2.3.4.2 Chitosan for the delivery of small interfering RNAs  
The structural differences between pDNA and siRNA are believed to affect nanoparticles 
complexation/stability and transfection efficiency. In an attempt to investigate the effect of chitosan 
physicochemical properties, i.e. DDA, Mn and N:P ratio on in vitro knockdown nanoparticles were 
formed, with or without cross-linking agents i.e. tripolyphosphate (TPP), and transfected in 
different cell lines. In vitro knockdown efficiency was found to increase with increasing Mn 
irrespective of the degree of deacetylation [20, 22, 23, 26, 29, 221]. Liu et al showed that low Mn 
chitosan (10kDa) was unable to form stable nanoparticles and mediate efficient transfection [23]. 
However, Malmo et al showed that low molecular weight chitosan (10kDa) were able to transfect 
cells and yield efficient knockdown (~ 80%) when formulated at a similar N:P ratio [20]. Chitosan-
mediated siRNA delivery has shown more efficient gene silencing at DDA above 80% [23]. 
However, the effect of the degree of deacetylation seemed minimal on knockdown [20, 22, 23, 26, 
29, 221]. Therefore, most of the studies involving chitosan-siRNA nanoparticles were conducted 
at an intermediate DDA between 80-85 % [21-23, 25, 29] except for Malmo et al, where a fully 
deacetylated chitosan (DDA ~99%) was used to study the effect of Mn and N:P ratio on knockdown 
efficiency [20]. In contrast to most studies, Ragelle et al showed that chitosan was unable to form 
43 
 
stable particles and mediate efficient in vitro knockdown when formulated at 80% DDA. Improved 
knockdown required the addition of TPP, and was maximized when linear polyethyleneimine was 
incorporated into the nanoparticles to improve endosomal escape [21]. In a remarkable contrast to 
pDNA, almost all these reports, except for Holzerny et al, used very high N:P ratio (>25) into their 
formulations. Such formulations could pose significant practical problems for in vivo delivery such 
as limited dosing, blood incompatibility and non-specific effects due to large quantities of free 
excess chitosan. The effect of pH on transfection efficiency was not studied. However, transfection 
was conducted at pH 7.2 in the presence/absence of serum and showed high knockdown efficiency 
indicating that siRNA nanoparticles are able to knockdown target genes at physiological pH, 
further highlighting differences with pDNA [20, 22, 23, 25, 29]. In sum, several discrepancies, and 
the lack of uniformity in transfection protocols among these studies make overall comparisons 
difficult and renders the results inconclusive in identifying optimal parameters for siRNA delivery. 
Therefore a systematic study of siRNA delivery with accurately characterized chitosans that 
investigates the effect of intrinsic (DDA, Mn and N:P ratio) and extrinsic parameters (serum, pH, 
ionic strength and mixing conditions) on cell uptake, transfection efficiency, toxicity, genotoxicity, 
and hemocompatibility is needed before in vivo evaluation.  
Several studies have demonstrated in vivo efficacy following intranasal [22], intratracheal [24], 
intraperitoneal [44, 222], and intravenous [42] administration. Intranasal administration of chitosan 
formulation 84-114 (DDA- Mn) at N:P 36 achieved 43% silencing efficiency in an EGFP 
transgenic mouse model following repeated administration of 1 mg/kg dose [22]. In this study, 
knockdown was not demonstrated using unbiased stereological methods. However, with a small 
number of animals (N=2) and the variegated nature of the transgenic model [223], careful 
conclusions as to objective knockdown should be considered. The same formulation viz. 84-114 
formulated at N:P 63 was tested in a collagen-induced arthritis model (CIA) [224]. An objective 
reduction of 43% in plasma TNF-α level was observed with a concomitant improvement in the 
arthritic score. This study omitted to test inflammatory responses in all animals and to demonstrate 
in vivo mRNA a reduction. Intraperitoneal administration of chitosan 95-150 at 0.5 mg/kg in a 
unilateral ureteral obstructive model of kidney fibrosis showed an objective decrease in the target 
gene (cyclooxygenase 2, or COX-2) in macrophages. The decrease in COX-2, measured by qPCR 
(gene knockdown) and western blot (functional knockdown), correlated with a decrease in 
prostaglandin 2, pro-inflammatory cytokines, kidney injury molecule (KIM-1) and histological 
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markers. Interestingly, authors showed that peritoneal macrophages internalized the nanoparticles 
and preferentially migrated into the UUO kidney [44]. Gao et al demonstrated that fully 
deacetylated chitosan (DDA 99%), at intermediate Mn (40 kDa) and high N:P ratio of 60 
accumulate in the kidney cortex following intravenous administration through Megalin-mediated 
endocytosis. Target gene knockdown was achieved (~50%) at both the mRNA and protein level 
following three administrations of 1 mg/kg [42]. In contrast, Ghosn et al showed that intravenous 
administration of chitosan and imidazole modified-chitosan accumulates in the liver with 
functional gene knockdown (GAPDH) achieved at doses ≥ 3 mg/kg [225]. 
2.4 Mechanisms of cell entry and endosomal escape of siRNA 
delivery systems  
The polyanionic and relatively large molecular weight (~ 14 kDa) of siRNA limit its diffusion into 
the pharmacological site of action; the cell cytoplasm. Delivery materials, presented above, 
facilitate siRNA translocation into the cytoplasm by means of endocytosis (Box.  2-2). LNPs have 
been demonstrated to enter hepatocytes through LDL receptor and LDL receptor-related protein 1 
(LRP-1) mediated endocytosis [60, 120]. LNPs undergo ApoE lipoprotein coating in the circulation 
and recognition by the LDL and LRP-1 receptors [120]. Gilleron et al found a biphasic 
internalization kinetic, with initial LNP uptake (rapid and inefficient) by clathrin-mediated 
endocytosis (receptor-dependent) followed by further accumulation by means of macropinocytosis 
(receptor-independent). Knockdown of the LDL receptor, LRP-1, and macropinocytosis regulators 
(CTBP1, Rac1, Rabankyrin-5) but not Caveolin-1 and CDC-42 (regulator of the clathrin-
independent pathway) led to a significant decrease (~ 60%) in LNP internalization [60]. LNPs 
accumulate in early endosomes (EE)-late endosome (LE) hybrid vesicular structures. These 
findings were also confirmed by Wittrup et al who showed that payload release occurs 
predominantly at the EE/LE conversion steps instead of release from lysosomes [12]. 
Cationic polymers such as chitosan and polyethyleneimine have been shown to enter cells using 
clathrin-mediated endocytosis. However, several reports also showed that polymeric particles 
composed of either of these polymers showed cell type preferences for specific internalization 
pathways [226]. In contrast to LNPs, polymeric particles are more polydisperse and subject to 
rearrangements (aggregation, disintegration, coating, etc.) in the presence of high ionic strength 
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and protein thus influencing uptake and explain such discrepancies. Lipophilic conjugates have 
been demonstrated to incorporate LDL and HDLs and enter hepatocyte via the LDL and HDL 
receptors [175] and are hypothesized to enter cells via LDL and HDL receptor-mediated 
endocytosis. Cyclodextrin-based polymer decorated with Tf (CDP) use the transferrin receptor 
(TfR) to enter the cells via clathrin-mediated endocytosis. GlaNAc-conjugated DPCs or siRNA 
bind to hepatocyte ASGP receptor and enter the cells using clathrin-mediated endocytosis [2, 201]. 
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Box.  2-2 Endocytosis definition, pathways, and dynamics 
Endocytosis is an umbrella term of a form of 
active transport in which cells internalize 
large macromolecules in an energy 
dependent process [227]. Endocytosis 
pathways can be subdivided into two 
categories viz. receptor-dependent and 
independent pathways. Receptor-dependent 
pathways involve clathrin (CME), caveolae 
and Flotillin mediated endocytosis (CvME), 
and phagocytosis (specific for immune 
cells). The receptor-independent pathway 
includes a form of CME and 
macropinocytosis. Recently, endocytic pathways that do not fall into any of the previously 
mentioned categories have been discovered and are often referred to as clathrin and caveolae-
independent pathways and occur at cholesterol-rich microdomains [228, 229]. Each of these 
pathways presents a set of features, distinct molecular events and involve complex molecular 
interactions which are reviewed in great details elsewhere [228, 229]. Regardless of the delivery 
method, the intracellular trafficking of the siRNA payload and the delivery system begins in the 
early endosome, progress into late endosomal vesicles, that become acidified (pH 5-6) by 
membrane-bound proton-pumps (ATPases), and relocates to the lysosomes. Lysosomes are 
further acidified (pH ~4.5) and contain various nucleases that promote degradation of the 
material and its payload. To avoid lysosomal degradation, the payload must escape at the early 
steps of the process (endosome) into the cytosol (see section 2.4).  
 
The internalization of the siRNA delivery system discussed above leads to sequestration in the 
dynamic endosomal compartments. Escape from these vesicles represents the most important 
barrier affecting the efficacy of the delivery systems and the intended therapeutic effect. The 
mechanisms of escape are still poorly understood and require future efforts to understand the 
mechanics and develop novel materials endowed with optimal escape capabilities.  
Figure 2-9: Different type of endocytosis. Image 
adapted from [227]. Copyright 2017, Dove Press 
with permission. 
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 Mechanism of escape of lipid nanoparticles 
Lipid nanoparticles composed of cationic or ionizable lipids have intrinsic fusogenic properties 
[138, 230] that are also augmented when co-lipids with fusogenic properties are included in the 
formulation [231]. In the endosomes, cationic and ionizable lipids form ion-pairs with endogenous 
anionic lipids in the endosomal membrane and undergo a phase transition where they shift from 
the lamellar structure to the hexagonal H2 structure. This transition in shape promotes lipid 
rearrangement and fusion (Figure 2-10) [140, 232]. Cholesterol, a major component in LNPs (25-
50% mol composition), has been found to play a major role in endosomal release by decreasing 
transition temperature of conical-shaped lipids, therefore aiding the conversion from the lamellar 
to the hexagonal phase [233]. Cholesterol is incorporated in LNPs to increase membrane rigidity, 
stability and cell internalization [10]. 
 
Figure 2-10 Schematic illustration of the uptake pathway and mechanism of endosomal release of 
cationic lipid nanoparticles. The schematic considers a receptor-independent mechanism of 
uptake. The same principle is believed to occur for ionizable lipid nanoparticles following PEG 
hydrolysis and ionization in the acidic environment of the endosome lumen. Adapted [136], 
Copyright 2017, Elsevier with permission.  
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 Mechanism of escape of cationic polymers and cytoplasmic release  
Cationic polymers such as polyethyleneimine, poly-L-lysine, and chitosan are believed to escape 
the endosome through the proton sponge effect [9]. During endosomal maturation, unsaturated 
amino groups on cationic polymers in the acidified environment of the endosome are capable of 
sequestering H+ ions (protons) that are supplied by the v-ATPase. This process keeps the v-ATPase 
channels functioning and leads to the retention of one Cl- ion and one H2O molecule per proton. 
Water entering the endosomes creates organelle swelling and rupture leading to particle deposition 
in the cytoplasm [9, 234]. The exact mechanism that promotes dissociation of self-assembled 
cationic polymers is not fully understood. It was suggested that competition with cytoplasmic 
polyanions (i.e. proteins and nucleic acids) could lead to nanoparticle disassembly and payload 
release [235]. 
 Mechanism of escape of molecular conjugates 
The escape mechanism of the DPC system described in section 2.3.3.2 of this chapter is based on 
the properties of the endosomolytic polymer or protein used (depending on the version used). 
Mellitin (Mel) is a protein with pore forming properties. At low concentrations mellitin bind to 
membrane phospholipids and form amphipathic α-helix oriented structure parallel to the 
membrane, increasing Mel concentration triggers the protein to insert the membrane, forming pores 
[236] from which delivery materials can escape.  
In the absence of escape mechanisms such as fusion, proton sponge, or pore-forming structure, the 
escape of GalNAc-siRNA conjugates remains to be elucidated. The exact mechanism cannot be 
elucidated pending the development of techniques allowing the intracellular tracking of low 
concentration of siRNAs in the endosome [60, 61]. However, Dowdy proposed that such escape 
could be the result of an extremely rare localized membrane destabilization event that occurs in the 
ASGPr recycling endosome [2]. The probability of such event increases with the rapid recycling 
rate of the receptor (~15-30 min) and the millions of siRNAs engaging their receptor consequently 
a number as low as 5000 siRNA could enter the cytoplasm and promote RNAi [61]. 
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 ORGANIZATION OF ARTICLES 
The scientific contribution made through this thesis is presented in this section. Chapter 4 to 7 
represent the core of this thesis and cover the research that was conducted to fulfill the objectives 
in Section 1.3. The results and their interpretation are presented in the form of published and 
submitted articles. The last two chapters of this thesis, or Chapter 8 and 9, represent a general 
discussion (Chapter 8) summarizing the implications of completed work, followed by a conclusion 
and future perspective (Chapter 9).  
In Chapter 4, a simple enzymatic method was developed to overcome a technical challenge 
encountered during the extraction of total RNA following transfection with chitosan-siRNA 
nanoparticles. The developed method permitted the extraction of high-quality RNA for subsequent 
molecular analysis using quantitative real-time PCR. In addition, the developed method was proven 
to be useful to eliminate bias associated with membrane-bound fluorescently labeled nanoparticles 
during flow cytometry analysis of uptake. This work has been published in the International 
Journal of Nanomedicine; 2010, IF 4.3 as a research manuscript entitled Chitosanase-based 
method for RNA isolation from cells transfected with chitosan/siRNA nanocomplexes for 
real-time RT-PCR in gene silencing. 
In Chapter 5, selected formulations were tested for their ability to form nanoparticles with siRNA 
and characterized for their size, ζ-potential, shape, and evaluated in vitro for uptake, toxicity and 
knockdown efficiency in multiple cell lines. These formulations were selected based on a seminal 
paper by Lavertu et al where molecular properties favoring in vitro plasmid DNA delivery were 
identified. The results presented in this article demonstrate, for the first time, nanoparticles 
prepared at low N:P ratio had favorable physicochemical characteristics and promote both efficient 
cell uptake and target gene knockdown in multiple cell lines. These novel findings contrast, most 
published data where high N:P ratio was a prerequisite to form stable particles and promote in vitro 
knockdown. This work has been published in the International Journal of Nanomedicine, 2012; IF 
4.3 as a research manuscript entitled Low molecular weight chitosan nanoparticulate system at 
low N:P ratio for nontoxic polynucleotide delivery. 
 
In Chapter 6, a library of chitosans was produced, accurately characterized and screened to 
investigate molecular properties favoring efficient in vitro and in vivo gene knockdown. In the first 
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part of the study, a full factorial design was used to screen the effect of chitosan molecular 
parameters such as the degree of deacetylation, molecular weight, N:P ratio on nanoparticle 
physicochemical characteristics ( i.e. size, ζ-potential, payload encapsulation efficiency and 
integrity), and in vitro uptake, toxicity, and target knockdown efficiency. Formulations with the 
highest knockdown efficiency and low toxicity were further characterized for the effect of Mn and 
N:P ratio on toxicity, genotoxicity, and the role of increasing serum proteins on knockdown. The 
study demonstrated that maximization of the response variable was positively correlated with an 
increase in the degree of deacetylation, Mn and N:P ratio. The interaction effects were studied but 
not published. In this study, chitosan was demonstrated to perturb reference gene stability 
highlighting the need to conduct microarray studies. In a second part, the influence of chitosan 
molecular weight on hemocompatibility, in vivo biodistribution using ex-vivo imaging and target 
knockdown was investigated. Nanoparticles accumulated in kidney cortices, specifically in 
proximal epithelial tubular cells and induced gene knockdown. This work has been submitted to 
Biomacromolecules; 2017, IF 5.83 as a research article entitled siRNA delivery with chitosan: 
influence of chitosan molecular weight, degree of deacetylation and amine to phosphate ratio 
on in vitro silencing efficiency, hemocompatibility, biodistribution and in vivo efficacy. 
 
In Chapter 7, the toxicity and efficacy of formulations selected in Chapter 6 were thoroughly 
assessed following intravenous administration and compared with cationic lipid nanoparticles 
(Invivofectamine®). First, formulations were characterized for their size, surface charge and 
polydispersity, and dose-dependent hemocompatibility as per ASTM guidelines. 
Hemocompatibility and hemagglutination were demonstrated to be dose and molecular weight 
dependent and could be totally abrogated through hyaluronic acid coating of nanoparticles. These 
findings allowed us to establish maximum dose to be injected for each type of formulation tested 
i.e. uncoated and HA coated. Immune stimulating properties, serological and hematological 
parameters were assessed in single ascending dose toxicity study. In contrast to LNPs, chitosan 
based formulations were safe and did not induce body weight loss upon single or multiple 
injections. In vivo biodistribution comparing uncoated versus HA coated nanoparticle revealed that 
both types of formulations accumulate in the proximal tubular cells of kidney cortices. However, 
potent target gene knockdown was only observed for uncoated nanoparticles. The enzymatic 
activity of GAPDH following knockdown was reduced by 50% further confirmed using multiple 
51 
 
techniques such as western blot and qualitative immunohistochemistry (IHC). In this study, we 
suggested several explanations for PTEC accumulation and poor performance of HA coated 
formulations that warrant further investigations. This work has been submitted to the Journal of 
Controlled Release; 2017, IF 7.44 as a research article entitled: Chitosan siRNA nanoparticles 
produce significant non-toxic functional gene silencing in kidney cortices and is currently 
under review. 
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Abstract 
Chitosan, a well-known natural cationic polysaccharide, has been successfully implemented in 
vitro and in vivo as a non-viral delivery system for both plasmid DNA and siRNA. While using 
chitosan/siRNA polyplexes to knock down specific targets, we have underestimated the effect of 
nucleic acids binding to chitosan when extracting RNA for subsequent quantitative PCR evaluation 
of silencing. In vitro transfection using chitosan/siRNA-based polyplexes reveals a very poor 
recovery of total RNA especially when using low cell numbers in 96 well plates. Here, we describe 
a method that dramatically enhances RNA extraction from chitosan/siRNA treated cells by using 
an enzymatic treatment with a type III chitosanase. We show that chitosanase treatment prior to 
RNA extraction greatly enhances the yield and the integrity of extracted RNA. This method will, 
therefore, eliminate the bias associated with lower RNA yield and integrity when quantifying gene 
silencing of chitosan-based systems using quantitative real-time PCR. 
 
Keywords: Chitosan, Chitosanase, siRNA, DPP-IV gene silencing, RIN, qPCR 
 
4.1 Introduction 
Chitosan is a natural polymer of β (1-4)-glucosamine and N-acetyl-D-glucosamine derived by 
partial deacetylation of chitin from crustacean shells. 1 Chitosan has a pKa of approximately 6.5, 
therefore, at lower pH values, the majority of the glucosamine residues on chitosan is cationic due 
to the protonation of amine groups, which enables the interaction with anionic components such as 
nucleic acids and cell surface macromolecules. Industrially, the process of partial deacetylation of 
chitin is controlled to yield specific chitosan types – entities – characterized by their molecular 
weight (MW) as well as their degree of deacetylation (DDA). These two parameters have a major 
influence on chitosan biological and physicochemical properties. 2, 3 For example, increasing 
chitosan’s DDA results in reduced biodegradability and biological activity given that acetyl groups 
promote its degradation by enzymes.  
Recent studies have demonstrated the ability of chitosan to efficiently deliver a wide variety of 
biologics including proteins, 4-6 plasmid DNA 7-11 and siRNA, 12-14 both in vitro and in vivo. The 
effectiveness of delivery is generally assessed by evaluating the transfection efficiency for plasmid 
54 
 
DNA or gene silencing for siRNA. Quantitative assessment of gene silencing can be performed by 
quantitative real-time PCR analysis of targeted genes. The sensitivity and accuracy of the latter 
method is influenced by many variables including: 1) the quality of tissues/cells, 2) the RNA 
extraction method, 3) RNA integrity, and 4) the reverse transcription and polymerase chain reaction 
used in RT-PCR. 15-18 Despite the development of relative quantification techniques like the Pfaffl 
method 19 and the ΔΔCT method, 20 RNA integrity remains an important issue for generating proper 
data. While using siRNA-chitosan polyplexes to knock down specific targets, we have 
underestimated the effect of nucleic acids binding to chitosan when extracting RNA for subsequent 
quantitative PCR evaluation of silencing. In fact, polysaccharide matrices (ie. agarose and alginate) 
used for tissue engineering have been shown to interfere with techniques required for protein 
analysis and with all the procedures currently used for nucleic acid purification. 9, 21, 22 Moreover, 
our results – described herein– show that chitosan interferes with RNA extraction from low cell 
numbers. Therefore, we specifically examined this issue by delivering chitosan-siRNA 
nanoparticles against dipeptidyl peptidase IV (DPP-IV) mRNA in three different cell lines and 
found that siRNA-chitosan treated cells reveal a very poor recovery of total RNA. The DPP-IV 
gene encodes a serine protease that cleaves His: Ala: Glu sequence at the N-terminal region of the 
incretin hormone glucagon-like peptide 1 (GLP-1). GLP-1 regulates glucose homeostasis 
postprandialy thus decreasing its bioavailability and consequently causing a decrease in glucose 
level. The inhibition of DPP-IV increases GLP-1 bioavailability hence it represents a potential 
therapeutic for type II diabetes. 
Here, we propose a method to overcome low RNA yield from chitosan/siRNA transfected cells 
this technical difficulty by enzymatically treating the cell lysate with Streptomyces griseus type III 
chitosanase in order to release mRNA that was bound to chitosan. In addition, we show that our 
technique is suitable for the removal of membrane-bound chitosan for subsequent analysis by 
FACS of transfected cells.  
  
55 
 
4.2 Materials and Methods  
 Preparation of chitosan/siRNA polyplexes 
siRNA sequences targeting the DPP-IV gene sequence were synthesized by Dharmacon (Thermo 
Scientific, Dharmacon RNAi Technologies, USA) and are available in the On Target Plus® 
catalogue. The siRNA sequence has a dual strand modification pattern to reduce off-target effects 
caused by both strands.  
A 10 kDa MW chitosan with a degree of deacetylation (DDA) of 92% was prepared and 
characterized as described previously 11 and dissolved overnight on a rotary mixer at 0.5% (w/v) 
in hydrochloric acid using a glucosamine: HCl ratio of 1:1. Chitosan solutions were then diluted 
with deionized water to reach the desired amine (deacetylated groups) to phosphate (of the nucleic 
acid) ratio (N/P ratio). Chitosan/siRNA polyplexes were formed at three different N/P ratios of 5, 
10 and 20. Prior to mixing with siRNA, the diluted chitosan solutions were sterile filtered with a 
0.2 µm syringe filter. Chitosan/siRNA nanoparticles were then prepared by adding 100 µl of the 
sterile diluted chitosan solution to 100 µl of siRNA (100nM) and mixed by rapid pipetting. The 
polyplexes were allowed to form during 30 min incubation at room temperature before transfection.  
Polyplexes were measured independently using Dynamic Light Scattering (DLS) and 
environmental scanning electronic microscopy (ESEM) and found that polyplexes have a mean 
diameter of approximately 50 nm.  
 
 Cell culture 
HT-29, HepG2 and Caco-2 cell lines from American Type Cell Culture (ATCC, Manassas, VA) 
were cultured in McCoys media (HT-29) and Dulbecco Minimum Essential Media (HepG2 and 
Caco-2) with 1.85 g/l of sodium bicarbonate and supplemented with 10% FBS (Cedarlane 
Laboratories, Burlington, ON) at 37˚C and 5% CO2. These cell types were chosen since they 
express DPP-IV enzyme and represent models for diabetes research.  For transfection, HT-29, 
HepG2 and Caco-2 cells were plated in 96-well culture plates (Corning, NY, USA) at 25,000 
cells/well using 100 μl/well of complete medium. The cells were transfected the following day at 
~50% confluency. 
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 Transfection with chitosan/siRNA nanoparticle complexes 
Complete transfection media (Dulbecco’s Modified Eagle Medium high glucose, 4-
Morpholineethanesulfonic acid (MES), pH 6.5) was equilibrated overnight in a 5% CO2 37˚C 
incubator.  Prior to transfection, pH adjustment to 6.5 was performed with 1 N sterile HCl (Sigma-
Aldrich, St.Louis, MO). For transfection, medium over cells was aspirated and replenished with 
100 μl transfection medium (DMEM HG, MES, pH 6.5) containing chitosan/siRNA complexes at 
a concentration of 10 pmol or 50 pmol siRNA/well corresponding to concentrations of 100 nM or 
500nM siRNA. Cells were incubated with chitosan/siRNA complexes for 24 hours until analysis. 
All experiments were done in triplicates, with a minimum of three separate experiments to 
demonstrate reproducibility. 
 Transfection with Dharmafect1TM 
Dharmafect1TM/siRNA complexes were prepared with a 1:2 ratio (w/v) of siRNA: Dharmafect1TM 
according to the manufacturer specifications and were used as a positive control.  
Cells were incubated for four hours in presence of Dharmafect 1/siRNA complexes in serum-free 
medium then replenished with complete media (DMEM HG, 10% FBS, pH 7,4) and incubated for 
an additional 20 hours before analysis.  
 Chitosanase treatment of transfected cells and polyplexes degradation 
Cells incubated with chitosan/siRNA polyplexes for 24 hours were treated with chitosanase 
(Sigma-Aldrich, cat # C9830) prior to RNA extraction in order to release anionic mRNA from 
potential binding sites on chitosan. A final concentration of 6.12 mU of chitosanase per μg of 
chitosan in DMEM at pH 6.5 (100 μl) or in RA1 lysis buffer (100 μl) + 2 μl of TCEP (Macherey-
Nagel™) were used. RA1 lysis buffer containing chitosanase was used to assess the enzyme 
activity in presence of guanidium thiocyanate. Chitosanase resuspended in DMEM or in lysis 
buffer was directly applied onto cell monolayer. Cells were then incubated at 37 ˚C for 60 min 
prior to RNA extraction and quantification for gene expression as described below.  
A second set of experiments using chitosan/ DPP-IVODN nanoparticules – with or without 
chitosanase treatment – were analyzed electrophoretically for the presence of chitosan and for 
OligoDeoxyNucleotides (ODN) release. Polyplexes were migrated for 120 min at 100V on a 13 % 
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polyacrylamide gel (BioRad Laboratories, Mississauga, ON) in 1X MES buffer (20 mM MES, 8 
mM sodium acetate, pH 6.5) and stained using coomassie Brillant Blue R250 (BioRad 
Laboratories, Mississauga, ON) for chitosan visualization or ethidium bromide (0.5 µg/ml) for 
ODN visualization. Gel documentation and analysis were done using the bio-vision 3000 system 
and the Vision-Capt software (Vilbert Lourmat, Marne-la-Vallée, France).  
 FACS analysis  
The cellular uptake of 5’6FAM labeled DPP-IVODN was analyzed using a BD Canto flow cytometer 
(Becton Dickinson, San Jose, CA) 24 hours post transfection. To determine the level of DNA 
cellular uptake, cells were transfected with polyplexes formed with 5’6FAM labeled DPP-IVODN 
as described above. Following 24 h incubation with polyplexes, cells were incubated with 
chitosanase for 60 min to dissociate and remove cell surface-associated complexes. For flow 
cytometry analysis, cells were washed twice in PBS, trypsinized and resuspended in ice-cold PBS. 
For each sample, 20,000 events were counted and a dot plot of the forward light scatter against the 
side scatter was used to establish a collection gate to exclude cell debris, dead cells and aggregates 
of cells. The 5’6FAM-positive cells were excited using a 488-nm laser line and detected using a 
530/30-nm band pass filter. To distinguish between autofluorescence and fluorescently labeled 
cells, we ran non-transfected cells as negative controls. The cellular uptake of the polyplexes was 
calculated as the percentage of 5’6FAM-DPP-IVODN labeled cells, and the relative amount of the 
internalized 5’6FAM-DPP-IVODN was estimated from the median fluorescence intensity of the 
5’6FAM-positive population. 
 Confocal imaging 
Polyplexes internalization was studied by confocal imaging. Chitosans were labeled with 
fluorescent rhodamine B isothiocyanate (RITC) (Sigma-Aldrich, St-Louis, MO) and DPP-IVODN 
(21 nucleic acid) were labeled with 6-FAM on their 5’extremities (Integrated DNA Technologies, 
inc). Cells were seeded 24 h prior to transfection in 35 mm glass bottom culture dishes (MatTek, 
Ashland, MA) using 500 μl of complete medium at 40,000 cells/dish. Chitosan/ODN polyplexes 
were incubated with cells at a concentration of 2.5 μg ODN/wells in media containing 10% serum 
at pH 6.5 for 24 h. Colocalisation was assessed qualitatively by the occurrence of yellow pixels 
resulting from the spatial overlap of red (Chitosan pseudocolor) and green pixels (ODN 
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pseudocolor) from 2 separate channels. Prior to imaging, cell membranes were stained for 5 min at 
37°C with 5 ug/ml of Cell Mask™ Deep red (Invitrogen, Carlsbad, CA) in complete media 
followed by two washes with cold PBS solution and resuspension in complete media. Imaging of 
live cells was done with a Zeiss LSM 510 META confocal Axioplan 200 microscope (Carl Zeiss 
AG, Feldbach, Switzerland).  
 RNA extraction and assessment methods (yield, purity and integrity) 
RNA extraction was performed using the RNA XS® extraction kit from Macherey-Nagel (Biolynx, 
Montréal, QC) according to the manufacturer protocol. For comparison purposes, RNA was also 
extracted with RNAqueous® from Ambion (Applied Biosystems, Streetsville, ON) according to 
the manufacturer protocol. Total RNA was quantified and RNA integrity measured using the 
Agilent BioAnalyzer 2100 (Agilent technologies, Mississauga, ON) following the manufacturer’s 
protocol. RNA integrity was evaluated by the ratio of 28S/18S ribosomal RNA (rRNA) 23 and the 
RNA integrity number (RIN). Agilent 2100 BioAnalyzer uses automated microfluidics, capillary 
electrophoresis, and fluorescence to evaluate RNA integrity. The RIN is a related measure of RNA 
quality that is based on a larger portion of the electrophoretic trace. The BioAnalyzer 2100 
automatically computes this parameter, and an ideal non-degraded RNA sample has a RIN of 10. 
 TaqMan® Gene Expression Assays – Endogenous controls 
Gene expression level for endogenous controls was determined using pre-validated Taqman Gene 
Expression Assays (Applied Biosystems, Streetsville, ON) PCR reactions for 384 well plate 
formats were performed using 1.5 µl of cDNA samples (25-50 ng), 5 µl of the Fast Universal qPCR 
MasterMix (Applied Biosystems, Streetsville, ON), 0.5 µl of the TaqMan Gene Expression Assay 
(20X) and 2.5 µl of water in a total volume of 10 µl. The following genes were used as endogenous 
control: TBP (TATA binding protein) and HPRT (hypoxanthine guanine phosphoribosyl 
transferase). 
 Universal Probe Library (UPL) Assays 
Gene expression levels were determined using assays designed with the Universal Probe Library 
from Roche (www.universalprobelibrary.com). This technology utilizes short hydrolysis probes of 
8 or 9 bases. The high melting temperature characteristic of longer probes is retained by using 
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Locked Nucleic Acid (LNA) nucleotide chemistry in these shorter probes. Since probes are only 8 
or 9 bases long, each probe can hybridize to over 7,000 transcripts; thus, a set of only 100 probes 
can enable the quantification of virtually any transcript in a transcriptome. RNA samples were 
reverse transcribed into cDNA using the first strand cDNA transcriptor kit following the 
manufacturer protocol (Roche, Laval, QC). PCR reactions for 384 well plate formats were 
performed using 2 µL of cDNA samples (25 ng), 5 µl of the Fast Universal qPCR MasterMix 
(Applied Biosystems, Streetsville, ON), 2 µM of each primer and 1 µM of a UPL probe # 71 
(Roche, Laval, QC) in a total volume of 10 µL.  
 Detection and analysis 
The ABI PRISM® 7900HT Sequence Detection System (Applied Biosystems) was used to detect 
cDNA amplification level and was programmed with an initial step of 3 minutes at 95˚C, followed 
by 45 cycles of: 5 seconds at 95˚C and 30 seconds at 60˚C. All reactions were run in triplicates and 
the average values of Ct (cycle threshold) were used for quantification. TBP (TATA binding 
protein), HPRT (hypoxanthine guanine phosphoribosyl transferase), were used as endogenous 
controls. 
The relative quantification of target genes was determined using the CT method. Briefly, the 
Ct values of target genes were referenced to an endogenous control gene (CT = Ct target – Ct endoC) 
and compared with a calibrator: CT = Ct Sample - Ct Calibrator. Relative expression (RQ) was 
calculated using the Sequence Detection System (SDS) 2.2.2 software (Applied Biosystems) using 
the formula RQ = 2-CT. 
 Statistical Analysis 
The measurement data were collected and expressed as means values ± standard deviation (SD). 
And were analyzed with the Statistica 9.0 (STATSOFT; Statistica, Tulsa, OK, USA). The 
Statistical significance was determined by one-way ANOVA followed by Newman-keuls post hoc 
test. Differences were considered significant at p<0.05 and highly significant at p<0.01. 
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4.3 Results  
 Cellular Uptake  
Transfection efficiency of Chitosan 92-10-5/DPP-IVODN, Chitosan 92-10-10/ DPP-IVODN and 
Chitosan 92-10-20/ DPP-IVODN complexes in HepG2 cells was evaluated using flow cytometry. 
We found out that polyplexes sedimentation on the cell surface adds a bias to cytometry data when 
calculating the percentage of positive cells or determining fluorescence intensity levels to assess 
the amount of internalized oligonucleotide.  
Our results show that almost 90% ± 2 of HepG2 cells internalized the polyplexes and no significant 
difference between the three N/P ratios was observed (Figure 4-1, a). Following chitosanase 
treatment, approximately a 10% reduction in the positive cell population was observed indicating 
that trypsinization and thorough washing alone did not fully dissociate surface bound polyplexes 
(Figure 4-1, a). Furthermore, confocal imaging shows membrane associated polyplexes following 
thorough washing which supports our FACS data. Although the percentage of 6FAM- DPP-IVODN 
positive cells was similar for the three N/P ratios, the amount of the internalized DPP-IVODN, as 
determined from the fluorescence intensity levels, varied as shown in (Figure 4-1, b).  
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Figure 4-1. FACS analysis of chitosan/DPP-IVODN polyplexes uptake in HepG2 cell line.  
Uptake of 5’-6FAM labeled DPP-IVODN in chitosanase treated and untreated cells 24 hours post 
transfection. a) Transfection efficiency was calculated as the percentage of 5’FAM-D 
 
Moreover, cells incubated with formulations that had higher N/P ratios showed lower amounts of 
internalized DNA. The excessive cellular uptake of polyplexes was further confirmed by confocal 
imaging, as shown in Figure 4.2. Large internalized assemblies of complexes were observed 2 h 
post incubation and an optimal dissociation was observed 24 h post transfection (Figure 4-2). The 
transfection efficiency of each group was evaluated in three independent experiments using flow 
cytometry.  
 
 
Figure 4-2. Confocal imaging of polyplexes uptake. Confocal microscopy images of HepG2 live 
cells 24 h post transfection with chitosan/DPP-IVODN polyplexes (N/P=5). Chitosan 92-10 (DDA, 
MW) was labeled with Rhodamine (red), the DPP-IVODN with 6FAM at the 5’extremity (green) 
and the cell membranes were stained prior to imaging with cell mask (blue). Membrane staining 
was performed to differentiate between internalized and membrane bound polyplexes. 
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 Effect of low molecular weight chitosan on RNA recovery  
The effect of low molecular weight chitosan (DDA=92, MW=10 kDa) at different N/P ratios on 
RNA extraction was assessed using the Bioanalyzer 2100 system (Figure 4-3). These results show 
very poor recovery of total RNA from low number cells transfected with chitosan/siRNA 
polyplexes compared to both DharmaFect®1 treated and non-transfected cells (Figure 4-3). We 
found that the majority of the samples had a recovery level below the detection threshold (10 ng/μl, 
RNA Integrity Number (RIN) >7). Additionally, our results indicated that lower N/P ratios or lower 
amounts of added polyplexes (corresponding to 50 pmol to 10 pmol siRNA per well) did not 
improve total RNA yield. The extraction efficiency with or without chitosanase treatment was 
evaluated in three independent experiments with triplicate in each experiment.  
 
 
Figure 4-3: Effect of Streptomyces griseus chitosanase on yield and integrity of total RNA 
extraction. Total RNA extraction was performed on HepG2 cells transfected with 10 pmol and 50 
pmol of nanoparticles siRNA/chitosan at 3 different N/P ratios indicated by the formulation code 
92-10-5, 92-10-10 or 92-10-20 (DDA, MW, N/P). Chitosanase was resuspended in DMEM pH 
6.5 and directly applied to cells at a final concentration of 6.12mU/μg of chitosan. Total RNA 
was extracted from chitosan transfected cell treated with or without chitosanase. The different 
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extractions were compared to control Dharmafect™ 1 transfected cells and non-transfected (NT) 
cells. (nt) = nucleotide, L= standard ladder, the green band is a lower marker, which allows 
sample alignment and permits comparison for RIN calculation. RIN= RNA integrity number, is 
an algorithm based numbering system that calculate RNA integrity with 10 being the most intact 
and 1 being fully degraded. 
 Effect of lysis buffer on Chitosanase activity 
We assessed both the effect of guanidium thiocyanate, a chaotropic agent, contained in commercial 
RA1 lysis buffer and high DDA (92% and 98% respectively) on S.griseus chitosanase activity. 
First, chitosan polyplexes were digested with S.griseus chitosanase and were compared to non-
digested samples (Figure 4-4).  
4 
Figure 4-4: Polyacrylamide gel electrophoresis of chitosan/DPP-IVODN polyplexes bearing 
different DDAs and N/P ratios, treated with or without Streptomyces griseus chitosanase. a) 
chitosan migration b) ODN migration. Lane 1 to 4 corresponds to chitosan/DPP-IVODN directly 
incubated with chitosanase during 60 minutes at 37ºC. Chitosan digestion allows the ODN 
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release. Lane 5 to 8 corresponds to chitosan/DPP-IVODN incubated at the similar conditions 
without chitosanase. Faster chitosan migration was observed when comparing lanes 5 and 6 due 
to different MW of theses formulations. Increased band intensity (lane 4-8) results from greater 
amounts of chitosan at higher N/P ratios 
 
Our results show that chitosan digestion was not affected at high DDA (98%). Moreover, DPP-
IVODN liberated from chitosanase treated polyplexes showed a quasi-total recovery indicating that 
smaller monomers did not bind nucleic acid. Second, chitosanase activity was assessed in lysis 
buffer. Our results show that S.griseus chitosanase activity is not altered or reduced in lysis buffer 
(Figure 4-5). These results suggest that the chitosanase digestion can be performed directly in the 
lysis buffer decreasing the processing time of the sample (Figure 4-5).  
 
Figure 4-5: Total RNA extraction from HepG2 transfected cells with 10 pmol siRNA. Following 
transfection, cells were treated with chitosanase for: a) 30 min, b) 60 and c) 60 min in lysis 
buffer. 
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 Gene silencing 
The ability of chitosan 92-10-5 formulation to deliver DPP-IV siRNA in three different cell lines 
was assessed using qPCR. Our results revealed an 80% and 78% silencing of the DPP-IV gene in 
HepG2 and Caco-2 cell lines respectively when compared to non-transfected cells. These results 
are similar to the liposome based positive control, Dharmafect 1™ (Table 4-1). Moreover, total 
RNA recovery from low cell number without chitosanase treatment was very low with RIN values 
below the set threshold accounting for the inability to assess gene inhibition using qPCR (Table 
4.1). HT-29 cell line was difficult to transfect using this specific chitosan/siRNA formulation due 
to the absence of cellular uptake as shown by our FACS and confocal microscopy results (data not 
shown). Although HT-29 cell line was difficult to transfect, recovery of total RNA was poor most 
probably due to extracellular excess of chitosan and to membrane bound polyplexes. Cellular 
viability in HepG2, Caco-2 and HT-29 cell lines was maintained after addition of the different 
chitosan formulations used for transfection, dismissing the likelihood of toxicity effects.  Gene 
silencing was evaluated in two independent experiments with triplicate in each experiment. 
 
Table 4-1: Effect of chitosanase treatment on RNA extraction, Relative Integrity Number (RIN) 
and real-time PCR (qPCR) analysis in three different DPP-IV expressing cell lines. Inhibition 
percentages of DPP-IV gene expression in siRNA/polyplexes transfected cells were determined 
in comparison with non-transfected cells: Effect of chitosanase treatment on RNA extraction, 
Relative Integrity Number (RIN) and real-time PCR (qPCR) analysis in three different DPP-IV 
expressing cell lines. Inhibition percentages of DPP-IV gene expression in siRNA/polyplexes 
transfected cells were determined in comparison with non-transfected cells 
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4.4 Discussion  
Current methods and commercial kits for RNA isolation are based on the use of acid guianidium 
thiocyanate buffers for cell lysis and protein denaturation. Depending on the methods used, either 
a phase separation followed by RNA precipitation is performed (TRIzol®) or silica based matrices 
(RNeasy®; RNA XS®) are used to electrostatically bind and recover RNA through washing and 
elution steps. These methods present major drawbacks when large polysaccharide fragments are 
present after sample digestion. These polysaccharide fragments can entrap nucleic acids physically 
thus reducing RNA after centrifugation. 24 Chitosan is a polymeric cation that has been shown to 
prevent the efficient purification of nucleic acids from cell entrapped matrices using available 
procedures and commercial kits. 10, 21 The low efficiency of purification is mainly due to the amine 
groups, which are protonated in acidic environments 25 such as the guanidinium thiocyanate buffer 
used in both Trizol® and silica based kits 26 hence promoting nucleic acid entrapment and/or  
binding. Another explanation to the poor recovery of total RNA when using silica based column is 
the fact that polysaccharide contaminants have been shown to decrease significantly the efficiency 
of spin columns. 26 To resolve these issues associated with chitosan protonation, successful 
attempts have been made to adjust the pH of guanidinium thiocyanate extraction buffers. 27 
However, RNA purity ratio could not be measured adequately due to possible polysaccharide 
contamination. In our study, we showed that chitosan/siRNA transfection of low cell numbers 
resulted in a poor recovery of total RNA for subsequent transcriptomic analysis. The poor recovery 
might be due to the high binding affinity of chitosan to nucleic acids as recently quantified. 
Notably, the majority of the chitosan in these preparations is soluble and not complexed to the 
polynucleotide according to our recent data using Asymetric Field Flow Fractionation.28 The main 
effect of chitosanase treatment may then be to eliminate the free fraction that could clearly bind to 
polyanionic mRNA and inhibit its extraction from chitosan treated cells. This binding effect would 
be further accentuated in the cell lysis buffer containing guanidium thiocyanate which has an acidic 
pH of ~5 and increases ionization of chitosan therefore augments its binding affinity to 
polynucleotides. 
According to their hydrolysis specificity of the β-glycosidic linkages in partially N-acetylated 
chitosan molecules, chitosanase can be classified into 3 classes. Streptomyces griseus chitosanase 
is a type III enzyme that catalyzes both the endohydrolysis of β-(1-4)-linkage between N-
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acetylglucosamine and D-glucosamine (GlcNAc-GlcN) and between D-glucosamine (GlcN-GlcN) 
residues in chitosane. 29 Sato et al found that the relative activity of the enzyme was 80% when 
degrading chitosan with 90% DDA compared to a 100% activity in the presence of chitosan with 
70% DDA. 29, 30 However, despite a lower activity when degrading high DDAs chitosan (>90%), 
Streptomyces griseus chitosanase is a powerful tool for nucleic acid recovery from chitosan 
nanoparticules bearing different DDAs as shown in this study. Our results show a dramatic 
enhancement in RNA yield and integrity when treating cells with S. griseus chitosanase for 60 
minutes prior to extraction. In addition, RNA yields – from transfected cells– are similar to those 
of non-transfected cells, suggesting a total recovery of RNA from chitosan transfected cells. 
Furthermore, our results show that a 30 minutes treatment can be sufficient to improve total RNA 
yield thus reducing sample processing time.  
Although guanidium thiocyanate is a potent chaotropic agent that alters dimensional structures of 
proteins including endonucleases,31 its concentration in RA1 lysis buffer does not seem to alter the 
function of this specific chitosanase. This observation is supported by the fact that some 
chitosanases are resistant to the high concentration of denaturants such as urea or guanidium 
thiocyanate.32-34 The chitosanase treatment of DPP-IVODN/chitosan polyplexes permitted the 
recovery of ~ 90% of the complexes ODN showing that the digestion of the low MW chitosan – 
92-10-5 – into smaller monomers did not interact with ODN release nor with silica based matrices 
for RNA purification. 
This new method has permitted us to obtain enough RNA with high integrity numbers to perform 
subsequent real-time RT-PCR and analysis. Our results revealed an 80% silencing of the DPP-IV 
gene with chitosan/siRNA when compared to non-transfected cells. Furthermore, silencing using 
this specific formulation achieved comparable efficiencies to the positive control Dharmafect™1 
liposome, suggesting the potential use of these chitosan formulations to deliver siRNA both in vitro 
and in vivo. HT-29 cell line was found to be more difficult to transfect with the specific 
chitosan/siRNA formulation, in particular at the cell uptake level as determined by FACS and 
confocal microscopy (data not shown). This observation is supported by the fact that chitosan has 
shown cell type dependency when transfecting DNA plasmid. 35 
The silencing effect was also observed at the protein level where we observed a decrease in DPP-
IV levels of approximately 55%, 48 hours post transfection (data not shown) demonstrating the 
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ability of the specific chitosan formulation to efficiently deliver siRNA against DPP-IV mRNA. 
The FACS analysis of DPP-IVODN positive cells showed approximately 80% transfection 
efficiency following chitosanase treatment. The latter permitted a reduction of ~10% in transfection 
efficiency when compared to the chitosanase untreated cells. The 10% signal bias is possibly due 
to the membrane bound chitosan as supported by confocal imaging. Therefore, this reduction may 
account for biased data hence increasing accuracy of transfection efficiency quantification.  
 
4.5 Conclusion 
In this study, we have demonstrated that i) mRNA is difficult to extract from chitosan/siRNA 
transfected cells for subsequent quantification of gene expression, ii) a relatively simple and 
inexpensive technique based on enzymatic digestion of chitosan permits the extraction and 
recovery of total RNA for subsequent quantification of messenger levels by qPCR, iii) the method 
described is suitable for the removal of membrane bound chitosan for FACS analysis of 
transfection efficiency when using labeled siRNA or ODNs, as a result reducing false positive data. 
Thus, this new method permits the quantification of gene silencing in chitosan delivery systems 
and eliminates any bias associated with chitosan binding to polynucleotides. 
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Abstract 
Chitosan, a natural polymer, is a promising system for the therapeutic delivery of both plasmid 
DNA and synthetic small interfering RNA. Reports attempting to identify the optimal parameters 
of chitosan for synthetic small interfering RNA delivery were inconclusive with high molecular 
weight at high amine-to-phosphate (N:P) ratios apparently required for efficient transfection. Here 
we show, for the first time, that low molecular weight chitosan (LMW-CS) formulations at low 
N:P ratios are suitable for the in vitro delivery of small interfering RNA. LMW-CS nanoparticles 
at low N:P ratios were positively charged (ζ-potential ~20mV) with an average size below 100 nm 
as demonstrated by dynamic light scattering and environmental scanning electron microscopy, 
respectively. Nanoparticles were spherical, a shape promoting decreased cytotoxicity and enhanced 
cellular uptake. Nanoparticle stability was effective for at least 20 hours at N:P ratios above two in 
a slightly acidic pH of 6.5. At a higher basic pH of 8, these nanoparticles were unraveled due to 
chitosan neutralization, exposing their polynucleotide cargo. Cellular uptake ranged from 50% to 
95% in six different cell lines as measured by cytometry. Increasing chitosan molecular weight 
improved nanoparticle stability as well as the ability of nanoparticles to protect the oligonucleotide 
cargo from nucleases at supraphysiological concentrations. The highest knockdown efficiency was 
obtained with the specific formulation 92-10-5 that combines sufficient nuclease protection with 
effective intracellular release. This system attained >70% knockdown of the messenger RNA, 
similar to commercially available lipoplexes, without apparent cytotoxicity. Contrary to previous 
reports, our data demonstrate that LMW-CS at low N:P ratios are efficient and nontoxic 
polynucleotide delivery systems capable of transfecting a plethora of cell lines.  
 
Keywords: siRNA, nonviral delivery system, chitosan, gene silencing, RecQL1, ApoB 
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5.1 Introduction  
RNA interference (RNAi), an evolutionary endogenous gene regulation mechanism based on 
double-stranded RNA (short hairpin RNA, microRNA, Piwi-interacting RNA, and small 
interfering RNA [siRNA]), has provided a potential new class of therapeutics.1 Since its discovery 
in Caenorhabditis elegans,2 RNAi has been proven effective in mammalian cells1,3–11 and has 
reached clinical trials.1,12–14 However, direct delivery of RNAi-inducing entities such as synthetic 
siRNA or short hairpin RNA continues to be problematic owing to their rapid 
extracellular/intracellular degradation by nucleases (i.e. RNAse and DNAse), limited blood 
stability, poor cellular uptake, and nonspecific targeting.15–17 As a consequence, the translation of 
RNAi into a clinical therapeutic reality is still pending resolution of these issues.  
Chemical modification of synthetic siRNAs has provided resistance to nuclease degradation and 
improved blood stability.18–22 For example, selective addition of a phosphorothioate linkage or 
substitution with 2′-O-methyl on the C2 position of specific riboses increases nuclease resistance 
of siRNAs without compromising activity.14,19,20 Nevertheless, some chemical modifications can 
increase cytotoxicity, off-target effects and reduce messenger RNA (mRNA) hybridization.23–27 
Despite progress achieved through chemical modification to increase siRNA half-life, transfection 
efficiency, cellular targeting, and uptake remain as obstacles to effective delivery. Therefore, 
packaging systems which can both protect and transport chemically unmodified/modified siRNA 
to target cells are required. 
Liposomes/Lipoplexes have been extensively used as non-viral vehicles for plasmid and RNAi 
entities and pose toxicity concerns. For example, the repeated administration of lipid-based 
delivery vehicles caused phospholipidosis.28 Intravenous injection of stable nucleic acid-lipid 
particles has successfully targeted the liver to silence the apolipoprotein B (ApoB) gene in mice 
and nonhuman primates.10 However, a significant 20-fold transient elevation in serum 
transaminases (aspartate transaminase, alanine transaminase) indicative of hepatocellular necrosis 
was identified at the effective dose. Liposomal formulations of nucleic acids are known inducers 
of inflammatory cytokines including tumor necrosis factor-alpha, interferon-gamma, and 
interleukin-6 which may be related to liver damage.29 Polyethylene glycol (PEG)ylation of 
liposomes, for the purpose of reducing their toxicity, was also demonstrated to elicit acute 
hypersensitivity after repeated dosing.30–32 Similarly, the highly studied cationic family of 
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polymers such as polyethylenimine demonstrated high gene transfer efficiency but was also 
associated with significant toxicity issues33,34 limiting their broad use in clinical trials. 
Polyethylenimine cytotoxicity was characterized as a two-phase process where the polycation–cell 
interaction induces loss of cell membrane integrity and the induction of programmed cell death. 
Insights into polyethylenimine toxicity highlight the importance of polycation/organelle 
interactions – ie, mitochondria and lysosomes – on the induction of toxicity.35,36 In general, cationic 
polymers display less toxicity associated with cytokine induction – immune activation – compared 
to their cationic lipid counterparts.37 
Chitosan, a family of cationic polymers of β-1-4 N-acetyl-glucosamine and D-glucosamine 
residues, has been extensively studied for the delivery of plasmid DNA (pDNA) and siRNA both 
in vitro and in vivo.3,8,17,38–44 Chitosan properties include mucoadhesivity,45 biocompatibility, 
biodegradability,46 nontoxicity, and low cost of production. Primary amine residues confer a 
polycationic nature to chitosan at pH values below its pKa (~6.5) thus enabling it to condense 
polyanionic compounds such as nucleic acids. Electrostatic interaction between chitosan and 
nucleic acids leads to the spontaneous formation of nanoparticles of different sizes and shapes.47 
The ability of chitosan-based nanoparticles to transfect cells efficiently depends on several 
parameters such as: (1) the degree of deacetylation (DDA), which represents the fraction of 
ionizable monomers; (2) the average molecular weight (Mn), proportional to chain length, and (3) 
the amine-to-phosphate (N:P) charge ratio represented by the amine-(chitosan)-to-phosphate (DNA 
or RNA) ratio used to form nanoparticles. 
We have previously demonstrated that maximization of in vitro transfection efficiency for the 
delivery of pDNA depends on a fine balance between these tunable parameters of chitosan39–41 and 
found maximum transgene expression for DDA:Mn values that run along a diagonal from high 
DDA/low Mn to low DDA/high Mn.
39 We also have demonstrated that specific chitosan 
formulations [DDA, Mn, and N:P ratio] efficiently express transgene in vivo.
38,42  
We also demonstrated that specific formulations are able to trigger an anti-transgene immune 
response;38 therefore, nanoparticles can be designed based on the fine-tuning of chitosan 
parameters for application-specific purposes such as genetic vaccination or gene therapy. 
The structural differences between pDNA and siRNA are believed to affect the 
complexation/stability of nanoparticles and optimal parameters required for effective delivery. 
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Chitosan has also been used for siRNA delivery both in vitro and in vivo.1,8,10,17,44 However, and 
despite attempts to identify optimal physicochemical parameters for siRNA delivery,44 
inconclusive results have been observed in the literature due to experimental discrepancies.8,17 For 
example, it was reported that intermediate DDA (80%) and high Mn (64–170 kDa) chitosan were 
more efficient than low molecular weight chitosan (LMW-CS) (10 kDa) in delivering siRNA.17,44 
However, high molecular weight chitosan are found to be cytotoxic,48–50 thus potentially limiting 
their use in future clinical trials. Additionally, most of the reports evaluating the physicochemical 
parameters of chitosan/siRNA nanoparticles were performed at high N:P ratios (N:P >25).8,17,44 
Such formulations bring significant practical problems including limited dosing due to aggregation 
and the nonspecific effects of large quantities of soluble chitosan.51  
Here, we investigate, for the first time, the ability of specific LMW-CS formulations (92-10-5, 80-
80-10, 80-40-5, and 80-10-10) [DDA, Mn, and N:P ratio] at low N:P ratios to in vitro deliver siRNA 
targeting: (1) the RecQL1 DNA helicase mRNA in the colon adenocarcinoma RecQL1 
overexpressing cell line (LS174T) and (2) ApoB mRNA in the hepatocarcinoma-derived cell line 
(HepG2). The choice of these two targets resides in their relevance to cancer and atherosclerosis, 
respectively.6,7,9,52,53 We also explored the ability of these formulations to transfect multiple cell 
lines such as A549, AsPC1, HEK293, and Raw264.7 without apparent toxicity. In this study, we 
hypothesized that, contrary to previous literature,8,17,43,44 low Mn chitosan (LMW-CS) complexed 
at low N:P ratios represent suitable formulations for siRNA delivery and gene knockdown; similar 
to our observations with pDNA.38–42 Additionally, we hypothesized that low N:P ratios assure 
sufficient protection and efficient delivery of the siRNA cargo. Moreover, we explore the 
physicochemical properties of these specific formulations with the prospect of optimizing 
nanoparticle transfection and silencing efficiencies. Our results demonstrate, for the first time, that 
LMW-CSs at low N:P ratios are effective and nontoxic delivery systems for polynucleotide and 
siRNA delivery for in vitro gene silencing.  
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5.2 Materials and methods 
 Synthesis siRNAs and dsODNs as a structural model of siRNA 
siRNAs targeting the RecQL1 DNA helicase and ApoB mRNAs were synthesized using a novel 
RNA synthesis chemistry, the 5′-silyl-2′-orthoester protecting groups (2′-ACE)54 combined 
with a standard phosphoramitide solid-phase technology by Dharmacon (Thermo Scientific, 
Dharmacon RNAi Technologies, Lafayette, CO). RecQL1 mRNA-specific siRNA (siRNA-
RecQL1) contains the sense sequence of 5′-GUUCAGACCACUUCAGCUUdTdT-3′ and 
antisense 5′-AAGCUGAAGUGGUCUGAACdTdT-3′ whereas ApoB mRNA-specific siRNA 
(siRNA-ApoB) contains the sense sequence of 5′-GUCAUCACACUGAAUACCAAU-3′ and 
antisense 5′-AUUGGUAUUCAGUGUGAUGACAC-3′. Mock siRNA were also used as a 
negative control. Mock siRNA is a non-targeting siRNA (Dharmacon, D-001710-01-05) designed 
to have minimal targeting of known genes in human, mouse, and rat cells. 
Double-stranded oligodeoxynucleotides (dsODNs, 21 bp) encoding the same sequences and 
mimicking siRNA physicochemical properties were used for nanoparticle characterization. The 
double-stranded oligodeoxynucleotide (dsODN) sequences were synthesized using the 
phosphoramidite chemistry (Integrated DNA Technologies Inc, Coralville, IO) and used for size 
and zeta potential determination, nanoparticle stability, and nuclease protection assays. For 
confocal microscopy and flow cytometry analysis, 6-carboxyfluorescein (6FAM) 5′-labeled 
dsODNs were used (Integrated DNA Technologies Inc). The rationale for using dsODN for 
chitosan nanoparticle physicochemical characterization is their siRNA-mimicking properties. 
These mimicking properties are due to similarities at the structural level (double-stranded structure, 
length, and nucleotide overhangs) between siRNA and dsODNs. Additionally, charge densities are 
similar between siRNA and dsODNs due to identical phosphate residue numbers on their backbone. 
The main differences between siRNA and dsODNs lie in the substitution of uracil to thymine (U 
 T) in the dsODN sequences, and in the deoxyribosilation of the dsODN sugar backbone. 
 Preparation and characterization of depolymerized chitosan 
Clinical-grade chitosan at different DDAs was obtained from BioSynthec Inc (Laval, QC, Canada) 
and depolymerized using nitrous acid to achieve specific number-average molecular weight targets 
(Mn) of 80, 40, and 10 kDa. Chitosan number- and weight-average molecular weights (Mn and Mw) 
79 
 
were determined by gel permeation chromatography using a Shimadzu LC-20AD isocratic pump, 
autosampler SIL-20AC HT, oven CTO-20AC coupled with a Dawn HELEOS II multiangle laser 
light scattering detector (Wyatt Technology Co, Santa Barbara, CA), a Viscostar II (Wyatt 
Technology Co), an Optilab rEX interferometric refractometer (Wyatt Technology Co), and two 
Shodex OHpak (SB-806M HQ and SB-805 HQ; Showa Denko America, Inc, New York, NY) 
columns eluted with a pH 4.5 acetic acid (0.15 M)/sodium acetate (0.1 M)/sodium azide (4 mM) 
buffer.55,56 The injection volume was 100 µL, the flow rate 0.8 mL min-1 and the temperature 25°C. 
The dn/dc value was previously calculated for chitosan with a DDA of 92% (for a laser’s 
wavelength of 658 nm) and is equal to 0.208 and 0.201 for chitosan with 80% DDA. The degree 
of deacetylation was determined by 1H NMR according to our previous reports.39,57  
 
 Preparation of chitosan nanoparticles 
Chitosans with specific Mn and DDA (Table 5.1) were dissolved overnight on a rotary mixer at 
0.5% (w/v) in hydrochloric acid using a glucosamine:HCl ratio of 1:1 at a final concentration of 5 
mg/mL. Sterile filtered solutions were then diluted with deionized water to obtain the desired ratio 
(N:P) of amine (chitosan deacetylated groups) to phosphate (dsODNs/siRNA nucleic acids). 
Nanoparticles (92-10-5, 80-10-10, 80-40-5, and 80-80-5) were then prepared by rapid mixing 
(pipetting) of 100 μL of diluted chitosan solution to 100 μL of dsODNs or siRNA at a concentration 
of 0.05 µg/µL or 100 nM. 
Table 5-1: Physicochemical characteristics of bulk chitosans 
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 Nanoparticle size and ζ-potential analysis 
The size of chitosan/dsODN-RecQL1 and chitosan/dsODN-ApoB nanoparticles – intensity 
average diameter – was determined by dynamic light scattering at an angle of 173° at room 
temperature using the Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK). Following 
nanoparticle formation, samples were diluted in 10 mM NaCl at a ratio of 1:10 and measured in 
triplicate. The ζ-potential was measured in triplicate using laser Doppler velocimetry at 25°C on 
the same instrument with the viscosity and dielectric constant of pure water used for calculations.  
 
 High-vacuum scanning electron microscopy (ESEM) 
Chitosan/dsODN-RecQL1 and chitosan/dsODN-ApoB nanoparticles were sprayed on silicon 
wafer substrate then sputter-coated with gold (Agar Manual Sputter Coater; Marivac Inc, Montreal, 
QC, Canada) and imaged using a Quanta 200 FEG Environmental Scanning Electron Microscope 
(FEI Inc, Hillsboro, OR). Observations were performed at 20 kV using the high-vacuum mode. 
The average particle diameter (± standard deviation) was determined using the XT Docu image 
analysis software (FEI Inc).  
 
 Nanoparticle stability assessment by polyacrylamide gel 
electrophoresis 
The stability of chitosan/dsODN nanoparticles at different pHs (6.5 and 8) and for different 
incubation times (0.5, 4, and 24 hours) was assessed using polyacrylamide gel electrophoresis. 
Upon formation, nanoparticles were mixed at a ratio of 1:1 with 2-(N-morpholino)ethanesulfonic 
acid buffer (MES 1X) (20 mM MES, 8 mM sodium acetate, pH 6.5) or Tris-acetate (TAE)-EDTA 
buffer (TAE 1X) (2 M Tris-acetate, 50 mM EDTA, pH 8). The samples were then migrated on a 
13% polyacrylamide gel (BioRad Laboratories, Mississauga, ON, Canada) for 2 hours at 100 mV 
in either MES or TAE buffer. Gels were stained with 0.5 µg/mL ethidium bromide solution 
(BioRad Laboratories) to visualize dsODNs. Gel documentation and image analysis were 
performed using a Bio-Vision 3000 (Vilbert Lourmat, Marne-la-Vallée, France) and the Vision-
Capt software, respectively. 
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 Nuclease protection assay 
The level of protection against nuclease attack offered by chitosan formulations (92-10-5, 80-80-
10, 80-40-5, and 80-80-5) was assessed electrophoretically on a 5% agarose gel. Chitosan/dsODN-
RecQL1 and chitosan/dsODN-ApoB nanoparticles at different [DDA, Mw, and N:P ratios] were 
incubated with 0.5, 1, 2, 5, or 10 units of DNAse I (Sigma-Aldrich, Oakville, ON, Canada) per µg 
of dsODNs in 20 µL of MES-MgCl2 buffer (20 mM MES, 1 mM MgCl2, pH 6.5) for 30 minutes 
at 37°C. The reaction was stopped by adding 2 µL of EDTA (50 mM) (Sigma-Aldrich). To ensure 
proper migration of the nondigested dsODNs, samples were treated with Streptomyces griseus 
type III chitosanase (Sigma-Aldrich) at 10 mU/μL for 1.5 hours at 37°C and stopped by placing 
the samples at –20°C for 15 minutes as previously described.3 Samples were migrated at 90 V 
during 1 hour then stained with 0.5 µg/mL ethidium bromide solution before visualization. 
Captured images were analyzed using Vision-Capt software (v 15.06; Vilber Lourmat, Paris, 
France). Relative amounts of dsODN-RecQL1 or dsODN-ApoB (%) were determined by 
comparison of the integrated signal intensity of nuclease-treated samples versus nontreated 
samples. 
 
 In vitro cell transfection 
5.2.8.1 Cell culture 
All cell lines were purchased from American Type Cell Culture (Manassas, VA). The HepG2 cell 
line was cultured in minimal essential medium (MEM). The HEK293, Raw294.7, and LS174T cell 
lines were cultured in high-glucose Dulbecco’s modified eagle’s media (DMEM-HG). The A549 
and AsPC1 cell lines were cultured in F12-K and Roswell Park Memorial Institute medium media, 
respectively. All cell culture media contained 1.85 g/L of sodium bicarbonate (NaHCO3) and were 
supplemented with 10% fetal bovine serum (Cedarlane Laboratories, Burlington, ON, Canada). All 
cell lines were cultured at 37°C in a 5% CO2 incubator. For transfection, cells were plated in 96-
well or 24-well culture plates (Corning, Lowell, MA) to obtain a ~50% confluence the day of 
transfection using 100 μL/well or 500 µL/well, respectively, of complete culture medium.  
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5.2.8.2 Cell transfection 
For in vitro transfection, DMEM-HG was prepared with 0.976 g/L of MES and 0.84 g/L of 
NaHCO3 at a pH of 6.5. Transfection media containing 10% fetal bovine serum was equilibrated 
overnight at 37°C in a 5% CO2 incubator and the pH was adjusted to 6.5 using sterile HCl (1N) 
prior to transfection. For siRNA transfection performed in a 96-well plate, chitosan/siRNA 
nanoparticles were prepared as described above, 30 minutes before use. A 100 µL siRNA solution 
at a concentration of 0.05 µg/µL was used for siRNA complexation with chitosan at a 1:1 ratio 
(v/v). Following complexation, nanoparticles were incubated in a ghost plate containing the 
transfection media (DMEM-HG + fetal bovine serum) at a final concentration of 1.35 ng/µL; 
equivalent to 10 pmol per well of siRNA. For dsODN transfection performed in a 24-well plate, 
nanoparticles were complexed as described above and incubated at a final concentration of 8.07 
ng/µL, equivalent to 60 pmol per well of dsODNs. Plates containing nanoparticles were 
equilibrated for 10 minutes at 37°C, 5% CO2. Medium over cells was aspirated and replenished 
with either 500 µL (24-well plate) or 100 µL per well (96-well plate) of the transfection medium 
containing dsODN- or siRNA-based nanoparticles. Cells were incubated with chitosan/siRNA or 
chitosan/dsODN nanoparticles until analysis 24 hours post transfection. The commercially 
available liposome, DharmaFECT™ (Dharmacon RNAi Technologies), was used as a positive 
control and both untreated cells and uncomplexed siRNA/dsODN-treated cells were used as 
negative controls. 
 
5.2.8.3 Transfection with DharmaFECT 
DharmaFECT was used as a positive control for transfection efficiency in all tested cell lines. 
DharmaFECT/dsODN (flow cytometry and confocal microscopy) or DharmaFECT/siRNA (qPCR 
and viability assay) lipoplexes (1:2 [w/v] ratio) were prepared following the manufacturer’s 
protocol.  
 
 In vitro cell viability assay 
Nanoparticle toxicity was evaluated using the alamarBlue® proliferation assay (Invitrogen, 
Carlsbad, CA). The principle of the assay is based on the natural reducing power of viable cells to 
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convert resazurin, a blue and nonfluorescent compound, into resofurin; a red and fluorescent 
molecule. Viable cells continuously convert resazurin to resofurin, thereby providing a quantitative 
measure of viability. Transfection was performed as described above using chitosan-siRNA 
nanoparticles. Five thousand cells/well were seeded 24 hours before transfection. To alleviate the 
experimental bias from the effect of RecQL1 gene silencing on cell viability, nontargeting siRNA 
(siRNA mock) was used instead. Twenty-four hours post transfection with chitosan-based 
nanoparticles, 20 µL of alamarBlue reagent, pre-warmed at 37oC was added to each well and 
incubated for another 4 hours. At the end of the incubation 100 µL of media containing reduced 
alamarBlue dye was transferred to a black Corning 96-well plate and read on an infinite 200 
fluorescence plate reader (Tecan Systems, San Jose, CA) with excitation 560 nm, emission 590 nm 
and a cut-off of 570 nm. Cells without the addition of alamarBlue were used as blank and dimethyl 
sulfoxide was used as a positive control of toxicity. The viability of nontransfected control cells 
was arbitrarily defined as 100%. The relative cell viability was calculated using the following 
formula: (fluorescence intensitysample/fluorescence intensitycontrol) × 100. 
 
 Uptake analysis by flow cytometry and confocal microscopy 
5.2.10.1 Fluorescence-activated cell sorting (FACS) analysis 
The cellular uptake of dsODNs was determined by transfecting AsPC1, A549, LS174T, HepG2, 
HEK293, and Raw264.7 cell lines with nanoparticles formed with (6FAM) 5′labeled dsODNs. 
Twenty-four hours post-transfection, cells were chitosanase treated for 60 minutes to eliminate any 
cell surface-associated nanoparticles left from the transfection as described previously.3 Afterward, 
cells were washed twice with phosphate-buffered saline, trypsinized, and resuspended in 
phosphate-buffered saline. The analysis of cell uptake was made using a BD Canto flow cytometer 
(Becton Dickinson, San Jose, CA). For each sample, 20,000 events were counted and to exclude 
cell debris, dead cells, and aggregated cells, a collection gate was established using a dot plot of 
the forward light scatter against the side scatter. Nontransfected cells were used as negative controls 
to discriminate (6FAM) positive cells from auto-fluorescence. 
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5.2.10.2 Confocal microscopy 
For nanoparticle internalization analysis, the LS174T, HepG2, HEK293, and Raw264.7 cell lines 
were seeded on 35 mm glass-bottom culture dishes (MatTek, Ashland, MA) at 40,000 cells/dish 
using 500 μL of complete culture medium. Nanoparticles were formed with fluorescent rhodamine 
B isothiocyanate-labeled chitosan and dsODNs labeled with 6FAM on their 5′ extremities 
(Integrated DNA Technologies). Prior to imaging, cell membranes were stained with 5 μg/mL of 
Cell MaskTM Deep Red (Invitrogen, Burlington, ON, Canada). Images were taken in multitrack 
mode using a Zeiss LSM 510 META confocal Axioplan 200 microscope (Carl Zeiss AG, Feldbach, 
Switzerland). Chitosan and dsODNs were visualized as red and green pseudocolors, respectively. 
The spatial overlap of these two colors produced yellow which permitted a qualitative assessment 
of colocalization. 
 
 Quantitative PCR (qPCR) analysis of RecQL1 and ApoB mRNA 
knockdown  
5.2.11.1 RNA extraction and assessment methods (yield, purity, and integrity) 
RNA extraction was performed using the RNA XS® extraction kit from Macherey-Nagel (Biolynx, 
Montréal, QC, Canada) according to the manufacturer’s protocol following chitosanase treatment, 
as described previously.3 Total RNA was quantified and RNA integrity was measured using the 
Agilent BioAnalyzer 2100 (Agilent Technologies, Mississauga, ON, Canada) following the 
manufacturer’s protocol. RNA integrity was evaluated by the ratio of 28S/18S ribosomal RNA58 
and the RNA integrity number (RIN). The Agilent 2100 BioAnalyzer uses automated 
microfluidics, capillary electrophoresis, and fluorescence to evaluate RNA integrity. The RIN is a 
relative measure of RNA quality that is based largely on electrophoretic trace analysis. The 
BioAnalyzer 2100 automatically computes RIN, where an ideal nondegraded RNA sample has RIN 
= 10. 
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5.2.11.2 Reverse transcription 
Total RNA was reverse transcribed in a final volume of 20 μL using the First Strand cDNA 
Transcriptor Kit (Roche Diagnostics, Laval, QC, Canada) with oligodT primers as described by 
the manufacturer’s protocol. Samples were stored at –20°C.  
 
5.2.11.3 Gene expression assays  
The RecQL1 and ApoB mRNA expression level was determined using assays designed with the 
Universal Probe Library (UPL) from Roche (Roche Applied Science, Laval, QC, Canada). 
Endogenous control (hypoxanthine guanine phosphoribosyl transferase) and glyceraldehyde 3-
phosphate dehydrogenase expression levels were determined using pre-validated TaqMan® Gene 
Expression Assays (Applied Biosystems, Carlsbad, CA). RecQL1 and ApoB mRNA (target 
detection) reactions for 384-well plate formats were performed using 1.5 µL of cDNA samples 
(25–50 ng), 5 µL of the Fast Universal qPCR MasterMix (Applied Biosystems) 2 µM of each 
primer, and 1 µM of a Universal Probe Library probe (RecQL1 [probe #29]/ApoB [probe #55]) in 
a total volume of 10 µL. For endogenous control assessment, reactions were performed using 
identical volume of cDNA, Fast Universal qPCR Master Mix, 0.5 µL of the TaqMan Gene 
Expression Assay (20X) and 2.5 µL of water in a total volume of 10 µL. 
 
5.2.11.4 Detection and analysis 
The ABI PRISM® 7900HT Sequence Detection System (Applied Biosystems) was used to detect 
the amplification level and was programmed with an initial step of 3 minutes at 95°C, followed by 
45 cycles of 5 seconds at 95°C and 30 seconds at 60°C. All reactions were run in triplicate and the 
average values of Cts (threshold cycle) were used for quantification. Glyceraldehyde 3-phosphate 
dehydrogenase and hypoxanthine guanine phosphoribosyl transferase were used as endogenous 
controls. The relative quantification of target genes was determined using the CT method. 
Briefly, the Ct values of target genes were normalized to an endogenous control gene (endogenous 
control) (CT = Cttarget – CtendoC) and compared with a calibrator: CT = Cttarget – 
Ctcalibrator. Relative expression (RQ) was calculated using the Sequence Detection System 2.2.2 
software using the RQ = 2-CT formula. 
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 Statistical analysis 
The statistical analysis was performed using Statistica 9.0 Software (STATSOFT; Statistica, Tulsa, 
OK). Data are expressed as mean ± standard deviation. Statistical significance was determined with 
one-way analysis of variance, followed by Tukey’s post hoc test. The results were considered 
significant and highly significant (P < 0.05 and P < 0.01, respectively). 
5.3 Results  
 Size and ζ-potential of chitosan nanoparticles  
All formulations of chitosan/dsODN nanoparticles were in the range of 41–109 nm as measured 
by environmental scanning electron microscopy (ESEM) and dynamic light scattering (Figure 5.1 
and Table 5.2).  
 
Figure 5-1: Environmental scanning electron microscopy images of spherical chitosan/dsODN 
nanoparticles. (A) 92-10-5 chitosan/dsODN-RecQL1 nanoparticles; (B) 80-40-5 
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chitosan/dsODN-RecQL1 nanoparticles; (C) 80-10-10 chitosan/dsODN-RecQL1 nanoparticles; 
(D) 92-10-5 chitosan/dsODN-ApoB nanoparticles; (E) 80-80-5 chitosan/dsODN-ApoB 
nanoparticles, and (F) 80-10-10 chitosan/dsODN-ApoB nanoparticles. 
Abbreviation: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide 
 
Chitosan/dsODN nanoparticles showed higher size values with increasing Mn. No statistically 
significant differences were observed when comparing DDAs for these specific formulations. The 
excess chitosan in all formulations resulted in positively charged nanoparticles as shown by ζ-
potential measurements (Table 5-2).  
Table 5-2: Size and zeta potential values obtained by dynamic light scattering for 
chitosan/dsODN-RecQL1 and chitosan/dsODN-ApoB nanoparticles 
 
 
 Chitosan/dsODN nanoparticle stability 
Chitosan-based nanoparticles were incubated for 0.5, 4, and 20 hours in two different buffers (pH 
6.5 and 8) to assess the effect of time and pH on nanoparticle stability (Figure 5-2). Nanoparticles 
were stable up to 20 hours at an N:P ratio above 2 in slightly acidic buffers (pH 6.5). At 4 hours 
following nanoparticle formation, and under slightly acidic conditions, no detectable dsODNs were 
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observed at N:P ratios of 2 or higher (Figure 5-2 A and 5-2 C). On the contrary, dsODN release 
was observed for the same N:P ratios at a pH of 8 (Figure 5-2 B and 5-2 D). Longer exposure time 
– 20 hours – at a pH of 6.5 resulted in increased dsODN-ApoB release at an N:P ratio of 2. This 
pattern was not observed for the dsODN-RecQL1 sequence. This may be due to sequence/structural 
differences between the two dsODNs. Furthermore, our results at a pH of 8 show a rapid partial-
to-complete dsODN release after 0.5 hour at an N:P ratio of 2 (Figure 5-2 B and 5.2D). At N:P 
ratio 10 and for the same pH of 8, chitosan showed a partial release of dsODNs indicating the effect 
of excess chitosan on preserving stability. Overall, our specific chitosan formulations assured 
nanoparticle stability for a minimum period of 20 hours at an N:P ratio above 2 in slightly acidic 
near-neutral pH environments.  
 
Figure 5-2: Chitosan nanoparticle temporal stability. Stability was assessed at 0.5, 4, and 24 
hours after complex formation using polyacrylamide gel electrophoresis at a pH of 6.5 (MES 1X) 
and pH8 (TAE 1X). Chitosan 92-10 at different N:P ratios (0.5, 2, and 10) was complexed with 
(A) dsODN-RecQL1 at pH of 6.5; (B) dsODN-RecQL1 at a pH of 8; (C) ds-ODN-ApoB at a pH 
of 6.5, and (D) ds-ODN-ApoB at a pH of 8. Unstable nanoparticles release dsODNs which 
become visible following EtBr staining on polyacrylamide gel following eethidium bromide 
staining of the polyacrylamid gel. 
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide; N:P, 
amine to phosphate. 
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 Nanoparticle protection assay  
For effective gene expression and/or inhibition, nucleic acids entrapped in the delivery vehicle 
must be protected from degradation by enzymes such as serum nucleases.59 The ability of chitosan-
based nanoparticles to protect siRNA mimicking dsODN sequences was assessed using a DNAse 
I protection assay against different chitosan formulations complexed with dsODN-RecQL1 or 
dsODN-ApoB. Upon incubation with DNAse I, naked dsODN-RecQL1 and dsODN-ApoB 
(controls) were completely degraded (Figure 5-3 A–D, lane 3). In contrast, DNAse I protection 
assay showed that all chitosans tested protected dsODNs from degradation at DNAse I 
concentrations <2 units DNAse I per µg dsODN (Figure 5-3). Chitosan formulations demonstrated 
an average of ~80% protection of dsODNs at DNAse I concentrations of 0.5 U/µg (Figure 5-3). 
The ability of LMW-CS (92-10, 80-40, 80-80, and 80-10) to protect dsODNs from nuclease 
degradation decreased with increased concentrations of DNAse I. Our results show that protection 
decreased from ~50% at a DNAse I concentration of 1 U/µg to less than ~20% at 2 U/µg (92-10 
and 80-10). Moreover, our results suggest that higher Mn chitosan (80-40 and 80-80) offers a 
slightly better protection of dsODNs as compared to lower Mn chitosan (92-10 and 80-10) at high 
DNAse I concentrations (2 U/µg) (Figure 5-3 A–D). The enhanced cargo protection observed with 
higher molecular weight chitosans is consistent with previous studies where higher binding 
affinities between high Mw chitosans and nucleic acids was demonstrated.60 Altogether, our results 
show that DNAse I protection is considerable when using intermediate to low DDA/Mn and 
preserves approximately 60% of nucleic acid when using 1 unit of DNAse I per µg of dsODNs.  
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Figure 5-3: Nuclease protection assays of chitosan/dsODN nanocomplexes. (A) Chitosan (92-10-
5, 80-40-5 or 80-10-10) complexed with dsODN-RecQL1. (B) dsODN-RecQL1 remaining after 
the DNAse I digestion was assessed using the signal intensity of the treated samples with the 
control (ie, 0 U DNAse I = 100% intensity). This comparison was made between the samples of 
the same chitosan formulation. (C) Chitosan (92-10-5, 80-80-5 or 80-10-10) complexed with 
dsODN-ApoB. (D) dsODN-ApoB remaining after the DNAse I digestion was similarly assessed 
as in (B). 
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide. 
 In vitro cell uptake analysis by flow cytometry and confocal 
microscopy  
Nanoparticle internalization into cells can be another rate-limiting step for effective drug delivery 
systems. In general, efficient nanoparticle internalization depends on several factors, such as the 
cell type, the physicochemical surface properties of the nanoparticles, and the bio–nano interface.61 
The internalization of RecQL1- and ApoB-bearing nanoparticles was assessed in two different sets 
91 
 
of relevant cell lines using flow cytometry (FACS). For the assessment of (6FAM) 5′-labeled 
RecQL1dsODN uptake, transfection and FACS analysis were performed on AsPC1, A549, and 
LS174T cancer cell lines whereas (6FAM) 5′ labeled ApoB dsODN uptake was performed on 
HEK293, HepG2, and Raw269.7 cell lines. Our FACS results show that cell uptake using 
chitosan/(6FAM) 5′-labeled dsODN nanoparticles achieved levels comparable to the commercially 
used lipoplex (DharmaFECT) (Figure 5-4 and 5-5), demonstrating the internalization efficiency of 
LMW-CS formulations in different cell lines. Moreover, our results indicate that different chitosan 
formulations show statistically significant differences in their cell uptake efficiency, with LMW-
CSs 92-10-5 and 80-10-10 more easily internalized compared to the higher molecular weight 80-
80-5 and 80-40-5, in a cell-line-dependent manner. Interestingly, the A549 and HEK293 cell lines 
demonstrated no statistical differences in uptake efficiency between the different chitosan 
formulations (Figure 5-4 and 5.5A).  
 
Figure 5-4. Polyacrylamide gel electrophoresis of chitosan/DPP-IVODN polyplexes bearing 
different DDAs and N/P ratios, treated with or without Streptomyces griseus chitosanase. a) 
chitosan migration b) ODN migration. Lane 1 to 4 corresponds to chitosan/DPP-IVODN directly 
incubated with chitosanase during 60 minutes at 37ºC. Chitosan digestion allows the ODN 
release. Lane 5 to 8 corresponds to chitosan/DPP-IVODN incubated at the similar conditions 
92 
 
without chitosanase. Faster chitosan migration was observed when comparing lanes 5 and 6 due 
to different MW of theses formulations. Increased band intensity (lane 4-8) results from greater 
amounts of chitosan at higher N/P ratios 
 
However, the A549 and HEK293 cell lines showed statistically significant increases in uptake 
when compared to the LS174T and Raw264.7 cell lines, again highlighting some important cell-
type dependencies. In general, LMW-CS (92-10-5 and 80-10-10) showed higher uptake efficiency, 
ranging from approximately 65% to 95% depending on the transfected cell line (Figure 5-4 and 5-
5A).  
 
Figure 5-5: Cellular uptake of dsODN-ApoB nanoparticles 24 hours post transfection in 
HEK293, Raw269.7, and HepG2 cell lines. Chitosan formulations 92-10-5, 80-80-5, and 80-10-
10 were complexed to (6FAM) 5′ labeled dsODN-ApoB and transfected at 60 pmol/well 24 hours 
prior to fluorescence-activated cell sorting analysis. (A) Uptake efficiency of ApoB dsODN in 
percentage (%). (B) Uptake efficiency of ApoB dsODN in HepG2 cells at different passage 
number. DharmaFECT was used as the positive uptake control. 
Notes: Values are mean ± SD; n = 3; *P >0.05; **P > 0.01. 
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Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide; SD, 
standard deviation. 
 
These results are in accordance with confocal microscopy data, where images representative of the 
whole population show that the vast majority of cells for each of the four cell types imaged show 
nanoparticle internalization (Figure 5-6). The lack of colocalization at 24 hours between dsODNs 
and chitosan indicates that complete release of the dsODN cargo was achieved 24 hours post 
transfection. Furthermore, the diffuse staining pattern of dsODNs seen in most transfected cells 
suggests that complexes have escaped endocytic vesicles (Figure 5-6), consistent with previous 
live cell imaging work using chitosan–plasmid DNA nanoparticles.41 
 
Figure 5-6: Confocal imaging of chitosan/dsODN nanocomplex uptake 24 hours post 
transfection. Chitosan 92-10 (DDA, Mn) was labeled with rhodamine (red) and dsODNs were 5′ 
labeled with (6FAM) (green). Chitosan 92-10 was complexed to dsODNs at an N:P ratio of 5. 
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Cell membranes were stained prior to imaging with CellMask™ (blue) to differentiate between 
internalized and membrane-bound nanoparticles. Images shown represent each separate channel, 
with dsODNs in green, chitosan in red, membrane in blue, differential interference contrast image 
in grey, and the merged images shown on the bottom left quadrant. (A) LS174T cells transfected 
with chitosan/ dsODN-RecQL1 nanoparticles. (B) HepG2 cells transfected with chitosan/dsODN-
ApoB nanoparticles. (C) HEK293 cells transfected with chitosan/dsODN-ApoB nanoparticles. 
(D) Raw 294.7 cells transfected with chitosan/dsODN-ApoB nanoparticles. 
Abbreviations: ApoB, apolipoprotein B; dsODN, double-stranded oligodeoxynucleotide; N:P, 
amine to phosphate. 
 
 Specific gene silencing and cell cytotoxicity evaluation of chitosan 
nanoparticles in different cell lines 
Gene silencing occurs when complementarity is achieved between the siRNA seed region and 
target mRNA.1 Chitosan-specific formulations (92-10-5, 80-40-5, 80-10-10, and 80-80-5) were 
assessed for mRNA knockdown in two different cell lines relevant to cancer and atherosclerosis, 
targeted by RecQL1 and ApoB siRNA, respectively. qPCR analysis revealed inhibition of RecQL1 
and ApoB since their coding mRNAs were downregulated more than twofold (Figure 5-7). More 
specifically, in LS174T cells, chitosan 92-10-5 showed a high level of silencing (~80%) of 
RecQL1, similar to the current commercial gold standard liposomal formulation (~80%), used here 
as a positive control. Formulations 80-40-5 and 80-10-10 also induced significant silencing but to 
a lower degree than 92-10-5 and also with an increase of non-specific mock silencing, especially 
for formulation 80-10-10, for reasons that remain to be elucidated.  
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Figure 5-7: Real-time polymerase chain reaction analysis of the inhibition of RecQL1 and ApoB 
gene expression in specific cell lines. LS174T cells were transfected with chitosan (92-10-5, 80-
40-5, and 80-10-10)/siRNA-RecQL1 nanoparticles, whereas HepG2 cells were transfected with 
chitosan (92-10-5)/siRNA-ApoB nanoparticles. The inhibition percentage was obtained by 
comparing the transfected and nontransfected cells, using the ΔΔCT method. 
Notes: Values are mean ± SD; n = 3; *P > 0.05; **P > 0.01. 
Abbreviations: ApoB, apolipoprotein B; siRNA, small interfering RNA; SD, standard deviation. 
 
For the HepG2 cell line, only the best performing 92-10-5 was tested and induced significant 
silencing (~55% versus ~80% for positive control) of ApoB but slightly lower than RecQL1 for 
LS174T. Importantly, our results showed that silencing efficiency with chitosan reached similar 
levels to the positive control, with a markedly reduced cytotoxicity from the delivery system as 
assessed using the alamarBlue assay (Figure 5-8).  
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Figure 5-8: Cell viability assessment using the alamarBlue® assay 24 hours post transfection with 
different chitosan/siRNA formulations. To alleviate the apoptotic effect of RecQL1 gene 
silencing for a proper assessment of chitosan-siRNA toxicity, mock siRNA was used for 
transfection in the LS174T cell line. The HepG2 cell line was transfected with ApoB siRNA. 
DharmaFECT was used for comparison purposes whereas dimethyl sulfoxide was used as a 
positive control of toxicity. 
Notes: Values are presented as mean ± SD; n = 3. 
Abbreviations: ApoB, apolipoprotein B; siRNA, small interfering RNA. 
 
5.4 Discussion 
In this study, we evaluated the efficiency of specific low molecular weight chitosan (LMW-CS) 
formulations at low N:P ratios for the in vitro delivery of siRNA targeting either RecQL1 or ApoB 
genes. RecQL1 is a DNA helicase playing a major role in homologous recombination, maintenance 
of genomic stability, and DNA repair at damaged replication forks.53,62 Overexpression of RecQL1 
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has been implicated in cancer by preventing cell apoptosis.6,7,63 As for ApoB, it is a major gene 
involved in atherosclerosis through its essential role in the formation of very low density 
lipoprotein which will therefore generate low density lipoproteins following triacylglycerol 
hydrolyzation in the circulation.52,64,65  
Nanoparticle size is one parameter affecting uptake and intracellular trafficking, both considered 
as potential rate-limiting steps for effective gene therapy.42,43 For instance, nano-sized particles 
have been shown to be internalized more efficiently than micro-sized particles.66–68 In this study, 
LMW-CS-based nanoparticles ranged in size from 41–110 nm, a size range promoting uptake, 
prolonged blood circulation, higher tissue penetration, and a relatively free passage from the 
mononuclear phagocyte system.47,69–71 Therefore, our results show that these specific LMW-CS 
nanoparticles at low N:P ratios meet performance criteria (Table 5-3) and are potentially relevant 
for in vivo administration.  
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Table 5-3: Safety and performance criteria for the development of effective nonviral gene 
delivery systems 
 
 
The different chitosan parameters – DDA, Mn, and N:P ratios – used in this study did not 
significantly affect nanoparticle size, with higher molecular weight chitosan promoting a slightly 
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increased size (Table 5-2). Our results are in contrast to previously published reports where the 
authors found increased nanoparticle size for lower molecular weight chitosan.44 This discrepancy 
may be due to differences in experimental conditions and to the high N:P ratio used in Liu et al and 
Howard et al reports8,44 versus low N:P ratios reported in our study. ESEM analysis revealed that 
these small nanoparticles were of spherical shape consistent with previous findings for pDNA,38 
siRNA,8 and dsODNs.72 The effect of nanoparticle shape on internalization efficiency showed 
spherical particles of similar size being internalized 500% more efficiently than rod-shaped 
particles.73–75 This is mainly explained by increased membrane-wrapping time required for 
elongated particles and greater thermodynamic forces required for their engulfment.61,75 It was 
previously demonstrated that the morphology of chitosan-pDNA nanoparticles is strongly 
dependent upon their charge ratios, and the variation of the latter resulted in nanoparticles with 
different topological conformations including spherical,76 toroidal,77,78 and globular 
morphologies.77,79 Chitosan-based nanoparticle shape may also seem to be affected by the type of 
nucleic acid – pDNA or siRNA/dsODN – used for complexation and the process of nanoparticle 
formation; ie, ionic gelation. The fact that these LMW-CS nanoparticles demonstrated a 
reproducible pattern of spherical particles at low N:P ratios may be indicative of higher 
internalization efficiency than nanoparticles of different topological conformations. 
Nanoparticle stability and nucleic acid protection are important parameters for efficient nucleic 
acid delivery. Our results of nuclease protection indicate that all LMW-CS formulations tested 
were able to protect dsODNs at supraphysiological concentrations of nucleases. Nuclease 
protection is of great importance for nucleic acid delivery systems through maintenance of cargo 
bioavailability and improved pharmacokinetic profile, thereby increasing the therapeutic potential 
of these nanoparticles. Increasing chitosan molecular weight resulted in an enhanced cargo 
protection (Figure 5-3) in agreement with previous findings.17,39,43,44,47 Nevertheless, enhancing the 
ability of nanoparticles to protect their siRNA from degradation may render their intracellular 
disassembly more difficult, as demonstrated with high molecular weight chitosan-pDNA 
nanoparticles.41 Further characterization of nanoparticle stability by gel retardation assays show 
that low Mn chitosan used at low N:P ratios can effectively complex and compact dsODNs into 
stable particles. We found LMW-CS nanoparticles at N:P ratios above 2 to be stable in slightly 
acidic buffers for at least 20 hours. These interesting findings are in contrast with most previous 
studies using chitosan-siRNA nanoparticles, where high Mn and high N:P ratios are usually 
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required to achieve particle stability.8,17,43,44,80 This discrepancy can be explained by the lower pH 
(pH 6.5) of the electrophoresis buffer in our study compared to the commonly used TAE buffer at 
a pH of 8 for chitosan-based nanoparticle characterization,8,17,43,44,81 a difference that was clearly 
highlighted by our gel retardation assay performed at both pHs (Figure 5-2). The use of a lower pH 
in the electrophoresis buffer results in higher degrees of chitosan ionization which translates to 
stronger electrostatic attraction to the polyanionic nucleic acid and hence more stable nanoparticles. 
This simple modification of the pH permits lower N:P ratios than those observed 
previously8,17,43,44,81 to achieve nanoparticle stability. A direct consequence of this modification 
translates into reduced dosing, aggregation, and other undesirable nonspecific effects of large 
quantities of soluble chitosan for in vivo delivery where nanoparticles are to be injected at 
physiological pH values close to the chitosan pKa of 6.5. 
In general, efficient nanoparticle internalization depends on factors such as cell type, 
physicochemical surface properties of the nanoparticles, and the bio-nano interface.61 In this report, 
we demonstrated that LMW-CS nanoparticles were efficiently internalized in multiple cell lines. 
The uptake efficiency as measured by flow cytometry ranged from 50% (Raw269.7) to 95% (A549 
and HEK293), depending on the cell line. Statistical analysis of uptake efficiency inter-cell lines 
showed meaningful differences when comparing the A549 and HEK293 (high uptake) to the 
LS174T and Raw 269.7 (medium uptake), indicating a cell-line dependency of chitosan uptake. 
The cell-line dependency of chitosan nanoparticles uptake was previously suggested to be 
associated with different endocytic pathways.82,83 Flow cytometry data showed LMW-CS 
nanoparticles to be efficiently internalized to levels similar or higher than commercially available 
liposomal systems such as DharmaFECT.  
Finally, the transfection efficiency of LMW-CS nanoparticles as measured by gene-silencing 
efficacy was evaluated in two different cell lines: RecQL1 in LS174T cells and ApoB in HepG2 
cells. The ability of these chitosan formulations to efficiently silence gene expression reached more 
than a twofold specific mRNA knockdown; with chitosan 92-10-5 being the most efficient and 
specific in the LS174T cell line. Other low molecular weight formulations also achieved good 
levels of gene silencing in the LS174T cell line. Interestingly, chitosan 80-10-10 achieved a high 
level of silencing with a concomitant increase in silencing when delivering mock siRNA. This 
intriguing observation is currently under investigation in our laboratory. The chitosan formulation 
92-10-5 complexed to ApoB siRNA showed lower target mRNA knockdown in HepG2 when 
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compared to the LS174T cell lines targeted with the RecQL1 siRNA. The silencing efficiency 
correlated well with uptake efficiency as observed by flow cytometry where chitosan 92-10-5 
showed both high uptake and high silencing efficiencies. Despite structural differences between 
pDNA and siRNA,47 the chitosan formulation 92-10-5 has shown the highest transfection 
efficiencies for both siRNA and pDNA to date.38–42 Taken together, our results show that LWM-
CS nanoparticles at low N:P ratios can achieve efficient uptake and gene silencing in vitro, serving 
as a proof of concept for their use as efficient siRNA delivery vectors in cancer and atherosclerotic 
animal models. Although in vitro and in vivo performance criteria differ, no consensus on such 
performances has been established. For in vivo performance, safety remains the major issue, with 
guidance available from the US Food and Drug Administration for the development of gene and 
cell therapy products.84 Therefore, the development of non-viral drug delivery systems for in vivo 
use should take into account physicochemical criteria, cell-based criteria, and, most importantly, 
in vivo performance and safety criteria (Table 5.3). The low-molecular-weight low-NP system 
presented here meets many of these criteria and has already been demonstrated as efficient in vivo 
for plasmid DNA delivery.38,42 Thus a complete characterization of the safety and in vivo 
performance of our LMW-CS system delivering RecQL1 and ApoB targeting siRNA is currently 
under investigation in animal models of cancer and atherosclerosis. 
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Abstract: Chitosan is a natural non-toxic and biodegradable polymer that has shown in vitro and 
in vivo efficacy for siRNA delivery. Previous reports investigating the effect of chitosan 
parameters, including the degree of deacetylation (DDA) and molecular weight (Mn), on 
nanoparticle performance have resulted in contradictory findings. To understand the influence of 
these parameters on in vitro transfection efficiency, toxicity, genotoxicity, hemocompatibility and 
in vivo bio-distribution, a library of precisely characterized chitosans was produced at different 
DDAs (98%, 92%, 80% and 72%) and Mn (5, 10, 40, 80 and 120 kDa). 8 chitosans were manually 
mixed with siRNA at amine to phosphate ratios of 5:1 and 30:1, and resulting nanoparticles 
characterized for their size and surface charge (ζ-potential) in the presence of 10 and 150 mM salt. 
Encapsulation efficiency (EE) and transfection efficiency were characterized at pH 6.5 and 8 for 
EE and pH 6.5 and 7.4 for in vitro transfection. Optimized formulations were selected for further 
characterization of the influence of Mn and N:P ratio on nanoparticle uptake, resulting metabolic 
activity, genotoxicity, and in vitro transfection in the presence of increasing concentrations of 
serum. Hemocompatibility and in vivo biodistribution were also investigated for different Mn, N:P 
ratio and dose. Nanoparticle uptake and gene silencing positively correlated with increased surface 
charge, which in turn was obtained at high DDA and high Mn. A minimum polymer length of ~60-
70 monomers, or Mn of ~10kDa, was required for stability and in vitro knockdown in the presence 
or absence of serum.  In vitro knockdown reached levels equivalent to the lipid control 
(DharmaFect® 2) with no metabolic toxicity or genotoxicity, the former in contrast to the lipid 
which severely impaired metabolic activity. The negative effect of serum on biological 
performance was dependent on DDA, Mn and N:P . The poor in vitro performance above 50% 
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serum is believed to be multifactorial in cause. In vivo biodistribution in mice show accumulation 
of nanoparticles in the proximal epithelial tubules of the kidney, where 40-50% functional 
knockdown was observed, suggesting potential applications in kidney diseases.  
Key words: Chitosan, siRNA, Degree of deacetylation, Molecular weight, Library screening, 
Biodistribution.  
6.1 Introduction  
Oligonucleotide (ON) therapeutics represent a novel class of molecules designed to modulate gene 
expression through direct interference with ribonucleic acids (RNA) or proteins [1]. Clinical 
translation depends on the efficient delivery and cellular uptake of large and negatively charged 
ON [2]. Advances in understanding ON biology, mechanism of action, physico-chemistry and their 
interactions with molecular machines (i.e. RNAi Inducing Silencing Complex) and/or sensors (i.e. 
Toll-Like Receptors) has allowed the introduction of design rules and chemical modifications that 
improve nuclease resistance and reduce immune activation and sequence-dependent off-target 
effects. For instance, chemical modifications of the phosphate backbone and the 2’position of the 
ribose protect small interfering RNA (siRNA) from nuclease digestion and thus modulate its 
pharmacokinetics (PK) and dynamics (PD) by improving serum half-life [3, 4]. In addition, 
modifications such as 2’OMe were demonstrated to prevent immune activation [5, 6] and limit off-
target effects due to improved thermodynamic stability (hybridization complementarity between 
anti-sense sequence and target mRNA) [7]. Although modifications improve serum half-life (t1/2) 
and promote siRNA binding to proteins, intracellular translocation to the pharmacological site of 
action and renal elimination cannot be circumvented by this strategy nor can improvement of 
sequence design. As a consequence, chemical conjugation with ligands or encapsulation in delivery 
systems constitute the two predominant strategies used in clinical development of siRNA delivery. 
Trivalent N-acetylgalactosamine (GalNAc) conjugation on the sense strand results in highly potent 
hepatocyte targeted siRNA able to escape endosomal compartments and achieve meaningful 
knockdown in phase II/III clinical trials [2]. Dynamic Poly-Conjugates (DPC), employ a similar 
strategy where cholesterol-conjugated siRNA is coadministered with a GalNAc targeted and 
polyethylene glycol masked endosomolytic peptide or polymer [8]. These two conjugation 
approaches continue to demonstrate potency in pre-clinical and clinical studies but face serious 
challenges with the recent discontinuation of the Revusiran and ARC-520/521 programs [9, 10]. 
112 
 
Discontinuation followed findings of imbalanced mortality in the Revusiran arm compared to 
placebo [9] and the death of a non-human primate administered with high doses of DPCs [10]. 
However, mechanistic insight leading to the observed mortality needs to be determined before 
being associated with the siRNA payload or the delivery system or other factors [9]. 
Encapsulation of siRNA into delivery systems physically protect the siRNA from serum nucleases, 
increase bioavailability and allow efficient delivery to certain targeted organs and cells using lipid 
nanoparticles (LNP) that have reached clinical trials [8, 9, 11]. However, LNPs are associated with 
serious side effects such as immune activation and their clinical administration is preceded by 
and/or accompanied with prophylactic anti-inflammatory steroids [12, 13]. The shortcomings of 
LNP based vectors are not limited to the above-mentioned issues but also include their limited 
capability to deliver nucleic acid cargos beyond the liver [14]. Therefore, delivery systems that 
meet criteria such as colloidal stability, high encapsulation efficiency, low toxicity, reduced renal 
clearance, and deliver siRNA efficiently to extrahepatic organs are critically needed. 
Chitosan is a family of cationic bio-copolymers composed of β (1-4) linked N-acetyl glucosamine 
(GlcNAc) and D-glucosamine (Glc) that has gained considerable attention for ON delivery. 
Chitosan is characterized by low in vitro and in vivo toxicity, ease of production/chemical 
conjugation, and is generally recognized as safe (GRAS) [15]. Chitosan can be easily fine-tuned to 
reach specific degrees of deacetylation (DDA), or fractions of protonatable amine (charge), and 
average molecular weights (Mw or Mn). The high degree of protonation of amino groups (NH2) 
occurring at a pH below chitosan pKa (~6.5-6.9) favors the spontaneous formation of nanosized 
polyelectrolyte complexes through electrostatic interaction with polyanionic molecules such as 
ON. 
Early work showed that transfection efficiency (TE) of plasmid-containing chitosan nanoparticles 
depended on a fine equilibrium between chitosan tunable parameters of DDA, Mn and the molar 
ratio of chitosan amine to plasmid phosphate (N:P) as well as other extrinsic factors such as pH 
and the presence of serum proteins [16-20]. Chitosan has also been used to deliver short double-
stranded siRNAs both in vitro [21-32] and in vivo [28, 32-37]. Most reports evaluating 
physicochemical parameters for efficient in vitro siRNA delivery were performed using partly 
deacetylated (DDA ~ 80-85%) chitosan formulated at high N:P ratio (>25) [26-31, 33]. Such 
formulations could pose significant practical problems for in vivo delivery such as premature 
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dissociation, limited dosing, blood incompatibility and non-specific effects due to large quantities 
of free excess chitosan. Although gene knockdown (KD) has been achieved, experimental 
discrepancies, differences in chitosan sources, and lack of characterization rendered results 
inconclusive in identifying optimal parameters for siRNA delivery [15]. Reports correlating 
transfection efficiency (TE) as a function of chitosan DDA, Mn and N:P ratio have been 
contradictory [24-27, 29]. Therefore a systematic study of siRNA delivery with accurately 
characterized chitosans that investigates the effect of intrinsic (DDA, Mn and N:P ratio) and 
extrinsic parameters (serum, pH, ionic strength and mixing conditions) on cell uptake, transfection 
efficiency, toxicity, genotoxicity, hemocompatibility and in vivo bio-distribution is needed.  
To understand the correlation between nanoparticle physicochemical properties and knockdown 
efficiency (KD), we produced a library of chitosans precisely characterized by gel permeation 
chromatography for molecular weight and 1H NMR for DDA. The effect of DDA, polymer length 
(Mn), mixing ratio (N:P) and pH was systematically examined and correlated with nanoparticle 
physicochemical properties including size, surface charge (ζ-potential), encapsulation efficiency 
(EE), and in vitro delivery. Potent formulations were selected for further characterization and tested 
in the presence of increased serum concentrations and correlated to knockdown efficiency. In 
addition, off-target effects and nanoparticle mediated toxicity were examined using a metabolic 
assay coupled with genotoxicity testing. The influence of experimental conditions on reference 
gene stability was determined using an MIQE [38] compliant assessment of mRNA knockdown. 
We also show that selected formulations may be intravenously administered at doses up to 14 
mg/kg of chitosan, accumulate in the kidney specifically in the proximal tubule epithelial cells 
(PTEC) and induce functional target knockdown in the kidney. 
6.2 Materials and methods 
 siRNA sequences and chitosan characterization  
siRNA sequences were custom synthesized by Dharmacon Inc (GE Dharmacon, Lafayette, CO, 
USA) except for the non-targeting siRNA (siNT) which was purchased as a predesigned product 
from the same supplier (D-001710-01-50). All siRNA sequences used in vitro were provided by 
the manufacturer in a lyophilized format following standard desalting. The anti-EGFP siRNA sense 
sequence was 5’-GAC GUA AAC GGC CAC AAG UUC-3’ and the antisense sequence was 3’-
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CGC UGC AUU UGC CGG UGU UCA-‘5, duplex Mw 13,360 g/mol. The siRNA sequence has 
been used in two chitosan-siRNA studies [28, 29]. The DY647 siRNA sequence was modified at the 
5’ end of the sense strand and purified by HPLC for in vivo administration.  
Chitosans (Table 7-1) at different DDAs were obtained from Marinard, (Laval, QC, Canada) and 
depolymerized in our laboratory using nitrous acid to achieve specific number-average molecular 
weight targets (Mn) of 5, 10, 40, 80 and 120 kDa (Table 7-1). Chitosan number and weight-average 
molecular weights (Mn and Mw) were determined by gel permeation chromatography (GPC) using 
a Shimadzu LC-20AD isocratic pump coupled with a Dawn HELEOS II multi-angle laser light 
scattering detector (Wyatt Technology Co, Santa Barbara, CA), an Optilab rEX interferometric 
refractometer (Wyatt Technology Co), and two Tosoh TSKgel (G6000PWxl-CP and G5000PWxl-
CP; Tosoh Bioscience LLC, King of Prussia, PA) columns. Chitosans were eluted at pH 4.5 using 
an acetic acid (0.15 M)/sodium acetate (0.1 M)/sodium azide (4 mM) buffer. The injection volume 
was 100µL, the flow rate 0.8 mL min−1 and temperature 25°C. The dn/dc values for chitosan with 
a 92 and 80% DDA were determined at 0.208 and 0.201 using a laser’s wavelength of 658 nm. The 
degree of deacetylation was determined by 1H NMR as per in house published methods [39]. 
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Table 6-1 Characterization of chitosans tested in this study. Different chitosans are denoted 
according to their chemical composition using the nomenclature [DDA-Mn] and are represented 
in the first column of the table. The degree of deacetylation (DDA) was determined by 1H NMR. 
The number and weight average molecular weight (Mn and Mw) were determined by gel 
permeation chromatography (GPC). The polydispersity index (PdI) was calculated as Mw/Mn. 
The degree of polymerization (Dp) or chain length was computed using the following equation 
𝐷𝑝 = (𝑀𝑛 𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛)/(𝑀𝑤 𝑚𝑜𝑛𝑜𝑚𝑒𝑟 𝑎𝑡 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐷𝐷𝐴) 
 
Chitosan DDA (%) Mn (kDa) Mw (kDa) PdI Dp 
72-10 75.4 11.8 17.9 1.60 69 
72-120 71.7 140.4 182.5 1.30 811 
80-10 84.4 10.8 14.5 1.34 64 
80-120 82.9 177.4 290.4 1.64 1,054 
92-5 91.7 4.3 6.4 1.51 26 
92-10 92.0 9.0 13.7 1.52 55 
92-40 92.5 40.7 54.9 1.35 248 
92-80 92.7 81.1 267.6 3.30 494 
92-120 91.9 137.6 180.7 1.31 836 
98-10 98.9 8.8 11.4 1.29 54 
98-120 98.5 127.5 188.3 1.47 788 
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 Preparation of nanoparticles by manual mixing 
Chitosans were dissolved overnight in nuclease free water (Life Technologies, Burlington, ON, 
Canada) and 1N HCl (Sigma-Aldrich, Oakville, ON, Canada), using a glucosamine to HCl ratio of 
1:1, to a final concentration of 5 mg/mL. The stock solutions were sterile filtered using a 0.22 µm 
PVDF filter and used to prepare solutions at specific N:P ratio by dilution in nuclease-free water. 
Before complexation, siRNA was diluted to a working concentration of 0.1 mg/mL. Unless 
otherwise stated, nanoparticles were formed by simple electrostatic complexation following 
manual addition of chitosan to siRNA at a 1:1 ratio (v/v). The final volume never exceeded 250 µL 
and chitosan was pipetted into siRNA. Nanoparticles were kept at room temperature for 20-30 
minutes before further use. 
 Determination of nanoparticle size and surface charge 
Size and surface charge (ζ-potential) of nanoparticles were determined by Dynamic Light 
Scattering (DLS) and Laser Doppler velocimetry using a ZetaSizer Nano ZS device (Malvern 
Instruments Ltd, Malvern, UK). The scattering angle of the detector was fixed at 173o and 
measurements were performed at 25oC using the viscosity of water as sample diluent. 
Nanoparticles were diluted 1:4 and 1:8 using sterile filtered NaCl solution (20 or 150mM) before 
determination of size and ζ-potential respectively. For data in Figure 6-1, size and ζ-potential were 
measured immediately post incubation in buffer (~2.5 min for size and 5 min for ζ-potential). For 
data in Figure S. 6-1 size and ζ-potential were measured at the respective time point post incubation 
in buffer. The Smoluchowski equation was used to calculate ζ-potential from the measured 
electrophoretic mobility. All measurements were done in duplicate and replicated twice (N=3, 
n=6).  
 Encapsulation efficiency and siRNA release  
The encapsulation efficiency (EE) of siRNA was determined using the Quant-iT™ Ribogreen® 
RNA reagent (Life Technologies, Burlington, ON, Canada) to assess siRNA free in solution after 
mixing with chitosan. Encapsulation efficiency (EE) was calculated as percentage fluorescence 
intensity relative to non-formulated siRNA. 
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6.2.4.1 siRNA release at different pH  
Nanoparticles were incubated in buffers with different pH, 25 mM MES (pH 6.5), 1X PBS (pH 
7.2) or 1X TAE (pH 8.0) and aliquots were taken at 24 hours post incubation. Aliquots were further 
diluted 1:200 in respective buffers, mixed with an equal volume of Quant-iT™ RiboGreen® 
reagent to detect free siRNA, incubated for 5 minutes at room temperature and fluorescence 
measured using the TECAN Infinite® M200 PRO microplate system (Tecan Systems, Mannedorf, 
Switzerland). 
6.2.4.2 siRNA release in the presence of heparin  
The effect of physiological concentrations of heparin on siRNA release was tested. Heparin 
(Sigma-Aldrich, Oakville, ON, Canada) solution at 1 mg/mL was prepared in nuclease free water, 
sterile filtered and diluted to 5 µg/mL. Nanoparticles were prepared as mentioned above and diluted 
1:2 in heparin, incubated for 1h and then diluted 1:100 in Tris-EDTA (TE 1X, pH 7.2) and a volume 
of 100 µL transferred into black plates (Corning, NY, USA). Quant-iT™ RiboGreen® reagent 
(1:200) was prepared in TE 1X (pH 7.2) and an equal volume (100µL) was added to the 
nanoparticles. Plates were incubated on a rotary mixer for 5 minutes in the dark and fluorescence 
measured using a TECAN Infinite® M200 PRO microplate system (Tecan Systems, Mannedorf, 
Switzerland). The excitation and emission wavelengths were 480 and 530 nm respectively. Naked 
siRNA, heparin alone, TE 1X, chitosan/heparin and siRNA/heparin were used as controls to assess 
background, assay interference and as subtraction blank. 
6.2.4.3 siRNA release in the presence of serum albumin 
The effect of physiological concentrations of bovine serum albumin (BSA) on siRNA release was 
tested. BSA stock solution (125 mg/mL) was prepared in nuclease free water, quantified using the 
microBCA assay (Life Technologies, Burlington, ON, Canada) and diluted to reach 50 mg/mL 
respectively. The Quant-iT™ RiboGreen® assay was identical to the heparin competition assay 
described above with the only difference that nanoparticles challenged with BSA were diluted 
1:2000 in TE 1 X (pH 7.2). This high dilution was used to overcome assay inhibition. Naked 
siRNA, BSA alone, TE 1X, chitosan-BSA and siRNA-BSA were used as controls to assess 
background, assay interference, and as subtraction blank. 
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 Cell culture  
The EGFP+ H1299 cell line (human lung carcinoma) was provided by Prof. Jorgen Kjems (Aarhus 
University, Denmark) and has been used in several chitosan-siRNA studies [26, 28, 29, 31, 33]. 
This cell line was generated by Dr Anne Chauchereaux (Gustave Roussy Institute, Paris, France) 
by transducing the parental H1299 cell line (ATCC, Manassas, VA, USA) with pd2EGFP-N1 
(Clonetech, Mountain View, CA, USA). The plasmid encodes a modified version of EGFP with a 
turnaround rate of 2 h (t1/2 ~2h). Cells were cultured in RPMI-1640 (ATCC, Manassas, VA, USA) 
supplemented with 10% heat-inactivated FBS (Life Technologies, Burlington, ON, Canada), 1% 
GlutaMAX™ (Life Technologies, Burlington, ON, Canada) and 500 µg/mL of G418 antibiotic at 
37oC in a 5% CO2 environment.  
 In vitro transfection  
For target gene knockdown and siRNA uptake, cells were seeded in 24 well plates at a density of 
45,000 cells/well to reach ~75-80% confluence on the day of transfection. Prior to transfection, 
cells were washed once with 500 µL of warm Ca2+/Mg2+ free PBS and replenished with fresh 
RPMI-1640 which contained varying amounts of FBS (0-94%). Nanoparticles were prepared as 
described above and a specific volume added to cells to reach the target siRNA concentration 25-
400 nM per well. Cells were incubated for either 4h (toxicity), 8h (genotoxicity) or 48 hours 
(knockdown, toxicity, and genotoxicity). For the serum challenge experiment, medium containing 
increasing amounts of FBS (0-94%) was aspirated and replaced with complete RPMI-1640 
medium 4 hours post transfection.  
DharmaFect® 2-siRNA nanoparticles were prepared by diluting siRNA stock solution to 0.025 
mg/mL (4 µM) in Opti-MEM® serum free media and complexed to the lipid component as per 
manufacturer recommendation; a volume of 6.4 µL of DharmaFect® 2 in 153.6 µL Opti-MEM® 
was used for complexation.  
 Assessment of EGFP knockdown and nanoparticle uptake using flow 
cytometry 
EGFP knockdown was measured using a MoFLo™ flow cytometer (Beckman Coulter, 
Mississauga, ON, Canada) equipped with a 488 nm argon laser for excitation (model ENTCII-621, 
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Coherent, Santa Clara, CA, USA) and a 510/20nm (FL1) band pass filter to detect fluorescence. 
Nanoparticle uptake was measured on a BD FACSAria™ equipped with a 633 laser and a 
660/20nm (FL1) band pass filter to detect fluorescence of internalized DY647 labeled siRNA. 
Before analysis, EGFP+ H1299 cells were washed twice with ice-cold Ca2+/Mg2+ free PBS, 
trypsinized and suspended in complete RPMI-1640 medium. For uptake, cells were incubated with 
Streptomyces griseus type III chitosanase as per [21] before washing and trypsinization. A dot plot 
of forward scatter (FSC) versus side scatter (SSC) was created and a collection gate established 
using the Summit 3.0 software (Beckman Coulter, Mississauga, ON, Canada) to exclude cell 
debris, dead and aggregated cells. 20,000 events per sample were recorded and non-transfected 
cells (untreated) were used to establish baseline EGFP expression in terms of absolute fluorescence 
intensity (FI). EGFP knockdown in treated samples was calculated as mean FI relative to non-
transfected cells ( 𝐾𝐷 (%) =
𝑚𝑒𝑎𝑛 𝐹𝐼 (𝑡𝑟𝑒𝑎𝑡𝑒𝑑)
𝑚𝑒𝑎𝑛 𝐹𝐼 (𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑)
×  100).  
 MIQE compliant quantitative real-time PCR (qPCR) 
The secondary structure of endogenous and target genes used in this study was in silico assessed 
using the mFold freeware [40]. The position of the primer and probe sequences relative to the 
structure was determined prior to qPCR analysis. Before extraction, transfected EGFP+ H1299 cells 
were treated with Streptomyces griseus type III chitosanase (Sigma-Aldrich, Oakville, ON, 
Canada) as described in [21]. Total RNA extraction was performed 48 hours post transfection using 
the RNeasy® Plus Mini extraction kit (Qiagen, Toronto, ON, Canada) as per manufacturer protocol. 
Following extraction, samples were digested with 2 µL TURBO™ DNA-free kit (Life 
Technologies, Burlington, ON, Canada) for 30 minutes to remove potential genomic DNA 
contamination and then inactivated with 5 µL DNase inactivation reagent, spun down for 1.5 
minutes at 10,000 g and the supernatant collected. The purity of total RNA was determined by 
measuring A230/A260, A260/A280 and A340 using a Jenway spectrophotometer. The integrity of total 
RNA (RIN) was determined using the Agilent 2100 Bioanalyzer system (Agilent Technologies, 
Mississauga, ON, Canada). Total RNA concentration was determined using the Quant-iT™ 
RiboGreen® Assay (Life Technologies, Burlington, ON, Canada). RiboGreen® reagent and 
extracted RNA samples were diluted 1:200 and 1:100 respectively using the supplied nuclease free 
TE 1X buffer (pH 8.0), mixed at 1:1 ratio (v/v) and a volume of 200 µL pipetted into 96 well black 
plates (Corning, NY, USA). Plates were incubated at room temperature in the dark for 5 minutes 
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before measuring fluorescence using a TECAN Infinite® M200 PRO microplate system (Tecan 
Systems, Mannedorf, Switzerland). The excitation and emission wavelengths were 485 and 530 
nm respectively and concentrations (ng/mL) were derived from a ribosomal RNA (rRNA) standard 
curves prepared on the same plate as per manufacturer recommendations. A total 1 µg of extracted 
RNA was reverse transcribed at 42oC for 60 min using the SuperScript® VILO™ cDNA synthesis 
kit (Life Technologies, Burlington, ON, Canada). For qPCR, 10 ng cDNA was amplified using 
TaqMan Fast Advanced Master Mix® (Life Technologies, Burlington, ON, Canada) on an ABI 
HT-7900 real-time PCR system (Applied Biosystems, Mississauga, ON, Canada). All reactions 
were performed in a 384 well plate in a final volume of 10 µL. Quantitative real-time PCR (qPCR) 
was performed using the following cycle conditions: 2-minute hold at 55oC, 10-minute hold at 
95oC followed by 40 cycles at 95oC for 15 s and 60oC for 1 min. Primer-probe efficiency was 
determined using the standard curve method. For each assay tested, a 6 log 10-fold dilution curve 
was constructed by plotting the quantification cycle (Cq) versus Log cDNA concentration and 
linearly regressed to fit the data. The PCR reaction efficiency was estimated using 𝐸 = 10
(−
1
𝑠𝑙𝑜𝑝𝑒
)
. 
The list of assays (primer-probe pairs) used in this study and their respective efficiencies can be 
found in the supplementary methods section. Reference gene stability was assessed using the 
geNorm statistical package (Biogazelle NV, Zwijnaarde, Belgium) with a panel of 10 reference 
genes under 10 experimental conditions including non-treated, lipid-treated, high and low N:P 
ratio, high and intermediate DDA and high and low Mn). The experiment was replicated once and 
the M (stability parameter) and V (pair wise variation of normalization factors) scores determined 
[41]. 
 Assessment of nanoparticle toxicity using the alamarBlue® assay 
The effect of nanoparticle on metabolic activity was measured using alamarBlue® (Life 
Technologies, Burlington, ON, Canada). Preliminary experiments were performed as per 
manufacturer protocols to define optimal cell density, incubation time and assess assay interference 
with chitosan. EGFP+ H1299 cells were seeded in 96 well plates (CellBIND®, Fisher Scientific, 
Mississauga, ON, Canada) at a density of 5,000 cells/well 20-24 hours prior to transfection. Cells 
were transfected as previously described at a final anti-EGFP siRNA concentration of 100 nM. 
Metabolic activity was measured at 4 hours and 44 hours post transfection by replacing medium 
over cells with 200 µL of complete RPMI-1640 medium supplemented with 10% alamarBlue® 
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reagent. Absorbance was measured at 570 and 600 nm using a TECAN Infinite® M200 PRO 
microplate system (Tecan Systems, Mannedorf, Switzerland) 4 hours after the addition of assay 
reagent. Metabolic activity of cells was evaluated as the percentage reduction of alamarBlue® 
relative to untreated cells.  
 Assessment of nanoparticle genotoxicity using the comet or single cell 
gel electrophoresis assay. 
The assessment of nanoparticle genotoxicity was performed using the Trevigen alkaline 
cometAssay® kit (Trevigen Inc, Gaithersburg, MD, USA) at 8 and 48 hours post-transfection. The 
8-hour time point was assessed to mimic the alamarBlue® time point (4 h transfection + 4 hours 
incubation with reagent). EGFP+ H1299 cells were transfected as described above, trypsinized, 
resuspended in complete RPMI-1640 media and counted using the Countess automated cell counter 
system (Life Technologies, Burlington, ON, Canada). Cells were centrifuged at 100 g for 3 
minutes, and the pellet suspended in ice cold PBS (Ca2+/Mg2+ free) at a concentration of 100,000 
cells/mL. Agarose embedding, lysis, and electrophoresis were performed according to the 
manufacturer protocol. Slides were stained with 100 µL of (1:10,000) SYBR gold® nucleic acid 
stain (Life technologies, Burlington, ON, Canada), dried at 37oC and imaged following excitation 
at 488 nm using an Axiovert epi-fluorescent microscope (Carl Zeiss, Toronto, ON, Canada). 
Images were analyzed using the Open Comet plugin [42] installed in the ImageJ freeware (NIH, 
Besthada, CA, USA). The experiment was replicated once and at least 100 comets were counted 
per experiment (N=2, n≥ 200).  
 Assessment of nanoparticle hemocompatibility at doses relevant for in 
vivo administration 
Hemolytic and hemagglutination properties of nanoparticles were tested according to ASTM 
E2524 [43] and Evani et al [44] respectively. Human blood was collected from consenting and 
healthy donors following protocol approval by the University Ethics Committee. Nanoparticles 
were prepared using an in-house automated in-line mixing system [45] and freeze-dried (FD) in 
the presence of 0.83% w/v trehalose (Sigma-Aldrich, Oakville, ON, Canada),  and 5.8 mM histidine 
(pH 6.5) (Sigma-Aldrich, Oakville, ON, Canada). FD samples were rehydrated to 12X using 
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nuclease free water to reach the highest tested concentration (or dose) and iso-osmolality then 
serially diluted using 10% w/v trehalose buffer (300 mOsm) to a final siRNA concentration of 0.1, 
0.25, 0.5, and 0.8 mg/mL. The plasma-free hemoglobin (PFH) in the blood was measured at 0.49 
mg/mL prior to initiating the assay. Total blood hemoglobin (TBH) was adjusted with PBS to a 
concentration of 10 ± 1 mg/mL. Nanoparticles were mixed with PBS and diluted TBH blood 
(TBHd) at a 1:7:1 volumetric ratio, with 100 µL of nanoparticles at the target concentration pipetted 
into an Eppendorf tube containing 700µL PBS and 100 µL of blood (TBHd 10 ± 1 mg/mL). For 
colorimetric determination of hemolysis, samples (700 µL) were incubated for 3 h in a water bath 
at 37 °C and visually inspected every 30 minutes for nanoparticle flocculation, dispersion, sinking 
or floating. The supernatant was collected following centrifugation at 800 g for 15 min and 
absorbance measured at 540 nm on a TECAN Infinite® M200 PRO microplate system (Tecan 
Systems, Mannedorf, Switzerland. A four-parameter regression algorithm (4PL) was used to obtain 
the calibration curve required to calculate the hemoglobin concentration in the supernatant of each 
sample (PFHsample). The percentage of hemolysis was computed as: 𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 (%) = 100 ×
(𝑃𝐹𝐻𝑠𝑎𝑚𝑝𝑙𝑒 𝑇𝐵𝐻𝑑⁄ ). For hemagglutination, the remaining 200 µL of each sample prepared above 
were pipetted in 96 well assay plates, incubated for 3h, visualized using an Axiovert light 
microscope and the area covered by red blood cells (RBCs) estimated and scored. 
 In vivo biodistribution and efficacy studies 
All in vivo experiments described in this manuscript were randomized double blinded and approved 
by the University of Montreal Ethics Committee (CDEA) and the Montreal Heart Institute 
Research Center Ethics Committee. Mice were purchased from Charles Rivers (Charles River, 
Quebec, Canada), housed and acclimatized in a specific pathogen-free facility with unrestricted 
access to water and food. Mice had body condition scores (BCS) of 3 [46] and their body weights 
(BW) were in the range of 20-25 g at the time of injection. All injection volumes were calculated 
as 10 µL/g of BW and injections performed within 10-15 seconds. Mice were euthanized under 
anesthesia (mixture of 3% Forane™ and 20-80% oxygen-air vol/vol) by cardiac puncture followed 
by cervical dislocation 
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6.2.12.1 Determination of chitosan-siRNA biodistribution using ex-vivo whole organ 
imaging  
Balb/c nude female (♀) mice aged 6 weeks and weighing 20-22 g were injected for the 
biodistribution experiments All test articles i.e. Naked siRNA, Invivofectamine® 2.0 and chitosan 
based nanoparticles formulated at N:P 5 (Mn 10, 40 and 120 kDa) were intravenously injected 
(I.V.) at a dose of 0.5 mg/kg DY647 labeled siRNA. The DY647 fluorophore was injected at a dose 
of 0.5 mg/kg. Mice were euthanized 4 hours post administration and immediately perfused using 
PBS (1 X 20 mL) and 10% Neutral Buffer Formalin (NBF, 1 X 40 mL). Ex-vivo imaging on 
collected organs was performed using a whole animal imaging system mounted with an EMCCD 
EM N2 camera (NUVU Cameras, Montreal, QC, Canada). Controls included PBS, naked DY647 
labeled siRNA, DY647 alone, and commercially available lipid control Invivofectamine® 2.0 (Life 
Technologies, Burlington, ON, Canada). The latter was prepared as per manufacturer 
recommendation. 
6.2.12.2 Determination of in vivo functional gene knockdown 
6.2.12.2.1 Preparation, lyophilization, reconstitution, and characterization of injected 
nanoparticles for in vivo efficacy 
Low (10kDa) and high (120kDa) molecular weight chitosans with a degree of deacetylation of 92 
and 98% (Table 6-1) were dissolved as described above to a final concentration of 5 mg/mL. The 
stock solutions were sterile filtered using a 0.22 µm PVDF filter (EMD Millipore, Etobicoke, ON, 
Canada) and used to prepare solutions, containing 1% trehalose and 3.8 mM histidine, at an N:P 
ratio of 5 by dilution in nuclease-free water, 4% w/v trehalose and 28 mM histidine (pH 6.5). Before 
complexation, anti-GAPDH siRNA stock solutions (4 mg/mL) were diluted to 0.2 mg/mL in the 
same buffer as chitosan. Nanoparticles were prepared at a final N:P ratio of 5:1 using simple manual 
mixing. All nanoparticles were incubated for 30 min at room temperature upon preparation before 
analyses or freeze-drying. Anti-GAPDH nanoparticles were lyophilized under sterile conditions 
using a Laboratory Series Freeze-Dryer PC/PLC (Millrock Technology, Kingston, NY, USA). An 
optimized 1-day cycle comprising the following program: rapid cooling to 5 °C, 30 min hold, rapid 
cooling to -5 °C, 30 min hold, temperature decrease from -5 to -40 oC, at a rate of 1 °C/min, 2 hours 
hold, initiation of primary drying for 10 h at -32 oC and 60 mTorr; followed by secondary drying 
cycle at 60 mTorr, increase in shelf temperature to 30°C, at rate of 0.2°C/min, and a 6 hours hold 
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was used. Nanoparticle volumes of 3.84, or 7 mL were freeze-dried in 10 or 20 mL serum vials 
respectively, using 20 mm butyl-lyophilization stoppers. Samples were backfilled with argon, 
stoppered, crimped, and stored at 4°C until reconstitution. All FD samples were reconstituted at 
the animal facility to 10-times their initial concentration using water for injection and their 
concentration adjusted by diluting with a nearly-isotonic aqueous solution comprising 10% w/v 
trehalose, so that the desired dosage (mg siRNA/kg animal body weight) would be reached upon 
injection of 10 µL of nanoparticles per gram of animal body weight. Immediately after injection, 
reconstituted nanoparticles were characterized for their size and polydispersity as described above. 
 
6.2.12.2.2 In vivo efficacy and monitoring of clinical signs and body weight 
Balb/c male (♂) mice aged 6-7 weeks and weighing 22-25g were used for the efficacy study (3 
animals/group). Uncoated anti-GAPDH NPs were prepared as described above and administered 
at 2.5 mg/kg every other day for a total of three injections and mice were sacrificed 72 hours 
following the last injection. Naked anti-GAPDH siRNAs (siGAPDH) were administered at 2.5 
mg/kg following the same schedule. Clinical signs were determined for a period of 4-hours post-
administration of test articles and at euthanasia. The clinical signs were recorded by trained 
personnel and qualified animal care technicians. Clinical signs were scored for body condition, 
general aspect, natural behavior, and provoked behavior. Body weight was recorded prior to each 
injection and at euthanasia using an Avery Berkel scale (Avery Berkel, Fairmont, MN, USA). Body 
weight was expressed as percent change relative to the previous injection. Mice were euthanized, 
under anesthesia, using cardiac puncture, followed by cervical dislocation, total circulating blood 
volume (tCBV) and organs collected. tCBV was serum separated and immediately stored at -80oC, 
and organs split into halves and stored in LiqN and fixed in 10% NBF before protein extraction 
and determination of GAPDH enzymatic activity. 
 
6.2.12.2.3 In vivo assessment of functional knockdown using the KDalert® assay 
Following collection, organs were snap frozen in liquid nitrogen and stored at -80oC until use.  
Frozen tissues were cut on dry ice, weighed (~20 mg), and disrupted using the TissueLyzer® II 
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system (Qiagen Inc, Toronto, ON, Canada). Tissues were disrupted using the 5 mm steel beads 
(Qiagen Inc, Toronto, ON, Canada) under the following conditions: 2 x 30 Hz, 20 seconds per 
cycle. Homogenized tissues were resuspended in 750 µL of KDalert™ lysis buffer (Life 
Technologies, Burlington, ON, Canada), and incubated on ice for 30 minutes with inversions every 
10 minutes. Lysates were clarified by centrifugation (2270 g, 30 minutes, 4°C), transferred to new 
tubes, and diluted (1:20), in KDalert™ lysis buffer. The standard curve was prepared by diluting 
GAPDH stock solution (26 U/mL) with lysis buffer at a 1:100 ratio (GAPDH: Lysis), followed by 
2-fold serial dilutions from 1:5 to 1:320. Twenty microliters of diluted samples and standards were 
transferred into 96 well plates (Corning, NY, USA), and 180µL of the KDalert™ Master Mix (Life 
Technologies, Burlington, ON, Canada) was pipetted into each well. Plates were incubated for 15 
minutes at room temperature and absorbance measured at 610 (10) nm using a TECAN Infinite® 
F-500 microplate system (Tecan Systems, Mannedorf, Switzerland). GAPDH activity in units (U) 
was computed from the standard curve and normalized to total protein content (mg) of the lysate 
sample as determined using the BioRad DC Protein assay kit (Bio-Rad Laboratories, Mississauga, 
ON, Canada). 
 
 Assessment of in vitro knockdown and nanoparticle biodistribution 
using confocal microscopy 
Visual confirmation of in vitro knockdown was performed using live cell imaging. EGFP+ H1299 
cells were seeded at a density of 25,000 cells/well onto an 8-chamber Lab-Tek® (MatTek, Ashland, 
MA, USA) and imaged in multitrack mode using a Zeiss LSM 510 META confocal Axioplan 200 
microscope (Carl Zeiss AG, Feldbach, Switzerland). For in vivo biodistribution and subcellular 
localization of DY647 labeled siRNA, organs were cryosectioned (5 µm), actin stained using 
phalloidin red and counterstained with Hoechst (Life Technologies, Burlington, ON, Canada).  
 Statistical analysis 
Data were collected and expressed as average ± standard deviation (stdev). Statistical analysis was 
conducted using STATISTICA® 12.0 (Dell Statsoft, Tulsa, OK, USA) and SigmaPlot® 13.0 (Systat 
software, San Jose, CA, USA) software packages. Unless otherwise stated, the General Linear 
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Model, One/Two-Factor ANOVA, and multiple regression analysis were performed on collected 
data. The design of experiment module in STATISTICA® 12.0 was used to generate full or 
fractional factorial designs and generate multifactorial modeling. Data from the comet experiments 
was also subjected to non-parametric analysis. 
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6.3 Results  
 Chitosan dictate nanoparticle uptake, target knockdown, ζ-potential and 
encapsulation efficiency at physiological pH while increasing Mn and N:P 
ratio have positive effects 
A library of chitosans was produced, precisely characterized (Table 6-1), and assessed under 
different experimental conditions (pH, ionic strength and presence/absence of serum) to understand 
molecular parameters favoring adequate physicochemical properties (size, surface charge, colloidal 
stability, and encapsulation efficiency) and efficient non-toxic in vitro knockdown (target 
knockdown and metabolic toxicity). As illustrated in Figure 6-1, nanoparticle size, measured 2.5 
minutes post-incubation in the buffer, increased with both polymer length (Mn) and ionic strength. 
In both low and high ionic strength, size increased 2-3 -fold due to an increase in Mn from 10 to 
120kDa. The effect of chitosan DDA and amine to phosphate ratio (N:P) on size was minimal. 
Nanoparticle surface charge (ζ-potential) decreased with increasing ionic strength, as expected due 
to salt-induced electrostatic screening. At low ionic strength, ζ-potential increased with increased 
DDA, Mn and N:P ratio. As shown in Figure 6-1C, and confirmed using multiple regression 
analysis, DDA had the strongest effect on ζ-potential followed by N:P ratio and Mn, respectively. 
Although ζ-potential was around 2-3 fold lower at high ionic strength, the tendency of increased ζ-
potential with a concomitant increase in DDA, Mn and N:P ratio was conserved (Figure 6-1C and 
D).  
Given that DDA and the N:P ratio did not significantly alter size, colloidal stability was 
investigated using low and high Mn chitosan-formulated at an N:P ratio of 5 (92-10-5 and 92-120-
5). As shown in Figure S. 6-1, nanoparticle size and polydispersity was independent of Mn in 10 
mM NaCl and stable up to at least 1-hour post complexation. Increasing the ionic strength to 150 
mM had a significant impact on colloidal stability with nanoparticles aggregating rapidly to reach 
the µm scale. The polydispersity index (PdI), a dimensionless measure of dispersion around the 
mean, reached its maximum value of 1 in 150 mM NaCl around 15 min post complexation 
indicating severe aggregation/high heterogeneity. Interestingly, colloidal instability increased with 
the increase of molecular weight.  
128 
 
 
Figure 6-1 Nanoparticle size and ζ-potential as a function of DDA, Mn, and amine to phosphate 
ratio (N:P) measured in the presence of 10 and 150 mM NaCl. A) Nanoparticle size (Z-ave 
diameter) vs DDA, Mn and N:P ratio in the presence of low ionic strength (10 mM NaCl, pH 5.5, 
measurement at 2.5 min post incubation in medium). B) Nanoparticle surface charge (ζ-potential) 
vs DDA, Mn and N:P ratio in the presence of low ionic strength (10 mM NaCl, pH 5.5). C) 
Nanoparticle size vs DDA, Mn and N:P ratio in the presence of high ionic strength (150 mM 
NaCl, pH 5.5). D) Nanoparticle surface charge (ζ-potential) vs DDA, Mn and N:P ratio in the 
presence of high ionic strength (150 mM NaCl, pH 5.5). Data represent the average ± standard 
deviation of 3 independent experiments with 2 technical replicates per experiment (N=3, n=6). 
Measurements in 150 mM NaCl were taken immediately after adding 150 mM NaCl. 
Measurements in 10 mM NaCl were stable over time (see Supp Info Figure S. 6-1) 
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Figure S. 6-1 Nanoparticle colloidal stability versus time. The effect of polymer length on 
nanoparticle size was investigated in medium containing 10 and 150mM salt (NaCl) over a 
period of 1h. Nanoparticles were prepared in water by manual mixing of chitosan and siRNA 
(0.1mg/mL) at 1:1 v/v to reach an N:P ratio of 5, diluted 1:8 in media and size measured over 
time. Measurements were conducted at 0, 7.5, 15, 30 and 60 minutes post dilution. Data represent 
the average of 2 independent experiments. Each DLS measurement consisted of 15 repeats. 
 
siRNA compositions should be able to protect the nucleic acid cargo in physiological fluids through 
a material specific mechanism of payload entrapment. As a consequence, encapsulation efficiency 
(EE), or the percentage of siRNA incorporated into the nanoparticle, was measured as a function 
of DDA, Mn, N:P ratio and pH using dye exclusion. In order to eliminate the effect of colloidal 
instability on dye exclusion, the assay was performed at low ionic strength. As shown in Figure 
6-2, all formulations were able to achieve complete payload encapsulation at pH 6.5. Increasing 
the pH from 6.5 to 8.0 resulted in dye accessing siRNA payload indicating release and highlighting 
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the importance of DDA, Mn and N:P ratio, and their interaction, on the integrity/stability of the 
particles and payload protection. Maximization of nanoparticle integrity at high pH could be 
achieved by increasing DDA, Mn and N:P ratio. 
 
Figure 6-2 Effect of DDA, Mn and N:P ratio on the encapsulation efficiency at two different pH. 
Nanoparticles were formed in water and incubated either in 25 mM MES (pH 6.5) or 1X TAE 
(pH 8.0) for 24 hours then assayed for siRNA release using the Quant-iT™ RiboGreen® assay. 
The percentage of siRNA release provided the percent encapsulation efficiency (% EE) computed 
relative to naked siRNA (N:P 0). Red color corresponds to 100% encapsulation efficiency (no 
release) while magenta corresponds to 0% encapsulation efficiency (all released). Average values 
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from 2 independent experiments with 3-4 technical replicates per experiment. At pH 6.5, 
complete encapsulation (0% release) of the payload is observed at all DDA, Mn and N:P ratio 
used to form nanoparticles. However, at pH 8.0, chitosan glucosamine units become deprotonated 
and their interaction with siRNA phosphate groups decreases promoting payload release. At pH 
8, an increase in DDA, Mn and N:P ratio is required to maintain nanoparticle integrity. 
 
In vitro performance of these formulations in the presence of 10% serum was assessed using the 
EGFP + H1299 cell line and correlated with nanoparticle physicochemical properties. As illustrated 
in Figure 6-3, EGFP knockdown significantly increased with increasing charge density (DDA), 
and to a lesser extent with increasing polymer length (Mn) and N:P ratio. The effect of pH on the 
biological performance of nanoparticles was minimal with a slight decrease in knockdown 
efficiency at higher pH observed for formulations with low-to-intermediate DDA (i.e. 72-10, 72-
120, 80-10 and 80-120). No pH dependent performance could be detected for formulations with 
high charge density (92-10, 92-120, 98-10 and 98-120) when transfection pH increased from 6.5 
to 7.4 (Figure 6-3). In contrast, a statistically insignificant improvement in knockdown at acidic 
pH was observed for formulations with low-to-intermedia charge density. Although the effect of 
N:P ratio was minimal in contrast to DDA, increasing N:P ratio could increase knockdown 
efficiency of formulations with low-to-intermediate DDA (Figure 6-3). 
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Figure 6-3 Effect of DDA, Mn, N:P ratio and pH on the biological performance of chitosan-
siRNA nanoparticles. Nanoparticles were formed in water following 1:1 (v/v) mixing of chitosan 
to siRNA (0.1 mg/mL). EGFP+ H1299 cells were transfected at a final siRNA concentration of 
100 nM. Data represent average ± standard deviation of at least 3 independent experiments with 
at least 2-3 technical replicates in each experiment (N=3, n=6-9). 
 
The effect of DDA, Mn and N:P ratio on nanoparticle internalization was investigated at 
physiological pH (7.2-7.4, 290mOsm) and in the presence of serum. As depicted in Figure 6-4A, 
nanoparticle internalization increased with increasing DDA, Mn and N:P ratio reminiscent of the 
trend observed in Figure 6-3. 
To understand the relationship between nanoparticle physicochemical characteristics and their 
biological activity, physiochemical parameters were correlated and regressed with respect to 
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knockdown efficiency. Figure 6-4 shows the relationship between size, surface ζ-potential, and 
knockdown efficiency. No correlation between size measured in 10 or 150 mM NaCl and 
knockdown was observed (Figure 6-4, B). However, nanoparticle ζ-potential, a parameter found to 
be strongly dependent on DDA, Mn and N:P ratio (Figure 6-1), showed strong correlation with 
EGFP knockdown with Pearson product moment correlation coefficient (PPMCC) reaching 0.74-
0.88. 
In order to demonstrate that observed knockdown is independent of metabolic disturbances, the 
viability of treated cells was determined relative to untreated controls using the alamarBlue® assay. 
The principle of the assay is based on the mitochondrial reduction of resazurin, a blue and non-
fluorescent molecule, into resorufin, a red and fluorescent molecule. As such, the number of cells 
and the incubation time were optimized before performing the assay since seeding density and 
population doubling time are critical parameters for accurate results.  
Figure S. 6-2 shows complete depletion of resazurin four hours post incubation at a cell density of 
65,000 cells/cm2. The optimal number of cells for viability testing was thereby determined to be 
15,625 cell/cm2, a cell density equivalent to 5,000 cells/well (96 well plate). 
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Figure S. 6-2 Effect of EGFP+ H1299 cell number on the reduction of alamarBlue®. Increasing 
cell numbers were seeded in 96 well plate, one day prior to the addition of alamarBlue®. 
Absorbance at 570 and 600nm was read 4 hours post-incubation and % reduction calculated 
using the following equation: % 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =
((𝑒𝑂𝑋)𝜆2𝐴𝜆1)−((𝑒𝑂𝑋)𝜆1𝐴𝜆2)
((𝑒𝑅𝐸𝐷)𝜆1𝐴′𝜆2)−((𝑒𝑅𝐸𝐷)𝜆2𝐴′𝜆1)
   where the εox is the 
molar extinction coefficient (ε) of alamarBlue® oxidized form, εRED is the molar extinction 
coefficient of the reduced form, A absorbance of test well, A’ absorbance of negative well 
(media+ alamarBlue® only), λ1 is 570nm and λ2 is 600nm. The optimal number of cells to be 
seeded 24 hours post transfection and tested for toxicity 48 hours post transfection with 
nanoparticles was determined to be 5,000 cells/well. 
 
As illustrated in Figure 6-4 D, a slight decrease of 5-15% in metabolic activity was recorded for all 
formulations tested except for the larger decrease observed with 98-10-5. Under identical 
transfection conditions where polymer and lipid-based nanoparticles are in contact with cells for 
48 hours, all formulations outperformed the lipid control. Under such conditions, DharmaFect® 2 
showed strong toxicity with around 60-80% cell death. However, it is noteworthy to mention that 
media replacement 5 hours post transfection abrogated changes in metabolic activity relative to 
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untreated cells for both chitosan and the lipid formulations and that no toxicity was observed when 
evaluated 4 hours post-transfection (data not shown). 
 
Figure 6-4 Cell uptake, knockdown, correlations to size and charge, cell toxicity. A) The effects 
of DDA, Mn and N:P ratio on uptake were measured in the EGFP+ H1299 cell line 48 hours post 
transfection at 100 nM siRNA B) Lack of correlation between EGFP knockdown and 
nanoparticle size measured at low and high ionic strength. C) Strong correlation between EGFP 
knockdown and nanoparticle surface charge (ζ-potential) measured at low and high ionic 
strength. D) Effect of different formulations prepared at N:P 5 on metabolic toxicity. All 
experiments in these figures were performed at pH 7.2-7.4 in the absence of serum. Media over 
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cells was aspirated and replenished with complete media 44 hours before analysis. All data 
shown represent average of at least 3 independent experiments with 2-3 technical replicates per 
experiment (N=3, n=6-9). Correlation graphs represent average values of size or ζ-potential 
correlated with average values of EGFP knockdown. 
 
 In vitro knockdown efficiency is Mn independent above a certain 
threshold with chitosan found to disturb global gene expression.  
Based on the above results obtained from in vitro knockdown and the correlation between chitosan 
DDA, Mn and N:P ratio and physicochemical properties (size, ζ-potential and EE) and/or biological 
performance (EGFP knockdown and viability), the family of polymers with a degree of 
deacetylation of 92% was selected for further characterization of the effect of Mn, N:P ratio and 
serum proteins on siRNA uptake and knockdown. As depicted in Figure 6-5 A, in vitro uptake, or 
internalization, of DY647 labeled siRNA requires a threshold of polymer length of 10 kDa, above 
which internalization appears to be independent of both Mn and N:P ratio. Below this Mn threshold 
of 10 kDa, the role of N:P ratio appears critical with a two-fold increase in siRNA uptake when 
increasing N:P ratio from 5 to 30 (Figure 6-5 A). As expected, EGFP knockdown followed a similar 
pattern since uptake and knockdown are generally correlated, given the ability of these 
nanoparticles to escape endosomal compartments [17, 47]. Knockdown efficiency was independent 
of Mn and N:P ratio above 40 kDa (Figure 6-5). To demonstrate that the decrease in EGFP 
fluorescence intensity was not related to toxic or non-specific effects of chitosan itself, mock 
transfections with naked chitosan (M) and transfections using non-targeting siRNA (siNT) were 
included as controls. As shown Figure 6-5 C and D, the delivery of siNT resulted in minimal EGFP 
knockdown, reaching a maximum of 10±2% with 92-40. In contrast, mock transfections mediated 
a modest 5-10% increase in EGFP expression for some chitosans. The pattern of EGFP knockdown 
and/or expression for both siNT and mock seem to follow a trend where longer chain chitosans 
appears to have a slight positive effect on EGFP expression.  
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Figure 6-5 Effect of Mn at 92% DDA (92-Mn) and N:P ratio on uptake and knockdown. The 
EGFP+ H1299 cell line was transfected in the presence of 10% serum at a final siRNA 
concentration of 100 nM. A) Uptake of DY647 labeled siRNA expressed as median fluorescence 
intensity (MFI). B) EGFP knockdown post transfection with anti EGFP nanoparticles. C) Lack of 
EGFP knockdown post transfection with non-targeting siNT nanoparticles; siNT represents a 
scrambled siRNA and is an indicator of specificity to the target siRNA sequence. D) Lack of 
EGFP knockdown following transfection with chitosan only. Data represent the average ± 
standard deviation of 3 independent experiments with 2 technical replicates per experiment (N=3, 
n=6). 
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Since siRNA is a small and rigid molecule compared to other nucleic acids previously studied with 
chitosan, we hypothesized that chitosan chain length below a threshold of ~ 60-70 monomers (10 
kDa) have a lower affinity for siRNA and therefore release siRNA in complex media (pH 7.4, high 
ionic strength and presence of serum). As shown in Figure S. 6-3, an increase in Mn from 5 to 10 
kDa or 10 to 120 kDa dramatically improves siRNA encapsulation at low N:P ratios. Although the 
effect of physiological pH on nanoparticle stability, below the Mn 10kDa threshold, is clear (Figure 
S. 6-3), it does not seem to totally account for the loss of internalization and knockdown efficiencies 
observed in Figure 6-5. 
 
Figure S. 6-3 siRNA encapsulation efficiency of low and high Mn chitosan. Nanoparticles were 
formed in water by manual mixing of siRNA (0.1mg/mL) with chitosan at different N:P ratio, 
incubated in low ionic strength pH controlled buffers (MES pH 6.5, TE pH 7.4 and TAE pH 8.0) 
for 24 hours and siRNA release quantified using the Quant-iT™ RiboGreen® Assay. The percent 
siRNA release was quantified relative to naked siRNA or N:P 0. At pH 6.5, complete siRNA 
encapsulation was observed regardless of the Mn and N:P ratio used. At pH 7.4 and 8.0, siRNA 
release shows a Mn and N:P dependence with higher Mn and N:P ratio required for efficient 
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encapsulation. However, at physiological pH and at N:P ratio of 5, the 5 and 10kDa chitosans 
were able to encapsulate siRNA 60 and 80% respectively. 
 
We subsequently verified the effect of serum on EGFP knockdown with low versus high Mn 
chitosans (10 vs 120 kDa). Figure 6-6 shows a decrease in performance in the presence of 10% 
serum for the 10 kDa chain which was rescued by increasing the N:P ratio from 5 to 30 indicating 
that a threshold of at least 10 kDa is needed to counter the negative effects of both pH and serum 
(Figure S. 6-3 and Figure 6-6). 
 
Figure 6-6 Effect of FBS, chitosan Mn and N:P ratio at 92% deacetylation on EGFP knockdown 
in H1299 cells. A) EGFP knockdown measured as the average fluorescence intensity (FI) relative 
to untreated cells 48 h post transfection with siEGFP. EGFP+ H1299 cells were transfected in the 
absence or presence of 10% serum for a period of 5 hours, media aspirated and replenished with 
complete RPMI-1640 media (pH 7.2-7.4, 290 mOsm) and incubated for 44 hours before analysis. 
B) EGFP mRNA knockdown measured using qPCR, normalized using the geometric average of 
EIF, PUM-1, and GAPDH and calibrated to untreated cells. EGFP+ H1299 cells were treated as 
described in A. C) Representative confocal laser scanning microscopy (CLSM) images. EGFP is 
indicated in green. In all experiments, siRNA was delivered at a final concentration of 100 nM 
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and data in A and B expressed as the average value of 3 independent experiments with 2-3 
technical replicates per experiment (N=3, n=6-9), *p-value < 0.01. 
 
Next, we confirmed assessed knockdown on the transcriptomic level by quantifying EGFP 
messenger RNA (mRNA) using MIQE compliant quantitative real-time PCR (qPCR). qPCR is a 
very sensitive and powerful technique but can generate biased results in several cases where a 
single or a combination of factors such as normalization strategy, validation of primer efficiency 
and/or RNA integrity are not properly controlled [38, 41, 48-53]. As a consequence, the stability 
of reference genes following treatments was validated in parallel with the validation of primer-
probe efficacy (Error! Reference source not found.). As seen in Figure 6-7, common reference 
genes i.e. β-actin and HPRT were highly unstable with M scores above 0.5. Treatment dependent 
fluctuations were also observed during modeling of treatment effect, with the removal of 
DharmaFect® 2 altering the classification of reference genes (Figure 6-7, B). This observation 
confirms that treatments with either lipid or chitosan-based nanoparticles have, in principle, a 
certain impact on the transcriptome or at least on these tested reference genes.  
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Figure 6-7 Effect of chitosan and DharmaFect® 2 treatment on reference gene stability. A panel 
of 10 reference genes was tested for expression stability under diverse experimental conditions. 
EGFP+ H1299 cells were transfected with the following formulations i.e. 92-10-5, 92-10-30, 92-
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120-5, 92-120-30, 98-10-5, 98-10-30 and DharmaFect® 2 at a final siRNA concentration of 100 
nM. Untreated cells were included in the analysis. A) panel shows the classification of the least to 
most stable (left to right) reference gene based on the average expression stability values, or 
geNorm M-Score, computed on the remaining control genes during stepwise exclusion of the 
least stable control gene, for samples from all treatments. B) panel shows the effect of the 
exclusion of DharmaFect® 2 from the statistical analysis. C) Panel shows the effect of the 
exclusion of both DharmaFect® 2 and untreated cells from the analysis. The M-Scores were 
computed using the geNorm statistical package on the average Cq of two independent 
experiments 
 
The high variability of β-actin could be attributed to poor assay efficiency (84%), which was 
confirmed to be treatment independent as assays had the same amplification efficiency on cDNA 
amplified from total RNA extracted from treated vs untreated samples (Error! Reference source n
ot found.).  
 
Table S 6-1 Efficiency of the primer-probe pairs used in this study. Reference gene specific 
primer-probe pairs were tested for their amplification efficiency on complementary DNA 
(cDNA) prepared from total RNA extracted from non-treated EGFP+ H1299 cells. In order to 
validate that chitosan treatment does not affect reaction efficiency, primer-probe pairs specific to 
β2M and RPL13A were also tested on cDNA prepared from total RNA extracted from cells 
treated (transfected) with 92-10-30. Formulations were designated [DDA(%)-Mn (kDa)-N:P 
ratio]. High N:P was chosen to ensure maximum potential contamination of total RNA with 
chitosan. Data show that almost all primer-probe pairs passed, except for ACTB, and that 
chitosan does not affect amplification efficiency 
Treatment Assay name ABI Assay ID Efficiency (%) R2 Fail/Pass 
Non-treated 
PUM1 Hs00472881_m1 96.0 0.998 Pass 
RPL13A Hs04194366_g1 92.0 0.995 Pass  
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Pol2A Hs00172187_m1 96.5 0.999 Pass 
β2M Hs00984230_m1 95.0 1.000 Pass 
TFRC Hs00951083_m1 95.0 0.999 Pass 
HPRT Hs01003267_m1 102.0 0.997 Pass 
ELF1 Hs00152844_m1  94.0 0.999 Pass 
GAPDH Hs02758991_g1 94.0 0.997 Pass 
ACTB Hs01060665_g1 84.0 0.998 Fail 
PBGD Hs00609297_m1 94.5 1.000 Pass 
RecQL1 Hs00262956_m1 92.0 0.999 Pass 
eGFP Mr03989638 98.5 0.998 Pass 
CS treated 
β2M Hs00984230_m1 95.0 1.000 Pass 
RPL13A Hs04194366_g1 92.0 0.995 Pass 
 
The V-score, or the pairwise variation between the normalization factors NFn and NFn+1, showed 
that accurate normalization could be achieved by using the geometric mean of the 2-3 most stable 
reference genes (Figure S. 6-4). Under optimal normalization conditions and following MIQE 
guidelines, a similar trend for the effect of Mn and N:P ratio in the presence/absence of serum was 
observed using quantitative PCR (Figure 6-6, B). The knockdown of EGFP in the H1299 cells was 
qualitatively confirmed by confocal laser scanning microscopy (CLSM), as shown in Figure 6-6 
C. 
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Figure S. 6-4 Pairwise comparison on normalization factors to determine the minimum number of 
reference genes needed for accurate normalization using the Vandsompele model. A) All 
treatments, B) Excluding DharmaFect® 2, C) Excluding DharmaFect® 2 and untreated cells. A 
minimum of 3 reference genes needs to be used for accurate normalization when comparing all 
treatments. 
 
 In vitro lipid nanoparticle (LNP) like potency (EC50) can be achieved, in 
the presence of serum, using chitosans with increasing Mn and N:P ratio  
The effect of Mn and N:P ratio on the minimum effective dose needed for EGFP knockdown in the 
H1299 cell line was determined in the presence of serum. The half maximal effective concentration 
(EC50), a measurement of nanoparticle potency, was computed from a 4-parameter sigmoidal curve 
(4-PL) 48 hours post-transfection. Table 6-2 shows that potency increased with increased Mn and 
N:P ratio. DharmaFect® 2, a lipid control developed for siRNA delivery in H1299 cells, had the 
lowest EC50 (Table 6-2) and was able to induce meaningful knockdown at an EC50 of 23 nM. 
Similar potency was obtained with the 92-120-30 formulation (EC50 of 29.3 nM). 
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Table 6-2 Effect of Mn and N:P ratio on in vitro dose-dependent knockdown. EC50 values were 
derived from a 4-parameter sigmoid curve fitted to data derived from 2 independent experiments 
with 2 technical replicates per experiment; Figure S. 6-5 in supplemental data for more 
information, p-value <0.05.  
Formulation N:P ratio EC50(nM) EC50 Standard error p-value 
Curve fit 
R2 
92-10 5 77.2 9.88 0.01 0.99 
92-10 30 42.8 4.32 0.00 0.99 
92-120 5 46.3 1.71 0.00 0.99 
92-120 30 29.4 4.52 0.02 0.99 
DharmaFect® 2 NA 23.8 3.28 0.02 0.99 
 
As shown in Figure S. 6-5, all formulations reached a plateau around 200 nM with a marginal 
increase in EGFP knockdown observed at higher concentrations. The delivery of non-targeting 
siRNA (siNT) at higher doses (Figure S. 6-5) compared to Figure 6-5, C, did not cause a meaningful 
increase in off-target effects. Again, siNT induced a small decrease/increase in EGFP expression 
with low and high Mn chitosan respectively indicating that off-target effects are probably due to 
reduced metabolic activity observed with low Mn chitosan (Figure 6-9, A).  
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Figure S. 6-5 Effects of charge density, chain length and N:P ratio on dose-dependent EGFP 
knockdown. Nanoparticles were formulated with either siEGFP (anti-EGFP) or siNT (non-
targeting) and EGFP+ H1299 cells transfected in the presence of 10% FBS at increasing siRNA 
concentrations. DharmaFect® 2 was used a positive control to benchmark efficacy. EGFP 
knockdown was analyzed 48 hours post transfection using flow cytometry.  Data represent 
average values ± standard deviation of 2 independent experiments with 2 technical replicates per 
experiment. 
 
 Reduction in knockdown efficiency due to serum can be mitigated by 
increasing Mn and N:P ratio 
Following observations regarding the effect of serum on the performance of low molecular weight 
chitosan, coupled with the fact that one use of nanoparticle is systemic administration in vivo, the 
effect of increasing serum concentration on biological performance was studied. In particular, the 
effect of Mn and N:P ratio on EGFP knockdown was investigated in the presence of increasing 
serum concentrations. As shown in Figure 6-8 A, nanoparticles rapidly lost their performance in 
the presence of increasing serum concentration. This loss of performance could be mitigated by 
higher Mn and/or N:P ratio. The latter seems to play an important role in promoting transfection in 
the presence of high concentration of serum (i.e. 94%). The effect of physiological concentrations 
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of heparin (2.5 µg/mL) [54] and albumin (25-40 mg/mL) at pH of 7.2-7.4 on payload release was 
studied by means of dye exclusion. As shown in Figure 6-8, C, a physiological concentration of 
heparin, equivalent to concentrations found in 94% serum, was able to displace the payload. 
Increasing both Mn and N:P ratio improved encapsulation efficiency but could not abrogate 
payload release. In contrast, serum albumin seems to have a protective effect (Figure 6-8, D) with 
no payload release observed following incubation of nanoparticles with physiological 
concentrations of the protein. 
 
Figure 6-8 Effect of increasing concentration of serum on the biological performance of 
nanoparticles. A) Effect of increasing serum concentration on EGFP knockdown. B) Percent loss 
of EGFP knockdown in the presence of 94% serum compared to transfection without serum. C) 
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Effect of physiological concentration of heparin sulfate (2.5 µg/mL) on payload release. Low (10 
kDa) and high (120 kDa) 92% deacetylated chitosan was formulated with siRNA at different N:P 
ratio and incubated for 1 hour in the absence and presence of heparin sulfate (pH 7.4). Increased 
fluorescence indicates increased payload release D) Effect of physiological concentration of BSA 
(25 mg/mL) on payload release. Low (10 kDa) and high (120 kDa) 92% DDA chitosan was 
formulated with siRNA at different N:P ratio and incubated for 1 hour in the absence and 
presence of BSA (pH 7.4). 
 Metabolic and genotoxic testing demonstrate the safety of chitosan-siRNA 
nanoparticles at low/high Mn and N:P ratios 
The effect of chitosan chain length and N:P ratio on metabolic activity and genomic integrity was 
assessed using the alamarBlue® and comet assays respectively. Figure 6-9 A shows a small 
decrease in metabolic activity with low molecular weight chitosan at both N:P ratio of 5 and 30. In 
contrast, no reduction in metabolic activity was observed for the high molecular weight chitosan. 
Increasing N:P ratio had no effect on metabolic activity, or cell viability, as revealed by the 
comparison of low vs high N:P ratio for the two Mn tested, 10 and 120 kDa (Figure 6-10A). 
Sequence-dependent activation of IFN, PKR, and TLRs, among others, has been demonstrated for 
other delivery systems and could potentially affect in vitro metabolic activity through translation 
inhibition or other mechanisms. As a consequence, mock transfections were performed in parallel 
to rule out sequence-dependent effects and showed no significant differences between mock and 
nanoparticles treated cells suggesting chitosan as the principal factor affecting metabolic activity 
(Figure 6-9, A). 
The effect of molecular weight and increasing N:P ratios, where the latter increases the amount of 
free chitosan not complexed to nanoparticles, on genotoxicity was measured by the comet assay at 
8 and 48 hours post transfection. The percentage DNA in the tail (PDT), or the proportion of 
damaged DNA, and the Olive Tail Moment (OTM), or the product of the tail length and the fraction 
of total DNA in the tail, were computed for all comets obtained for each treatment (Figure 6-9, B 
and C). Interestingly, opposing trends were observed for low vs high Mn (Figure 6-9, B). An 
identical, but less pronounced, pattern was observed for OTM (Figure 6-9, C). The significance of 
the observed increase, for either parameter recorded, was evaluated using the Kruskal-Wallis (KW) 
non-parametric statistics. Significant differences between treatments were only detected for percent 
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DNA in tail (PDT) (Figure 6-9, B) and is probably due to approximation bias in tail length 
assessment. Therefore, and due to lack of agreement between the two parameters (PDT vs OTM), 
the KW test was deemed questionable to demonstrate genotoxic effects. As a consequence, an 
analytical approach based on [55] was used. Each series of measures was reduced to the median 
and the 75th percentile, two representative parameters of comet distribution, and a regression 
analysis followed by an ANCOVA performed. Figure 6-9D, show no significant effect of the 
molecular weight or the N:P ratio suggesting no genotoxic effect of chitosan.  
 
 
Figure 6-9 Effect of chitosan Mn and N:P ratio at 92% DDA on in vitro toxicity and genotoxicity. 
A) Metabolic activity relative to untreated EGFP+ H1299 cells measured by the alamarBlue® 
assay. Activity was measured 48 h posttransfection. Mock chitosan (M) was used at N:P 30 to 
assess the effect of siRNA encapsulation on metabolic activity. DharmaFect® 2 (DF), a 
commercial lipid-based system, was used as a comparator. Dimethyl sulfoxide (DS) was used as 
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positive control of toxicity. B) Effect of increasing Mn and N:P ratio on genotoxicity as measured 
using the comet assay parameter "% DNA in tail (PDT)". The PDT represents the percentage of 
DNA migrated in the tail of the comet or the proportion of damage to total DNA. C) Effect of 
increasing Mn and N:P ratio on genotoxicity as measured using the parameter "Olive tail moment 
(OTM)". OTM represents a parameter that is insensitive to the measurement of tail length. D) 
Correlation between median PDT and N:P ratio for 10 vs 120 kDa chitosan. For the alamarBlue® 
assay, data represent average metabolic activity ± standard deviation of 3 independent 
experiments with 2-3 technical replicates per experiment (N=3, n=6-9). For the comet assay, box 
plots were constructed from data of 2 independent experiments with more than 100 
comet/experiment/treatment. 
 
 
Figure S. 6-6 Representative images of comets 48 hours post transfection with nanoparticles. The 
montage was prepared with ImageJ. Hydrogen peroxide (H2O2) at 100 and 200 µM was used as 
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positive control for genotoxicity. DharmaFect® 2 siRNA nanoparticles were used as a 
comparator. Formulations at low and high Mn (92-10 and 92-120) were prepared at different N:P 
ratio (5, 30, 60 and 120) and transfected at final siRNA concentration of 100 nM (~0.00132 
mg/mL). Equivalent concentration of chitosan at specific N:P ratio was 0.004, 0.018, 0.037 and 
0.074 mg/mL for the N:P 5, 30, 60 and 120 respectively. Naked chitosan, or mock (M), was used 
as a control to account for the effect of the siRNA sequence. Typical comets are observed post 
treatment with the positive control. A dose-dependent increase in comet tail length can be seen 
when comparing 100 vs 200 µM H2O2. 
 
Table S 6-2 Descriptive statistics of the data collected for genotoxicity parameters 
Parameters tested % DNA tail Olive Moment Tail/Total Area 
Treatment Size Mean 
Std 
Dev 
Std. 
Error 
C.I. of 
Mean 
Mean 
Std 
Dev 
Std. 
Error 
C.I. of 
Mean 
Mean 
Std 
Dev 
Std. 
Error 
C.I. of 
Mean 
Non-treated  203 7.2 8.7 0.6 1.2 0.8 2.0 0.1 0.3 17.4 10.0 0.7 1.4 
100µM H2O2 207 92.6 9.7 0.9 1.9 32.4 4.9 0.5 0.9 92.7 9.6 0.9 1.9 
200µM H2O2 285 90.6 14.0 1.5 3.0 36.5 7.0 0.7 1.5 90.3 13.2 1.4 2.8 
DharmaFect 
2 
217 7.0 5.7 0.7 1.3 0.9 1.0 0.1 0.2 17.7 9.4 1.1 2.2 
1992-10-05 251 10.4 13.0 1.2 2.4 1.5 2.6 0.2 0.5 21.7 14.3 1.3 2.6 
1992-10-30 322 8.6 7.0 0.6 1.2 0.9 1.3 0.1 0.2 17.2 9.2 0.8 1.6 
92-10-60 313 11.4 6.9 0.6 1.2 1.2 1.0 0.1 0.2 19.0 8.3 0.7 1.4 
92-10-120 205 12.7 11.8 1.1 2.2 1.4 1.6 0.2 0.3 20.4 13.1 1.2 2.5 
92-120-5 218 12.9 15.4 1.4 2.7 1.2 1.8 0.2 0.3 19.4 14.8 1.3 2.6 
92-120-30 219 9.4 9.1 0.7 1.4 1.0 1.2 0.1 0.2 17.8 10.3 0.8 1.6 
92-120-60 223 9.6 12.6 1.2 2.3 0.9 1.5 0.1 0.3 17.1 12.4 1.2 2.3 
92-120-120 208 7.4 3.9 0.4 0.7 0.6 0.5 0.0 0.1 16.0 4.9 0.5 0.9 
 
 Chitosan induce Mn- and dose-dependent hemolysis and aggregation of 
red blood cells 
Assessment of metabolic activity and genotoxicity demonstrated the safety of chitosan-based NPs 
in vitro (Figure 6-9). However, neither the alamarBlue® nor the comet assay are predictive of 
toxicity that might occur when nanoparticles interact with blood following intravenous 
administration (I.V.). As such, the effect of chain length (Mn) and dose on blood compatibility was 
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investigated according to the ASTM-E2524 standard [43]. As illustrated in Figure 6-10, a dose-
dependent increase in hemolysis was observed for both low and high Mn chitosan. The 5 % ASTM 
hemolysis threshold was crossed at a blood concentration of 0.321 and 0.04 mg/mL for the 92-10-
5 and 92-120-5 respectively. Assuming an N:P ratio of 5, the maximum siRNA dose that could 
potentially be intravenously (I.V.) administered at the observed threshold crossing point is 8 and 1 
mg/kg respectively. Increasing the siRNA dose or chitosan concentration in blood from 0.040 to 
0.321 mg/mL increased hemolysis by two-fold indicating a nonlinear relationship. Positive i.e. PLL 
and TX-100 and negative controls i.e. PEG and HA controls were within the ASTM standard 
(Figure 6-10, inset) whereas excipients (buffer) and siRNA were found to be non-hemolytic, i.e. 
below the threshold, confirming that dose dependent hemolysis is attributed to chitosan. In parallel 
to hemolysis, Mn and dose-dependent red blood cells (RBC) agglutination was investigated to 
further understand chitosan-blood interaction. Table 6-3 shows that both 92-10-5 and 92-120-5 
induced dose-dependent RBC agglutination above a Circulating Blood Volume (tCBV) 
concentration of 0.04 mg/mL. The degree of hemagglutination, as qualitatively assessed by 
aggregate size, increased with both dose and Mn (Table 6-3).  
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Figure 6-10 Effect of Mn and dose on hemocompatibility via red blood cell (RBC) lysis. Low (10 
kDa) versus high (120 kDa) molecular weight chitosans were formulated with HPLC-grade 
siRNA at an N:P ratio of 5. Increasing doses of siRNA were mixed with human pooled blood and 
% hemolysis determined as per ASTM-E2524 [43]. The concentration of chitosan (mg/mL) in the 
test vial (equivalent to the concentration in total circulating blood volume or tCBV), the 
equivalent chitosan dose in mg/kg of body weight and the corresponding siRNA dose in mg/kg 
for N:P of 5 are shown. The inset shows data from positive and negative controls. Poly-L-Lysine 
(PLL), Triton-X-100 (TX-100), Polyethylene glycol (PEG), buffer (excipients at 1% trehalose, 
5.8 mM histidine, pH 6.5), Hyaluronic acid 866 kDa (HA) and siRNA. Data represent the 
average ± standard deviation of 2 independent experiments with 3-6 technical replicate per 
experiment (N=2, n= 6-12). 
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Table 6-3 Effect of Mn and dose (concentration) on red blood cell agglutination. Agglutination 
was measured qualitatively and scored. (-) No aggregation, (+) Low agglutination, few 
aggregates (++) Medium agglutination, several large aggregates, (+++) Strong agglutination, 
clumps, (++++) Very strong agglutination, large clumps. 
Formulation Chitosan dose (mg/kg) Equivalent blood Conc. (mg/mL) Aggregation 
92-10-05 
2.8 0.04 - 
7 0.1 + 
14 0.2 ++ 
22.4 0.321 ++ 
92-120-5 
2.8 0.04 - 
7 0.1 +++ 
14 0.2 ++++ 
22.4 0.321 ++++ 
PEG NA Not calculated  - 
Buffer  NA Not calculated - 
HA NA 1.26 - 
siRNA NA 0.321 - 
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 Chitosan promotes extrahepatic siRNA delivery to proximal epithelial 
tubular cells of the kidney and induces target specific functional 
knockdown. 
The effect of Mn on in vivo biodistribution using whole animal based ex-vivo imaging and CLSM 
was examined. As shown in Figure 6-11, chitosan based nanoparticles accumulated in the kidney 
and gallbladder of Balb/c nude mice following intravenous administration at a dose of 0.5 mg/kg 
(10 µg siRNA/animal). Naked siRNA followed its known tendency for elimination past the kidneys 
[35, 56-58]. However, siRNA accumulated in the kidneys many folds higher when complexed with 
chitosan suggesting a protective and targeting role of the delivery vector. Invivofectamine® 2.0 
(InV) formulated siRNA, or InV LNP, showed a strong signal in liver/gallbladder, followed by 
spleen and kidneys. In order to examine the cellular accumulation of siRNA in the kidney, 
histological sections were generated and examined under confocal microscopy. As shown in Figure 
6-12, the amount of siRNA in the kidney proximal tubules was greatly enhanced in comparison 
with naked siRNA and Invivofectamine® 2.0. Interestingly no glomerular accumulation was 
observed at this dose for either chitosan-based nanoparticle or controls (data not shown). Confocal 
microscopy showed punctate intracellular accumulation in proximal tubule cells (PTEC) indicating 
that siRNA was internalized across the brush border membrane lining PTECs (Figure 6-12). The 
efficacy of these uncoated systems to knockdown the glyceraldehyde-3 phosphate (GAPDH) gene 
was determined in the kidney cortex (Figure 6-13). In light of the in vitro performance described 
in this report, the effect of DDA and Mn was investigated in vivo through the comparison of 
compositions with different DDA (i.e. 98 vs 92%) and Mn (i.e. 10 vs 120 kDa). As shown Figure 
6-13 A, nanoparticle physicochemical characteristics post-freeze drying, rehydration and injection 
(in excipients) demonstrated a similar Mn-dependent size increase as previously seen in NaCl 
(Figure 6-1). Low (10 kDa) and high (120 kDa) Mn chitosan were around 100 and 150 nm 
respectively (Figure 6-13). Cationic lipid nanoparticles (LNPs) and polymer based systems 
generally induce systemic toxicity, accompanied with a sharp reduction in body weight, upon 
intravenous administration through liver toxicity and immune stimulation. Our data show that 
multiple chitosan administration, below the hemolytic dose (Figure 6-13), did not induce a 
significant reduction in body weight except for the 98-10 formulation demonstrating tolerance. 
Mice injected with 98-10-5 quickly recovered upon the second administration (Figure 6-13, C). In 
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this study in vivo efficacy was demonstrated through functional GAPDH knockdown where both 
low Mn (10 kDa) chitosan demonstrated the highest efficacy (~ 40-50% knockdown) (Figure 6-13). 
In contrast to our in vitro data (Figure 6-8), high Mn (120 kDa) chitosans did not outperform their 
low Mn counterparts (Figure 6-13, D). As expected, chitosan improved knockdown efficiency in 
kidney cortex in comparison with naked siRNA with 30-35% more knockdown (Figure 6-13, D). 
 
Figure 6-11Effect of Mn on the bio-distribution of chitosan-siRNA nanoparticles. Nanoparticles 
were injected in Balb/c nude mice at a dose of 0.5 mg/kg of DY647 labeled siRNA (equivalent 
dose of 1.4 mg/kg of chitosan) and organs imaged ex-vivo 4 hours post administration. 
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Figure 6-12 Histological and CLSM images of nanoparticles accumulated in PTEC. 
Nanoparticles were injected in Balb/c nude mice at a dose of 0.5 mg/kg of DY647 labeled siRNA 
(equivalent dose of 1.4 mg/kg of chitosan), organs perfused and collected 4 hours post 
administration, fixed and cryosectioned (5 µm). For CLSM, sections were stained with phalloidin 
red and Hoechst. (PBS) Phosphate Buffered Saline, (siNaked) naked DY647 labeled siRNA, (InV 
LNP) Invivofectamine® 2.0-DY647 siRNA-lipid nanoparticles, (PTEC) Proximal epithelial tubular 
cells, (NPs) Nanoparticles. DY647 siRNA = Green, Nucleus = Blue and Brush borders= Red 
(actin staining). 
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Figure 6-13 Effect of DDA and Mn on in vivo knockdown in the kidney. A) Size of the injected 
nanoparticles. Nanoparticles were rehydrated in excipients to reach a target dose of 2.5 mg/kg, 
injected and the remaining volume, diluted 1:8 in excipients and assessed for size using dynamic 
light scattering. B) Polydispersity index (PdI) of injected nanoparticles. The PdI was 
automatically computed during DLS in A. C) Changes in body weight following multiple 
injections. Mice body weight was monitored for a period of 8 days and measured before injection 
and at euthanasia as an indirect assessment of general toxicity. Arrows and cross represent 
injection and euthanasia respectively. D) Functional target knockdown in the kidney. 
Nanoparticles were manually prepared, freeze-dried, rehydrated with excipients and injected in 
Balb/c mice at a dose of 2.5 mg/kg siRNA. Seventy-two hours after the last administration, 
kidneys were collected, excised, lysed and the GAPDH enzymatic activity assessed using the 
KDalert® assay and normalized to total protein content. Cleveland dot plot represents 3 animals 
per treatment group, with average and standard deviation represented in the form of bars. 
Statistical significance was computed with One-Way ANOVA followed by Tukey test for 
multiple comparisons: *p< 0.01, **p <0.001, ***p < 0.00001 
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Figure S. 6-7 Effect of siRNA and salt concentration on nanoparticle size. In a previous 
experiment (Figure 6-1, A), the effect of DDA and N:P ratio on nanoparticle size was found to be 
negligible relative to Mn, when particles were mixed with siRNA (0.1mg/mL) and suspended in 
10mM NaCl (pH 5.5). As a consequence, one chitosan and one N:P ratio i.e. DDA 92%; N:P 5 
were selected to further study the effect of siRNA (mg/mL) and NaCl (mM) concentration on 
nanoparticle size. The latter was measured in 10mM NaCl using 10 versus 120kDa following 
manual mixing with specific siRNA concentration (mg/mL). For size measurements using 
dynamic light scattering, particles were formed as described in the materials and methods of this 
manuscript and diluted (1:8) either in 10 or 150mM NaCl and size measured after 2.5 min post-
160 
 
incubation. A) 92-10-5 B) 92-120-5. Data represent the average ± standard deviation of two 
independent experiment with a technical triplicate in each experiment (N=2, n=6). 
 
6.4 Discussion  
This study demonstrates the importance of chitosan DDA (charge density), polymer length Mn, 
and N:P ratio on nanoparticle physicochemical properties and biological performance. The effect 
of chitosan DDA which controls charge density, or the number of protonatable amines (NH2), 
played a predominant role in dictating successful in vitro knockdown (Figure 6-3). The positive 
effect of high charge density, achieved at high DDA, on knockdown efficiency can be attributed to 
several factors including increased binding affinity for siRNA, increased electrostatic interaction 
with cell membranes and increased endosomal buffering capacity. None of the previous studies 
[25-29, 31] investigating the influence of chitosan molecular parameters on siRNA delivery 
examined the biological relevance of DDA. Instead, these reports varied polymer length and the 
amine to phosphate molar ratio (N:P) to optimize in vitro knockdown efficiency (KD). In our study, 
the degree of polymerization, or chain length (Mn), and the N:P ratio had a positive but marginal 
effect on knockdown efficiency (Figure 6-3). This observation is in agreement with results reported 
previously [24, 26] where increased polymer length and N:P ratio had minimal effects on target 
knockdown efficiency. These findings are distinctly different from previous work on chitosan 
mediated plasmid delivery (pDNA), where a fine balance and coupling between Mn and DDA was 
found to be important for effective complexation and to promote intracellular decomplexation and 
transgene expression [16, 17, 20]. Those previous studies with plasmid as payload found that 
modulation of either chain length or charge density in order to reduce nanoparticle stability to a 
threshold where particles are able to protect pDNA and promote intracellular dissociation was 
required for efficient transgene expression. This dependence that coupled DDA to Mn achieve 
expression from plasmids is in contrast to siRNA, most likely since pDNA is a long and flexible 
molecule with an excess of phosphate binding sites on each molecule compared to amine sites on 
each chitosan chain, permitting a stronger and higher affinity binding of chitosan to pDNA versus 
chitosan to the shorter siRNA [16, 17, 20]. Compared to plasmid DNA, siRNA is a small and rigid 
molecule, that binds to chitosan with a lower affinity [24] compared to pDNA [19]. Our findings 
highlight differences in design principles for the development of chitosan-based nanoparticles for 
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the delivery of different types of nucleic acids. In the current study, we found a simultaneous 
increase in DDA, Mn and N:P ratio could optimise siRNA-based knockdown (Figure 6-2) versus 
the complex interaction of these parameters that need to be accounted for to optimize expression 
from plasmids. 
In the current study, increased chain length (Mn) and N:P ratio increased biological performance 
and the former needed to be above a certain Mn threshold of 10 kDa (~60-70 monomers) (Figure 
6-5). EGFP knockdown efficiency and nanoparticle internalization were both reduced when 
nanoparticles were formulated at 5 kDa and required an increase in Mn and/or N:P ratio to rescue 
efficiency. This observation is in agreement with previous findings [26, 29]. Low in vitro 
performance was not only attributed to nanoparticle integrity (Figure 6-2) at pH above chitosan 
pKa (6.5-6.9) but also due to the presence of serum (Figure 6-6). Low Mn formulations showed 
inferior performance in presence of serum and required an increase in Mn or N:P ratio for improved 
potency (Figure 6-6), suggesting nanoparticle destabilization occurring through competitive 
displacement with negatively charged serum components. The negative effect of serum on 
nanoparticle integrity has been previously demonstrated for cationic liposomes [59] and chitosan-
PEI hybrid nanoparticles [25]. Although we could not elucidate the precise effect of serum, heparin 
and albumin were found to have antagonistic effects on siRNA release with heparin increasing and 
albumin decreasing release (Figure 6-8, C and D). Cooperation between competing serum 
components, ionic strength, pH and their effects on nanoparticles is believed to drive the need for 
higher Mn and N:P ratio for particle stability (Figure 6-1, 2 and 8). This observation was confirmed 
in the presence of relevant in vivo concentrations of serum, where nanoparticle performance 
decreased in a Mn and N:P dependent manner (Figure 6-8, A and B). The in vivo relevance of high 
N:P ratio and its effect on potency in the presence of physiological concentrations of serum may 
not be accurately estimated by the in vitro environment due to the ability of the free excess chitosan 
to partition to different compartments than the nanoparticles. However, these findings are important 
for the development of efficient in vivo delivery systems where a combination of high DDA and 
Mn needs to be used to maintain stability and induce efficient target knockdown. Nanoparticle size 
and surface charge are two important parameters that affect colloidal stability, pharmacokinetics, 
biocompatibility and nanoparticle-cell interactions [60]. In this study, size increased with 
increasing polymer length (Mn) and ionic strength (Figure 6-1). In contrast to size, nanoparticle ζ-
potential, increased with increased DDA, Mn and N:P ratio and decreased with increasing ionic 
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strength. As expected, an increase in the DDA, or number of ionizable amine groups (NH2) per 
chain (density), increases the charge density of the polymer and consequently has a direct and 
positive influence on ζ-potential. However, surface charge is not, at least theoretically, expected to 
increase with increasing Mn since 1) the pairing of chitosan positive charge and siRNA negative 
charge groups is not obviously Mn-dependent and 2) an increase in size, due to an increase in Mn, 
is translated to a lower electrophoretic mobility and thus a lower apparent ζ-potential. Nevertheless, 
this Mn-dependent increase in ζ-potential may be due to chains that are partly bound at the surface 
resulting in pendant chains that are longer for higher Mn that increase surface charge or possibly 
more chitosan chains are bound in particles through greater cooperativity of binding to siRNA. The 
reduction of ζ-potential at high ionic strength is due to surface charge screening. A decrease in 
surface potential decreases electrostatic repulsive forces between particles, therefore, causing 
colloidal instability and an apparent increase in size measured by dynamic light scattering (Figure 
6-1). The effect of ionic strength on colloidal stability over time showed strong aggregation (Figure 
S. 6-1) and could, therefore, influence nanoparticle performance in vivo through unintended blood 
interactions. In this study, ζ-potential positively correlated with knockdown efficiency (Figure 6-4, 
C) confirming previous reports [16, 61]. As expected, the lack of correlation between size and 
EGFP knockdown could be explained by serum dependent size stabilization occurring through 
rapid protein corona formation [18].  
siRNA and/or vector-based off-target effects continue to pose problems at the bench and the 
bedside [9, 62, 63]. A thorough evaluation of off-target effects was conducted in our study (Figure 
6-5) with non-targeting siRNA (siNT) and mock transfections (M) performed in parallel to 
treatments. As shown in Figure 6-5 C and D, the delivery of siNT showed insignificant knockdown 
while mock transfections mediated a slight increase in EGFP expression for some chitosans. In 
both cases, target knockdown and/or expression reached a maximum of ±10% indicating a 
relatively safe profile. The pattern of EGFP knockdown and/or expression seem to follow a trend 
where long vs short chains appear to have opposite effects. This is reminiscent of the marginal 
toxicity observed when assessing metabolic activity in transfected cells (Figure 6-4 and 9A). 
Therefore, the decrease in EGFP expression for both siNT and mock transfections observed with 
short chains, and independent of the N:P ratio, is possibly associated with marginal metabolic 
toxicity observed at low Mn (Figure 6-4 and 6.9A). Consistent with this idea, Malmo et al [26] 
found that mock transfection with fully deacetylated chitosan consistently reduced EGFP 
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expression by about 10% and that a dose-dependent response was associated with around 0-25% 
decrease. Although no metabolic decrease was mentioned in [26], the number of seeded cells was 
above the linear response of the assay and therefore, toxicity was not accurately estimated for 
correlation with mock-induced EGFP knockdown. However, this toxicity issue, was indirectly 
highlighted during qPCR calibration relative to siNT treated instead of non-treated cells, which 
according to the authors was justified by differences in confluence between chitosan treated and 
untreated cells [26]. 
Since qPCR normalization to one reference gene is associated with a high error bias [41, 48, 49], 
a pilot study to identify the most stable reference genes under our experimental conditions was 
conducted. The relevance of our findings are not limited to the normalization strategy and 
reduction in quantification bias, but also since chitosan treatment influenced the stability of the 
reference gene panel assayed (Figure 6-7). This result suggested that chitosan, and depending on 
its DDA, Mn and N:P ratio, disturbs global gene expression indicative of a certain parallelism 
with linear polyethyleneimine (lPEI) [64] and cationic lipids [65]. The impact of chitosan on the 
global transcriptome might be due to random binding of chitosan with intracellular nucleic acids 
or molecular machines through electrostatic or hydrophobic interactions. 
In order to mediate their intended effects, chitosan based nanoparticles are endocytosed, the 
payload released in the cytoplasm but could also accumulate in the nucleus [17]. In the cytoplasm, 
cationic polymers can interact with vesicular and mitochondrial membranes [66], disrupt normal 
protein synthesis via electrostatic interaction with polyanionic component in the cytoplasm, and/or 
induce the activation of molecular sensors. Endosomal release also exposes the cytoplasm to 
injuries from hydrolytic enzymes [60] while chitosan translocation into the nucleus could 
potentially induce genetic damage either through electrostatic interactions, hydrolysis from co-
impurities or through physical obstruction during chromosomal separation at the anaphase. 
Formulations used in this study were relatively non-toxic with around 10±10% reduction in cell 
viability (Figure 6-9). Toxicity increased with lower molecular weight chitosan with high DDA 
(Figure 6-9D and 6.9A). The observed toxicity was demonstrated to be siRNA-independent as 
shown in mock transfections at high N:P ratio (Figure 6-9, A). These results are affirmed in other 
studies, where chitosan showed minimal toxicity when formulated at N:P ratio ranging from 5-60 
[16, 21-24, 26, 28, 31]. In contrast, Liu et al. [29] have shown significantly reduced metabolic 
activity in H1299 cells. The apparent toxicity is probably due to the extremely high free chitosan 
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content (N:P 150), serum free conditions and assay specific differences. Chitosan-induced DNA 
damage was found to be statistically insignificant (Figure 6-9, D) indicating that neither the 
nanoparticle or the ascending concentrations of free chitosan or siRNA sequence were genotoxic.  
The cationic nature of chitosan favors interaction with cellular blood components that could 
potentially have deleterious effects in vivo. However, this aspect of probable toxicity has been 
neglected [15-18, 20-29, 31, 33, 37, 67] with in vivo reports often using extremely high N:P ratios 
without reporting any signs of toxicities [28, 32-36]. However, high N:P ratio could pose serious 
adverse effects in light of reports suggesting blood-material interaction, reviewed in [68]. Our data 
show that chitosan-based nanoparticles could induce hemolysis and hemagglutination in a dose-
dependent manner and, consequently highlight careful dosing to avoid hemotoxicity and/or 
embolism (Figure 6-10 and Table 6-3). 
Intravenous administration of chitosan-siRNA nanoparticles showed accumulation in the kidneys. 
Finer examination of kidney structures revealed a punctate pattern of siRNA [17] in the cytoplasm 
of the proximal epithelial tubular cells (PTECs) suggesting translocation through the glomerular 
basement membrane (GBM) (Figure 6-12). Although naked siRNA filters through the kidneys 
([69] and Figure 6-11) and a fraction accumulate in PTECs ([69] and Figure 6-12), our data clearly 
indicate a role for chitosan in increasing the efficiency of siRNA accumulation into PTECs (Figure 
6-11 and 6-12) probably through glucosamine (Glc)-Megalin interaction and subsequent 
internalization [34, 70]. However, nanoparticle translocation through the GBM remains to be 
elucidated mechanistically since fenestration and the extracellular matrix limit nanoparticle 
translocation and diffusion. Translocation and PTEC accumulation could be achieved through 
either non-conventional mechanisms as observed with 200-300 nm carbon nanotubes [71] or 
through nanoparticle disassembly at the highly negative GBM and reassembly in the lumen as 
proposed for cyclodextrin-based nanoparticles [72]. Alternative delivery through the fenestrated 
peritubular capillaries could occur but also faces similar diffusion challenges through the 
negatively charged interstitium. Irrespective of the mechanism involved, chitosan based 
nanoparticles, not only accumulate in the cytoplasm of PTEC, but also induce functional 
knockdown (Figure 6-13) without causing deleterious effects on body weight. (Figure 6-13, D). 
In this study, in vivo efficacy was demonstrated through functional GAPDH knockdown where 
both low Mn (10 kDa) chitosans demonstrated the highest efficacy (~ 40-50% knockdown at the 
protein level) (Figure 6-13). In contrast to the in vitro data in Figure 6-8, high Mn (120kDa) 
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chitosans did not outperform their low Mn counterparts (Figure 6-13, D) highlighting fundamental 
differences between in vitro and in vivo validation. Gao et al [34] demonstrated that low Mn (40 
kDa) fully deacetylated chitosan is able to achieve around 50% knockdown in PTEC when 
formulated at N:P ratio of 60 with higher Mn and/or lower N:P ratio unable distribute to the 
kidneys. In contrast, we have demonstrated that low and high Mn – except for the high Mn fully 
deacetylated chitosan –  are able to achieve 40-50% target knockdown when formulated at low 
N:P ratio highlighting proper physicochemical characterization since nanoparticle 
physicochemical properties before injection, in [34], are highly questionable with non-
homogenous and polydisperse NP (400-800 nm). The distribution of naked – LNA modified anti-
GAPDH (siGAPDH) – siRNA in mice exhibited a predictable pattern based on the known 
propensity of oligonucleotides to accumulate in the kidneys [35, 73, 74] and resulted in poor (~ 
15%) knockdown (Figure 6-13, D) confirming prior reports [69, 74]. Formulation with chitosan 
significantly increased knockdown efficiency by~30-35% compared to fresh naked siRNA 
suggesting a clear and positive role of the delivery system.  
Compared to the potency of lipid systems (~70-90%) in advanced pre-clinical or clinical 
development [13, 75-77], functional target knockdown obtained with our system (~40-50%) 
appears to be lower. However, considerations such as half-life of the target gene (GAPDH vs 
FVII), potency of the payload, and tissue dependent technical challenges could explain these 
differences. Accurate estimation of target knockdown using conventional techniques, such as 
quantitative PCR, enzymatic activity or immunoblotting, depends on 1) the abundance of the 
target cell type (fraction of cells transfected relative to the organ), 2) the ability of the delivery 
system to transfect different cell types composing an organ and/or 3) the tissue – or cell – 
specificity of a target gene. Inasmuch as chitosan displays specific targeting to PTECs, a cell-type 
that represents a minor fraction of the cells in the kidney, assessment of target knockdown using 
conventional techniques is necessarily underestimated unless the target gene is PTEC specific and 
only expressed in this cell subtype. In contrast, LNPs accumulate in hepatocytes, the predominant 
cell type in the liver, permitting non-biased (accurate) estimation of target knockdown. Therefore, 
functional knockdown obtained in this report underestimates the true efficiency of our system to 
silence a target gene in PTECs, and suggest that precise evaluation of target knockdown requires 
the development of novel methods capable of estimating knockdown in a specific subset of cells 
composing an organ. 
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Hepatobiliary elimination in the gall bladder (Figure 6-11) indicates that a fraction of the injected 
nanoparticles is large enough to bypass liver fenestration and is probably in the size range of 0.3-
1 µm in blood [78]. Taken together, our findings are of critical importance to siRNA delivery 
since extra-hepatic targeting could be naturally achieved without chemical modifications or ligand 
targeting and accumulation occurred in PTECs, with functional target knockdown around 50% in 
kidney cortex, further differentiating this system from cyclodextrin-based NPs that accumulate in 
glomeruli and podocytes [72]. As a consequence, unmodified chitosan-siRNA nanoparticles could 
potentially be used for the treatment of PTEC associated kidney fibrotic diseases.  
6.5 Conclusion  
This study highlights the importance of chitosan DDA (charge density), chain length and 
nanoparticle amine to phosphate molar ratio for efficient and nontoxic in vitro performance. Highly 
deacetylated chitosans are superior siRNA delivery systems compared to partially acetylated 
chitosans. Highly deacetylated chitosans provide the optimal balance between biological 
performance and toxicity. These specific formulations displayed potent knockdown, low toxicity, 
and present minimal non-specific effects and no genotoxicity. Most importantly, chitosan was 
demonstrated to exhibit extra-hepatic accumulation to kidney proximal epithelial tubular cells 
where functional knockdown of ~50% at the protein level was demonstrated. This study further 
suggests that increased colloidal stability may improve hemocompatibility and maintain their 
natural kidney targeting ability. 
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Abstract: Nanoparticle toxicity represents a major hurdle limiting clinical translation with both 
cationic lipids and polymers that can produce preclinical toxicity and serious adverse events in 
clinical trials. Advancements in cationic lipid head groups have improved the therapeutic window 
but clinical application still requires the administration of prophylactic anti-inflammatory steroids. 
Chitosans, a family of natural polycationic and bio-degradable polymers have shown in vitro and 
in vivo efficacy for nucleic acid delivery. However, the effect of chitosan molecular weight (Mn), 
dose and payload type – i.e. unmodified versus modified siRNA – on cytokine induction, 
hematological and serological responses, body weight and clinical signs have not been investigated 
nor reported following intravenous (I.V.) administration in mice. To understand the influence of 
Mn, dose, payload and hyaluronic acid (HA) coating, on in vivo toxicity, immune stimulation, 
biodistribution and efficacy, precisely characterized low (10 kDa) and high (120 kDa) Mn chitosans 
with a fixed degree of deacetylation of 92% were produced and formulated with unmodified 
(immune stimulating) vs chemically modified (non-immune stimulating) siRNA, and tested for 
hemocompatibility as per ASTM standards for dose selection and I.V. administration to mice. 
Cytokine induction (IL-1β, IL-6, TNF-α, IFN-γ and KC), hematological (Hb, Hematocrit, platelets, 
…) and serological (ALT, AST, BUN, Cr, ...) responses were assessed at 4 (Cytokine) and 24 hours 
(Serology) post-administration. HA was used to coat nanoparticle to improve hemocompatibility. 
Body weight and clinical signs were monitored following single versus multiple injections. In vivo 
biodistribution and the efficacy of uncoated and HA-coated formulations to induce functional target 
knockdown were also investigated, and compared with cationic lipid nanoparticles 
(Invivofectamine®). Hemolysis was found to be dose and Mn-dependent with HA coating 
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abrogating hemolysis. In comparison with cationic lipid nanoparticles (LNPs), uncoated and HA-
coated chitosan NPs did not induce either immune stimulation or hematologic toxicity upon I.V. 
administration. Liver and kidney biomarkers remained unchanged with chitosan formulations 
while high doses of LNPs led, as previously reported, to increased transaminase levels and a 
decrease in body weight following repeated administration. In vivo biodistribution in mice show 
extra-hepatic accumulation of both uncoated and HA-coated NPs in the proximal epithelial tubules 
of the kidney with functional knockdown (measured by multiple techniques) reaching 60% 
suggesting potential applications in the treatment of kidney diseases. 
7.1 Introduction 
Small interfering RNA (siRNA) is a novel class of molecules with promising potential in treating 
previously un-druggable diseases via gene-specific knockdown. The clinical maturity of this potent 
and gene specific technology depends on the efficient delivery and cell uptake of these relatively 
large and negatively charged siRNA molecules without inducing any short or long term toxicities. 
Pharmacokinetic behavior, including absorption, distribution, metabolism, and excretion (ADME) 
depends on the chemical and structural architecture of these molecules [1]. Naked, and unmodified 
siRNA, are highly prone to nuclease degradation and are swiftly eliminated into the bladder 
resulting in poor target knockdown [2]. Modification of the sugar, and/or the backbone increases 
nuclease resistance, modifies pharmacokinetic/biodistribution profiles of these molecules via 
interaction with serum proteins and can reduce off-target effects. The modification pattern, type 
and position have been demonstrated to play an important role in abrogating off-target effects, 
improving guide strand loading into the RNA-Induced Silencing Complex (RISC) and dictating 
efficient target knockdown [1]. For instance, modifications such as 2’OMe were demonstrated to 
reduce immune activation [3, 4] and limit off-target effects via improved hybridization 
complementarity between the siRNA guide sequence and target mRNA [5]. Albeit very efficient, 
chemical modifications do not yet alleviate the problems of targeting siRNA delivery to the desired 
pharmacological site of action, limited endosomal release, or rapid renal elimination. 
Consequently, ligand-mediated targeting and encapsulation into delivery systems represent the two 
major delivery strategies used in clinical development. N-acetylgalactosamine (GalNAc)-
conjugation directs siRNA to liver hepatocytes and demonstrates potent target gene knockdown in 
phase II/III clinical trials [6]. GalNAc conjugated siRNA has also been co-delivered to the liver 
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along a GalNAc targeted and polyethylene glycol masked endosomolytic peptide or polymer as 
part of the Dynamic Polyconjugate System (DPC) [7]. These two conjugation approaches require 
highly modified siRNA to achieve knockdown [8] and demonstrate potency in pre-clinical and 
clinical studies. However, these approaches face serious challenges with the recent discontinuation 
of the investigational Alnylam Revusiran and Arrowhead ARC- 520/521 programs [9, 10] in 
response to imbalanced mortality in the TTR amyloidosis with cardiomyopathy phase III trial 
compared to placebo [9] and the death of a non-human primate administered with high doses of 
DPCs [10]. However, association between observed mortality and components of the payload (i.e. 
siRNA, or the delivery system) or other factors [9] still need to be mechanistically understood. 
Lipid-based nanoparticles (LNPs), physically protect the siRNA from serum nucleases and have a 
natural tendency to interact with negatively charged lipoproteins (i.e. ApoB A/E) and induce 
clinically meaningful target knockdown in liver hepatocytes [7, 9, 11]. In contrast to conjugates, 
LNPs require less chemical modification of the siRNA payload but are associated with serious side 
effects such as immune activation [12-15] and reduced potency following repeated administration 
[16, 17]. LNP clinical administration is preceded by and/or accompanied with prophylactic anti-
inflammatory steroids [12, 14, 18]. Additionally, LNPs are limited in their ability to deliver nucleic 
acid cargos beyond the liver [19]. Therefore, delivery systems that meet criteria such as colloidal 
stability, high encapsulation efficiency, low toxicity, and deliver siRNA efficiently to extrahepatic 
organs are critically needed. 
Chitosan is a family of cationic bio-copolymers composed of β (1-4) linked N-acetyl glucosamine 
(GlcNAc) and D-glucosamine (Glc) that has gained considerable attention for nucleic acid (NA) 
delivery due to its low toxicity, ease of production, and chemical modification. Chitosan can be 
fine-tuned to reach a specific degree of deacetylation (DDA), or fraction of protonatable amine 
(charge), and average molecular weights (Mw or Mn). The high degree of protonation of amino 
groups (NH2) occurring at a pH below chitosan pKa (~6.5-6.9) favors spontaneous assembly of 
polyelectrolyte complexes, or nanoparticles, through electrostatic interactions and have been used 
to deliver siRNAs both in vitro [20-30] and in vivo [26, 30-35]. The system has been in part 
developed in our laboratory, where we previously demonstrated that siRNA could be delivered, 
both in vitro [20, 21, 36, 37] and in vivo [38, 39], at low nitrogen to phosphate molar (N:P) ratios 
to avoid limited dosing, blood incompatibility and non-specific effects due to large quantities of 
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free excess chitosan at higher N:P ratios. As a cationic polymer, chitosan can interact with blood 
components, activate platelets, induce erythrocyte lysis [40] and, depending on its DDA, cause 
cytokine induction through macrophage/monocyte stimulation [41, 42]. These aspects of toxicity, 
at least in the nanoparticle field, have been neglected [20-27, 29, 31, 35, 36, 43-46] with in vivo 
reports often using extremely high N:P ratios without reporting any signs of toxicity and/or 
parameters such as clinical signs, hematological and/or serological biomarkers [26, 30-34]. In 
addition, and in contrast to LNPs, in vivo induction of cytokines was never characterized. 
Therefore, a systemic study with accurately characterized chitosan that investigates 
hemocompatibility, in vivo acute toxicity and demonstrates knockdown following I.V. 
administration of nanoparticles is needed. 
Here we report the complete hemocompatibility profile of uncoated and hyaluronic acid coated 
(HA) formulations and show that HA coating eliminates interaction with erythrocytes. Acute single 
ascending dose toxicity was assessed by measuring cytokine induction (4-hours post injection), 
hematological and serological biomarkers (24-hours post injection) and changes in body weight 
following single vs repeated administration. In addition, clinical signs and histopathological 
sections of main organs are reported to support the safety of our formulations. In vivo real-time 
imaging, and confocal microscopy was used to show the biodistribution profile and intracellular 
localization of both uncoated and HA coated nanoparticles. Functional target knockdown was 
measured by means of multiple techniques such as an enzymatic activity assay, western blotting 
and was qualitatively confirmed by immunohistochemistry. In this study, the biodistribution, 
toxicity, and efficacy of commercially available LNPs (Invivofectamine®) were compared with the 
uncoated and HA coated systems. 
7.2 Material and Methods 
 Materials  
Medical grade hyaluronic acid (HA, 866 kDa, HA1M-1) was purchased from Life Core Biomedical 
(Life Core Biomedical LLC, Chaska, MN, USA), Lipopolysaccharide (LPS) serotype O55:B5 
(TLRgrade™) from Enzo Life Sciences (Enzo life sciences, Farmingdale, NY, USA), Isoflurane 
(Forane™) from Baxter (Baxter Canada, Mississauga, ON, Canada), BD Vacutainer SST Gold 
from WVR international (VWR International, Mont-Royal, QC, Canada), IDEXX green top 
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Lithium-Heparin and yellow top serum microtainers from IDEXX Laboratories (IDEXX 
Laboratories, Markham, ON, Canada), Altogen in vivo transfection kit from Altogen Biosystems 
(Altogen Biosystems, Las Vegas, NV, USA), Invivofectamine® 2.0 and 3.0, phosphate buffered 
saline (PBS), UltraPure™ DNase⁄RNase-Free water, 10% Neutral Buffer Formalin, AlexaFluor 
546 phalloidin with ProLong® Diamond antifade containing DAPI and nuclease free water from 
Life Technologies (Burlington, ON, Canada). D-trehalose, L-histidine, diethyl pyrocarbonate 
(DEPC), 1N HCl, and RNaseZAP™ from Sigma-Aldrich (Sigma-Aldrich, Oakville, ON, Canada). 
Rabbit monoclonal anti-GAPDH (Ab181602) and, biotinylated goat anti-Rabbit IgG (Ab97049) 
were purchased from Abcam (Abcam, Cambridge, UK). Serum vials (223685, 223686 and 223687) 
were purchased from Wheaton (Wheaton, Millville, NJ, USA), and butyl Stoppers (73828A-21) 
from Kimble Chase (Kimble Chase, Rockwood, TN, USA). PVDF filters (.22 µm) and Amicon 
Ultra-15 centrifugal filter units were from EDM Millipore (EDM Millipore Ltd, Etobicoke, ON, 
Canada) 
 siRNA sequences and chitosan characterization  
The native and 2’O methyl (2’OMe) modified anti-ApoB siRNA sequences were custom 
synthesized by Dharmacon Inc (GE Dharmacon, Lafayette, CO, USA). The anti-ApoB siRNA 
sense sequence was 5’- GUC AUC ACA CUG AAU ACC AAU -3’ and the antisense sequence 
was 5’-5' P.AUU GGU AUU CAG UGU GAU GAC AC -‘3, duplex Mw 14,053.5 g/mol with P 
denoting a phosphate group. The 2’OMe modified siRNA had the same antisense sequence and the 
following sense sequence 5’-GuC AuC ACA CuG AAu ACC AAu-‘3, with lower case letters 
denoting 2’O methylation and a duplex Mw of 14,122.8 g/mol. The anti-GAPDH siRNA was 
purchased from Life Technologies as a predesigned Ambion® In Vivo GAPDH Positive Control 
siRNA (Life Technologies, Burlington, ON, Canada). The anti-GAPDH sense sequence was 5’-
GGU CAU CCA UGA CAA CUU UTT-3’, duplex Mw 13,400 g/mol. This siRNA sequence was 
LNA modified for increased stability. The position of the LNA modifications, as well as other 
Silencer™ modifications, was not disclosed by the manufacturer. All siRNA sequences were 
provided in a lyophilized format following HPLC purification and were subjected to quality control 
(i.e. endotoxin content, LC-MS, PAGE and UV/Vis spectrophotometric analysis). 
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Chitosans were obtained from Marinard, (Laval, QC, Canada) and depolymerized in our laboratory 
using nitrous acid to achieve specific number-average molecular weight targets (Mn) of 10 and 120 
kDa (Table 7-1). Chitosan number and weight-average molecular weights (Mn and Mw) were 
determined by gel permeation chromatography (GPC) using a Shimadzu LC-20AD isocratic pump 
coupled with a Dawn HELEOS II multi-angle laser light scattering detector (Wyatt Technology 
Co, Santa Barbara, CA), an Optilab rEX interferometric refractometer (Wyatt Technology Co), and 
two Tosoh TSKgel (G6000PWxl-CP and G5000PWxl-CP; Tosoh Bioscience LLC, King of 
Prussia, PA) columns. Chitosans were eluted at pH 4.5 using an acetic acid (0.15 M)/sodium acetate 
(0.1 M)/sodium azide (4 mM) buffer. The injection volume was 100 µL, the flow rate 0.8 mL min−1 
and temperature 25°C. The dn/dc value was determined at 0.208 using a laser’s wavelength of 658 
nm. The degree of deacetylation was determined by 1H NMR as per in house published methods 
[47]. 
Table 7-1 Characterization of chitosans tested in this study. Different chitosans are denoted 
according to their chemical composition using the nomenclature [DDA-Mn] and are represented 
in the first column of the table. The degree of deacetylation (DDA) was determined by 1H NMR. 
The number and weight average molecular weight (Mn and Mw) were determined by gel 
permeation chromatography (GPC). The polydispersity index (PdI) was calculated as Mw/Mn. 
The degree of polymerization (Dp) or chain length was computed using the following equation 
𝑫𝒑 =
𝑴𝒏 𝒄𝒉𝒊𝒕𝒐𝒔𝒂𝒏
𝑨𝒗𝒆𝒓𝒂𝒈𝒆 𝒎𝒐𝒏𝒐𝒎𝒆𝒓 𝒎𝒐𝒍𝒂𝒓 𝒎𝒂𝒔𝒔 𝒂𝒕 𝒔𝒑𝒆𝒄𝒊𝒇𝒊𝒄 𝑫𝑫𝑨
 
Chitosan DDA (%) Mn (kDa) Mw (kDa) PdI Dp 
92-10 92.0 9.0 13.7 1.52 55 
92-120 91.9 138 181 1.31 836 
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 Preparation of chitosan-based nanoparticles 
7.2.3.1 Preparation of chitosan, hyaluronic acid, and siRNA working solutions 
Low (10 kDa) and high (120 kDa) molecular weight chitosans were dissolved overnight in nuclease 
free water and 1N HCl, using a glucosamine to HCl ratio of 1:1, to a final concentration of 5 
mg/mL. Hyaluronic acid (HA), was prepared by dissolving sodium hyaluronate in nuclease-free 
water at a final concentration of 1 mg/mL. The stock solutions were sterile filtered using a 0.22 µm 
PVDF filter and used to prepare solutions, containing 0.83% w/v trehalose and 5.83 mM histidine 
(toxicity) or 1% trehalose and 3.8 mM histidine (efficacy), at a specific amine: phosphate: HA 
carboxyl molar ratio (N:P:C = 2:1:1.5) by dilution in nuclease-free water, 4% w/v trehalose and 28 
mM histidine (pH 6.5). Before complexation, anti-ApoB (native and 2’Ome modified) and anti-
GAPDH siRNA stock solutions were diluted to 0.2 mg/mL in the same buffer as chitosan and/or 
HA (0.83% trehalose and 5.83 mM histidine or 1% trehalose and 3.8 mM histidine). Nanoparticles 
were prepared as described below.  
7.2.3.2 Preparation, lyophilization and reconstitution of uncoated and HA-coated anti-
ApoB nanoparticles (NPs) for the assessment of in vivo toxicity  
Uncoated and HA-coated anti-ApoB nanoparticles were prepared at a final N:P:C ratio of 5:1:0 
and 2:1:1.5 respectively using the advanced Automated Inline Mixing System (AIMS) as described 
in [37]. Chitosan at a specific N:P ratio (5:1 or 2:1) was mixed, using a closed and sterile system 
comprising an LS14 Pharmapure tubing (1/16”) and two Masterflex L/S digital peristaltic pumps 
(Cole-Parmer, Montreal, QC, Canada), with siRNA (0.2 mg/mL) using a Y-connector and a mixing 
flow rate of 150 mL/min (Re=4000). Anti-ApoB nanoparticles prepared at N:P 2 were HA-coated 
to a final N:P:C of 2:1:1.5 using the primary version of the AIMS. The chitosan-siRNA 
nanoparticles (N:P:C of 2:1:0) were mixed with HA using a Y connector at a 1:2 vol:vol ratio and 
a mixing flow rate of 150 mL/min (nanoparticles) and 75 mL/min for HA. All nanoparticles were 
incubated for 30 min at room temperature upon preparation before analyses or freeze-drying. In 
order to inactivate possible nucleases, the whole closed system was treated with 
diethylpyrocarbonate (DEPC), autoclaved and flushed with nuclease free water.  
Anti-ApoB nanoparticles were lyophilized, under sterile conditions, using a 3-day cycle as 
described in [48]. Nanoparticle volumes of 2 and 5 mL were pipetted into 5 and 10 mL serum vials 
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respectively, mounted with 20 mm butyl lyophilization stoppers, and freeze-dried using a 
Laboratory Series Freeze-Dryer PC/PLC (Millrock Technology, Kingston, NY, USA). Samples 
were backfilled with argon, stoppered, crimped, and stored at 4°C until reconstitution. All freeze-
dried samples were reconstituted to 12 times their initial concentration using water for injection 
(208 or 417 µL to samples in 5 or 10 mL serum vials), respectively, incubated at room temperature 
for 5-10 minutes, and the concentration adjusted, by dilution with a nearly-isotonic aqueous 
solution of 10% w/v trehalose and 70 mM histidine (pH 6.5), so that the desired dosage (mg 
siRNA/kg animal body weight) would be reached upon injection of 10 µL of nanoparticle 
suspension per gram of body weight (BW).  
7.2.3.3 Preparation of uncoated and HA-coated anti-GAPDH nanoparticles for 
assessment of in vivo target knockdown 
Anti-GAPDH siRNA (0.2 mg/mL), Low Mn (10 kDa), high Mn (120 kDa) and hyaluronic acid 
(HA) working solutions were prepared as described above. Uncoated chitosan-siGAPDH 
nanoparticles were prepared at an N:P ratio of 5 by simple electrostatic mixing at a 1:1 vol:vol. HA 
coated nanoparticles, were prepared at an N:P ratio of 2.5:1 by manual mixing (1:1 vol:vol), 
incubated at room temperature for 15 minutes, and coated with HA by mixing 1 part of HA working 
solution (0.4 mg/mL) to 2 parts of chitosan-siGAPDH nanoparticles for a final N:P:C ratio of 
2.5:1:2. The final volume never exceeded 1 mL and chitosan was pipetted into siRNA. 
Nanoparticles were kept at room temperature for 20-30 minutes before administration to animals.  
  Preparation of Invivofectamine®-siRNA-lipid nanoparticles (LNPs) 
Invivofectamine® 2.0 and 3.0 were prepared as per manufacturer recommendation. For 
Invivofectamine® 2.0, a volume of 250 µL of anti-ApoB siRNA (3 mg/mL) was diluted (1:2) in 
complexation buffer, mixed with 500 µL of Invivofectamine® 2.0, vortexed for 30 seconds, 
incubated at 50 oC for 30 minutes, diluted with 14 mL phosphate-buffered saline and concentrated 
at 4000 g using an Amicon Ultra-15 centrifugal filter unit (EDM Millipore Ltd, Etobicoke, ON, 
Canada) to a final volume of 872 µL (0.8 mg/mL siRNA).  
For Invivofectamine®3.0, anti-GAPDH siRNA solution (2.4 mg/mL) was mixed with 
complexation buffer at 1:1 ratio and immediately added to Invivofectmine® 3.0 at a 1:1 vol/vol 
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ratio, vortexed for 30 seconds, incubated at 50oC for 30 minutes and diluted to 0.25 mg/mL siRNA 
using PBS (pH 7.4). All LNPs were subjected to quality control (i.e. DLS, Doppler velocimetry, 
UV measurements and sterility assessment), stored at 4oC for 10-16 hours before administration 
into mice. Note: Invivofectamine® 3.0 was used as a replacement for Invivofectamine® 2.0 which 
was discontinued at the time of the efficacy study. 
 Determination of size and surface charge  
Size and surface charge (ζ-potential) of nanoparticles were determined by Dynamic Light 
Scattering (DLS) and Laser Doppler velocimetry using a ZetaSizer Nano ZS device (Malvern 
Instruments Ltd, Malvern, UK). The scattering angle of the detector was fixed at 173o and 
measurements were performed at 25oC using the viscosity of water as sample diluent. 
Nanoparticles were diluted to 1X their initial concentration using nuclease-free water, followed by 
a dilution 1:4 and 1:8 using sterile filtered 1% trehalose solution before determination of size and 
ζ-potential respectively. The Smoluchowski equation was used to calculate ζ-potential from the 
measured electrophoretic mobility. All measurements were done in triplicate and replicated at least 
once (N=2-3, n=6-9).  
 Hemocompatibility  
Hemolytic and hemagglutination properties of uncoated and HA-coated nanoparticles were tested 
according to ASTM E2524 [49] and Evani et al [50] respectively. Human blood was collected on 
consenting and healthy donors following protocol approval by the University Ethics Committee. 
Anti-ApoB nanoparticles were prepared as described above, freeze-dried (FD) in the presence of 
0.83% w/v trehalose, and 5.8 mM histidine (pH 6.5), and rehydrated to 12X the pre-FD 
concentration using nuclease free water to reach the highest tested concentration (or dose) at iso-
osmolality and then serially diluted using 10% w/v trehalose buffer (300 mOsm) to a final siRNA 
concentration of 0.1, 0.25, 0.5, and 0.8 mg/mL. The plasma-free hemoglobin (PFH) in the blood 
was measured at 0.49 mg/mL prior to initiating the assay. Total blood hemoglobin (TBH) was 
adjusted with PBS to a concentration of 10 ± 1 mg/mL (dTBH). Nanoparticles were mixed with 
PBS and diluted in dTBH at a 1:7:1 volumetric ratio, with 100 µL of nanoparticles at the target 
concentration pipetted into an Eppendorf tube containing 700 µL PBS and 100 µL of blood (dTBH 
10 ± 1 mg/mL). For colorimetric determination of hemolysis, samples (700 µL) were incubated for 
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3 h in a water bath at 37°C and visually inspected every 30 minutes for nanoparticle flocculation, 
dispersion, sinking or floating. The supernatant was collected following centrifugation at 800 g for 
15 min and absorbance measured at 540 nm on a TECAN Infinite® M200 PRO microplate system 
(Tecan Systems, Mannedorf, Switzerland). A four-parameter regression algorithm (4PL) was used 
to obtain the calibration curve required to calculate the hemoglobin concentration in the supernatant 
of each sample (PFH sample). The percentage of hemolysis was computed as 𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 (%) =
100 × (𝑃𝐹𝐻𝑠𝑎𝑚𝑝𝑙𝑒 𝑇𝐵𝐻𝑑⁄ ). For hemagglutination, the remaining 200 µL of each sample prepared 
above were pipetted in 96 well assay plates, incubated for 3h, visualized using an Axiovert light 
microscope and the area covered by red blood cells (RBCs) estimated and scored. 
 In vivo studies 
All in vivo experiments described in this manuscript were randomized double blinded and approved 
by the University of Montreal Ethics Committee (CDEA) and the Montreal Heart Institute 
Research Center Ethics Committee. Mice were purchased from Charles Rivers (Charles River, 
Quebec, Canada), housed and acclimatized in a specific pathogen-free facility with unrestricted 
access to water and food. Mice had body condition scores (BCS) of 3 [51] and their body weights 
(BW) were in the range of 20-25 g at the time of injection. All injection volumes were calculated 
as 10 µL/g of BW and injections performed within 10-15 seconds. Mice were euthanized under 
anesthesia (mixture of 3% Forane™ and 20-80% oxygen-air vol/vol) by cardiac puncture followed 
by cervical dislocation. 
7.2.7.1 Determination of chitosan-siRNA biodistribution using ex-vivo organ imaging  
Balb/c nude female (♀) mice aged 6 weeks and weighing 20-22 g were injected for the 
biodistribution experiments. All test articles i.e. naked siRNA, Invivofectamine® 2.0 and chitosan 
based nanoparticles formulated at an N:P:C of 5:1:0 or 2:1:1.5 (Mn 10 and 120 kDa) were 
administered at a dose of 0.25 mg/kg DY647 labeled siRNA, except for the HA-coated NPs which 
were administered at 0.165 mg/kg. The DY647 fluorophore was administered at a dose of 0.5 mg/kg. 
Mice were euthanized 4 hours post administration and immediately perfused using PBS (1 X 20 
mL) and 10% Neutral Buffer Formalin (NBF, 1 X 40 mL). Ex-vivo imaging on collected organs 
was performed using a whole animal imaging system mounted with an EMCCD EM N2 camera 
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(NUVU Cameras, Montreal, QC, Canada). Controls included PBS, naked DY647 labeled siRNA, 
DY647 alone, and commercially available lipid control Invivofectamine® 2.0. 
7.2.7.2 Determination of chitosan-siRNA nanoparticle in vivo toxicity 
CD-1® (ICR) female (♀) and male (♂) mice aged 4-5 weeks and weighing 22-24g were used for 
the toxicity study. Mice (7 / group; 4 ♀ and 3 ♂) were administered the test and control articles. 
Mandibular blood collection was performed prior and 4 hours post administration of test articles, 
and serum separated at 10,000 g following 10-minute incubation at room temperature and stored 
at -80oC. Two out of the 7 mice (2/7) were euthanized at 4 hours (1 ♀ and 1 ♂), and the remaining 
five mice per group (4 ♀ and 1 ♂) euthanized 24 hours post administration of test articles. At each 
time point (4 versus 24 h), the total circulating blood volume (tCBV) was collected by intracardiac 
puncture, and organs harvested, washed in PBS, split in half and one-half immediately stored in 
Liquid nitrogen (LiqN) while the second half fixed in 10% NFB. 
7.2.7.3 Hematological and serological parameters 
The total circulating blood volume was split into lithium heparin (LH) and serum separation tubes 
(SST), serum separated and samples stored on ice and sent to IDEXX Laboratories for the 
comprehensive complete blood count (CCBC) and the CC4 clinical chemistry panels. Analysis was 
performed in less than 24 hours using a Sysmex XTV 2000 (Sysmex, Mississauga, ON, Canada) 
and Beckman AU680 analyzers (Beckman Coulter Ltd, Mississauga, ON, Canada). 
7.2.7.4 Determination of cytokine levels  
Serum samples collected at baseline (0 h) and 4 hours post-administration of test articles were 
assayed for the induction of pro-inflammatory cytokine (TNF-α, IL-1β, IL-6, KC and IFN-γ) using 
the Luminex® technology. Plates were designed using the Bio-Plex® assay builder (Bio-Rad 
Laboratories, Mississauga, ON, Canada) and subjected to the manufacturer quality control. For 
each plate, a standard curve was prepared by diluting the Bio-Plex® Pro Mouse Cytokine Standard 
23-Plex in the Bio-Plex® in standard diluent followed by 4-fold serial dilutions from 1:4 to 1:65536 
in the same diluent. Samples were thawed on ice, cleared by centrifugation (10,000 g, 10 minutes, 
4oC), diluted 1:4 using the Bio-Plex® Sample diluent (Bio-Rad Laboratories, Mississauga, ON, 
Canada), and a volume of 20 µL transferred to assay plates pre filled pooled capture antibodies. 
The plates were incubated for 30 minutes under orbital shaking (800 rpm, room temperature), 
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washed as per manufacturer recommendation using a Bio-Plex® Pro II Wash Station (Bio-Rad 
Laboratories, Mississauga, ON, Canada), incubated with biotinylated detection antibodies (30 
minutes, 800 rpm, RT), washed and revealed post-incubation for 10 minutes with streptavidin-
phycoerythrin (800 rpm, RT). Data was acquired on a Bio-Plex® 200 system using RP1 PMT 
setting (Bio-Rad Laboratories, Mississauga, ON, Canada) with a minimum of 50 beads per region 
analyzed. For each cytokine, a 5-parameter regression algorithm (5-PL) was used to fit the data 
and interpolate cytokine values in serum samples. In order to account for inter-plate variability, 
two samples (i.e. one LPS and one Invivofectamine® 2.0 (8 mg/kg) sample) were used as interplate 
calibrators (IPC). 
 Determination of chitosan-siRNA nanoparticle in vivo efficacy 
Balb/c male (♂) mice aged 6-7 weeks and weighing 22-25g were used for the efficacy study. 
Uncoated anti-GAPDH NPs (viz. 92-10-5 and 92-120-5) and HA coated nanoparticles (viz. HA92-
10) were administered at 1 mg/kg (uncoated) and 8 mg/kg siRNA (HA coated) every other day for 
a total of three injections. Mice were sacrificed 72 hours following the last injection. Naked anti-
GAPDH siRNA (siGAPDH) and Altogen lipid nanoparticles (Altogen LNP) were I.V. 
administered at 2.5 mg/kg every other day for a total of three injections and sacrificed 72 hours 
following the last administration. The liver targeting Invivofectamine® 3.0 lipid nanoparticles (Inv 
LNP), were I.V. injected at 2.5mg/kg as a single injection and mice were sacrificed 72 hours post 
administration. Mice were euthanized as previously described and tCBV and organs collected. 
tCBV was serum separated and immediately stored at -80 oC, and organs split into halves and 
stored in LiqN and fixed in 10% NBF before protein extraction, determination of GAPDH 
enzymatic activity, western blotting, histology, and immunohistochemistry. 
7.2.8.1 Assessment of GAPDH enzymatic activity using the KDalert® assay 
Following collection, organs were snap frozen in liquid nitrogen and stored at -80oC until use. 
Frozen tissues were cut on dry ice, weighed (~20 mg), and disrupted using the TissueLyzer® II 
system (Qiagen Inc, Toronto, ON, Canada). Tissues were disrupted using the 5 mm steel beads 
(Qiagen Inc, Toronto, ON, Canada) under the following conditions: 2 x 30 Hz, 20 seconds per 
cycle. Homogenized tissues were resuspended in 750 µL of KDalert™ lysis buffer (Life 
Technologies, Burlington, ON, Canada), and incubated on ice for 30 minutes with inversions every 
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10 minutes. Lysates were clarified by centrifugation (2270 g, 30 minutes, 4°C), transferred to new 
tubes, and diluted (1:20), in KDalert™ lysis buffer. The standard curve was prepared by diluting 
GAPDH stock solution (26 U/mL) with lysis buffer at a 1:100 ratio (GAPDH: Lysis), followed by 
2-fold serial dilutions from 1:5 to 1:320. Twenty microliters of diluted samples, and standards were 
transferred into 96 well plates (Corning, NY, USA), and 180 µL of the KDalert™ Master Mix (Life 
Technologies, Burlington, ON, Canada) was pipetted into each well. Plates were incubated for 15 
minutes at room temperature and absorbance measured at 610 (±10) nm using a TECAN Infinite® 
F-500 microplate system (Tecan Systems, Mannedorf, Switzerland). GAPDH activity was 
computed from the standard curve and normalized to total protein content of the lysate sample as 
determined using the BioRad DC Protein assay kit (Bio-Rad Laboratories, Mississauga, ON, 
Canada).  
7.2.8.2 Western blotting 
Affinity-purified monoclonal antibodies used were against GAPDH and vinculin. Kidney cortex 
were excised, homogenized using the TissueLyzer® II system (Qiagen Inc, Toronto, ON, Canada) 
as described above and suspended in KD Alert lysis solution (Life Technologies, Mississauga, ON, 
Canada) in the presence of a protease cocktail inhibitor, and centrifuged at 2,270 g for 30 minutes 
at 4oC. The supernatant was quantified using the the BioRad DC Protein assay kit (Bio-Rad 
Laboratories, Mississauga, ON, Canada) and diluted in SDS buffer containing a final concentration 
of 62 mM Tris (hydroxymethyl)-aminomethane, 0.1 M SDS, 8.7% glycerol, 0.09 mM 
bromophenol blue, and 0.04 M dithiothreitol (DTT). Samples were heated for 5 min at 90oC, loaded 
into Protean mini TGX SDS-PAGE (4–12%) gradient polyacrylamide gels (Bio-Rad Laboratories, 
Mississauga, ON, Canada), and overnight wet transferred to Amersham™ HyBond® P PVDF 
membranes (GE Lifesciences, Mississauga, ON, Canada). Membranes were dried and blocked for 
1 h at room temperature in 5% nonfat milk, probed overnight at 4°C with anti-GAPDH primary 
antibody (1:1000), washed (3X, 15 min, 1% Triton in the presence of blocking buffer), and 
incubated with HRP conjugated anti-rabbit IgG1 secondary antibody (1:500) for 1h, washed, 
revealed using the Clarity Max™ ECL substrate (Bio-Rad Laboratories, Mississauga, ON, Canada) 
and visualized using the ChemiDoc MP™ system (Bio-Rad Laboratories, Mississauga, ON, 
Canada). Protein band quantification was performed using ChemiDoc MP™ software. 
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7.2.8.3 Clinical signs and body weight 
Mice clinical signs were determined for a period of 4-hours post-administration of test articles and 
at euthanasia. The clinical signs were recorded by trained personnel and qualified animal care 
technicians. Clinical signs were scored for body condition, general aspect, natural behavior, and 
provoked behavior. The Mouse Grimace Scale (MGS) was also used for scoring of clinical signs 
in case of distress. Body weight was recorded prior to each injection and at euthanasia using an 
Avery Berkel scale (Avery Berkel, Fairmont, MN, USA). Body weight was expressed as percent 
change relative to the previous injection.  
7.2.8.4 Histology and immunohistochemistry 
Samples were fixed in 10% neutral buffered formalin (NBF) prefilled HistoTainer™ II (Simport, 
Beloeil, QC, Canada), dehydrated in graded ethanol series, cleared with xylene and embedded in 
paraffin. Sections (5 µm) were collected on Superfrost™ Plus stain slides (Fisher Scientific, 
Ottawa, ON, Canada), and stained with Hematoxylin and Eosin. Prior to immunohistochemistry, 
antigen retrieval was performed with 10 mM Tris/1 mM EDTA pH 9 at 60oC. Sections were 
blocked with 20% (v/v) goat serum/0.1 % (v/v) Triton X-100/PBS for 1 hour at room temperature 
and then incubated for 16 hours at 4oC with Rabbit monoclonal anti-GAPDH (Ab181602) diluted 
1:250 in 10% (v/v) goat serum/0.1 % (v/v) Triton X-100/PBS. Sections were then incubated for 1 
hour at room temperature with Biotinylated goat anti-Rabbit IgG (Ab97049) diluted 1:500 in 10% 
(v/v) goat serum/0.1 % (v/v) Triton X-100/PBS. Revelation was performed with the Vectastain 
Avidin-Biotin Complex (ABC)-Alkaline Phosphatase (AP) and AP Red substrate kits (Vector 
Laboratories, Burlingame, CA, USA). Sections were counterstained with Weigert Iron 
Hematoxylin prior to dehydration, clearing, and mounting. Slides were scanned using a 
NanoZoomer digital slide scanner (Hamamatsu, Boston, MA, USA) and visualized using the NDP® 
view 2.0 software (Hamamatsu, Boston, MA, USA). 
7.2.8.5 Confocal laser scanning microscopy  
For in vivo biodistribution and subcellular localization of DY647 labeled siRNA, organs were 
cryosectioned (5 µm), actin stained using AlexaFluor 546 phalloidin and mounted with ProLong® 
Diamond antifade containing DAPI. Sections were imaged in a multitrack mode using a Zeiss LSM 
510 META confocal Axioplan 200 microscope (Carl Zeiss AG, Feldbach, Switzerland). 
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 Statistical analysis 
Data were collected and expressed as the average ± standard deviation (stdev). Statistical analysis 
was conducted using GraphPad Prism® 7.0 (GraphPad Software Inc, La Jolla, CA, USA) software 
package. Unless otherwise stated, One-Factor ANOVA followed by Dunnet test for multiple 
comparisons was performed on collected data.   
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7.3 Results  
 Uncoated chitosan NPs induced hemolysis and hemagglutination at 
high doses which were abrogated by hyaluronic acid (HA) coating 
Cationic polymers and lipids are often associated with an ability to interact with blood proteins and 
erythrocytes leading to decreased transfection, rapid clearance, embolism and hemolysis with 
abrogation of these negative effects achieved through PEGylation and/or the use of helper lipids 
(i.e. balancing between hydrophobic and cationic components). In order to select for dose, and 
investigate the effect of polymer length (Mn), free chitosan and hyaluronic acid coating (HA) on 
blood compatibility, erythrocyte hemolysis, and agglutination were investigated according to the 
ASTM-E2524 standard [49] and Evani et al [50] respectively. As shown in Figure 7-1, a dose-
dependent increase in hemolysis was observed for both low (10 kDa) and high (120 kDa) Mn 
chitosan. Erythrocyte lysis was abolished with a reduction in free chitosan from N:P 5 to 2 followed 
by HA coating. As a consequence, the maximum siRNA dose that could potentially be 
intravenously administered with chitosan depends on Mn, N:P ratio (or the fraction of free 
chitosan) and HA coating. According to the ASTM standard, a hemolytic index below 5% is 
regarded as safe [49]. In as much as doses of 5 and 1 mg/kg siRNA could be administered with low 
(10 kDa) and high (120 kDa) Mn chitosan, respectively, when formulated at N:P 5 and doses of at 
least 8 mg/kg siRNA for N:P 2 and HA-coated nanoparticles (Figure 7-1). Hemolysis increased 
two-fold with an increase in siRNA dose or chitosan concentration in blood from 0.040 to 0.321 
mg/mL indicating a nonlinear relationship for high Mn chitosan. Positive i.e. PLL and TX-100 and 
negative controls i.e. PEG and HA controls were within the ASTM standard [49] (Figure 7-1, Inset) 
whereas excipients (buffer) and siRNA were found to be non-hemolytic, i.e. below the threshold, 
confirming that dose dependent hemolysis be attributed to chitosan. 
Lipid nanoparticles (InvLNP) assayed at 1 and 8 mg/kg siRNA showed around 5% hemolysis with 
no dose effect (Figure 7-1, Inset) indicating minimal interaction with blood erythrocytes at pH 7.4, 
consistent with previous data for ionizable/cationic (pKa ~ 6.5) and PEGylated LNPs [52-54]. The 
influence of dose, Mn, N:P ratio and HA coating on hemagglutination, or erythrocyte aggregation 
was investigated to better understand chitosan-blood interaction and limit potential in vivo toxicity. 
Supplemental Figure S. 7-1 shows that both low and high Mn chitosan induced dose-dependent 
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hemagglutination above a threshold of 1 mg/kg siRNA, but could be eliminated with the reduction 
of free chitosan and HA coating. 
 
Figure 7-1 Hemocompatibility profiling of uncoated and HA coated chitosan-siRNA 
nanoparticles via red blood cell (RBC) lysis. Low (10 kDa) versus high (120 kDa) molecular 
weight chitosans were formulated with HPLC-grade siRNA at an N:P ratio of 5. HA coated 
formulations were formulated at an N:P:C of 2:1:1.5. Increasing doses of siRNA were mixed 
with human pooled blood and % hemolysis determined as per ASTM-E2524 [49]. The 
concentration of chitosan (mg/mL) in the test vial (equivalent to the concentration in total 
circulating blood volume or tCBV), the equivalent chitosan dose in mg/kg of body weight and the 
corresponding siRNA dose in mg/kg for N:P of 5 are shown. Inset shows data from positive and 
negative controls. Poly-L-Lysine (PLL), Triton-X-100 (TX-100), Polyethylene glycol (PEG), 
Excipients (1% trehalose, 5.8 mM histidine, pH 6.5), Hyaluronic acid 866 kDa (HA), siRNA (8 
mg/kg) and Invivofectamine® 2.0 (1 versus 8 mg/kg of siRNA). Data represent the average ± 
standard deviation of 2 independent experiments with 3-6 technical replicates per experiment 
(N=2, n= 6-12). 
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Figure S. 7-1Hemocompatibility profiling of uncoated and HA coated chitosan-siRNA 
nanoparticles via erythrocyte aggregation. Low (10 kDa) versus high (120 kDa) molecular weight 
chitosans were formulated with HPLC-grade siRNA at an N:P ratio of 5. HA coated formulations 
were formulated at an N:P:C of 2:1:1.5. Increasing doses of siRNA were mixed with human 
pooled blood, incubated and imaged for qualitative assessment of hemagglutination. In the 
absence of hemagglutination, erythrocytes (RBC) deposit in the bottom of the U-shaped well and 
194 
 
form a ring (see Non-treated, PEG, siRNA in B). In contrast, when hemagglutination occurs, 
aggregates become visible, stay suspended in solution and depending on the extent of 
agglutination may prevent the formation of the ring. A) Treatment samples at different doses of 
siRNA. B) Controls. 
 
 Uncoated and HA coated chitosan NPs promoted extrahepatic delivery 
of siRNA to kidney proximal tubular epithelial cells (PTEC)  
Next, we examined the effect of polymer length (Mn) and HA coating on in-vivo biodistribution 
using whole animal based ex-vivo imaging and confocal laser scanning microscopy (CLSM). As 
illustrated in Figure 7-2, chitosan based NPs accumulated in the kidney and gallbladder following 
intravenous administration of 0.25 mg/kg (5 µg siRNA/animal). Hyaluronic acid coating of the 
NPs seemed to increase siRNA accumulation in the kidney and gallbladder without altering the 
biodistribution profile observed with uncoated NPs. In contrast to polyethyleneimine (PEI)-siRNA 
based nanoparticles, chitosan, whether coated or uncoated, did not accumulate in the lungs or 
spleen indicating striking differences with the PEI delivery platform [55]. Controls, such as 
Invivofectamine® 2.0 LNPs (Inv LNP), naked siRNA and DY647 alone, accumulated in the liver 
and spleen (Inv LNP), kidney (naked siRNA) and bladder (DY647) respectively (data not shown). 
The fluorescent signal intensity of siRNA in the kidney was several folds lower compared to 
chitosan and HA chitosan NPs indicating a clear role of the delivery system in enhancing siRNA 
accumulation in the kidney. In order to examine cellular accumulation of siRNA in the kidney, 
histological sections were examined under confocal laser scanning microscopy (CLSM). As shown 
in Figure 7-2 B, siRNA formulated in NPs accumulated predominantly in the proximal tubule 
epithelial cells (PTECs) independent of chitosan Mn and HA coating. Nevertheless, siRNA 
accumulation in PTECs was greatly enhanced with HA coating as exemplified with an increase in 
fluorescence at a lower dose of 0.165 vs 0.25 mg/kg for uncoated NPs. Actin staining using 
phalloidin red revealed a typical punctuate siRNA pattern across the brush border membrane lining 
the PTEC, indicating intracellular localization (Figure 7-2, Insets). In contrast to lipid NPs, 
chitosan-based NPs accumulation in the kidney represents a new approach to treat PTEC dependent 
pathologies. 
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Figure 7-2 In vivo Biodistribution of uncoated and HA coated chitosan-siRNA nanoparticles. A) 
Effect of Mn and HA coating on the biodistribution of chitosan-siRNA nanoparticles. Uncoated 
nanoparticles were injected in Balb/c nude mice at a dose of 0.25 mg/kg of DY647 labelled siRNA 
(equivalent dose of 0.7 mg/kg of chitosan), HA coated nanoparticles were injected at a dose of 
0.165 mg/kg of DY647 labelled siRNA (equivalent dose of 0.2 mg/kg of chitosan) and organs 
imaged ex-vivo 4 hours post administration. B) Histological and CLSM images of nanoparticles 
accumulated in PTEC. Nanoparticles were injected as described above, organs perfused and 
collected 4 hours post-administration, fixed and cryosectioned (5 µm). For CLSM insets, sections 
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were stained with phalloidin red and DAPI. (PBS) Phosphate Buffered Saline, (siNaked) naked 
DY647 labeled siRNA, (Invivofectamine) lipid nanoparticles, (PTEC) Proximal epithelial tubular 
cells, (NPs) Nanoparticles. Lumen (L), DY647 siRNA = Green, Nucleus (N) = Blue and Brush 
borders= Red (actin staining). 
 Characterization of the injected nanoparticles 
As shown in Figure 7-3 A, lipid and chitosan based NPs were in the range of 60-100 nm with 
hyaluronic acid coating (HA) increasing chitosan NP size by two-fold. The polydispersity index 
(PdI), a dimensionless measure of dispersion around the mean, was below 0.2 indicating 
homogeneous particles. As expected, chitosan based NPs were positively charged with a ζ-potential 
between 25-30 mV. Hyaluronic acid (HA) coating at an N:P:C ratio of 2:1:1.5 inverted the surface 
charge to around -30 mV representative of HA coating. Lipid nanoparticles (Inv LNP) were quasi-
neutral (~ 8-10 mV). Although the exact composition of Inv LNPs is not disclosed by the 
manufacturer, a quasi-neutral surface charge is probably associated with PEGylation or the use of 
an increased molar ratio of neutral to cationic lipids in the formulation. 
Compared with inline mixed NPs (Figure 7-3, A and C), manually mixed chitosan-based 
nanoparticles had a similar size and surface charge (Figure 7-3 D and F) but a higher PdI indicating 
a homogenous but more disperse population of particles. As expected, and although theoretically 
less likely, surface charge increased with an increase in polymer length (Mn). The effect of siRNA 
composition and chemical modification had no impact on NP physicochemical characteristics 
(Figure 7-3 ). A slight concomitant increase in size and decrease in surface charge was observed 
for Inv LNP (Figure 7-3 A and C, vs D and E) and is considered to be composition dependent since 
Invivofectamine® 3.0 (Figure 7-3, D, E and F) is a novel formulation with higher potency than its 
previous counterpart Invivofectamine® 2.0 (Figure 7-3 A, B and C). The Altogen LNP, a liposome-
based formulation claiming kidney targeting ability, showed a size around 325 nm and ζ-potential 
around 5-10 mV. 
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Figure 7-3 Size, polydispersity index and surface charge (ζ-potential) of chitosan-based siRNA 
nanoparticles and lipid-based nanoparticles (LNPs). Invivofectamine® 2.0 (Inv LNP) were 
formulated with unmodified (siApoB Nat) or 2’O-methyl modified anti-ApoB siRNA (2’Ome 
siApoB) sequences (panels A, B and C). Invivofectamine® 3.0 and Altogen LNPs were 
formulated with LNA-modified anti-GAPDH siRNA (panels D, E and F). Low molecular weight 
chitosan, with a degree of deacetylation of 92% and molecular weight (Mn) of 10 kDa (92-10) 
was formulated with siApoB Nat or 2’Ome siApoB at an amine to phosphate ratio (N:P ratio) of 
5 (panels A, B and C). Low Mn (10 kDa) and high Mn (120 kDa) chitosans were formulated with 
LNA-modified anti-GAPDH siRNA at an N:P ratio of 5 (panels D, E and F). Hyaluronic acid 
(HA, 866 kDa) coated chitosan nanoparticles (HA92-10) were prepared at an N:P ratio of 2 and 
coated with HA at a phosphate to carboxyl ratio (P:C) of 1.5 (panels A, B, C, D, E and F). Size, 
PdI and ζ-potential of lipid nanoparticles (LNPs) were measured in phosphate buffered saline 
(PBS, pH 7.4). Size, PdI and ζ-potential of uncoated and HA coated chitosan-siRNA 
nanoparticles were measured in excipients (1% trehalose (w/w), 5.8 or 3.5 mM histidine, pH 6.5). 
A) Size (Z-ave diameter in nm), B) Polydispersity index (pdI), and C) Surface charge (ζ-
potential) of nanoparticles injected for the assessment of toxicity. D) Size (Z-ave diameter in 
nm), E) Polydispersity index (pdI), and F) Surface charge (ζ-potential) of nanoparticles injected 
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for the assessment of in vivo knockdown efficacy. Data represent the average ± standard 
deviation of 3 independent experiments with 2 technical replicates per experiment (N=3, n=6). 
 
 Unlike Lipid nanoparticles, uncoated and HA coated chitosan NPs did not 
induce immune stimulation and hematologic toxicity upon intravenous 
administration 
Systemic acute in vivo immune stimulation was investigated following I.V. administration of single 
ascending dose and compared with commercially available LNPs (Invivofectamine®). In order to 
exclude the role of siRNA in immune stimulation, all NPs were formulated with either unmodified 
or 2’O-methyl (2’Ome) modified anti-ApoB siRNA sequence (siApoB). This specific anti-ApoB 
sequence was previously demonstrated to activate the immune system and induce systemic toxicity 
when formulated with Chol: DSPC: PEG-cDMA: DLinDMA (molar ratio 48:20:2:30) based 
liposomes (SNALPs) or polyethyleneimine (PEI) [4] with the aforementioned deleterious side 
effects abrogated through selective and position dependent chemical modifications of the ribose 
backbone. As illustrated in Figure 7-4, pro-inflammatory type I cytokines (IL-1β, TNF-α, IFN-γ, 
IL-6 and KC) measured in serum 4 hours post-injection were markedly induced by bacterial 
lipopolysaccharide (LPS), a potent TLR-4 activator [56, 57], and lipid nanoparticles (Inv LNP) 
with no significant induction observed for uncoated and HA coated nanoparticles. Inv LNPs 
showed a dose-dependent and statistically significant induction of IFN-γ, IL-6 and KC and a minor 
TNF-α increase in serum. As expected, chemical modification (2’Ome) of the uridine (U) and 
guanine (G) nucleotides of the anti-ApoB siRNA (siApoB 2’Ome) abolished cytokine induction 
except for the murine IL-8 functional homolog KC (CXCL1). In contrast, uncoated and HA coated 
chitosan, and irrespective of the injected dose or payload did not significantly induce any of the 
assayed pro-inflammatory cytokines (i.e. IL-1β, TNF-α, IFN-γ, IL-6 and KC) demonstrating low 
in vivo immune stimulating potential following intravenous injection of chitosan-based systems. 
Interestingly, a small but statistically significant reduction in IL-1β was observed with all 
formulations containing chitosan regardless of the payload (Figure 7-4). Although, the decrease in 
IL-1β was only observed with chitosan injected mice, pre versus post-injection levels of IL-1β and 
TNF-α showed no significant changes and were generally lower than the PBS and excipient groups 
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(Figure 7-4 vs Supplemental Fig.S2), consequently excluding a treatment effect. However, the 
baseline difference between negative controls (i.e. PBS and Excipients) and chitosan treated groups 
could be attributed to different batches of mice (two orders of mice from the same supplier). In 
addition, pre versus post-injection (4h) indicate that KC levels increased by two-fold upon chitosan 
administration, yet remained statistically insignificant. 
 
Figure 7-4 Cytokine induction 4 hours post injection of a single ascending dose of 
Invivofectamine® 2.0, uncoated and HA coated chitosan-siRNA nanoparticles in CD-1® (ICR) 
mice. PBS (Phosphate buffered saline), LPS (Lipopolysaccharide), Inv LNP (Invivofectamine® 
2.0-siRNA Lipid Nanoparticles), siApoB Nat (unmodified anti-ApoB siRNA sequence), siApoB 
2’Ome (2’O methyl-modified anti-ApoB siRNA sequence), and HA (Hyaluronic acid, 866 kDa). 
Mice were I.V. injected with test articles, serum collected and analyzed 4 hours post injection 
using the BioPlex™ 200 system. Each symbol represents an animal and data represent average 
values ± standard deviation of 5-7 animals. Statistical significance versus PBS-treated animals 
was computed with One-Way ANOVA followed by Dunnett test for multiple comparisons: *p< 
0.01, **p <0.001, ***p < 0.00001. Note: In order to not bias the average, cytokine levels 
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(animals) below the range of detection (< OOR) were excluded and not considered as 0 or LLOQ 
(pg/mL). 
 
Figure S. 7-2 Cytokine levels pre-injection of Invivofectamine® 2.0, uncoated and HA coated 
chitosan-siRNA nanoparticles into CD1 mice. PBS (Phosphate buffered saline), LPS 
(Lipopolysaccharide), Inv LNP (Invivofectamine® 2.0-siRNA Lipid Nanoparticles), siApoB Nat 
(unmodified anti-ApoB siRNA sequence), siApoB 2’Ome (2’O methyl-modified anti-ApoB 
siRNA sequence), and HA (Hyaluronic acid, 866kDa). Mice were intravenously injected with test 
articles, serum collected and analyzed 4 hours post injection using the BioPlex 200 system. Each 
symbol represents an animal. Note: In order to not artificially manipulate the average, cytokine 
levels (animals) that were below the range of detection (< OOR) were excluded and not 
considered as 0 or LLOQ (pg/mL). 
 
We next examined the acute effect of NPs on hematological parameters and immune cells 24 hours 
post administration. As illustrated in Figure 7-5, hemoglobin and hematocrit levels decreased, 
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relative to PBS treated mice, with high doses of LNPs (8 mg/kg) and increased with uncoated 
chitosan NPs at high dose (2.5 mg/kg) with no correlation observed when these values were 
compared to the absolute reticulocyte count. Platelet counts decreased significantly with both LPS 
and InV LNPs encapsulating the native ApoB sequence (siApoB Nat) indicating acute 
thrombocytopenia (decreased platelet counts). The use of chemically modified siRNA (siApoB 
2’Ome) abrogated the sharp decline in platelets (Figure 7-5) confirming previous results where 
thrombocytopenia was linked to both the dianophore (i.e. chemical modifications) and 
pharmacophore (i.e. sequence motifs) of the encapsulated nucleic acid [58]. In contrast to the LNPs 
used in this study, no sequence or vector dependent thrombocytopenic effect was observed with 
both uncoated and HA coated chitosan NPs (Figure 7-5). LPS, Inv LNPs, and high doses of 
uncoated (2.5 mg/kg) and HA coated (8 mg/kg) chitosan-based NPs, decreased the circulating 
lymphocyte count (Figure 7-5) with an ostensible sequence dependent lymphopenic effect. 
However, the effect of chitosan-based NPs in decreasing the lymphocyte count was weaker than 
lipid NPs with values at the lower limit of the CD-1® (ICR) normal reference values. Basophils, 
eosinophils, neutrophils and monocytes were all unaffected by any of the treatments administered 
to both male and female CD-1® (ICR) mice (Figure 7-5). 
202 
 
 
Figure 7-5 Hematological profiling of Invivofectamine® 2.0, uncoated and HA coated chitosan-
siRNA nanoparticles following single ascending dose administration in CD-1® (ICR) mice. PBS 
(Phosphate buffered saline), LPS (Lipopolysaccharide), Inv LNP (Invivofectamine® 2.0-siRNA 
Lipid Nanoparticles), siApoB Nat (unmodified anti-ApoB siRNA sequence), siApoB 2’Ome 
(2’O methyl-modified anti-ApoB siRNA sequence), and HA (Hyaluronic acid, 866 kDa). Mice 
were intravenously injected with test articles, blood collected and analyzed 24 hours post 
injection at IDEXX Laboratories. Each symbol represents an animal and lines represent average 
values ± standard deviation of 5-7 animals except for InvLNP siApoB Nat (8 mg/kg) where 3 
animals were assayed for hematology. The gray shaded area represents the normal values (95% 
confidence interval, N= 266 divided as 133 ♀ and 133 ♂) of 8-12 week old CD-1® (ICR) mice 
from Charles Rivers Laboratories (North American colonies) [59]. Statistical significance versus 
PBS-treated animals was computed with One-Way ANOVA followed by Dunnett test for 
multiple comparisons: *p< 0.01, **p <0.001, ***p < 0.00001. Note: Normal range limits in this 
figure are not firm boundaries and should be used as guidelines since a large range of values was 
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reported in the literature and could be accounted for by variation in age, sex, sampling technique 
and testing methodology (i.e. instrument, technique …). 
 
 Liver and kidney biomarkers remain unchanged with uncoated and HA 
coated chitosan NPs while high doses of lipid NPs led to increased 
transaminase levels 
Since cationic lipid-based systems and liposomes, in addition to their immune stimulating 
properties, are known inducers of liver biomarkers such as alanine transaminase (ALT) and 
aspartate transaminase (AST), we investigated the effect of our formulations on serum biomarkers 
and compared them with LNPs (Figure 7-6) As shown in Figure 7-6, blood urea nitrogen (BUN) 
and creatinine (Cr), both byproducts of protein and creatine catabolism in the liver and muscles 
respectively and considered clinically relevant indicators (biomarkers) of kidney function, were 
within the normal reference ranges and statistically comparable to the PBS control group following 
injection with uncoated and HA coated chitosan-based NPs. Our results indicated that chitosan-
based NPs (uncoated and HA coated) targeting kidney PTEC (Figure 7-2) were well tolerated for 
at least 24 hours post-injection with no changes in kidney biomarkers (i.e. function). An increase 
in BUN with a concomitant decrease in Cr was observed for the LPS treated group consistent with 
increased protein catabolism, reduced clearance and induction of cytokines (Figure 7-4) associated 
with fever like symptoms or infections. Surprisingly a decrease in Cr with a normal BUN value 
was observed with Invivofectamine® 2.0-siRNA LNP (Inv LNP siApoB Nat) only at low dose. In 
contrast to lipid nanoparticles (LNPs) or liposomes, information on liver (or systemic) toxicity 
following administration of uncoated (positively charged) and HA coated (negatively charged) 
chitosan NPs is lacking. As illustrated in Figure 7-6, ALT, AST and ALP levels were within the 
normal range and comparable to the PBS control 24 hours post-administration of chitosan-based 
NPs indicating the absence of liver (or systemic) toxicity. As expected, cationic LNPs (Inv LNPs) 
demonstrated a dose-dependent increase in liver biomarkers with 2 to 3-fold increase in the 
ALT/AST ratio consistent with previous data [60, 61]. γ-glutamyl transferase (γGT), a relevant 
biomarker for liver and bile duct injury, total bilirubin (TBil) and creatine kinase (CK), a biomarker 
for muscle toxicity, were within the normal range for all formulations tested (i.e. Inv LNPs, 
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uncoated and HA coated chitosan). Despite the statistically significant increase in γGT observed 
for the high dose Inv LNP formulation, the clinical relevance of this increase is anecdotal due to 
high variability in γGT normal range (i.e. 0-12 IU/L). The lack of γGT expression 24 hours 
following administration of uncoated and HA coated nanoparticle indicate that hepatobiliary 
excretion (Figure 7-2, A) of these formulations is safe. Lipopolysaccharide (LPS) induced a 
decrease in alkaline phosphatase (ALP) and albumin/globulin ratio with no effect on ALT, AST, 
γGT, TBil and CK. 
 
Figure 7-6 Serological profiling of Invivofectamine® 2.0, uncoated and HA coated chitosan-
siRNA nanoparticles following single ascending dose administration in CD-1® (ICR) mice. PBS 
(Phosphate buffered saline), LPS (Lipopolysaccharide), Inv LNP (Invivofectamine® 2.0-siRNA 
Lipid Nanoparticles), siApoB Nat (unmodified anti-ApoB siRNA sequence), siApoB 2’Ome 
(2’O methyl-modified anti-ApoB siRNA sequence), and HA (Hyaluronic acid, 866 kDa), BUN 
(Blood Urea Nitrogen), ALT (alanine transaminase), AST (aspartate transaminase), ALP 
(Alkaline phosphatase), γGTT (gamma glutamyl transferase). Mice were intravenously injected 
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with test articles, blood collected and analyzed 24 hours post injection at IDEXX Laboratories. 
Each symbol represents an animal and data represent average values ± standard deviation of 5-7 
animals except for InvLNP siApoB Nat (8 mg/kg) where 3 animals were assayed for hematology. 
The gray shaded area represents the normal values (95% confidence interval, N= 266 divided as 
133 ♀ and 133 ♂) of 8-12 week old CD-1® (ICR) mice from Charles Rivers Laboratories (North 
American colonies) [59]. Statistical significance versus PBS-treated animals was computed with 
One-Way ANOVA followed by Dunnett test for multiple comparisons: *p< 0.01, **p <0.001, 
***p < 0.00001. Note:  Normal range limits in this figure are not firm boundaries and should be 
used as guidelines since a large range of values was reported in the literature and could be 
accounted for by variation in age, sex, sampling technique and testing methodology (i.e. 
instrument, technique …). 
 
 Despite normal clinical signs post-administration of NPs, a decrease in 
body weight was observed with cationic lipid nanoparticles, specifically 
following multiple injections 
Next, we examined global changes in body weight (BW) following single (Figure 7-7, A) and 
multiple (Figure 7-7, B) intravenous administrations of uncoated, HA-coated and lipid 
nanoparticles formulated with either native or chemically modified siRNA. Cationic lipid 
nanoparticles at doses between 1 to 8 mg/kg have been shown to induce a reduction in BW which 
was associated with vector and/or sequence dependent immune stimulation, and/or elevated 
ALT/AST [58, 62, 63]. As shown in Figure 7-7, a small decrease in BW (~ 0-2 %) was observed 
for quasi-neutral Inv LNPs ( ζ-potential ~ 11 ± 3 mV), HA coated NPs (ζ-potential ~ -25 ± 5 mV) 
and low doses (1 mg/kg) of uncoated NPs (ζ-potential ~ 25 ± 5 mV) following a single I.V. 
injection. However, and due to variability, the observed difference was not statistically significant 
compared with PBS, excipient and naked siRNA groups that showed a steady, or a small (< 1 %) 
increase in, body weight. The LPS treated group showed a sharp decline in BW (4 ± 0.5 %) that 
could possibly be linked with elevated cytokine levels (i.e. IL-1β, IL-6, TNF-α, IFN-γ and KC) 
compared with other groups that had lower (i.e. Inv LNP) or did not induce cytokine release (i.e. 
uncoated and HA coated NPs) (Figure 7-4). The sharp decrease in BW correlated with clinical 
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signs (Table 7-2) where LPS injected mice showed signs of lethargy, delayed responsiveness to 
stimuli and changes in their general appearance around 4 hours post-injection and with decreased 
ALP levels (Figure 7-6). Given the demonstrated safety of uncoated and HA coated NPs (Figure 
7-4, 5, 6 and 7) administered as a single injection, we assumed no changes in cytokine induction, 
hematological and serological parameter upon multiple injections. However, we monitored clinical 
signs, body weights, and gross organ pathology as a general toxic assessment following multiple 
injections (Figure 7-7and Table S.1). As expected, uncoated and HA coated chitosan NPs did not 
induce a decrease in BW. Interestingly, an initial decrease in BW between 0.5 and 2 % was 
observed for uncoated chitosan upon the first injection, followed by a steady increase in BW after 
the second injection (day 3). Moreover, there was no difference between low (10 kDa) and high 
Mn (120 kDa) formulations on BW. Invivofectamine® 3.0, a cationic lipid formulation with 
improved potency relative to its previous 2.0 generation, induced a sharp decrease (4 ± 1 %) in 
body weight typical of lipid based and liposomal formulations [15, 58, 62, 63].  
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Figure 7-7 Changes in body weight following intravenous nanoparticle administration. A) 
Percent change in body weight following a single intravenous injection in CD-1® (ICR) mice. 
Invivofectamine® 2.0 lipid nanoparticles (Inv LNP) were formulated with unmodified (siApoB 
Nat) and 2’O-methyl modified ApoB siRNA (siApoB 2’Ome) and injected at 1 and 8 mg/kg. 
Uncoated chitosan was formulated with siApoB Nat and siApoB 2’Ome at an N:P ratio of 5 and 
injected at 1 and 2.5 mg/kg. Hyaluronic acid (HA, 866 kDa) coated nanoparticles were prepared 
at an N:P:C of 2:1:1.5 and injected at 1 and 8 mg/kg. The injected doses were chosen from the 
hemocompatibility data (Figure 7-1) where the maximum dose results in hemolysis below the 
ASTM threshold. B) Percent change in body weight following three I.V. injections in Balb/c 
mice. Invivofectamine® 3.0 (Inv LNP) and Altogen (Altogen LNP) lipid nanoparticles were 
formulated with LNA-modified GAPDH siRNA (siGAPDH) and injected at 2.5 mg/kg. Low Mn 
(10 kDa) and high Mn (120 kDa) chitosan nanoparticles were formulated with siGAPDH at an 
N:P ratio of 5 and I.V. injected at 1 mg/kg. Hyaluronic acid (HA, 866 kDa) coated nanoparticles 
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were prepared at an N:P:C of 2:1:1.5 and injected at 8 mg/kg. The injected doses were chosen 
from the hemocompatibility data (Figure 7-1) where the maximum dose results in hemolysis 
below the ASTM threshold and following personal communication with the manufacturers of 
Invivofectamine® 3.0 and Altogen. For panel A and B, body weight (g) was collected before each 
injection and at euthanasia. Red arrows and crosses illustrate injection and euthanasia 
respectively. Data represent the average ± standard deviation of 5-7 mice/group. Phosphate 
buffered saline (PBS) and lipopolysaccharide (LPS) were used as controls. 
Table 7-2 Clinical signs collected following a single ascending dose of LNPs, uncoated and HA 
coated chitosan-siRNA nanoparticles. General aspect score (GAS), or the general physical aspect 
of the animal (i.e. hunchback position, piloerection, vocalization …), the natural behaviour score 
(NBS), or the behavioral aspect of the animal relative to its habitat and littermates (i.e. litter 
aspect, activity, nesting …) and the provoked behaviour score (PKBS), or the animal response to 
stimuli (i.e. pen tap on the cage …) were collected by three independent scorers and reported in 
this table along with the frequency. 
TA (dose) 
Clinical signs 
parameters 
Time (h) post injection 
4h (frequency) 24h (frequency) 
PBS 
GAS 0 (7/7) 0 (7/7) 
NBS 0 (7/7) 0 (7/7) 
PKBS 0 (7/7) 0 (7/7) 
LPS GAS 3 (7/7) 0 (7/7) 
(4mg/kg) NBS 0 (7/7) 0 (7/7) 
  PKBS 3 (7/7) 0 (7/7) 
siApoB Nat GAS 0 (7/7) 0 (7/7) 
(8 mg/kg) NBS 0 (7/7) 0 (7/7) 
  PKBS 0 (7/7) 0 (7/7) 
siApoB 2’Ome 
 (8mg/kg) 
GAS 0 (7/7) 0 (7/7) 
NBS 0 (7/7) 0 (7/7) 
PKBS 0 (7/7) 0 (7/7) 
InvLNP siApoB Nat GAS 0 (7/7) 0 (7/7) 
(1 mg/kg) NBS 0 (7/7) 0 (7/7) 
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  PKBS 0 (7/7) 0 (7/7) 
InvLNP siApoB Nat GAS 1 (7/7) 0 (7/7) 
(8 mg/kg) NBS 0 (7/7) 0 (7/7) 
  PKBS 1 (7/7) 0 (7/7) 
InvLNP siApoB 2’Ome GAS 1 (7/7) 0 (7/7) 
(8 mg/kg) NBS 0 (7/7) 0 (7/7) 
  PKBS 1 (7/7) 0 (7/7) 
92-10-5 siApoB Nat 
(1mg/kg) 
GAS 0 (7/7) 0 (7/7) 
NBS 0 (7/7) 0 (7/7) 
PKBS 0 (7/7) 0 (7/7) 
92-10-5 siApoB Nat  
(2.5 mg/kg) 
GAS 1 (7/7) 0 (7/7) 
NBS 0 (7/7) 0 (7/7) 
PKBS 1 (7/7) 0 (7/7) 
92-10-5 siApoB 2’Ome GAS 1 (4/7) 0 (7/7) 
(2.5 mg/kg) NBS 0 (7/7) 0 (7/7) 
 PKBS 1 (3/7) 0 (7/7) 
HA92-10 siApoB Nat GAS 0 (7/7) 0 (7/7) 
(1 mg/kg) NBS 0 (7/7) 0 (7/7) 
  PKBS 0 (7/7) 0 (7/7) 
HA92-10 siApoB Nat GAS 0 (7/7) 0 (7/7) 
(8 mg/kg) NBS 0 (7/7) 0 (7/7) 
  PKBS 0 (7/7) 0 (7/7) 
HA92-10 siApoB 2’Ome GAS 0 (7/7) 0 (7/7) 
(8 mg/kg) NBS 0 (7/7) 0 (7/7) 
  PKBS 0 (7/7) 0 (7/7) 
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 Uncoated and HA coated chitosan NPs did not induce histopathological 
changes in main organs following I.V injection at low and high doses  
Histopathological changes are often associated with nanoparticle toxicity and accumulation in 
target organs. We, therefore, monitored gross and microscopic morphological changes in main 
organs 24 hours post-injection. As shown in Figure 7-8, tissue sections from liver and kidney 
display no difference relative to PBS-treated group indicating that NPs accumulating in PTECs 
(Figure 7-2) are relatively safe. A thorough examination of these organs showed no changes in cell 
morphology, absence of apoptotic cells and/or immune infiltration. Similar results were obtained 
at lower doses of uncoated and HA coated NPs and for other organs such as the heart, lungs, and 
spleen (Figure S. 7-1 and S-4) highlighting the safety of these formulations. Histopathological 
examination of tissues upon multiple injections underlined the safety of these NPs (data not shown) 
with similar results obtained in comparison with a single injection. In contrast to chitosan-based 
NPs, immune cell infiltration close to liver sinusoids was observed for the high dose of Inv LNP 
(8 mg/kg) (Data not shown). 
 
Figure 7-8 Histopathological comparison of liver and kidney tissue sections following 
intravenous administration of high doses of uncoated and HA coated nanoparticles. Uncoated and 
HA coated nanoparticles were formulated with both unmodified (siApoB Nat) and 2’O-methyl 
modified ApoB siRNA sequences (2’Ome siApoB) at an N:P:C of 5:1:0 for uncoated and 2:1:1.5 
for HA-coated formulations, freeze-dried, rehydrated using excipients and I.V. injected at a dose 
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of 2.5 (uncoated) and 8 (HA coated) mg/kg siRNA. Animals were euthanatized 24 hours post-
administration, organ collected, fixed and processed for histopathological analysis. Phosphate 
buffered saline (PBS) and lipopolysaccharide (LPS) were used as controls. Organs from at least 
two animals per treatment group were processed and analyzed. Heart, Lungs and Spleen tissues 
from low (1 mg/kg) and high doses (2.5 and 8 mg/kg) are depicted in Supplemental Figure S. 7-4. 
Tissues show the absence of morphological changes, alterations, clots, apoptotic/necrotic cells or 
infiltration of immune cells. 
 
 
Figure S. 7-3 Histopathological comparison of liver and kidney tissue sections following 
intravenous administration of low doses of uncoated and HA coated nanoparticles. Uncoated and 
HA coated nanoparticles were formulated with unmodified (siApoB Nat) at an N:P:C ratio of 
5:1:0 for uncoated and 2:1:1.5  for HA-coated formulations, freeze-dried, rehydrated using 
excipients and intravenously injected at a dose of 1 mg/kg siRNA. Animals were euthanatized 24 
hours post-administration, organ collected, fixed and processed for histopathological analysis. 
Tissues show the absence of morphological changes, alterations, clots, apoptotic/necrotic cells or 
infiltration of immune cells. 
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Figure S. 7-4 Histopathological comparison of spleen, heart and lung tissue sections following 
intravenous administration of high doses of uncoated and HA coated nanoparticles. Uncoated and 
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HA coated nanoparticles were formulated with either unmodified (siApoB Nat) or 2’O-methyl 
modified ApoB siRNA (2’Ome ApoB ) at an N:P:C ratio of 5:1:0 for uncoated and 2:1:1.5  for 
HA-coated formulations, freeze-dried, rehydrated using excipients and intravenously injected at a 
dose of 2.5 (uncoated) and 8 (HA coated) mg/kg siRNA. Animals were euthanatized 24 hours 
post-administration, organ collected, fixed and processed for histopathological analysis. 
Phosphate buffered saline (PBS) and lipopolysaccharide (LPS) were used as controls. Organs 
from at least two animals per treatment group were processed and analyzed. Tissues show 
absence of morphological changes, alterations, clots, apoptotic/necrotic cells or infiltration of 
immune cells. 
 
 Uncoated chitosan NPs demonstrated functional gene-specific 
knockdown in kidney cortex independent of polymer length (Mn) 
We next examined the efficacy of uncoated and HA-coated NPs through the assessment of 
functional GAPDH knockdown in inbred Balb/c mice. Nanoparticles were manually prepared, and 
injected via the tail vein, except for the HA formulation which was freeze-dried (FD), following 
manual mixing, to reach the specific dose and rehydrated before injection. As illustrated in Figure 
7-9, statistically significant functional knockdown of 55%, as assessed by GAPDH enzymatic 
activity (Figure 7-9, A), was achieved in the kidney cortex following administration of 1 mg/kg of 
uncoated chitosan NPs. Low (10 kDa) and high (120 kDa) Mn chitosan achieved similar 
knockdown efficiency with a small, but improved performance observed with low Mn chitosan 
(Figure 7-9, A and B). Assessment of GAPDH knockdown by western blot showed a similar trend 
in knockdown between low versus high Mn chitosan with minor differences that could be attributed 
to the different techniques used for target knockdown assessment (Enzymatic versus immune 
detection). Interestingly, the HA coated formulation, injected at the higher dose of 8 mg/kg, 
produced no knockdown of the target gene. Naked siRNA has a natural tendency to accumulate in 
the kidney [33, 64-67] and is used as a strategy in phase III clinical trial to target p53 in ischemia-
reperfusion kidney injury (NCT02610296). In our study, chemically modified siRNA, containing 
Locked Nucleic Acid (LNA) combined with other AMBION Silencer® Select modifications 
(undisclosed), resulted in only 16% target knockdown when injected at a dose of 2.5 mg/kg 
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indicating a clear, and positive effect, of the chitosan delivery system to improve siRNA 
knockdown efficiency nearly 4 fold to 55%. Surprisingly, a commercially available kidney-
targeted liposome, Altogen LNP, did not achieve knockdown possibly due to its large size (~ 300 
nm) pre-injection which could increase to around 400-500 nm upon injection in blood. Qualitative 
confirmation of target knockdown was performed using immunohistochemistry on kidney sections 
from chitosan and PBS-treated mice. As shown in Figure 7-9 C, specific target knockdown was 
achieved in the cortex of chitosan NP treated kidneys. Taken together, our data showed that 
uncoated chitosans (both high and low Mn ) with a degree of deacetylation (DDA) of 92%, are safe 
(Figure 7-5 and 6), non-immune stimulating delivery systems (Figure 7-4) that targets kidney 
PTECs (Figure 7-2), and are well tolerated upon single and multiple injection to achieve significant 
functional knockdown in kidney cortices (Figure 7-9, A, B and C). 
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Figure 7-9 Efficacy of in vivo target knockdown. A) GAPDH activity (U) normalized per tissue 
mass (mg). Kidneys were collected, snap frozen in liquid nitrogen, and cortex excised, 
homogenized, protein extracted and assayed using the GAPDH KDalert™ enzymatic kit. (ns) 
non-significant and numbers express % knockdown relative to PBS. B) Western blot detection of 
GAPDH in kidney lysate. GAPDH signal was normalized to the vinculin loading control. The 
inset shows an actual example of a western blot membrane used for quantification. The 
membrane shows three different animals injected with PBS (control) and with 92-10-5 (1 mg/kg 
siGAPDH). Numbers in the histogram columns represent % knockdown relative to PBS. C) 
Qualitative assessment of GAPDH knockdown in the kidney by immunohistochemistry. Panels a, 
b, c, and d show a kidney section collected from a PBS-treated animal, stained with anti-GAPDH 
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antibody (a and b) and isotype control (c and d). Panels e, f, g, and h show a kidney section 
collected from a chitosan (92-10-5) treated animal, stained with anti-GAPDH antibody (e and f) 
and isotype control (g and h). Data represent average values ± standard deviation of 5 animals 
except for 92-120-5 siGAPDH (1 mg/kg) where 4 animals were assayed. Statistical significance 
versus PBS-treated animals was computed with One-Way ANOVA followed by Dunnett test for 
multiple comparisons: *p< 0.01, **p <0.001, ***p < 0.00001. 
 
7.4 Discussion  
Here, we investigated the effect of chitosan polymer length, dose, and surface modification with 
hyaluronic acid (HA) on the hemolytic potential, acute and organ toxicity, cytokine induction, in 
vivo biodistribution and target knockdown efficacy in addition to comparing chitosan NPs with 
commercially available cationic lipid nanoparticles (Invivofectamine®). Hemolytic and 
hemagglutination properties have been well characterized for cationic polymers such as PEI [68, 
69] and chitosan [40] with chitooligosaccharide (Mn < 5 kDa) found to be non-hemolytic but cause 
dose-dependent erythrocyte aggregation [70]. In our study, we have shown that uncoated chitosan 
NPs display dose and molecular weight dependent hemolytic and hemagglutination properties that 
could be abrogated with the use of nanoparticles prepared at low nitrogen to phosphate ratio (N:P 
ratio) or following HA coating (Figure 7-1) consequently highlighting careful dosing to avoid 
hemotoxicity and/or embolism. The hemolytic/hemagglutination potential of chitosan could occur 
through interaction with negatively charged erythrocyte (RBC) membranes via a pore forming 
mechanism, followed by a subsequence osmotic shock, and/or through regulation of surface protein 
and increase in surface roughness as demonstrated for methacrylate based polymers [71] and 
chitooligosaccharides [70] respectively. In addition, the interaction between chitosan amino groups 
and acidic groups on erythrocytes could promote polyelectrolyte complex formation leading to 
RBC aggregation as seen for other biomaterials [72]. NP coating with HA, a biocompatible and 
negatively charged molecule, eliminated both hemolysis and RBC aggregation possibly due to 
limited interaction with erythrocyte membranes through electrostatic repulsion and reduced 
interaction with serum components (Figure 7-1. In contrast to uncoated chitosan, lipid 
nanoparticles (LNPs) did not show dose-dependent hemolysis (Figure 7-1, Inset) probably due to 
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surface PEGylation implied by the quasi-neutral ζ-potential ~ 8-10mV (Figure 7-3). Shielding with 
polyethylene glycol (PEG) has been the method of choice to limit LNP hemolysis with high PEG 
density required for improved biocompatibility and reduced cytokine induction [52] and is 
incorporated in most if not all LNPs that are commercially available or in clinical development. In 
contrast to PEGylation, electrostatic coating with HA has demonstrated a similar protective effect 
permitting dose increase to at least 8 mg/kg (Figure 7-1). 
Immune stimulating properties of nanoparticles, or their payloads, can be studied by monitoring 
the expression of cytokines in plasma, serum or target tissues [4, 58, 62, 63] and represent one of 
the major hurdles for clinical translation [14]. In the current study, uncoated and HA-coated 
chitosan NPs did not induce type I pro-inflammatory cytokines (IL-1β, TNF-α, IFN-γ and IL-6) 
except for a small but statistically insignificant increase in KC, a human IL-8 homolog (Figure 7-4) 
indicating a non-immunogenic effect 4 hours post-administration. KC is a chemoattractant 
cytokine with distinct, or quasi-unique target specificity for neutrophils and is produced by a 
variety of epithelial and endothelial cells (EC) [73, 74]. The absence of neutrophil invasion, 24 
hours post-administration, in main organs (Supplemental Fig. S3 and S4) and in kidney tissues 
(Figure 7-8) where chitosan has been found to accumulate (Figure 7-2) suggests an epithelial cell-
independent mechanism of KC expression. However, platelet activation, aggregation and cytokine 
release (i.e. TGF-β1, PDGF-AB) have been observed following in vitro assessment of chitosan in 
hemostatic aggregation experiments [75] suggesting that KC levels post-administration of chitosan 
(Figure 7-4) could be attributed to platelet activation and their release from Weibel-Palade bodies. 
The adjuvant and immune stimulating effect of chitosan have been well described both in vitro and 
in vivo, and involve the activation of dendritic cells, and the secretion of Type-I pro-inflammatory 
cytokines (i.e. IFN-α/β/γ, IL-1β, TNF-α …), through NLRP3 inflammasome activation and the 
recently discovered cGAS/STING pathway for lower DDA (80%) chitosans [41, 42, 76-78]. The 
apparent contradiction between the lack of cytokine activation (Figure 7-4) and the literature could 
be explained by differences in routes of administration, dose, degrees of deacetylation and priming 
of immune cells. For instance, most studies demonstrating the anti-allergic properties of chitin and 
chitosan (Th2 inhibition) via the expression of Type-I cytokines have been tested in vitro and/or 
using the intranasal, intraperitoneal, intraocular and intravaginal routes of administration [42, 76]. 
However, in all these studies, priming strategies were used and could explain cytokine induction 
consistent with the finding that chitosan stimulated significant cytokine release only from primed 
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BMMΦ [77]. In this study, we did not measure cytokine levels at subsequent time points which 
could also explain the absence of cytokine induction, that only appeared around 9 h and peaked 24 
hours post stimulation [42]. Other considerations such as Mn, contaminants, particle size may also 
contribute to the observed difference. 
Lipid nanoparticles (LNPs), and liposomes are known, and potent, immune activators in vitro and 
in vivo with immune stimulation governed by the lipid and cationic head groups, and/or the 
combination with the nucleic acid payload [4, 15, 52, 58, 63]. In this study, Invivofectamine® LNPs 
demonstrated a dose-dependent induction of IFN-γ, IL-6 and KC and a minor TNF-α increase in 
serum (Figure 7-4). Immune stimulation was abrogated with the 2’Ome modified siRNA 
confirming previous results with LNPs [4, 58] highlighting major differences with our chitosan 
system where cytokine induction was not observed with any payload. In this study, we chose TNF-
α because it is a potent cytokine that is invariably activated, and immediately released, by all Toll-
Like receptors (TLRs) [79, 80]. Therefore, the TNF-α stimulation observed with lipid nanoparticle 
used in this study, while not induced with chitosan, suggests a TLR based mechanism of immune 
induction reminiscent of Chol:DSPC:DOTAP (3:1:1) cationic liposomes [63]. 
In the absence of cytokine induction (Figure 7-4), we next examined the acute toxic effects of 
chitosan, dose, siRNA sequence, HA-coating on hematological and serological parameters. 
Hematocrit (HCT) and total hemoglobin (Hb) levels were unchanged relative to PBS and within 
the normal reference ranges of CD-1® (ICR) mice indicating a relatively safe and non-hemolytic 
profile for all formulation tested. Lower Hb, but not HCT, levels compared with the reference range 
could be observed intragroup and might be due to differences in gender, age and quantification 
techniques used to establish the reference ranges [59, 81]. However, Hb levels were comparable to 
the PBS group and considered normal in this study. In contrast to chitosan NP, and their HA coated 
form, LNPs used in this study sharply decreased platelet counts consistent with previous 
observations [15, 58]. In this study, platelet decreases, or thrombocytopenia, post-LNP injection 
was sequence dependent consistent with [58]. Thrombocytopenia was also observed for antisense 
oligonucleotide (ASO) administered at doses above 200 mg/kg, which resulted in a halt in both the 
IONIS CARDIO-TTR and the NEURO-TTR phase III trials, and could be traced to the 
phosphorothioate (PS) backbone modification [82]. In the present study, as seen in a previous study 
[58], the anti-ApoB siRNA was not PS modified, supporting further mechanistic investigation. 
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Interestingly, lymphocyte counts decreased with both lipid and chitosan based formulations when 
formulated with the native immune stimulatory [4] anti-ApoB sequence Figure 7-5). All other 
parameters tested such as circulating basophils, eosinophils, monocytes, and neutrophils were 
normal and within the normal standard ranges for CD-1® (ICR) mice [59, 81]. 
Chitosan accumulation in the kidney (Figure 7-2) did not impair kidney function since levels of 
blood urea nitrogen and creatine remained normal (Figure 7-6). However, one major drawback of 
this study consists of the lack of BUN and creatinine measurements in urine which is more 
predictive than their serum counterparts as they permit the computation of the glomerular filtration 
rate (GFR), a clinical indicator of renal function. BUN and creatinine, are also indirect indicators 
of liver health, and therefore support the absence of liver toxicity as indicated by normal 
transaminase levels such as ALT, AST and ALP (Figure 7-6). In contrast to uncoated and HA 
coated NPs, lipid nanoparticles showed a typical dose-dependent increase in transaminases (Figure 
7-6) indicating transient liver toxicity [15, 62, 63]. This was further accompanied by a reduction in 
body weight (Figure 7-7) further highlighting systemic (liver) toxicity with LNPs. In general, a 
decrease in body weight has been observed with lipid nanoparticles [15, 58, 62, 63] and could be 
attributed to either the lipids [15, 62, 63] or to properties of the encapsulated nucleic acid payload 
[58]. In the present study, the decrease in body weight is believed to be due to the general toxicity 
induced by the lipid system, since injections were performed with a Locked Nucleic Acid (LNA) 
modified sequence containing 2’Ome and phosphorothioate (PS). However, further examination 
of the immune stimulation properties of this sequence, in the lipid encapsulated form is required. 
Lipopolysaccharide (LPS) treatment increased BUN, and decreased Cr levels in serum typical of 
catabolic processes induced following induction of cytokines (Figure 7-4) in fever like symptoms 
or infections [83]. Alkaline phosphatase (AP), an enzyme endowed with LPS detoxifying 
properties decreased following I.V. injection of LPS (Figure 7-6). The reduction is mainly 
attributed to malnutrition and weight loss (Figure 7-7A), and correlates with overt clinical signs 
including lethargy, decreased reactivity to stimuli and changed in the general appearance of mice 
(Table 7-2). However, and under the current experimental conditions, we cannot rule out another, 
less possible but valid, hypothesis to explain AP reduction in serum, likely due to AP depletion 
following LPS detoxification. 
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Organ and tissue toxicity is generally recognized by morphological changes, immune infiltration, 
apoptosis and/or necrosis. In the current study, no morphological changes, including an absence of 
infiltrating neutrophils, apoptotic and/or necrotic cells were observed in main organs upon single 
(Figure 7-8 and Supplemental Figure S. 7-3 and S4) and multiple injections (data not shown) 
further confirming the safety of uncoated and HA coated NPs. However, immune infiltration in 
liver was observed with high doses (8 mg/kg) of Invivofectamine® 2.0 (data not shown) supporting 
immune stimulation data (Figure 7-4). Considering the data discussed above, sub-acute and chronic 
toxicity studies should be performed as per the international conference on harmonization (ICH) 
and the Food and Drug Administration (FDA) guidelines, with cytokine induction assessed at 
multiple time points, in order to draw a complete toxicity profile. 
Intravenous administration was shown to cause accumulation of chitosan-siRNA NPs in kidneys 
(Figure 7-2) and promote siRNA translocation through the glomerular basement membrane (GBM) 
as evidenced by the intracytoplasmic localization and punctuate pattern of siRNA Figure 7-2, B 
and Inset). PTEC internalization of chitosan has been previously demonstrated to be dependent on 
glucosamine (Glc)-Megalin interaction and subsequent endocytosis [32, 84]. Hyaluronic acid 
coating modified the physicochemical properties of nanoparticles, with a shift in size and ζ-
potential indicating effective coating (Figure 7-3), without modifying the kidney-targeted 
biodistribution pattern possibly via CD44 internalization. Indeed, PTECs express at least five 
CD44 splice variants that play an important role in HA internalization and could be blocked using 
anti-CD44 antibodies [85]. In addition, HA has been shown to increase colloidal stability of NPs 
in serum [23] but HA could shed in circulation, therefore, exposing the chitosan-siRNA core (N:P 
2) that subsequently accumulate in PTEC via Megalin-mediated endocytosis. This two hypothesis, 
could be validated through a PK/PD study in CD44 and Megalin double negative transgenic mice 
or CD44 negative with drug-induced Megalin shedding. Independent of the observed PTEC 
accumulation, the mechanism of NP translocation through GBM still remains unclear since 
fenestration and ECM restrict translocation and diffusion of NPs. Non-conventional mechanisms 
such as those observed with 200-300 nm carbon nanotubes [86], or through nanoparticle 
disassembly at the highly negative GBM and reassembly in the lumen as proposed for cyclodextrin-
based nanoparticles [87] might provide an explanation for GBM translocation and PTEC 
accumulation. Alternative delivery through the fenestrated peritubular capillaries could occur but 
also faces similar diffusion challenges through the negatively charged interstitium. In addition to 
222 
 
kidney, uncoated and HA-coated NPs accumulate in the gallbladder (Gb) (Figure 7-2) suggesting 
hepatobiliary elimination of nanoparticles, or a fraction thereof, with a size above liver 
fenestrations suggesting that a fraction of the injected NPs was in the range of 0.3-1 µm [88]. 
Considering the biodistribution and the toxicity assessment of uncoated and HA-coated NPs, we 
next examined the efficacy of these NPs to induce target specific knockdown. The glyceraldehyde 
3-phosphate (GAPDH) gene was selected as a target due to its ubiquitous expression in tissues and 
the availability of in vivo validated, and chemically modified, siRNA sequences. In this study, 
functional GAPDH knockdown in the kidney cortex was achieved upon three injections of 
uncoated NPs (Figure 7-9, A). GAPDH enzymatic activity was reduced in kidney lysate by around 
55% and 45% using low (10 kDa) and high (120 kDa) Mn chitosan respectively. Western blot 
analysis and qualitative immunohistochemistry confirmed the enzymatic activity data and showed 
cortex specific knockdown (Figure 7-9, B and C). In contrast to uncoated chitosan, HA-coated NPs 
accumulated in the kidney (Figure 7-3) but did not induce target knockdown (Figure 7-9, A). This 
result could be explained by the need of excess chitosan (N:P = 5:1 in uncoated vs 2.5:1 in HA-
coated) to promote endosomal release [89], possibly through the proton sponge effect. As a 
consequence, it is likely that HA-coated NPs formulated at an N:P:C 2.5:1:2 are able to translocate 
to the cytoplasm of PTEC (Figure 7-2) but remain sequestrated in endolysosomal compartments 
due to poor endosomal buffering capacity and reduced proton sponge effect. In addition, the 
negatively charged HA molecule, if co-localizing with chitosan, could contribute to lower 
endosomal release by masking positive charge in the endosome, therefore, reducing the capacity 
of endocytosed chitosan to mediate endosomal rupture. Independent of the two hypotheses, further 
validation through in vivo rescue experiments – i.e. injection of HA-coated NPs, followed by, or 
co-injected with, free chitosan – and intracellular trafficking studies are needed. In contrast to HA-
coated NPs (N:P:C of 2.5:1:2), uncoated chitosan formulations prepared at an N:P ratio of 5 contain 
around 70% free chitosan [90] that could colocalize in PTEC endosomes and promote endosomal 
rupture, explaining the observed efficacy (Figure 7-9). Endosomal colocalization strategies 
involving cholesterol-conjugated siRNA and GalNAc-conjugated endosomodisruptive polymers 
have been previously described and applied in the clinic as a Dynamic Polyconjugate (DPC) 
system. 
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In contrast to chitosan, Invivofectamine® LNPs accumulated in liver (data not shown) and induced 
target knockdown (Supplemental Fig.S5) confirming previous findings with the same delivery 
system [91]. Knockdown levels obtained in this study with LNPs are lower than previously 
reported data [64, 91] and could be explained by differences in target gene half-lives (t1/2). Full 
depletion of the target protein after complete mRNA knockdown (> 95%), given steady and long-
term knockdown, requires around 5 half-lives indicating the importance of time point selection for 
knockdown assessment. As such, knockdown is underestimated for long (i.e. GAPDH >35 h [92]) 
versus short half-life targets (i.e. factor VII, tearoyl-CoA Desaturase or tbid …). 
Compared to the potency of LNPs in biopharmaceutical pipelines (~70-90%) [18, 93], functional 
target knockdown obtained with our system (~50-60%) appears lower. However, considerations 
such as half-life of the target gene, potency of the siRNA, and tissue dependent technical 
challenges could explain these differences. Given that chitosan accumulates in PTECs (minor cell 
subtype of the kidney) versus LNPs in hepatocytes (predominant cell type in liver), assessment of 
target knockdown using conventional techniques (i.e. qPCR, enzymatic activity, western 
blotting…) that average expression levels across all cell types in the tissue sample is inevitably 
underestimated. Therefore, functional knockdown obtained in this report underestimates the true 
efficiency of our system to silence a target gene in PTECs, and highlight that precise evaluation 
of knockdown requires the development of methods capable of estimating knockdown in a 
specific subset of cells composing an organ. 
Taken together, our findings are critically important in revealing that uncoated and HA-coated 
NPs display no toxicity along with extra-hepatic delivery of siRNA leading to a functional 
knockdown in kidney cortices. The efficacy of our uncoated system in inducing functional target 
knockdown in PTECs specifically differentiates it from cyclodextrin-based NPs accumulating in 
the glomerulus and podocytes [87]. This study also highlights the potential of hyaluronic acid 
coated chitosan hybrid system as a potential system that accumulates in the kidney and could be 
delivered at high doses without hemolytic and/or adverse events. Further investigation is needed 
to elucidate the mechanism of PTEC accumulation and lack of knockdown efficacy observed with 
the HA-coated system in this report despite similar distribution properties.  
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7.5 Conclusion  
Uncoated chitosan NPs were shown to have hemolytic potential in a dose and Mn-dependent 
manner with hyaluronic acid coating abrogating this negative effect. In contrast to lipid-based 
nanoparticles, and liposomes, uncoated and HA coated chitosan NPs did not induce 
proinflammatory Type-I cytokines except for a small but statistically insignificant increase 
observed with the human IL-8 homolog, KC. Toxicological profiling showed that both uncoated 
and HA coated chitosan NPs injected at low and high doses were safe as demonstrated by normal 
hematological parameters and serological biomarkers. In this study, lipid nanoparticles 
(Invivofectamine®), induced a dose-dependent cytokine release and caused acute toxicity 
exemplified by increased serum transaminases and a sharp reduction in body weight. In vivo 
biodistribution showed cytoplasmic accumulation of siRNA in the proximal tubular epithelial cells 
of the kidney, with a clear role for chitosan, whether uncoated or HA-coated, in improved 
bioaccumulation. Nanoparticle efficacy showed 50-65% functional knockdown with a clear 
confinement to the kidney cortex after I.V. administration. In contrast, we have found that HA 
coating sharply reduced knockdown despite accumulation in the kidney cortex suggesting the 
incorporation of endosomolytic moieties in such NPs may improve endosomal release. Taken 
together, our data indicate that chitosan NPs are safe delivery systems with the potential to treat 
kidney diseases, specifically in PTEC related pathologies. 
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 GENERAL DISCUSSION  
This study was carried out with the purpose of identifying molecular properties favoring efficient, 
and non-toxic, in vitro and in vivo delivery of siRNA (Objective 1 & 2). Furthermore, the efficacy 
of selected formulations to induce potent functional gene knockdown was tested in mice after 
thorough profiling of hemocompatibility, single ascending dose acute toxicity and biodistribution 
(Objective 3). This study demonstrates the importance of chitosan degree of deacetylation (charge 
density), polymer length, and N:P ratio on nanoparticle physicochemical properties and biological 
performance. Results showed that nanoparticle uptake and target gene knockdown positively 
correlated with an increase in all three parameters, with polymer length and N:P ratio playing 
positive but marginal roles. Systemic administration of sub-hemolytic doses revealed extrahepatic 
distribution to the cytoplasm of renal proximal epithelial tubular cells. Nanoparticles were non-
toxic compared to their lipid counterparts and had no impact on clinical signs, hematological and 
serological biomarkers, cytokine induction and changes in body weight. Functional target 
knockdown reached 50-60% in renal cortices. 
Our data show that chitosan degree of deacetylation (DDA), or the number of protonatable amines 
(NH2), played a predominant role in dictating successful in vitro knockdown. The positive effect 
of high charge density, achieved at high DDA, on knockdown efficiency can be attributed to several 
factors including increased binding affinity for siRNA, increased electrostatic interaction with cell 
membranes and increased endosomal buffering capacity. None of the previous studies [20-23, 25, 
27] investigating the influence of chitosan molecular parameters on siRNA delivery examined the 
biological relevance of DDA. Instead, polymer length and the amine to phosphate molar ratio (N:P) 
was varied to optimize in vitro knockdown efficiency. In our study, the molecular weight, or chain 
length (Mn), and the N:P ratio had a positive but marginal effect on knockdown efficiency. This 
observation is in agreement with results reported previously [20, 29] where increased polymer 
length and N:P ratio had minimal effects on target knockdown efficiency. However, and as 
hypothesised in Objective 1, our findings are distinctly different from previous work on chitosan 
mediated plasmid delivery (pDNA), where a fine balance or the modulation of either the molecular 
weight (chain length) or the degree of deacetylation (charge density) was required in order to 
reduce nanoparticle stability to a threshold where particles are able to protect pDNA and promote 
intracellular dissociation for efficient transgene expression [37, 39, 40]. These differences could 
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be due to different affinities between chitosan and the nucleic acids. pDNA is a large and flexible 
molecule able to form multiple interchain bridges with high affinity [210] (avidity) with the 
polymer compared to the short and rigid siRNA molecule [29]. 
In the current study, the importance of chain length (Mn) and N:P ratio was demonstrated below a 
certain Mn threshold where nanoparticle internalization and target knockdown were both reduced 
when nanoparticles were formulated below 10 kDa. Low in vitro performance was not only 
attributed to nanoparticle integrity at pH above chitosan pKa (6.5-6.9) but also due to the presence 
of serum. Low Mn formulations showed inferior performance in presence of serum and required 
an increase in Mn or N:P ratio for improved potency, suggesting nanoparticle destabilization 
occurring through competitive displacement with negatively charged serum components. The 
negative effect of serum on nanoparticle integrity has been previously demonstrated for cationic 
liposomes [126] and chitosan-PEI hybrid nanoparticles [21] with the inclusion of helper lipids i.e 
DOPE and cholesterol or surface modification (e.g. PEGylation or HA coating) abrogating these 
negative effects. Although we could not elucidate the precise effect of serum, heparin and albumin 
were found to have antagonistic effects on siRNA release with heparin increasing and albumin 
decreasing release partially confirming our hypothesis (Hypothesis 1). These opposed effects 
confirm previous findings with albumin antagonizing the negative effects of heparin and oleic acid 
on cationic liposomes formulated without helper lipids [126]. In our study, cooperation between 
competing serum components, ionic strength, pH and their effects on nanoparticles is believed to 
drive the need for higher Mn and N:P ratio for particle stability. This observation was confirmed 
in the presence of relevant in vivo concentrations of serum, where nanoparticle performance 
decreased in a Mn and N:P dependent manner.  
Nanoparticle size and surface charge are two important parameters that affect colloidal stability, 
pharmacokinetics, biocompatibility and nanoparticle-cell interactions [237]. In this study, size 
increased with increasing polymer length (Mn) and ionic strength. In contrast to size, nanoparticle 
ζ-potential, increased with increased DDA, Mn and N:P ratio and decreased with increasing ionic 
strength. As expected, an increase in the number of ionizable amine groups (NH2) per chain (DDA), 
increases the charge density of the polymer and consequently has a direct and positive influence 
on ζ-potential. However, surface charge is not, at least theoretically, expected to increase with 
increasing Mn since 1) the pairing of chitosan positive charge and siRNA negative charge groups 
is not obviously Mn-dependent and 2) an increase in size, due to an increase in Mn, is translated to 
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a lower electrophoretic mobility and thus a lower apparent ζ-potential. Nevertheless, this Mn-
dependent increase in ζ-potential may be due to chains that are partly bound at the surface resulting 
in pendant chains that are longer for higher Mn that increase surface charge, or possibly more 
chitosan chains are bound in particles through greater cooperativity of binding to siRNA. The effect 
of ionic strength on colloidal stability over time showed strong aggregation and could, therefore, 
influence nanoparticle performance in vivo through unintended blood interactions. In this study, ζ-
potential positively correlated with knockdown efficiency confirming previous reports [37, 238]. 
However, a lack of correlation between size and EGFP knockdown was observed and could be 
explained by serum dependent size stabilization occurring through rapid protein corona formation 
[38]. Nimesh et al found that the size of chitosan-based nanoparticles rapidly increases in the 
presence of serum then stabilizes around 300-500 nm without loss in performance [38].  
siRNA and/or vector-based off-target effects continue to pose problems at the bench and the 
bedside [239-241]. A thorough evaluation of off-target effects was conducted in our study with 
non-targeting siRNA (siNT) and mock transfections (M) performed in parallel to treatments. The 
delivery of siNT showed insignificant knockdown while mock transfections mediated a slight 
increase in EGFP expression for some chitosans. In both cases, target knockdown and/or 
expression reached a maximum of ±10% indicating a relatively safe profile. The pattern of EGFP 
knockdown and/or expression seem to follow a trend where long vs short chains appear to have 
opposite effects. This is reminiscent of the marginal toxicity observed when assessing metabolic 
activity in transfected cells. Therefore, the decrease in EGFP expression for both siNT and mock 
transfections observed with short chains, and independent of the N:P ratio, is possibly associated 
with marginal metabolic toxicity observed at low Mn. Consistent with this idea, Malmo et al [20] 
found that mock transfection with fully deacetylated chitosan consistently reduced EGFP 
expression by about 10% and that a dose-dependent response was associated with around 0-25% 
decrease. Although no metabolic decrease was mentioned in [20], the number of seeded cells was 
above the linear response of the assay and therefore, toxicity was not accurately estimated for 
correlation with mock-induced EGFP knockdown. However, this toxicity issue was indirectly 
highlighted during qPCR calibration relative to siNT treated instead of non-treated cells, which 
according to the authors was justified by differences in confluence between chitosan treated and 
untreated cells [20]. 
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Our results suggested that chitosan, and depending on its DDA, Mn and N:P ratio, disturbs global 
gene expression indicative of a certain parallelism with linear polyethyleneimine (lPEI) [242] and 
cationic lipids [243]. PEI has been shown to induce the expression of apoptotic genes, inflammation 
and oxidative stress responses while cationic lipids were generally associated with increased 
expression of stress-related genes. The impact of chitosan on the global transcriptome might be 
due to random binding of chitosan with intracellular nucleic acids or molecular machines through 
electrostatic or hydrophobic interactions. 
Nanoparticle toxicity is a major hurdle for clinical translation and could be due to 1) physical 
interactions with vesicular and mitochondrial membranes [244], 2) disruption of normal protein 
synthesis via electrostatic interaction with polyanionic component in the cytoplasm, and/or 3) 
injuries from hydrolytic enzymes released during endosomal escape [237]. Formulations used in 
this study were relatively non-toxic with around 10±10% reduction in cell viability confirming our 
hypothesis (Objective 2). Toxicity increased with lower molecular weight chitosan with high DDA. 
Mock transfections demonstrated that toxicity is payload independent. These results are affirmed 
in other studies, where chitosan showed minimal toxicity when formulated at N:P ratio ranging 
from 5-60 [20, 22, 27, 29, 33, 34, 36, 37]. In contrast, Liu et al. [23] have shown significantly 
reduced metabolic activity in H1299 cells. The apparent toxicity is probably due to the extremely 
high free chitosan content (N:P 150), serum free conditions and assay specific differences. Chitosan 
translocation into the nucleus could potentially induce genetic damage either through electrostatic 
interactions, hydrolysis from co-impurities or through physical obstruction during chromosomal 
separation at the anaphase. We found DNA damage to be statistically insignificant indicating that 
neither the nanoparticle nor the ascending concentrations of free chitosan or siRNA sequence were 
genotoxic and therefore confirming our hypothesis (Objective 2).  
The cationic nature of chitosan favors interaction with cellular blood components that could 
potentially have deleterious effects in vivo. However, this aspect of probable toxicity has been 
neglected [20-25, 27-29, 33-40, 245] with in vivo reports often using extremely high N:P ratios 
without reporting any signs of toxicities [22, 24, 41-44]. However, high N:P ratio could pose 
serious adverse effects in light of reports suggesting blood-material interaction [30]. In our study, 
we showed that uncoated chitosan NPs display dose and molecular weight dependent hemolytic 
and hemagglutination properties that could be abrogated with the use of nanoparticles prepared at 
low nitrogen to phosphate ratio (N:P ratio) or following HA coating confirming our hypothesis 
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(Objective 2) and consequently highlighting careful dosing to avoid hemotoxicity and/or 
embolism. The hemolytic/hemagglutination potential of chitosan could occur through interaction 
with negatively charged erythrocyte (RBC) membranes via a pore forming mechanism, followed 
by a subsequence osmotic shock, and/or through regulation of surface protein and increase in 
surface roughness as demonstrated for methacrylate based polymers [246] and 
chitooligosaccharides [247], respectively. In addition, the interaction between chitosan amino 
groups and acidic groups on erythrocytes could promote polyelectrolyte complex formation leading 
to RBC aggregation as seen for other biomaterials [248]. NP coating with HA, a biocompatible and 
negatively charged molecule, eliminated both hemolysis and RBC aggregation possibly due to 
limited interaction with erythrocyte membranes through electrostatic repulsion and reduced 
interaction with serum components permitting dose increase to at least 8 mg/kg. In contrast to 
uncoated chitosan, lipid nanoparticles (LNPs) did not show dose-dependent hemolysis probably 
due to surface PEGylation implied by the quasi-neutral surface charge. Shielding with polyethylene 
glycol (PEG) has been the method of choice to limit LNP hemolysis with high PEG density 
required for improved biocompatibility and reduced cytokine induction [249] and is incorporated 
in most if not all LNPs that are commercially available or in clinical development.  
Immune stimulating properties of nanoparticles or their payloads represent one of the major hurdles 
for clinical translation [250]. In the current study, uncoated and HA-coated chitosan NPs did not 
induce type I pro-inflammatory cytokines (IL-1β, TNF-α, IFN-γ and IL-6) except for a small but 
statistically insignificant increase in KC, a human IL-8 homolog indicating a non-immunogenic 
effect 4 hours post-administration. KC is a chemoattractant cytokine with distinct, or quasi-unique 
target specificity for neutrophils and is produced by a variety of epithelial and endothelial cells 
(EC) [251, 252]. The absence of neutrophil invasion, 24 hours post-administration, in main organs 
and in kidney tissues where chitosan has been found to accumulate suggests an epithelial cell-
independent mechanism of KC expression. However, platelet activation, aggregation and cytokine 
release (i.e. TGF-β1, PDGF-AB) have been observed following in vitro assessment of chitosan in 
hemostatic aggregation experiments [253] suggesting that KC levels post-administration of 
chitosan could be attributed to platelet activation and their release from Weibel-Palade bodies. The 
adjuvant and immune stimulating effect of chitosan have been well described both in vitro and in 
vivo, and involve the activation of dendritic cells, and the secretion of Type-I pro-inflammatory 
cytokines (i.e. IFN-α/β/γ, IL-1β, TNF-α …), through NLRP3 inflammasome activation and the 
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recently discovered cGAS/STING pathway for lower DDA (80%) chitosans [31, 32, 208, 254, 
255]. The apparent contradiction between the lack of cytokine activation and the literature could 
be explained by differences in routes of administration, dose, degrees of deacetylation and priming 
of immune cells. For instance, most studies demonstrating the anti-allergic properties of chitin and 
chitosan (Th2 inhibition) via the expression of Type-I cytokines have been tested in vitro and/or 
using the intranasal, intraperitoneal, intraocular and intravaginal routes of administration [32, 208]. 
However, in all these studies, priming strategies were used and could explain cytokine induction 
consistent with the finding that chitosan stimulated significant cytokine release only from primed 
BMMΦ [254]. In this study, we did not measure cytokine levels at subsequent time points which 
could also explain the absence of cytokine induction, that only appeared around 9 h and peaked 24 
hours post stimulation [32]. Other considerations such as Mn, contaminants, particle size may also 
contribute to the observed difference. 
Lipid nanoparticles (LNPs) and liposomes are known immune activators with several groups 
demonstrating that immune stimulation is governed by the lipid and cationic head groups, and/or 
the combination with the nucleic acid payload [14, 76, 81, 249, 256]. In this study, 
Invivofectamine® LNPs demonstrated a dose-dependent induction of IFNγ, IL-6 and KC and a 
minor TNF-α increase in serum. Immune stimulation was abrogated with the 2’OMe modified 
siRNA confirming previous results with LNPs [76, 81] highlighting major differences with our 
chitosan system where cytokine induction was not observed with any payload. In this study, we 
chose TNF-α because it is a potent cytokine that is invariably activated, and immediately released, 
by all Toll-Like receptors (TLRs) [257, 258]. Therefore, the TNF-α stimulation observed with lipid 
nanoparticle used in this study, while not induced with chitosan, suggests a TLR based mechanism 
of immune induction reminiscent of Chol:DSPC:DOTAP (3:1:1) cationic liposomes [14]. 
In the absence of cytokine induction, hematocrit (HCT) and total hemoglobin (Hb) levels were 
unchanged relative to PBS and within the normal reference ranges of CD-1® (ICR) mice indicating 
a relatively safe and non-hemolytic profile for all formulation tested. Lower Hb, but not HCT, 
levels compared with the reference range could be observed intragroup and might be due to 
differences in gender, age and quantification techniques used to establish the reference ranges [259, 
260]. However, Hb levels were comparable to the PBS group and considered normal in this study. 
In contrast to chitosan NP, and their HA coated form, LNPs used in this study sharply decreased 
platelet counts consistent with previous observations [76, 256]. Thrombocytopenia was only 
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observed with LNPs confirming previous data [76]. Interestingly, lymphocyte counts decreased 
with both lipid and chitosan based formulations when formulated with the native immune 
stimulatory sequence [81]. All other parameters tested such as circulating basophils, eosinophils, 
monocytes, and neutrophils were normal and within the normal standard ranges for CD-1® (ICR) 
mice [259, 260]. 
Chitosan accumulation in the kidney did not impair kidney function since levels of blood urea 
nitrogen and creatine remained normal. However, one major drawback of this study consists of the 
lack of BUN and creatinine measurements in urine which are more predictive than their serum 
counterparts as they permit the computation of the glomerular filtration rate (GFR), a clinical 
indicator of renal function. BUN and creatinine, are also indirect indicators of liver health, and 
therefore support the absence of liver toxicity as indicated by normal transaminase levels. In 
contrast to uncoated and HA coated NPs, lipid nanoparticles showed a typical dose-dependent 
increase in transaminases accompanied by a reduction in body weight indicating transient liver 
toxicity and highlighting systemic toxicity [14, 256, 261]. In general, a decrease in body weight 
has been observed with lipid nanoparticles [14, 76, 256, 261] and could be attributed to either the 
lipids [14, 256, 261] or to properties of the encapsulated nucleic acid payload [76]. In the present 
study, the decrease in body weight is believed to be due to the general toxicity induced by the lipid 
system, since injections were performed with a non-immune stimulatory LNA modified sequence 
containing methylated sugars and PS modification in the backbone. Lipopolysaccharide (LPS) 
treatment increased BUN, and decreased Cr levels in serum typical of catabolic processes induced 
following induction of cytokines in fever like symptoms or infections [262], and further confirming 
that negative data obtained with chitosan are not due to assay dependent technical issues. Alkaline 
phosphatase (AP), an enzyme endowed with LPS detoxifying properties decreased following I.V. 
injection of LPS, can probably be attributed to malnutrition and weight loss, which correlated with 
overt clinical signs including lethargy, decreased reactivity to stimuli and changed in the general 
appearance of mice. However, and under the current experimental conditions, we cannot rule out 
another, less possible but valid hypothesis to explain AP reduction in serum, likely due to AP 
depletion following LPS detoxification. The absence of toxicity was confirmed by histopathology 
with no morphological changes, including an absence of infiltrating neutrophils, apoptotic and/or 
necrotic cells observed in main organs.  
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In contrast to polyethyleneimine (PEI), intravenous administration of chitosan-siRNA 
nanoparticles showed exclusive accumulation in the kidneys. Finer examination of kidney 
structures revealed a punctate pattern of siRNA [39] in the cytoplasm of the proximal epithelial 
tubular cells (PTECs) suggesting translocation through the glomerular basement membrane 
(GBM). PEI a cationic polymer that spontaneously form nanoparticles with similar 
physicochemical properties and colloidal stability compared to chitosan has been found to 
accumulate in lungs, liver, spleen and kidneys following intravenous administration [41]. Although 
naked siRNA filters through the kidneys [263] and a fraction accumulate in PTECs [263], our data 
clearly indicate a role for chitosan in increasing the efficiency of siRNA accumulation into PTECs 
probably through glucosamine (Glc)-Megalin interaction and subsequent internalization [42, 264]. 
In contrast to our hypothesis (Objective 3), hyaluronic acid coating modified physicochemical 
properties of nanoparticles without alteration of the kidney-targeted biodistribution pattern.  
PTECs express at least five CD44 splice variants that play an important role in HA internalization 
and could be blocked using anti-CD44 antibodies [265]. In addition, HA has been shown to 
increase colloidal stability of NPs in serum [21] but could shed in circulation, therefore, exposing 
the chitosan-siRNA core (N:P 2) that subsequently accumulate in PTEC via Megalin-mediated 
endocytosis. In either case, nanoparticle translocation through the GBM remains to be elucidated 
mechanistically since fenestration and the extracellular matrix limit nanoparticle translocation and 
diffusion. Translocation and PTEC accumulation could be achieved through either non-
conventional mechanisms as observed with 200-300 nm carbon nanotubes [266] or through 
nanoparticle disassembly at the highly negative GBM and reassembly in the lumen as proposed for 
cyclodextrin-based nanoparticles [174]. Alternative delivery through the fenestrated peritubular 
capillaries could occur but also faces similar diffusion challenges through the negatively charged 
interstitium. 
Irrespective of the mechanism involved, chitosan based nanoparticles, not only accumulate in the 
cytoplasm of PTEC, but also induce functional knockdown without causing deleterious effects on 
body weight. In this study, in vivo efficacy was demonstrated through functional GAPDH 
knockdown where both low Mn (10 kDa) chitosans demonstrated the highest efficacy (~ 40-50% 
knockdown at the protein level). Western blot analysis and qualitative immunohistochemistry 
confirmed the enzymatic activity data and showed cortex specific knockdown. In contrast to the in 
vitro data, high Mn (120 kDa) chitosans did not outperform their low Mn counterparts emphasizing 
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fundamental differences between in vitro and in vivo validation. Gao et al [42] demonstrated that 
low Mn (40 kDa) fully deacetylated chitosan is able to achieve around 50 % knockdown in PTECs 
when formulated at N:P ratio of 60 with higher Mn and/or lower N:P ratio unable to distribute to 
the kidneys. In contrast, we have demonstrated that low and high Mn – except for the high Mn 
fully decetylated chitosan – are able to achieve 40-50% target knockdown when formulated at low 
N:P ratio. The discrepancy between our data and those presented in [42] \ is most probably due to 
aggregation since physicochemical properties of the injected nanoparticles [42] are questionable 
with non-homogenous and polydisperse NPs (400-800 nm). The distribution of naked siRNA in 
mice exhibited a predictable pattern based on the known propensity of oligonucleotides to 
accumulate in the kidneys [41, 267, 268] and resulted in poor (~ 15%) knockdown confirming prior 
reports [263, 268]. Formulation with chitosan significantly increased knockdown efficiency 
by~30-35% compared to fresh naked siRNA suggesting a clear and positive role of the delivery 
system (3-fold improvement).  
HA-coated NPs accumulated in the kidney but did not induce target knockdown even at higher 
doses compared to uncoated nanoparticles consequently refuting our hypothesis (Objective 3). This 
result could be explained by the need for excess chitosan (N:P = 5:1 in uncoated vs 2.5:1 in HA 
coated) to promote endosomal release [216], possibly through the proton sponge effect. As a 
consequence, it is likely that HA coated NPs formulated at an N:P:C 2.5:1:2 are able to translocate 
to the cytoplasm of PTEC but remain sequestrated in endolysosomal compartments due to poor 
endosomal buffering capacity and reduced proton sponge effect. In addition, the negatively charged 
HA molecule, assumed to colocalize with chitosan, could contribute to lower endosomal release 
by masking positive charge in the endosome, therefore, reducing the capacity of endocytosed 
chitosan to mediate endosomal rupture. In contrast to HA-coated NPs (N:P:C of 2.5:1:2), uncoated 
chitosan formulations prepared at an N:P ratio of 5 contain around 70% free chitosan [210] that 
could colocalize in PTEC endosomes and promote endosomal rupture, explaining the observed 
efficacy. 
 
Compared to the potency of lipid systems (~70-90%) in advanced pre-clinical or clinical 
development [121, 139, 140, 142], functional target knockdown obtained with our system (~40-
50%) appears to be lower. However, considerations such as half-life of the target gene (GAPDH 
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versus factor VII), potency of the payload, and tissue dependent technical challenges could explain 
these differences. Accurate estimation of target knockdown using conventional techniques, such 
as quantitative PCR, enzymatic activity or immunoblotting, depends on 1) the abundance of the 
target cell type (fraction of cells transfected relative to the organ), 2) the ability of the delivery 
system to transfect different cell types composing an organ and/or 3) the tissue – or cell – specificity 
of a target gene. Inasmuch as chitosan displays specific targeting to PTECs, a cell-type that 
represents a minor fraction of the cells in the kidney, assessment of target knockdown using 
conventional techniques is necessarily underestimated unless the target gene is PTEC specific and 
only expressed in this cell subtype. In contrast, LNPs accumulate in hepatocytes, the predominant 
cell type in the liver, permitting non-biased (accurate) estimation of target knockdown. Therefore, 
functional knockdown obtained in this report underestimates the true efficiency of our system to 
silence a target gene in PTECs, and suggest that precise evaluation of target knockdown requires 
the development of novel methods capable of estimating knockdown in a specific subset of cells 
composing an organ. 
Taken together, our findings are of critical importance to siRNA delivery since extra-hepatic 
targeting could be naturally achieved without chemical modifications or ligand targeting and 
accumulation occurred in PTECs, with functional target knockdown around 50% in kidney cortex, 
further differentiating this system from cyclodextrin-based NPs that accumulate in glomeruli and 
podocytes [174]. As a consequence, unmodified chitosan-siRNA nanoparticles could potentially 
be used for the treatment of PTEC associated kidney fibrotic diseases.  
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 CONCLUSION AND RECOMMENDATIONS 
The work presented in this thesis demonstrates the application of chitosan in nucleic acid delivery 
in vitro and in vivo and highlight the role of chitosan molecular parameters on nanoparticle 
physicochemical characteristics and bioactivity. In a first study, we showed that a simple method 
based on the enzymatic digestion of chitosan permits the extraction and recovery of total RNA for 
subsequent quantification of gene expression and downstream molecular analysis (Chapter 4). In 
addition, the method was found suitable for the removal of membrane-bound chitosan during flow 
cytometry-based assessment of nanoparticle uptake and demonstrated that assessment of 
nanoparticle internalization is biased by ~10-15% (Chapter 4). In a subsequent study, we found 
that nanoparticles can be formulated at a low N:P ratio (N:P 5), and induce potent and nontoxic in 
vitro knockdown in multiple cell lines. In contrast to previously published data, we showed that 
low molecular weight chitosan, prepared at low N:P ratio, effectively complex nucleic acids into 
stable particles and protect the payload from nuclease digestion in slightly acidic conditions. The 
modification of the electrophoresis buffer from basic to slightly acidic showed that nanoparticles 
with low N:P ratio could be selected based on their stability (Chapter 5).  
 
In a subsequent study (Chapter 6), we found the following: 1) both in vitro nanoparticle 
internalization and target gene knockdown were maximized with a concomitant increase in the 
degree of deacetylation, molecular weight and N:P ratio, 2) minimal molecular weight (10 kDa) is 
required for efficient transfection and target knockdown, 3) serum had a negative impact on the 
transfection efficiency of low molecular weight formulations, which could be abrogated by 
increasing both Mn and the N:P ratio, 4) increasing serum concentrations decreased knockdown 
efficiency in a dose-dependent manner, with formulations at high Mn/N:P ratio being the most 
performant due to increased stability, 5) in vitro treatment with chitosan influenced the expression 
of a panel of reference genes and 6) irrespective of the Mn and N:P ratio, absence of genotoxic 
effect at 4 and 48 hours were demonstrated in this study. These findings revealed the exact 
molecular requirement for potent and nontoxic in vitro target knockdown and the selection of 
optimal formulation for further development and testing in animals. 
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In vivo, chitosan was found to accumulate in the proximal tubules epithelial cells of the kidney 
(Chapters 6 & 7), with undetectable toxic effects as per evaluation of serological and 
hematological biomarkers (Chapter 7). In addition, chitosan did not induce pro-inflammatory 
cytokines at the maximum tested dose for both uncoated and hyaluronic acid-coated formulations 
further confirming the safety of this system in comparison with Invivofectamine® (Lipid 
nanoparticle) (Chapter 7). Perhaps the most important finding in this thesis, along with the absence 
of toxic effects (Chapter 7), is the demonstrated potent functional gene knockdown in kidney 
cortices (Chapter 6 & 7). Interestingly, nanoparticle surface decoration (electrostatic) with 
hyaluronic acid did not impair biodistribution but mitigated potency (Chapter 7).  
 
The comprehensive analysis of diverse factors studied in this research project revealed underlying 
important factor for the development of chitosan-based nanoparticles for the delivery of small 
interfering RNA.  In addition, these studies demonstrated the safety of specific formulations for in 
vivo application and in a proof of concept study showed potent functional gene knockdown in 
kidney cortices. In sum, formulations with extrahepatic capabilities were identified and are 
believed to have promising potential for the treatment of kidney related diseases and cancer. All 
through this thesis, we realized significant progress in advancing the field of chitosan for the 
delivery of short oligonucleotides; however, with each finding, technical challenge, and 
conclusion, more questions were open for contemplation, which when answered can make further 
contributions toward the development of advanced chitosan-based systems intended to deliver 
small interfering RNA in vivo.  
 
Although beyond the scope of this research, the following recommendations are worth considering 
in the future: 
1. Demonstration of higher knockdown in PTEC isolates – In this study, nanoparticles were 
shown to accumulate in kidney cortices, specifically in the proximal epithelial tubular cells 
(PTECs). Since PTECs represent only a fraction of the renal cortex, assessment of target 
gene knockdown is undoubtedly underestimated using conventional techniques that 
averages expression levels across all cell types of a tissue sample. Therefore, isolation of 
primary PTECs, following intravenous administration of nanoparticles, would allow for 
246 
 
further development in the efficacy of the delivery system through increased PTEC specific 
knockdown.  
2. Evaluation of therapeutic efficiency in a model of kidney fibrosis – Proximal epithelial 
tubular cells have been demonstrated to cause fibrotic diseases through activation of the 
TGF-β pathway. The unilateral ureteral obstruction (UUO) or streptozotocin-induced type-
1 diabetes models are relatively simple models of renal fibrosis mimicking features in 
humans. These models could be used to demonstrate the therapeutic effect of nanoparticles 
targeting a TGF-β downstream target, known as SMAD-3. 
3. Validation of hypothesis for limited HA-coated nanoparticle efficacy – HA-coated 
nanoparticles demonstrated excellent biocompatibility and safety profiles but failed to 
induce target gene knockdown. We, therefore, hypothesized that the lack of free chitosan 
reduces endosomal escape, and supported our claims, with published observations by 
members of our group. Here we propose to validate our hypothesis by injecting HA coated 
nanoparticles, followed by an injection of free chitosan. This fraction of chitosan colocalize 
in the endosome promoting the release of HA coated samples and subsequent gene 
knockdown. We also propose to test other hyaluronic acid polymers with different degrees 
of sulfation and molecular weight to exclude a specific problem with the HA polymer used 
in this thesis (HA, 866 kDa).  
4. Characterization of endosomal escape and comparison with lipid nanoparticles – As 
mentioned throughout this thesis, endosomal escape is the most rate-limiting step in gene 
delivery. Improvement of target knockdown and therapeutic window can be achieved by 
improving endosomal escape. In comparison with lipid nanoparticle, awareness in the 
endosomal escape mechanisms for chitosan nanoparticle is embryonic with most studies 
hypothesizing on the mechanism of release without its quantitative assessment. Prior 
studies in our laboratory determined the kinetics of escape for plasmid DNA. Here we 
suggest to study endocytosis, and endosomal escape in primary PTEC cultures using live 
cell imaging and spinning disk confocal microscopy. 
5. Improvement of colloidal stability and inclusion of endosomolytic moieties – Colloidal 
stability in the presence of high ionic strength and serum protein need to be addressed for 
uncoated nanoparticles through PEGylation or surface coating (i.e. polyacrylic acid). 
However, limited in vivo efficiency, probably due to reduced endosomal release in the 
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absence of free chitosan might limits strategies to improve colloidal stability. As a 
consequence, we suggest the inclusion of endosomolytic moieties in nanoparticle during 
the colloidal stabilization process to circumvent poor endosomal release.  
6. Evaluation of repeated dose toxicity – Proper development of delivery systems, or drug 
molecules, requires the assessment of both acute and chronic toxicity. Since chitosan 
biodegradable properties depend on the degree of deacetylation, and to a lesser extent on 
molecular weight, formulation with high degree of deacetylation i.e. 92 and 98%, can 
accumulate in kidney PTEC eliciting long-term toxicity. Studies targeted at evaluation of 
repeated dose toxicity on a period of 3-6 month to understand elimination kinetics, design 
novel formulations with biodegradable linkers, and limit renal toxicity can be undertaken 
in future.
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